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Abstract
The precise co-ordination of cell proliferation and developmental pathways is essential for 
the development of multicellular organisms and the maintenance of tissue homeostasis. 
The intestine (endoderm) of the nematode Caenorhabditis elegans is used as a model 
system to study the control of cell proliferation during development, because it consists of 
only 20 cells. These cells are generated in the embryo by a precise division-pattem that is 
largely invariant between different animals. Previously, a cdc-25.1(ij48) gain-of-function 
allele has been identified that produces increased numbers of intestinal cells. CDC-25.1 
belongs to the eukaryotic CDC25 family of positive-acting cell cycle regulators. 
Intriguingly, in cdc-25.1(ij48) mutants, proliferation of other tissues is unaffected, but 
knockdown of CDC-25.1 by RNAi produces reduced cell divisions in most lineages. Thus, 
there is a general requirement for cdc-25.1 function in all embryonic blastomeres, but the 
cdc-25.1(ij48) mutant primarily affects proliferation of the intestine. It is therefore 
interesting to elucidate the mechanism underlying this tissue-specific phenotype.
The ij48 lesion in CDC-25.1 constitutes a serine to phenylalanine mutation (CDC-
25.1 (S46F)) in a highly conserved putative DSG consensus site, which may act as a site of 
negative regulation of CDC-25.1. In mammalian cells, the DSG motif of CDC25A acts as 
a recruitment site for the ubiquitin ligase component p-TrCP, mediating ubiquitin- 
dependent degradation of CDC25A. However, to date no difference in the abundance or 
localisation of CDC-25.1 (S46F) was identified.
In this thesis, I set out to identify negative regulators of CDC-25.1 that control CDC-25.1 
through S46, possibly in the intestine. Compelling evidence is provided demonstrating that 
LIN-23, the C. elegans orthologue of human (3-TrCP, negatively regulates the abundance 
of CDC-25.1 through S46 in C. elegans, specifically in early embryos. Surprisingly, the 
control of CDC-25.1 abundance is not restricted to intestinal cells, suggesting that the 
intestinal cell proliferation is more sensitive to elevated CDC-25.1 protein levels than other 
cell types. In a search for other molecules that may regulate the DSG site, GSK-3, APR-1 
and WRM-1 were found to also cause excess intestinal cells. Intriguingly, their function is 
independent of S46 in CDC-25.1, because gsk-3, apr-1 or wrm-1 RNAi produce a 
synergistic increase in intestinal cells when combined with the cdc-25.1 (ij48) allele. Thus, 
this thesis provides new insights to further our understanding of how the multicellular 
organism C. elegans controls proliferation of an entire tissue, the intestine.
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Definitions
aa amino acid
APC adenomatous polyposis coli
APC/C anaphase-promoting complex/cyclosome
APR APC-related
C mesectoderm precursor
CDC cell-division cycle
CDK cyclin-dependent kinase
CKI cyclin-dependent kinase inhibitor
CK1 casein kinase 1
DNA deoxyribonucleic acid
E endoderm precursor
EMS mesendoderm precursor
cDNA complementary deoxyribonucleic acid
F I, 2 or 3 first, second or third filial generation
GFP green fluorescent protein
GSK gycogen synthase kinase
L I, 2, 3 or 4 first, second, third or fourth larval stage
LIN abnormal cell lineage
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mRNA messenger RNA
MOM more mesoderm
MS mesoderm precursor
n.s. not significant
OD optical density
PCR polymerase chain reaction
POP posterior pharynx defective
RT-PCR reverse transcriptase-PCR
RNA ribonucleic acid
RNAi ribonucleic acid-mediated interference
P-TrCP beta-transducin repeat-containing protein
SCF SKIP 1 /CULLIN1 /F-Box
s.d. standard deviation
SKN skin excess
SKR SKP1 related
WRM worm armadillo
WB Western blot
WT wild-type
C. elegans mutant phenotypes:
dumpy (Dpy), uncoordinated (Unc), abnormal cell lineage (Lin)
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Measurements
Amp ampere
bp base pair
cm centimetre
g  value of acceleration due to gravity
hr hour
kb kilobase
kDa kilodalton
L litre
M molar
Mb megabase
mg milligram
min minute
ml millilitre
mm millimetre
mM millimolar
ng nanogram
nm nanometre
nM nanomolar
rpm revolutions per minute
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sec second
V volt
jig microgram
pi microlitre
jam micrometre
°C degree Centigrade
% per cent
16
Chapter 1 
INTRODUCTION
1 Introduction
1.1 Why study C. elegans?
The correct integration of cell proliferation with developmental pathways is vital for the 
generation o f multicellular organisms including humans. Though studies on cell 
proliferation in single cell organisms, such as yeast or mammalian tissue culture cells, have 
provided fundamental insights into the nature of cell division, clearly they cannot answer 
how cell division is integrated into the development of a whole multicellular organism. 
Questions that arise are: how is cell growth, cell division and differentiation co-ordinated 
to create an organism and to maintain tissue homeostasis? How are endogenous cell 
proliferation pathways integrated with external signals? Clearly, these are big questions 
and cannot be answered in a single set of experiments. However, detailed questions as to 
how proliferation of a single cell lineage of any multicellular organism is controlled will 
provide a significant piece of information to disentangle the puzzle.
The nematode C. elegans is used as a genetic model organism to elucidate the integration 
of cell proliferation with development in a whole model organism, because it has multiple 
features, which make it a powerful tool for investigative research (Riddle et al., 1997). It is 
easy to culture and can be raised in the laboratory on a diet of Escherichia coli. 
Furthermore, it has a rapid life cycle and its profuse growth permits the large-scale 
production of several million animals. The development of a single animal into a ~1 mm 
worm is completed within three days and one adult hermaphrodite produces about 300 
progeny through self-fertilisation. Its small size allows most assays to be carried out in 
Petri dishes or in liquid culture, and large-scale screening can even be performed in 
Microtiter plates. Importantly, the worm is transparent and the use of in vivo fluorescence 
markers allows the analysis of cellular processes, such as cell proliferation during 
embryogenesis, in the living animal. Additionally, C. elegans is the first multicellular 
organism for which the complete genomic sequence has been unravelled in 1998 (The C. 
elegans Sequencing Consortium, 1998) and this organism is becoming increasingly 
popular as a biological model system to study numerous aspects of cellular proliferation 
and development. This in part evolves from the fact that many C. elegans genes have 
considerable homology to mammalian counterparts, some of which have been associated 
with human disease states (Kamath et al., 2003; Rubin et al., 2000; The C. elegans 
Sequencing Consortium, 1998; Tu et al., 2006). The significance of C. elegans research 
was also recognised by the Nobel Prize awards to C. elegans researchers: S. Brenner, J.
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Sulston and H.R. Horvitz in 2002 for their findings on the genetic regulation of organ 
development and programmed cell death and furthermore in 2006 to C.C. Mello and A.Z. 
Fire for their discovery of gene silencing by double-stranded RNA (RNAi). Their 
contributions have been widely acknowledged as a major break-through in medical 
research with the discovery of genes involved in apoptosis and the ability to knock down 
genes using double-stranded RNA interference (Nobelprize.org, 2007).
Intriguingly, the entire cell lineage of the worm, which comprises the timing, location and 
ancestral relationship of all cell divisions during embryonic and post-embryonic 
development, is traced and largely invariant from one animal to the next (Sulston and 
Horvitz, 1977; Sulston et al., 1983). Thus, it is possible to observe the origin and behaviour 
of a single cell throughout the development of the worm. Therefore, C. elegans provides an 
excellent model system to study cell proliferation during development.
1.1.1 The phylogenetic features ofC. elegans
C. elegans is a free-living organism of the phylum Nematoda and is classified to the 
terrestrial form of Secementea belonging to the order Rhabditida and family of 
Rhabditidae. Members of the phylum Nematoda are diverse and have adapted to inhabit 
many types of marine and terrestrial environments, however despite their different life 
styles they have maintained a common body shape. Like all nematodes, the basic body 
plan of C. elegans consists of two concentric tubes separated by a pseudocoelomic space, 
the gonad. The inner tube consists of the intestine, whereas the outer tube comprises the 
collagenous cuticle, the hypodermis, musculature and nerve cells (Wood, 1988b).
1 .1.2 The biology of C. elegans
C. elegans is a simple organism that feeds primarily on bacteria and reproduces with a life 
cycle of only three days at optimal temperatures. The predominant sex is hermaphrodite, 
which can produce both oocytes and sperm. Hermaphrodites are able to self-fertilise or 
cross-fertilise with infrequently occurring males. Both, hermaphrodites and males are 
approximately 1 mm in length and 70 pm in diameter and can be easily distinguished 
under the light microscope (Riddle et al., 1997). The body wall and egg shell of C. elegans 
are transparent, which allows the precise observation of developmental processes and has 
contributed to the identification of exact developmental patterns (Sulston and Horvitz, 
1977; Sulston et al., 1983). The time from embryogenesis to hatching comprises about 14 
hours post-fertilisation. During this time about 550 cells are generated, such that the newly
19
hatching larva consists of 558 cells, which increase to 959 in the adult hermaphrodite and 
1031 in the adult male and are invariant from one animal to the next (Sulston and Horvitz, 
1977; Sulston et al., 1983). All juvenile worms proceed through four larval stages (LI to 
L4) and transition between the stages, termed moult, is characterised by the shedding of the 
old cuticle and production of a new one. A fifth form of larval stage, the dauer larva, has 
evolved as a means of long-term survival under suboptimal environmental conditions, such 
as lack of food or too high population density. When optimal growth conditions resume, 
the dauer larva moults to L4 and continues normal development through adulthood 
(Riddle, 1988).
1.1.3 The C. elegans genome
The genome of C. elegans comprises an approximately 100-megabase sequence, which 
encodes 19735 predicted protein-coding genes and more than 1300 non-coding RNA genes 
(Hillier et al., 2005; The C. elegans Sequencing Consortium, 1998). These are placed on 
five autosomes and one sex chromosome. The genome of wild-type N2 Bristol 
hermaphrodites consists of a diploid set o f autosomes and two sex chromosomes, whereas 
males possess 11 chromosomes comprising five pairs of autosomes and one sex 
chromosome. The hermaphrodite is the predominant form and males arise spontaneously 
through chromosomal non-disjunction of the X chromosome during meiosis (Wood, 
1988b). More than 40% of C. elegans genes show homology to other eukaryotes (Kamath 
et al., 2003) and many have been implicated in human diseases, such as cancer, 
cardiovascular or neurological disorders (Kamath et al., 2003; Rubin et al., 2000). 22% of 
C. elegans genes with homology to human disease genes are essential for C. elegans 
viability (Tu et al., 2006).
1.1.4 C. elegans anatomy
The complete C. elegans anatomy is known, mainly as the result o f electron micrographs 
of serial sections. Furthermore, the acquired knowledge of the cell division timing within 
each tissue contributed to the complete assignment of the C. elegans anatomy (Sulston et 
al., 1983). An introduction to the C. elegans anatomy is summarised below (mainly 
according to (White, 1988), see Figure 1.1, A). The cuticle forms the outermost surface of 
C. elegans and functions to maintain the body shape of the worm. It is mainly composed of 
collagen that is synthesised and secreted by the underlying hypodermis. A series of 
circumferential ridges (annuli) run along the length of the cuticle and two longitudinal 
ridges (alae) run along the lateral surface of the LI larva and the adult worm. These alae
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are synthesised by a specialised set of hypodermal cells, the seam cells. The hypodermis 
that is underlying the cuticle is syncytial, arising by cell fusion during development, and is 
generally divided into four groups, the main body syncytium (hyp-7), the seam cells, the 
hypodermal cells of the head and tail, and the interfacial hypodermal cells. The main 
function of the hypodermis is the secretion of the cuticle and elimination of cells that 
undergo programmed cell death. A basement membrane separates the hypodermis from the 
underlying body wall muscles, which are arranged into four stripes running the length of 
the animal.
The nervous system consists of 302 neurons in the adult hermaphrodite. It has a simple 
mainly unbranched morphology where processes are organised as bundles that run 
longitudinally along the ventral and dorsal midline of the animal. A nerve ring of 
circumferential bundles of processes surrounding the pharynx connects to the preanal 
ganglion in the posterior of the animal through a ventral cord that extends the length of the 
animal. The inner surface of the nerve ring comprises axons of motor neurons whereas the 
outside connects to muscle cells. Hence, the nerve ring functions to integrate sensory 
information from the head region to the body wall muscle cells.
C. elegans feeds through a pharynx in the anterior, which functions to ingest, concentrate 
and process food into the intestine. The pharynx is contained as a system of muscle-, 
epithelial- and nerve cells that are bounded by a basement membrane. The pharynx is 
connected to the intestine through a pharyngeal-intestinal valve. The intestinal cells are all 
generated during embryonic development. They form a tube of 20 cells that are arranged as 
an anterior quartet of cells (int-1) followed by eight posterior pairs of cells (int-2 to int-9) 
(for details see (1.2)). The major function of the intestine is to digest ingested material 
through secretion of digestive enzymes into the lumen and absorption o f digested material. 
Additionally, the intestine functions to nurture the germ cells by production of yolk 
proteins. The intestine is connected to the rectum via an intestinal-rectal valve. The rectum 
is contained of a set of three muscles that are controlling excretion.
During post-embryonic development, several sex-specific structures are formed leading to 
the structurally distinct development of the hermaphrodite and male gonad. The C. elegans 
adult hermaphrodite germline is a bilobed organ that expands anteriorly and posteriorly 
from the centre of the animal. Each gonad arm forms a U shaped structure that originates 
from a distal ovary into a loop that is connected to the oviduct followed by the 
spermatheca, the spermathecal valve and the uterus. The ovary consists of a germline 
syncytium where individual germline nuclei are generated that are each surrounded by a
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nuclear membrane but share a common cytoplasm (Hirsh et al., 1976). The germ cell 
nuclei are kept in a mitotic stage, due to the mitogenic influence of the distal tip cell 
present at the distal end of each ovary (Kimble, 1981). As the mitotic germ cells progress 
towards the oviduct they enter the meiotic cycle and complete cellularisation. The first 40 
germ cells, generated during the fourth larval stage, differentiate into 150 sperm whereas 
the remainder develop into oocytes (Hirsh et al., 1976; Ward and Carrel, 1979). The germ 
cell nuclei present in the loop are found in the pachytene stage and are kept in the 
diakinesis stage of meiosis I in the oviduct (Hirsh et al., 1976). As the oocytes mature and 
ovulate they enter the spermatheca where fertilisation occurs (McCarter et al., 1997; Ward 
and Carrel, 1979). The meiotic divisions complete before entry into the uterus (McCarter et 
al., 1999) where embryogenesis initiates.
C. elegans males contain a specialised tail, the copulatory bursa, that contains specialised 
muscles, neurons and hypodermal structures required for mating (Sulston et al., 1980). 
Males do not contain a rectum, but instead have a cloaca in the posterior ventral region of 
the animal. The male gonad is a single lobed U-shaped structure that consists of the testis, 
the seminal vesicle and the vas deference. The testis contains two distal tip cells, which 
maintain the germ cells in mitosis. All germ cells are connected through a rachis and as 
they enter into the seminal vesicle proceed through two meiotic divisions to form 
spermatids, which are stored in the seminal vesicle and are released via the vas deference 
and cloaca upon copulation (Hirsh et al., 1976).
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Figure 1.1 C. elegans anatomy and development. A) Anatomy o f  the C. elegans hermaphrodite (top) and 
male (bottom). Adapted from (Altun, 2005). B) Formation o f  founder cells during C. elegans early 
embnogenesis. Top: Formation o f  anterior-posterior polarity through the first mitotic cleavage o f  the zygote 
into AB and PI. Subsequent cleavages o f  PI into EMS and P2 provide the progenitor for endoderm (E). 
Adapted from (Gilbert, 2003), bottom: lineage tree o f  the five somatic founder cells AB, MS, E, D, C and the 
germ ine precursor P4 and their corresponding cell fates. Adapted from (Sulston et al., 1983).
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1.1.5 C. elegans embryogenesis
Embryogenesis, from fertilisation to hatching, takes about 14 hours at 20°C and is 
commonly divided into three stages: 1) zygote formation and determination of founder 
cells, 2) gastrulation and 3) morphogenesis. One important feature during early 
embryogenesis is the formation of five somatic founder cells and a germ line precursor 
through asymmetric cleavages (Figure 1.1, B). The somatic founder cells, termed AB, MS, 
E, C and D produce ectoderm (nervous tissue and hypodermis), pharynx (AB), mesoderm 
(MS), endoderm (E), mesectoderm (C) and body-wall muscles (D), respectively. The 
germline precursor is termed P4 and a sister blastomere of D.
After fertilisation in the spermatheca, the maternal pronucleus proceeds through the final 
stages o f meiosis I and II and extrudes two polar bodies in the anterior. At this point the 
eggshell becomes insoluble to most solutes through the synthesis of a vitelline membrane. 
Turbulent cytoplasmic movements together with contractions of the anterior cell 
membrane are followed by the initiation of a pseudo-cleavage furrow, which subsequently 
retracts. The egg pronucleus then moves towards the posterior end of the zygote to meet 
the sperm pronucleus. Upon meeting, a 90° rotation occurs and the nuclear envelopes 
break down. The formation of a mitotic spindle initiates the first asymmetric mitotic 
cleavage along the anterior-posterior axis into the two founder cells AB and PI. During the 
second division, AB divides equatorially and PI transversely to produce EMS and P2. 
Further cleavages result in the formation of E and MS from EMS and P3 and C from P2. 
P3 further divides to give rise to P4 and D (Figure 1.1, B). Gastrulation is initiated around 
130 minutes after fertilisation when the first two E cells move from the ventral side to the 
centre of the embryo. This time roughly coincides with the delivery of the egg to the 
exterior environment of the hermaphrodite. The inward movement of the two E cells 
creates a ring blastopore and movement of the P4 blastomere to the blastopore follows. 
Mesodermal cells subsequently move inward from the anterior side and are followed by 
the D, C and AB cells. Further cell divisions and movements occur until around 350 
minutes post-fertilisation, where cell proliferation ceases and morphogenesis begins. 
During this time the round egg develops into an elongated cylindrical worm that hatches at 
about 800 minutes post-fertilisation (see Figure 1.2; for a detailed description of 
embryogenesis see (Gilbert, 2003; Wood, 1988a)
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Figure 1.2 Timeline of C. elegans embryogenesis. Time-scale (left) o f  embryogenesis at 20°C from 
fertilisation to hatching. Developmental stages, according to the cell number, are depicted close to the right 
o f  the scale bar. To the right: Nomarski images o f  main developmental stages. Image from (Altun, 2005).
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1.2 Development of the C. elegans intestine
The C. elegans intestine offers an excellent model system to study cell proliferation, 
because it only consist of 20 cells that are clonally derived from the single progenitor cell 
E present in the eight-cell stage embryo (Sulston et ah, 1983). In the four-cell stage 
embryo, the asymmetric cleavage of the endomesodermal precursor EMS into MS 
(mesodermal precursor) and E (endoderm precursor) is one of the defining features of 
endoderm development and the result of an external signal of the EMS neighbouring cell 
P2 (for details see (1.2.2)). Once endoderm is specified, through formation of E from EMS, 
endoderm can develop independently of any surrounding tissues, as isolation of the E 
blastomere results in the formation of a complete intestine (Hermann et ah, 2000; Laufer et 
ah, 1980; Leung et ah, 1999). The specification of endoderm requires also an intrinsic 
signal of transcriptional activation through endoderm-specific genes (for details see (1.2.1).
Intriguingly, the divisions of the endodermal cells follow a precise timing and pattern that 
is invariant from one animal to the next and requires both symmetric and asymmetric 
cleavages, as examined by (Leung et ah, 1999; Sulston et ah, 1983). The lineage timing of 
intestinal cells is depicted in Figure 1.3. The first division of E occurs at the ventral surface 
of the embryo, in an anterior-to-posterior direction, to generate the Ea and Ep descendants. 
At the 26-cell stage of embryonic development, gastrulation is initiated and the two E 
descendants migrate into the interior of the embryo. This migration of Ea and Ep generates 
a ventral cleft. Subsequently, the two E descendants divide in a left-to-right direction to 
create four intestinal cells. This is followed by further anterior-to-posterior divisions and 
cell intercalation to generate 16 intestinal cells that are evident as two rows of eight cells at 
around 300 minutes post-fertilisation. At this time, three anterior cells (int-2 to int-4) 
generate a 90° twist with respect to the remaining intestinal cells. The three anterior cells in 
the right row move counter-clockwise to the left, whereas the three cells on the left row 
move clockwise to the right. This rotation requires the LIN-12 signalling pathway 
(Hermann et al., 2000) and increases to a further 180° in the hatching larva (Sulston and 
Horvitz, 1977). Thus, in the embryo, at around 300 min post-fertilisation, the developing 
intestine consists of 16 cells, 12 of which undergo no further cell division. Only four cells 
divide further, the anterior cells in a dorsal/ventral direction to generate an anterior quartet 
of cells and the posterior cells in the anterior/posterior direction.
At hatching, the intestine consists of a tube of 20 cells that is arranged as an anterior 
quartet of cells followed by eight posterior pairs of cells (Figure 1.3). During post-
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embryonic development only the 14 most posterior cells undergo one round of nuclear 
division early in the LI lethargus (Sulston and Horvitz, 1977) resulting in binucleate cells. 
All intestinal cells undergo one round of endoreduplication at each larval moult leading to 
a polyploidy of 32 N in the adult worm (Hedgecock and White, 1985).
In summary, development of the C. elegans intestine is the result of a careful interplay of 
cell extrinsic and intrinsic signals. At around 300 minutes post-fertilisation, the developing 
intestine consists of 16 cells, of which only four undergo one further division ultimately 
producing 20 cells. Hence, there is asymmetry in the cell division pattern of some sister 
cells. To date, a vast amount of information is available that identified the external and 
internal signals required for endoderm formation. However, it is equally as fascinating to 
unscramble the mechanism controlling the regulated cell division pattern during intestinal 
development on a molecular level.
The Johnstone laboratory has recently identified genes regulating the highly synchronized 
cell divisions of the E lineage, using a standard genetic approach of performing a mutant 
screen to detect animals with altered numbers of intestinal nuclei, facilitated by an 
intestinal-specific GFP marker. This revealed the identification of two alleles, cdc- 
25.1(ij48) and lin-62(ij52), both of which cause extra intestinal cells that are bom during 
embryogenesis (Clucas, 2003; Clucas et al., 2002). CDC-25.1 acts as a general cell cycle 
regulator, whereas LIN-62 has not been identified to date. This study will mainly focus on 
the molecular characterisation of CDC-25.1 and information about CDC-25.1 will follow 
in this introduction. However, to facilitate an understanding of the subject, the extrinsic 
and intrinsic signals that specify endoderm is firstly summarised below.
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Figure 1.3 C. elegans endoderm developm ent. Top: Lineage analysis o f  embryonic endoderm 
development. Vertical lines represent cleavages. Left: time after fertilisation. Between 200 and 300 minutes 
16 cells are born (numbers represent the intestinal position o f  each cell in the fully developed intestine). Only 
four cells undergo one further cleavage generating four int-1, two int-8 and two int-9 cells. To the right: 
embryo and larva to illustrate the position o f  endoderm cells. White circles represent positions o f  intestinal 
nuclei in the zygote (top) and larva (bottom), 300 min does not represent the larval stage, because the time o f  
hatching is beyond this time-scale. Bottom: schematic representation o f  the adult intestine. Intestinal numbers 
correlate with the numbers from the top lineage analysis, adapted from (Maduro and Rothman, 2002, Sulston 
etal. ,  1983, White, 1988).
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1.2.1 Cell autonomous endoderm specification in C. elegans
1.2.1.1 EMS specification through SKN-1
As mentioned above, C. elegans intestinal development is in part specified through cell 
autonomous signals. Several gene products have been identified that act intrinsically to 
determine PI-derived somatic founder cells (for a schematic outline see Figure 1.4, A). 
These proteins are maternally provided and termed SKN-1, PIE-1 and PAL-1. SKN-1 (skin 
excess), a bZIP/homeodomain transcription factor (Blackwell et al., 1994), is essential for 
EMS specification as skn-l(-) mutants result in loss of pharyngeal and intestinal cells that 
are normally produced from EMS daughter cells MS and E, respectively (Bowerman et al., 
1992). Instead, homozygous skn-l(-) mutants produce excess hypodermal cells from EMS, 
a fate that is normally produced from the EMS sister cell P2 (Bowerman et al., 1993; 
Bowerman et al., 1992). The function of SKN-1 is restricted to EMS only, though the 
protein is present in both EMS and P2 (Bowerman et al., 1993). This is achieved through 
the action of maternal PIE-1, a general transcriptional inhibitor (Batchelder et al., 1999; 
Seydoux et al., 1996; Tenenhaus et al., 1998), that is segregated to higher levels present in 
P2 (Mello et al., 1996; Seydoux et al., 1996; Tenenhaus et al., 1998) and shown to prevent 
SKN-1 activity in P2 (Mello et al., 1992). The C-like fate produced in EMS cells lacking 
skn-1 activity is due to the presence of PAL-1, a CAUDAL-like transcription factor 
(Hunter and Kenyon, 1996). PAL-1 is found in all PI-derived blastomeres and necessary 
for the specification of C fate. In wild-type EMS cells, PAL-1 activity is masked through 
SKN-1 activity, thus skn-1 (-) mutants produce a C-like fate due to the presence of PAL-1. 
Similarly, skn-1 /pal-1 double mutants produce no muscle cells, indicating that PAL-1 is 
required for C fate (Hunter and Kenyon, 1996).
However, SKN-1 protein is also present in C cells, but its activity is repressed through the 
action of the kinase GSK-3 (for glycogen synthase kinase, previously named sgg-1) 
present in the C blastomere (Maduro et al., 2001). Removal of both, gsk-3 and pal-1, by 
RNAi causes C to acquire an EMS-like fate (in which Ca and Cp adopt an MS and E fate, 
respectively) that depends on skn-1 activity (Maduro et al., 2001). This demonstrates that 
in the absence of gsk-3 and pal-1, SKN-1 can activate mesendodermal targets to induce 
EMS fate in C. Interestingly, removal of gsk-3 alone can give rise to E cells from an 
isolated P2 (Maduro et al., 2001) or C blastomere (Schlesinger et al., 1999), indicating that 
even in the presence of pal-1, but the absence of gsk-3, the blastomere C is able to induce 
endoderm probably from Cp as suggested in one study (Maduro et al., 2001).
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Figure 1.4 Schem atic representation o f C. elegans endoderm specification. A) Transcriptional cascade to 
specify endoderm. Arrow: activation, blocked arrow: inhibition. Maternal factors SKN-1, POP-1 and PAL-1 
are present in EMS and P2 descendants as indicated. The anterior o f  EMS activates SKN-1 dependent 
mesodermal genes, high levels o f  unsignalled POP-1 represses endoderm genes resulting in MS formation. In 
the posterior o f  EMS, SKN-1 activates the med genes that activate the end  genes. Wnt-signalled POP-1 can 
also activate end-1 and some PAL-1 can activate the end-1 genes (weak contribution indicated by dashed 
lines) producing endoderm. In the C lineage (derived from P2), SKN-1 activity is masked through the action 
o f  GSK-3, PAL-1 induces C-specific genes. B) The Wnt signalling pathway. MOM-1, -2 and -5 activate 
GSK-3 and orient the EMS mitotic spindle. GSK-3 and APR-1 induce WRM-1 nuclear localisation, whereas 
MOM-4 activates LIT-1. A WRM-l/LIT-1 complex phosphorylates POP-1 in E and reduces nuclear POP-1 
levels. Un-signalled POP-1 in MS represses E formation and induces mesoderm. Low nuclear levels of  
signalled POP-1 in E activates endoderm. Details are given in the text. Adapted from (Maduro et al., 2007, 
Maduro et al., 2005b. Maduro and Rothman, 2002, Nakamura et al., 2005, Thorpe et al., 2000).
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1.2.1.2 SKN-1 transcriptional targets vital for endoderm specification
Production of intestinal cells from EMS is in part the result o f transcriptional activation of 
endoderm-specific genes. Each transcriptional tier is tightly integrated into a cellular 
division. On top of this transcriptional cascade acts the SKN-1 protein. Direct targets of 
SKN-1 in EMS have been identified as med-1 and med-2 (mesendoderm determining), two 
nearly identical genes. The promoters of these genes contain several SKN-1 binding sites 
(RTCAT) and direct binding of SKN-1 to these sites in vitro has been demonstrated 
(Blackwell et al., 1994; Maduro et al., 2001). Furthermore, removal of med-1/2 by RNAi 
mimics the skn-1 (-) mutant phenotype. Expression of the med-1,2 mRNA is first detected 
in the EMS cell (Maduro et al., 2007) and a med-1 ::GFP transgenic reporter is present in 
the nucleus of the EMS, MS and E cells (Maduro et al., 2001). Ectopic expression of SKN- 
1 from a heat shock promoter causes widespread expression of MED-1 ::GFP (Maduro and 
Rothman, 2002). The med-1/2 genes encode GATA transcription factors that recognise 
specific sequence elements ((A/T)GATA(A/G)) present in the 5’ promoter sequence of 
their target substrates.
Downstream targets of the med genes are the end-1 and end-3 (endoderm determining) 
genes. MED-1 interacts with both end promoters in vivo and in vitro (Broitman-Maduro et 
al., 2005; Maduro et al., 2002) and ectopic MED-1 expression results in widespread 
expression of an END-1::GFP reporter (Maduro and Rothman, 2002). Furthermore, 
removal of skn-1, the upstream activator of the med genes by RNAi depletes end-3 mRNA 
from the embryo (Maduro et al., 2007). Ectopic expression of end-1 (Zhu et al., 1998) or 
end-3 (Maduro et al., 2005a) can induce endoderm expression and only simultaneous 
removal of both end-1 and end-3 by RNAi results in reduction of endoderm and a 
conversion of E into mesectodermal C fate (Maduro et al., 2005a). The end transcripts are 
first apparent in the E blastomere and persist up to the stage when two (end-3) (Maduro et 
al., 2007) or four (end-1) E cells are bom (Maduro et al., 2007; Zhu et al., 1997). 
Interestingly, at the 2E-cell stage the end-1,3 mRNA levels are higher in the posterior Ep 
descendant (Maduro et al., 2007).
Intriguingly, lack of skn-1 or med-1,2 result only in a semi-penetrant loss-of-endoderm 
defect, indicating that another pathway may contribute to the specification of endoderm. 
Indeed, concomitant loss of skn-1 by RNAi with pal-1 or the TCF transcription factor pop- 
1 cause a synergistic loss-of-endoderm defect. And concomitant removal of all skn-1, pop- 
1 and pal-1 by RNAi results in the complete loss of endoderm (Maduro et al., 2005b). 
Thus, POP-1 and PAL-1 can contribute to E specification. Binding of GFP::POP-l to
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transgenic end-3 and end-1 promoter sequences has been demonstrated in vivo (Maduro et 
al., 2002). Intriguingly, it has become evident that removal of end-3 and pop-1 cause the 
complete absence of end-1 mRNA transcripts in the 2E-cell stage embryo and a synergistic 
loss of endoderm (Maduro et al., 2007). This contrasts the finding that removal of pop-1 
alone causes elevated expression of end-1 mRNA is MS (Maduro et al., 2007) and 
misspecification of endoderm from the MS lineage (Lin et al., 1995). The explanation for 
this result is given by the fact that the EMS progenitor o f the E cell receives a Wnt signal 
from its posterior neighbour P2 in the four-cell stage embryo. This causes E to express low 
levels of Wnt-signalled POP-1, whereas MS possesses high levels of un-signalled POP-1 
that acts as a repressor of E fate (the Wnt signalling pathway is explained in (1.2.2.1)). 
Thus, END-3 and maybe PAL-1 and Wnt-signalled POP-1 can activate end-1 transcription 
in E.
The transient expression of the end transcripts suggested the presence of other endoderm 
determining genes in the C. elegans E lineage. Indeed, with elt-2 another GATA factor has 
been identified that is expressed in the intestine (Fukushige et al., 1998). ELT-2 was 
initially discovered through its ability to bind to the ges-1 promoter (Hawkins and 
McGhee, 1995), a gut-specific esterase that is present in all terminally differentiated 
intestinal cells (Edgar and McGhee, 1986; Kennedy et al., 1993). The elt-2 promoter 
contains several GATA binding sites (Fukushige et al., 1998) and ectopic expression of the 
end-1 (Zhu et al., 1998) or end-3 (Maduro et al., 2005a) genes result in widespread 
expression of ELT-2. Additionally, ectopic expression of ELT-2 results in the activation of 
its own promoter. ELT-2 protein is detected in the first two E descendants and persists 
until adulthood, thus auto-regulation can ensure constitutive expression in terminally 
differentiated intestinal cells (Fukushige et al., 1998). Global transcriptome analysis of 
intestine-specific genes revealed that GATA motifs are present in all promoters of 
intestine-specific genes, including digestive enzymes, stress response genes or proteases 
(McGhee et al., 2007).
1.2.2 External signals vital for endoderm specification
Apart from cell intrinsic regulations, cell-cell interactions have been described as essential 
for endoderm specification. (Goldstein, 1992) demonstrated that the EMS blastomere, 
isolated from an early four-cell stage embryo, gives rise to endodermal cells when it is 
recombined with its posterior sister cell P2, but not with the anterior sisters of EMS, 
termed ABa or ABp. This correlates with the finding that PI but not AB in isolation can 
induce E cell fate (Priess and Thomson, 1987). Interestingly, the entire EMS blastomere
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has the capability to respond to P2. When EMS is isolated from a four-cell stage embryo 
and its anterior half brought in contact with an isolated P2, the anterior half that would 
normally produce MS induces E formation (Goldstein et al., 1993). Thus, in the absence of 
P2 signalling the E lineage takes on the timing of cell divisions similar to the MS lineage 
(Goldstein, 1992; Goldstein et al., 1993). Signalling of P2 to EMS has to occur at a distinct 
timeframe of around nine to three minutes prior to cytokinesis in EMS in order to produce 
endoderm (Goldstein, 1995). Intriguingly, P2 has an intrinsic capability to induce 
endoderm formation. When SKN-1 activity is not repressed in the P2 blastomere, through 
an inactivating mutation in the transcriptional repressor pie-l(-), the isolated P2 blastomere 
has the capability to divide into MS and E (Goldstein, 1995). Furthermore, the P2-derived 
signal induces a spindle rotation in the EMS blastomere resulting in anterior-posterior 
polarity through asymmetric cleavage of EMS in the larger MS and a smaller E blastomere 
that is vital for specification of the endoderm fate (Schlesinger et al., 1999).
1.2.2.1 Wnt pathway components specify endoderm
The components of this P2-EMS signal have been identified and comprise a Wnt, a MAP 
kinase and Src signalling pathway that converge to induce endoderm formation in EMS 
(for schematic outline see Figure 1.4, B). First evidence evolved from mutant screens for 
production of more mesoderm, which identified several maternal factors, the mom genes 
(for more mesoderm), whose loss of activity promote lack of endoderm (Rocheleau et al., 
1997; Thorpe et al., 1997). In these mutants EMS produces only mesoderm instead of 
mesoderm and endoderm. The mom genes have been cloned and three genes show 
significant homology to members of the Wnt signalling pathway in other systems 
(Rocheleau et al., 1997). mom-4 has subsequently been identified as a member of the 
mitogen-activated kinase (MAPK) family (Meneghini et al., 1999). Additionally, reverse 
genetics led to the discovery of C. elegans wrm-1 (worm armadillo) and apr-1 (APC- 
related). RNAi against wrm-1 and apr-1 result in loss of intestinal cells from E, instead E 
produces pharyngeal tissue (Rocheleau et al., 1997). wrm-1 shows significant homology to 
human p-catenin (23% in the arm repeats), and apr-1 to the human tumour suppressor gene 
APC (adenomatous polyposis coli, 31% in the arm repeats), respectively (Rocheleau et al., 
1997). Furthermore, RNAi against a glycogen synthase kinase homologue, gsk-3 (formally 
sgg-1), also revealed a positive function in endoderm specification from EMS (Schlesinger 
et al., 1999). EMS spindle orientation, that is vital for correct partitioning of the MS and E 
potential, is abrogated in several mutant mom genes and after gsk-3 RNAi, probably 
accounting for some of the loss-of-endoderm potential. However, no obvious spindle 
defect was observed by RNAi against mom-2, mom-4, apr-1 and wrm-1, indicating that
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these genes are not involved in EMS spindle orientation (Schlesinger et al., 1999) and act 
to specify endoderm by other means.
Wnt signalling is a conserved pathway that has been described to contribute in multiple 
developmental processes, including cell proliferation, tissue polarisation and morphology 
or synaptic differentiation (Logan and Nusse, 2004). The canonical Wnt-signalling 
pathway results in the conversion of a transcriptional repressor TCF (T-cell factor) into an 
activator for expression of Wnt-specific target genes. Secretion of Wnt, a cysteine-rich 
glycoprotein ligand, causes cytoplasmic stabilisation o f P-catenin. In the absence of Wnt, 
p-catenin is rapidly degraded through the action of the glycogen synthase kinase GSK3P 
and C K la  in complex with APC and Axin. Stabilised P-catenin then shuttles to the 
nucleus where it forms a complex with the transcriptional repressor TCF converting it into 
an activator for the transcription of Wnt-specific target genes (Han, 1997; Kikuchi et al., 
2006; Logan and Nusse, 2004; Thorpe et al., 2000). Wnt target genes are very diverse and 
thus Wnt effects are likely to cause differential effects on target gene transcription.
In C. elegans, specification of endoderm fate follows a non-canonical Wnt signalling 
pathway. In this pathway, Wnt signalling from P2 requires the positive action of the 
putative destruction components GSK-3 and APR-1. RNAi against the C. elegans gsk-3 
(Schlesinger et al., 1999) and apr-1 (Rocheleau et al., 1997) result in loss of intestinal cells 
from EMS. Thus, in C. elegans the putative p-catenin destruction components gsk-3 and 
apr-1 are positively required for endoderm induction, which contrasts the canonical Wnt 
pathway where the presence of the Wnt signal inactivates the GSK-3/APC destruction 
complex. In C. elegans, wrm-1 (p-catenin) is positively required to induce endoderm, 
suggesting that GSK-3 and APR-1 do not act to degrade WRM-1 (Rocheleau et al., 1997). 
The precise mechanism by which GSK-3 and APR-1 act on WRM-1 is not known, but a 
recent study suggests that GSK-3 and APR-1 function are important to localise WRM-1 to 
the nuclear compartment in E but not MS (Nakamura et al., 2005).
1.2.2.2 The role of POP-1 in the Wnt pathway
Interestingly, a loss-of-function mutation in the TCF homolog pop-1 results in opposing 
phenotypes compared to gsk-3, wrm-1 or apr-1 RNAi. In pop-1 mutant embryos, both 
daughters of EMS adopt an E-like fate (Lin et al., 1995; Thorpe et al., 1997). Wnt 
signalling from P2 is required to induce asymmetric POP-1 localisation in MS and E. High 
nuclear POP-1 levels are evident in MS and low levels in E (Calvo et al., 2001; Lin et al., 
1998; Lin et al., 1995; Meneghini et al., 1999; Rocheleau et al., 1997; Rocheleau et al.,
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1999; Thorpe et al., 1997). A repressive function of POP-1 on endoderm fate has been 
illustrated. Inhibition of POP-1 activity in MS results in ectopic expression of end-1 ::GFP 
in MS (Calvo et al., 2001; Shetty et al., 2005). POP-1 can repress the expression of an end- 
1 promoter construct in tissue culture cells, probably through the binding of the histone 
deacetylase HDA-1 and UNC-37. RNAi against HDA-1 results in up-regulated expression 
of an end-1 ::GFP reporter in MS that is increased after concomitant unc-37 RNAi (Calvo 
et al., 2001).
Thus, high POP-1 levels in MS repress endoderm, whereas low POP-1 levels in E are 
required to release the repressive action of endoderm-specific genes in E and promote 
endoderm fate. POP-1 nuclear asymmetry requires the action of Wnt pathway components 
(Rocheleau et al., 1997; Thorpe et al., 1997). Similarly, inactivation of pop-1 is epistatic to 
inactivation of other Wnt components for endoderm production (Lin et al., 1998; 
Rocheleau et al., 1997; Rocheleau et al., 1999). Thus, POP-1 acts as the downstream 
molecule for P2-derived Wnt signalling to EMS and represses E fate in MS. However, 
further work revealed a positive function for POP-1 in transcriptional activation of 
endoderm genes in E as introduced below.
LIT-1 (loss of intestine) is another member of the MAPK pathway and involved in 
endoderm specification. A lit-1 mutant causes loss of intestinal cells and up-regulation of 
POP-1 in E cells (Rocheleau et al., 1999). Furthermore, WRM-1 (p-catenin) and LIT-1 co­
expression results in WRM-l/LIT-1 complex formation that phosphorylates POP-1 in 
mammalian tissue culture cells (Lo et al., 2004; Rocheleau et al., 1999). Phosphorylated 
POP-1 redistributes into the cytoplasm when co-expressed with WRM-1 and LIT-1 in 
mammalian cells (Lo et al., 2004; Rocheleau et al., 1999). Furthermore, in C. elegans 
embryos phosphorylated POP-1 is exported from the nucleus likely due to the action of 
WRM-1 and LIT-1 that are required for the phosphorylation of POP-1 (Lo et al., 2004). 
However, low POP-1 protein in E alone is not responsible for the activating function of 
POP-1 in E compared to MS. It has become apparent that POP-1 can activate endoderm- 
specific genes in E. As introduced in (1.2.1.2), one downstream target of POP-1 is the end- 
1 gene. When pop-1 RNAi is performed under conditions where the upstream 
transcriptional regulators of end-1 are depleted by RNAi, a complete loss of the end-1 
transcript and endoderm fate is visible, indicating that POP-1 can activate end-1 
transcription in E. Consistently, expression of an end-1 ::GFP promoter construct in 
endoderm cells requires the presence of POP-1, and furthermore, relies on an active Wnt 
signalling pathway (Shetty et al., 2005).
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In addition to the Wnt and MAPK pathways, mutations of the C. elegans Src pathway 
enhance endoderm defects of Wnt pathway components that act upstream of GSK-3, 
WRM-1 and POP-1 (Bei et al., 2002), probably in part through its function to orient the 
EMS spindle (Walston and Hardin, 2006).
Thus, the Wnt, MAPK and Src pathways co-operate in C. elegans endoderm specification 
to induce anterior-posterior polarity of the endoderm progenitor EMS blastomere. This is 
accomplished through asymmetric cleavage of the progenitor cell EMS into a larger cell 
MS and a smaller cell E that differ in their distribution of nuclear POP-1 proteins levels. 
High nuclear POP-1 levels repress endoderm fate in MS. Wnt signalling causes WRM- 
l/LIT-1 to phosphorylate POP-1, resulting in POP-1 nuclear export from E. However, a 
fraction of Wnt-modified nuclear POP-1 in E can activate endoderm fate (see Figure 1.4 
B).
To sum up, endoderm formation in C. elegans is a highly regulated process that requires 
the integration of at least two inputs, an internal transcriptional cascade that is coordinated 
with an external Wnt signalling pathway. Each transcriptional tier is integrated to another 
round of cell division. However, little data are currently available as to how cell division 
itself is controlled in this tissue. Gaining mechanistical insight into the proliferation of this 
tissue is therefore an important task.
Intriguingly, two separate cdc-25.1 gain-of-function alleles have previously been identified 
by two independent laboratories that trigger a tissue-specific hyperproliferation of 
intestinal cells (Clucas, 2003; Clucas et al., 2002; Kostic and Roy, 2002), highlighting the 
importance of CDC-25.1 for controlling the regulated cell division of the intestine in the 
embryo. However, a precise mechanism that unravels the control of CDC-25.1 in this 
tissue has been lacking in these studies. The cdc-25. l(ij48) hypermorphic allele has been 
identified in the Johnstone laboratory in a genetic search for genes that control the 
regulated pattern of intestinal cell divisions with the aid of an intestinal-specific GFP 
marker (Clucas, 2003; Clucas et al., 2002). Deciphering the molecular mechanism 
underlying the dysregulation of cdc-25. l( ij48) is vital to further the understanding of CDC-
25.1 control during embryogenesis and the focus of this study. Details on the known 
functions of CDC-25.1 will be introduced below.
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1.3 Intestinal cell proliferation is controlled by CDC-25.1
1.3.1 CDC25 function in eukaryotes
CDC-25.1 belongs to the family of CDC25 dual-specific phosphatases that act as positive 
regulators of the cell cycle (Ashcroft et al., 1998). The founding member of this family was 
identified in the fission yeast S. pombe as a temperature sensitive mutant that resulted in 
cell division defects (Fantes, 1979; Russell and Nurse, 1986). Subsequently, research on 
CDC25 in different model systems has expanded rapidly and broadened our understanding 
as to how the tight regulation of CDC25 maintains a functional division cycle. The 
eukaryotic cell-division cycle is a conserved highly regulated multi-step process that 
involves the careful interplay of numerous proteins that guide the cell cycle through a 
precise sequence of events, terminating with the production of two separate daughter cells 
(reviewed in (Schafer, 1998; van den Heuvel, 2005)). Vital to this process is the specific 
temporal activation of cyclin-dependent kinases (CDKs) and their regulatory subunits, the 
cyclins, that direct the somatic cell through specific morphological stages termed Gi 
(gapi), S (DNA synthesis), G2 (gap2) and M (mitosis) phase. However, gap phases are 
typically omitted during the rapid early embryonic cell cycles in C. elegans (van den 
Heuvel, 2005).
One of the hallmarks of cell cycle control is the specific activation of CDKs at distinct cell 
cycle stages. CDK activity is controlled by the action of several auxiliary proteins that 
phosphorylate CDKs on specific tyrosine and threonine residues, resulting in either 
activation or inhibition of the kinase. Furthermore, binding of cyclin to the kinase is a 
prerequisite for kinase activation such that degradation of cyclins at specific cell cycle 
boundaries, through the ubiquitination pathway, further enhances the directionality of cell 
cycle progression (Schafer, 1998; van den Heuvel, 2005). In metazoans phosphorylation on 
T14 and Y15 in CDK1 results in inactivation of CDK1 (Atherton-Fessler et al., 1994; 
Gautier et al., 1991; Norbury et al., 1991). This is achieved by the action of WEE1 (Y15, 
(Mueller et al., 1995)) or MYT-1 kinase (T14, Y15, (Kombluth et al., 1994)). The dual­
specific phosphatase CDC25 acts as a positive regulator of the cell cycle by 
dephosphorylating the inhibitory phosphates on T14 or Y15 in CDKs (Gautier et al., 1991; 
Honda et al., 1993; Sebastian et al., 1993). Additionally, CDKs can regulate CDC25 
function through phosphorylation creating a positive feedback loop (Hoffmann et al., 1993; 
Hoffmann et al., 1994; Izumi and Mailer, 1993). Mammalian cells have three different 
CDC25 counterparts (Galaktionov and Beach, 1991; Sadhu et al., 1990) that cooperate at
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different cell cycle stages (Boutros et al., 2006). Common to the CDC25 family members 
is a catalytic phosphatase domain present in their C-terminus. This region of the protein 
shares the highest homology between different family members, whereas the N-terminal 
part is far less conserved, suggesting it might act as a regulatory element (Sadhu et al., 
1990).
1.3.2 The C. elegans cdc-25 family
The C. elegans cdc-25 family consists of four genes, cdc-25.1 to cdc-25.4 that were 
identified by (Ashcroft et al., 1998) and are encoded on different chromosomes, cdc-25.1, 
2, 3 and 4 are positioned on linkage group I, V, III and II, respectively and thus appear not 
to have arisen from gene duplication. The exon/intron structures vary greatly and the 
encoded proteins differ in their length, cdc-25.1 is the largest protein comprising of 604 
amino acids, whereas cdc-25.2, cdc-25.3 and cdc-25.4 encode for 480, 316 and 372 amino 
acids, respectively. The overall sequence homology within this gene family is quite low 
and mainly comprises the phosphatase domain present in the C-terminus (in case o f CDC-
25.1 between aa 286 - 406), where the overall identity is 31% (Ashcroft et al., 1998).
Northern blot analysis revealed low mRNA expression levels of cdc-25.1 during the larval 
stages, but enhanced expression in young adult animals with proliferating germlines 
(Ashcroft et al., 1999). Furthermore, indirect immunofluorescence, using antibodies 
against CDC-25.1, revealed expression of CDC-25.1 in the two germline precursors during 
larval development (Ashcroft and Golden, 2002), the proliferating germline (Ashcroft et 
al., 1999; Clucas, 2003; Clucas et al., 2002) and in all early embryonic blast cells (Ashcroft 
et al., 1999; Clucas, 2003; Clucas et al., 2002; Kostic and Roy, 2002) (details on the 
staining are described in Chapter 5, (5.1.1)). However, the cdc-25.4 mRNA has not been 
amplified and the authors suggested that it could be possible that the protein is only 
transiently expressed during development (Ashcroft et al., 1998). The precise expression 
patterns for CDC-25.2 and CDC-25.3 in the embryo remain unknown. RNAi suggests a 
function of CDC-25.2 during embryo (Kamath et al., 2003; Simmer et al., 2003; 
Sonnichsen et al., 2005) and larval development (Ashcroft et al., 1999; Kamath et al., 
2003; Simmer et al., 2003). A cdc-25.3::GFP transgene was expressed in all embryonic 
nuclei beginning at the 24-cell stage (Ashcroft et al., 1999). However, RNAi against cdc- 
25.3 suggests that this protein may not be essential for C. elegans development (Ashcroft 
et al., 1999). Thus, it appears that in C. elegans multiple cdc-25 genes are expressed at 
different developmental stages and might control different aspects of C. elegans 
development.
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1.3.3 CDC-25.1 functions during post-embryonic development
RNAi against cdc-25.1 results in sterility of FI survivors that are derived from RNAi- 
treated mothers (Ashcroft and Golden, 2002; Ashcroft et al., 1999; Clucas, 2003; Clucas et 
al., 2002). Moreover, a deletion mutant of CDC-25.1 demonstrates the importance for 
zygotic expression of CDC-25.1 (Ashcroft and Golden, 2002). In homozygous cdc- 
25. J(nr2026) deletion mutants, proliferation of germ cells is inhibited resulting in sterile 
adults. However, unlike cdc-25.1 RNAi that results in embryonic defects (1.3.4), 
homozygous progeny that are derived from heterozygous mothers progress normally 
through embryogenesis and hatch, presumably due to the presence of maternally provided 
CDC-25.1 coming from heterozygous mothers (Ashcroft and Golden, 2002). Thus, zygotic 
expression of cdc-25.1 is important for germline proliferation. Consistent with this, CDC-
25.1 protein is detected in germline precursor cells during larval development (Ashcroft 
and Golden, 2002) and in the proliferating germline (Ashcroft et al., 1999; Clucas, 2003; 
Clucas et al., 2002).
1.3.4 CDC-25.1 functions during embryonic development
Pioneering work by (Ashcroft et al., 1999) first described an essential function for CDC-
25.1 during embryonic development of C. elegans. The authors demonstrated that cdc-25.1 
RNAi causes embryonic lethality with embryos arresting at around the 100-cell stage. 
Subsequent RNAi experiments against cdc-25.1 confirmed this result (Clucas, 2003; 
Clucas et al., 2002; Kostic and Roy, 2002), indicating that CDC-25.1 function is required 
in the early embryo. The detailed analysis by (Ashcroft et al., 1999) reported that cdc-25.1 
RNAi causes defects in the completion of meiosis in fertilised embryos, through aberrant 
meiotic spindle positioning and chromatin segregation defects, resulting in aneuploidy of 
the dying embryo. During the first mitotic division of the zygote, cdc-25.1 RNAi causes a 
mis-positioning of the mitotic spindle and a delay of the cell division timing compared to 
the wild-type. Furthermore, failures to execute the physical separation of cells 
(cytokinesis) in subsequent divisions became apparent. Besides the mainly nuclear 
localisation of CDC-25.1 in interphase cells o f all embryonic blast cells, the authors 
detected a specific cortical staining of CDC-25.1 in embryos and suggested a possible role 
for this protein in connecting the microtubule apparatus with the cell cortex during cell 
divisions. The nuclear and cortical staining was also later observed by the Johnstone 
laboratory (Clucas, 2003; Clucas et al., 2002). Immunocytochemistry demonstrated that 
wild-type CDC-25.1 is present in all embryonic blast cells up to the 28-cell stage (Ashcroft
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et al., 1999; Kostic and Roy, 2002) or the 100-cell stage (Clucas, 2003; Clucas et al., 
2002), indicating that the protein might be functionally required in several early embryonic 
blastomeres. Indeed, cdc-25.1 RNAi, using tissue-specific GFP markers for intestinal and 
hypodermal cells, displayed decreased numbers of both intestinal and hypodermal cells 
(Clucas, 2003; Clucas et al., 2002), indicating that the proliferation of at least two tissue 
types requires CDC-25.1 function.
1.3.5 cdc-25.1 mutants cause hyperplasia
The cdc-25. l( ij48) allele has been recently identified in the Johnstone laboratory in a 
mutant screen that was set out to identify genes acting downstream of E specification and 
controlling the regulated cell division pattern of intestinal cells during embryogenesis 
(Clucas, 2003; Clucas et al., 2002). The cdc-25. l(ij48) mutant phenotype is introduced 
below.
1.3.5.1 cdc-25.1 (ij48) is a gain-of-function allele
cdc-25. l(ij48) mutants cause an increase in the number of intestinal cells that are bom in 
the embryo, as evident by the use of an intestinal-specific GFP marker (elt-2::GFP), but 
also by examination of the intestinal cell lineage in the embryo, cdc-25. l(ij48) encodes a 
gain-of-function allele that acts in a strictly maternal pattern. Homozygous cdc-25. l( ij48) 
mothers produce offspring with 100% hyperplasia phenotype. However, heterozygous cdc- 
25. l(ij 48) mothers produce offspring with a hyperplasia phenotype that does not follow the 
Mendelian segregation where genetically wild-type animals display the hyperplasia 
phenotype. The spectrum of the hyperplasia phenotype in FI animals from heterozygous 
mothers ranged from 22 to 96% with an average of 76%. Furthermore, when the ij48 allele 
is crossed into wild-type hermaphrodites 100% of the FI offspring show the wild-type 
phenotype, consistent with the maternal behaviour o f this allele. This indicates that zygotic 
cdc-25.1 function in the embryo does not influence the embryonic hyperplasia phenotype. 
However, when the cdc-25. l( ij48) allele is placed over a deficiency, such that mothers 
carry only one copy of cdc-25. l(ij48), only 2.5% of the FI offspring display hyperplasia, 
indicating that lowering the gene-dose can suppress the phenotype. It was thus concluded 
that the cdc-25.1 (ij48) allele acts as a hypermorphic maternal effect mutation.
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1.3.5.2 cdc-25.1 (ij48) promotes tissue-specific hyperproliferation
Knockdown o f CDC-25.1 by RNAi in a wild-type strain results in decreased numbers of 
intestinal cells. When cdc-25. l( ij48) mothers are treated with cdc-25.1 RNAi the resulting 
progeny show some suppression of intestinal hyperplasia. The ij48 allele causes a true 
hyperplasia as, unlike the wild-type invariant pattern, in cdc-25. l(ij48) animals the pattern 
of intestinal cell divisions is very variable. There is a general shortening of the intestinal 
cell cycle, such that the fourth and fifth division occur considerably earlier than in the 
wild-type, and frequently a fifth and sixth division occur that are not evident in some of the 
wild-type cells. Other aspects of intestinal cell function are retained and the mutants are 
viable. The excessive proliferation caused through the ij48 mutation is specific to the 
intestinal cell divisions, as cell lineage analysis from a neighbouring blastomere D does not 
show any proliferation defects. Additionally, there appears to be no defect in germline 
proliferation or in the number of seam cells, as determined by Nomarski optics or a GFP 
marker that is specifically expressed in seam cells. Thus, wild-type cdc-25.1 is required for 
normal patterns of proliferation in several cell types and the ij48 mutant of cdc-25.1 is 
capable o f directing normal proliferation in all those cell types where it is required, 
however with exception of the intestine where it triggers a hyperplasia.
1.3.5.3 The cdc-25.1 (ij48) mutation and comparison to cdc-25.1 (rr31)
The ij48 lesion is located within the amino-terminal, putative regulatory, region of CDC-
25.1 and causes a serine to phenylalanine substitution at residue 46 in the encoded CDC-
25.1 protein, CDC-25.1(S46F). This residue falls within a motif that is conserved between 
CDC-25.1 and CDC-25.2 of C. elegans, but is not present in CDC-25.3 or CDC-25.4 and 
conserved between C. briggsae and C. elegans CDC-25.1, thus indicating the importance 
of this region for accurate CDC-25.1 function (Clucas, 2003; Clucas et al., 2002). 
Confirming the significance of this region for CDC-25.1 function, a cdc-25.1(rr31) allele 
has been independently identified in the Roy laboratory, cdc-25.1(rr31) causes a possibly 
identical intestinal hyperplasia phenotype and encodes a glycine to aspartic acid 
substitution (G47D) (Kostic and Roy, 2002). This allele is also a gain-of-function mutation 
(Kostic and Roy, 2002), but unlike the dysregulated pattern described for cdc-25. l(ij48) 
(Clucas, 2003; Clucas et al., 2002), cdc-25.1 (rr31) causes a synchronized pattern of cell 
divisions with one additional cell division occurring after the 8E-cell stage giving rise to 32 
intestinal cells (Kostic and Roy, 2002). The reason for the differential cell division defects 
caused through two very similar mutations in cdc-25.1 is presently unclear and requires 
further investigation to determine whether both phenotypes are different or not.
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The cdc-25.1(rr31) allele has been proposed to function at the G]/S transition during C. 
elegans intestinal development. This has been demonstrated through expression of GFP 
reporter constructs that are strongly expressed in cells entering S phase (Hong et al., 1998) 
and transient overexpression of wild-type and mutant CDC-25.1 in the adult hermaphrodite 
(Kostic and Roy, 2002). However, overexpression of cdc-25(rr31) failed to induce extra 
intestinal divisions under these experimental conditions and given the fact that CDC-25.1 
is not normally detected at this late stage, it remains to be identified whether this result 
truly reflects CDC-25.1 function in the embryo. RNAi experiments against the Gi type 
cyclin (cye-1) could repress intestinal hyperplasia of cdc-25.1 (rr31) in the embryo. Such 
repression was not observed with another Gi type cyclin (cyd-1), indicating that the cdc- 
25. l(rr 31) effect might act at the G|/S transition (Kostic and Roy, 2002). Intriguingly, 
these authors showed that Wnt signalling is required for the cdc-25.1(rr31) mutant 
phenotype.
Analysis of the cdc-25. l( ij48) mutation site revealed that it is part of a conserved DSG 
phosphodegron motif present in multiple eukaryotic proteins, including human CDC25A, 
whose abundance are regulated through this site by the ubiquitin ligase P-TrCP (for details 
see Chapter 3, (3.1.2.3)). It is therefore possible that the conserved region surrounding the 
site of the ij48 lesion may be a site of interaction with molecules that negatively regulate 
the activity of CDC-25.1, possibly specifically in the intestine. LIN-23, the C. elegans 
orthologue of mammalian 13-TrCP, was an interesting candidate, as lin-23 mutations caused 
increased nuclei during embryogenesis, but no intestinal-specific hyperproliferation 
phenotype has been published to date (Kipreos et al., 2000). However, preliminary 
experiments in the Johnstone lab (Dr. I.L. Johnstone pers. comm.) had detected increased 
numbers of intestinal nuclei in lin-23 RNAi-treated embryos, suggesting a possible role for 
LIN-23 in negatively regulating CDC-25.1. However, in their previous published study no 
difference in CDC-25.1(S46F) protein stability had been detected when compared to wild- 
type (Clucas et al., 2002), which contrasts the findings by the Roy laboratory, who reported 
that the CDC-25.1(G47D) mutant persists longer in embryos than the wild-type protein 
(Kostic and Roy, 2002).
1.4 Research aims and objectives
Here, the function of the cdc-25.1 (ij48) allele, generated in the Johnstone laboratory, is 
further explored in order to decipher the molecular mechanism underlying the tissue- 
specific regulation of cell divisions in the multicellular organism C. elegans. It was
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predicted that the cdc-25. l(ij48) allele escapes the negative regulation of at least one other 
factor, possibly in a tissue-specific fashion. Thus, a mixture of reverse genetics and 
biochemical approaches was utilised in order to identify negative regulators of CDC-25.1 
acting through S46.
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Materials and Methods
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2 Materials and Methods
2.1 Materials
All chemicals and other materials were purchased from the following commercial sources, 
unless otherwise indicated:
Abeam (http://www.abcam.com/). Abgene (http://www.abgene.com/). Amersham 
Biosciences (http://www.amersham.co.uk). Bio-Rad (http://www.bio-rad.com). Covalab 
(http://www.covalab.com). Difco (http://www.bd.com/industrial), Fisher Scientific 
(http://www.fisher.co.uk). Fluka (http://www.sigmaaldrich.com/), GibcoBRL Life 
Technologies (http://www.lifetechnologies.com). Invitrogen (http://www.invitrogen.com/), 
Menzel GmbH (http://www.menzel.de/). Mobitec (http://www.mobitec.de). Molecular 
Probes (http://www.probes.com). New England Biolabs (http://www.neb.com), Novagen 
(http://www.merckbiosciences.co.uk/). Pierce (http://www.piercenet.com), Promega 
(http://www.promega.com). Qiagen (http://www.qiagen.com). Roche 
(http://www.roche.com), Santa Cruz Biotechnology (http://www.scbt.com/), Schleicher 
and Schuell (http://www.schleicher-schuell.de). Sigma (http://www.sigmaaldrich.com). 
SNBTS (http://www.snbts.org.uk/), Stratagene (http://www.stratagene.com). Vector 
Laboratories (http://www.vectorlabs.com/).
2.1.1 Chemical Abbreviations
BSA bovine serum albumin
DAPI 4, 6-diamidino-2-phenylindole
DTT l ,4-dithiothreitol
DMSO dimethyl sulfoxide
DOC sodium deoxycholate
dH20 deionised water
EDTA ethylenediaminetetraacetic acid
EMS ethyl methanesulfonate
IPTG isopropyl P-D-1 -thiogalactopyranoside
LB Luria Bertani broth
NGM nematode growth medium
PBS phosphate-buffered saline
PBS-G phosphate-buffered saline-glycerol
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PBS-T phosphate-buffered saline-Tween 20
PIC protease inhibitor cocktail
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SWLB single worm lysis buffer
TBE tris borate EDTA
Tris-HCl 2-amino-2-hydroxymethyl-1,3-propanediol-hydrochloride
Tween 20 polyoxyethylenesorbitan monolaurate
WLB worm lysis buffer
2.1.2 Stock solutions and media
Blocking solution (lx): 5% dried milk powder in lx PBS-T. Made fresh before use.
Tris-Glycine (20x): 250 mM Tris base (30.28 g/L), l .9 M Glycine ( l 42.6 g/L) filled up to 
l L with dHiO. Stored at room temperature.
Blotting buffer (lx): 50 ml Tris-Glycine (20x), 20% (v/v) methanol, 0.01% (w/v) SDS, 
filled up to 1 L with dFLO. Made fresh prior to use. Pre-cooled at 4°C.
Bleach solution (lx): 2.5 ml 5 M KOH, 6 ml NaOCL (10-20%, Fluka) adjusted to 50 ml 
with dFLO. Made fresh prior to use.
Coomassie blue staining solution (lx): 1 g/L Coomassie brilliant blue R-250 (first 
solubilised in methanol), 45% (v/v) methanol, 10% (v/v) glacial acetic acid in dE^O. 
Filtered through Whatman no.l filter to remove non-solubilised particles. Stored in closed 
container at room temperature.
Destaining solution (lx): 20% (v/v) ethanol, 10% (v/v) glacial acetic acid in dE^O. Stored 
in closed container at room temperature.
DNA sample loading buffer (6x): 40% (w/v) sucrose, 0.02% (w/v) Xylene Cyanol, sterile 
filtered with 0.2 pm filter, aliquoted and stored at -20°C.
Ethidium bromide: 10 mg/ml stock in dfLO, final concentration 1 pg/ml in agarose gels. 
Stored at room temperature, protected from light.
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IPTG: 1 M stock in sterile dH20. Sterile filtered with 0.2 jam filter, aliquoted and stored at 
-20°C.
L-Broth: 1% (w/v) Bacto tryptone (Difco, Michigan, USA), 0.5% (w/v) yeast extract 
(Difco), 0.5% (w/v) NaCl in dH20. Autoclaved at 121°C and stored at room temperature.
L-Broth agar: as for L-Broth + 1.5 g/100 ml Bacto-agar (Difco). Autoclaved and 
subsequently cooled to around 60°C prior to addition of desired antibiotics (when 
required), poured with sterile technique onto plastic dishes, allowed to solidify and stored 
for short periods at 4°C.
M9 Buffer (lx): 20 mM KH2P 0 4, 40 mM Na2H P04, 80 mM NaCl, 1 mM MgS04. 
Autoclaved and stored at room temperature.
Na2EDTA: 0.5 M stock in dH20, adjusted to pH 8.0 with NaOH. Autoclaved and stored at 
room temperature.
NGM agar: 0.3% (w/v) NaCl, 2% agar (w/v) (Difco), 0.25% (w/v) peptone (Difco), 
0.0005% (w/v) cholesterol (1 ml/L of 5 mg/ml stock in ethanol) in dH20 . Autoclaved, then 
CaCl2 and M gS04 added to 1 mM final concentration (1 ml/L of 1 M stock solution) and 
potassium phosphate buffer pH 6.0 to 25 mM final concentration (25 ml/L 1 M stock) just 
prior to pouring plates. Solidified plates stored at room temperature.
NGM agarose: as NGM agar, but agar was substituted with agarose.
Phenol: for DNA manipulations, purchased liquefied (Sigma) and equilibrated with 10 
mM Tris HC1 pH 8.0,1 mM EDTA. For RNA manipulations, Phenol was purchased 
liquefied and saturated with 0.1 M citrate buffer, pH 4.3. Stored at 4°C.
Phenol/Chloroform: equal volumes of phenol (above) and chloroform:isoamyl alcohol 
24:1 were mixed. Stored at 4°C.
Phosphate buffered saline (lx  PBS): 1/10 dilution in dH20  of purchased aqueous lOx 
PBS (Gibco) to obtain a 137 mM NaCl, 2.7 mM KC1 and 10 mM phosphate buffer solution 
(pH 7.4 at 25°C).
PBS-G: as PBS with addition of 8.7% (v/v) glycerol. Stored at room temperature.
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PBS-T: as PBS with the addition of Tween 20 to a final concentration of 0.1% (v/v).
Stored at room temperature.
Potassium citrate (1 M): 210.1 g citric acid monohydrate in 900 ml dP^O, adjusted to pH 
6.0, by addition of KOH pellets, and filled up to 1 L with dH2 0 . Autoclaved and stored at 
room temperature.
Potassium phosphate buffer (1 M): prepared from 1 M KH2PO4 and 1 M K2HPO4 , mixed 
in appropriate ratio for desired pH. Autoclaved and stored at room temperature.
Proteinase K: 20 mg/ml stock in sterile dH2 0 . Stored at -20°C.
S-Basal: 100 mM NaCl (5.9 g/L), 50 mM potassium phosphate pH 6.0 (50 ml/L o f 1 M 
stock solution), 0.0005% (w/v) cholesterol (1 ml/L of 5 mg/ml stock in ethanol). 
Autoclaved and stored at room temperature.
Protease inhibitor cocktail PIC (50x): complete, EDTA-free protease inhibitor tablets for 
inhibition of serine and cysteine proteases (Roche) dissolved in d ^ O  (1 tablet/1 ml dH2 0 ) 
and stored at -20°C for a maximum of four weeks.
RNA lysis buffer (lx): 0.5% (w/v) SDS, 5% (v/v) beta-mercaptoethanol, 10 mM EDTA,
10 mM Tris pH 7.5, 0.5 mg/ml Proteinase K, stored at -20°C.
S-Medium: 10 mM Potassium citrate pH 6.0 (10 ml/L of a 1 M stock solution), 10 ml/L 
Trace metals, 3 mM MgSC>4 (3 ml/L of a 1 M stock solution), 3 mM CaCL (3 ml/L of a 1 
M stock solution) diluted in 1 L S-basal, using sterile technique, just prior to use.
Sodium dodecyl sulfate (SDS): 20% (w/v) stock solution in sterile dH2 0 . Stored at room 
temperature.
SDS sample loading buffer (2x): 125 mM Tris pH 6.8, 4% (w/v) SDS, 20% (v/v) 
glycerol, 0.03% (w/v) Bromophenol blue. Sterile filtered with 0.2 jam filter. 250 jal of beta- 
mercaptoethanol (14.3 M stock) added to 5 ml, stored at -20°C.
SDS running buffer (lOx): purchased from Bio-Rad. 250 mM Tris, 1.92 M Glycine, 1% 
(w/v) SDS. Stored at room temperature.
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Single worm lysis buffer (SWLB, lx): 50 mM KC1, 10 mM Tris (pH 8.3), 2.5 mM 
MgCb, 0.45% (v/v) Tween 20, 0.01% (w/v) gelatine. Autoclaved and stored in aliquots at 
-20°C. Proteinase K (Roche) added to 50 pg/pl prior to use.
Single worm PCR Taq buffer (lOx): 100 mM Tris (pH 8.3), 500 mM KC1, 15 mM 
MgCl2 , 0.01% (w/v) gelatine. Autoclaved and stored in aliquots at -20°C.
SOB medium (1L): 20 g Bacto-tryptone, 5 g Bacto-yeast extract, 0.5 g NaCl and 10 ml 
250 mM KC1 added to 960 ml d ^ O , the pH was adjusted to pH 7.0 with NaOH and the 
medium autoclaved. 10 ml of 1 M MgCb were added prior to use.
Sodium acetate (pH 5.2): 3 M Sodium acetate in dH2 0 . Adjusted to pH 5.2 with glacial 
acetic acid. Autoclaved and stored at room temperature.
SOC medium: 2 ml sterile 1 M glucose added freshly to 100 ml SOB before use. Stored in 
aliquots at -20°C.
TBE (lOx): 0.9 M Tris-HCl, 0.9 M Boric acid, 25 mM Na2EDTA pH 8.0 in dH2 0 . Stored 
at room temperature.
TE (lx): 1 mM EDTA, 10 mM Tris-HCl (pH as required) in dH2 0 . Autoclaved and stored 
at room temperature. TE at pH 8.0 was used for all DNA manipulations, unless otherwise 
stated.
Trace metals (lOOx): 5 mM Na2EDTA, 2.5 mM FeS0 4  7 H2 0 , 1 mM MnCl2 4 H2 0 , 1 mM 
ZnS0 4  7 H2O, 0.1 mM CUSO4 5 H2O in 1 L d ^ O . Sterile filtered with 0.2 pm filter, 
aliquoted in 50 ml conicals and stored at room temperature in the dark.
Tris-HCl: molarity and pH as required (pH adjusted with HC1). Autoclaved and stored at 
room temperature.
Worm lysis buffer (WLB, lx): 10 mM Tris pH 8.0, 100 mM NaCl, 10 mM EDTA, 1% 
(w/v) SDS, 1% (v/v) beta-mercaptoethanol, 100 pg/ml Proteinase K.
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2.1.3 Molecular weight markers
2.1.3.1 DNA markers
1 kb plus DNA ladder: 100, 200, 300, 400, 500, 650, 850, 1000, 1650, 2000, 3000, 4000, 
5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000 bp (Invitrogen).
2.1.3.2 Protein markers
Prestained Broad Range (6-175 kDa): 6.5, 16.5, 25, 32.5, 47.5, 62, 83, 175 kDa (New 
England Biolabs).
Prestained Broad Range: 6.9, 20.4, 29.4, 37.2, 53.5, 97.3, 115.6 kDa (Bio-Rad).
2.1.4 Vectors and plasmids
Name Description Use Source
pBluescript II SK(+/-) 
(pBS)
2 9 6 1 bp, Ampr, T7, T3 
and lac promoter
standard cloning, 
C. elegans DNA  
transformation
Stratagene
L4440
2790 bp, Ampr, two T7 
promoters in opposite 
directions
RNAi by feeding gift from A. Fire
pQE-30
3481 bp, Ampr, T5 
promoter, lac operator, 
N-terminal 6xHis tag
recombinant protein 
expression in bacteria
Qiagen
PQE-80L
4700 bp, Ampr, T5 
promoter, lac operator, 
N-terminal 6xHis tag, 
lacf1 gene
recombinant protein 
expression in bacteria
Qiagen
pREP4
3740 bp, Kanr, lacl 
gene
recombinant protein 
expression in bacteria
Qiagen
pGEX-6P-l
4984 bp, Ampr, tac 
promoter, N terminal 
GST tag, lacf1 gene
recombinant protein 
expression in bacteria
Amersham Biosciences
pIC26
16397 bp, Ampr, pie- 
1 ::GFP-TEV-S, unc- 
119(F)
LAP tag cloning gift from I. Cheeseman
p76-!6B
Ampr, 10.7kb, unc- 
76(+)
marker for C. elegans 
DNA transformation
gift from L. Bloom
Table 2.1 Common vectors and plasmid clones.
A. Fire (S tan fo rd  University S choo l  of Medicine, S tanford ,  USA), I. C h e e s e m a n  (Ludwig Institute for 
C a n c e r  R e s e a r c h ,  La Jolla, USA) a n d  L. Bloom (Phy los  Inc., Lexington, USA).
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2.1.5 Oligonucleotides
2.1.5.1 Vector oligonucleotides
Name Sequence (5’->3’) Use
M 13 reverse CAGGAAACAGCTATGACC sequencing, colony screening
T3 AATTAACCCTCACTAAAGGG sequencing, colony screening
T7 GTAATACGACTCACTATAGGG sequencing, colony screening
pQE for GTATCACGAGGCCCTTTCGTCT sequencing, colony screening
pQE rev CATTACTGGATCTATCAACAGGAG sequencing, colony screening
pGex for ATAGCATGGCCTTTGCAGG sequencing, colony screening
pGex rev GAGCTGCATGTGTCAGAGG sequencing, colony screening
pL4-3’ GTGCTGCAAGGCGATTAAGTTG sequencing
Table 2.2 Vector oligonucleotides.
2.1.5.2 Oligonucleotides for cdc-25.1
Name Sequence (5’~>3’) Use
25seq600 CACAGAGTGACAAATCTTGTC sequencing
2 5 S e q l100 AGAAAACGGCGAAGCCAGTT sequencing
25Seql400 GTGCTTT AACCTCT ACTGGA AG sequencing
LapSeq TGTAACAGCTGCTGGGATTAC sequencing
25-343seq GAGCTGCGTGATGAGCTGACAGAC sequencing
Elt2xho2 TTTTCTCGAGCGAGCTGAATACACGTGCT
pBS-elt-2v.LAP:: cdc- 
25.1 cloning
Elt-2Bam TTTTGGATCCTCTATAATCTATTTTCTAGTTTC
pBS-elt-2r.LAP::cdc- 
25.1 cloning
25gBam TTTTGGATCCGCTACCACCGGGGAAAAAGC
pBS-elt-2:: LAP:: cdc- 
25.1, pQE-30-cdc-25.1 
cloning
25gXba TTTTTCTAGAGCTGAGATTAATGTGAACGC
pBS-elt-2::LAP::cdc- 
25.1 cloning
25cSac TTTTG AGCTCTT ATTCGGCGTCGTCAG A A AT
pQE-30-cc/o25. /  
cloning
25.1-Ty-sens GATCATGGAGGTCCATACTAACCAGGATCCACTTG
ACC
pBS-elt-2::TY: :cdc-25.1 
cloning
25.1-Ty-as GATCGGTCAAGTGGATCCTGGTTAGTATGGACCTCC
AT
pBS-elt-2::TY::cdc-25.1
cloning
25.1Notagsen GATCGCTGCAGGATCATGC
pB S-elt-2: \cdc-25.1 
cloning
25.1Notagas GATCGCATGATCCTGCAGC
pBS-elt-2::cdc-25.1 
cloning
Table 2.3 cdc-25.1 oligonucleotides.
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2.1.5.3 Oligonucleotides for lin-23
Name Sequence (5’->3’) Use
I in-23-473 CAGTGCGACGAATCTGTGAA sequencing
lin-23-%14 GGAGAGTGCATTAAAACGTTAA sequencing
I in-23 -1281 CGTGCGATGCATTCGATTTG sequencing
lin-23-1683 CTGCTCGTCGACACAATGCC sequencing
lin-23 prom CTCACCTGATTATATGAGATC sequencing
lin-23-Fig TTTT ACT AGTCTTGTCGTCGTCATCCTTGT AGTCTGG 
GCCACCATCTGGCATCTCTTC
pBS-lin-23: :Flag-TY 
cloning
lin-23 tag5 CGACGAGGAATTGCATGTCTTC pBS-lin-23 ::FLAG-TY cloning
lin-23-TY TTTTACTAGTGAGGTCCATACTAACCAGGACCCACT 
TG ACT A A A ATCT AC ACTCCTTCCC ATTTT
pBS-lin-23::FLAG-TY
cloning
lin-23-5'1 gen TTTTGGTACCCCAAATTTGCCTCTGATTCCG pBS-lin-23 (genomic) 
cloning
///7-23-3’gen TTTTGGTACCGTTGCAGAAATGCTCAAATCGG
pBS-lin-23 (genomic) 
cloning
//>?-22-GSTfl TTTTCCCGGGTTCTTCACCGCACCGAGCTTCAAC
pG EX-6Pl-/w-2J
cloning
lin-23-G STdf TTTTCCCGGGTCATGTCTTCTACAGTAAATTATATC
CA
pGEX-6Pl-/w-23zJ F- 
box cloning
I in-2 3- 
GSTSTP TTTTCCCGGGTTATGGGCCACCATCTGGCATCTC
pG EX-6 PI -lin-23 wt 
and A F-box cloning
lin-23 crssgen GGAGTGTAGATTTTATGGGC PCR screening o f lin-23 
allele in C. elegans
Table 2.4 lin-23 oligonucleotides.
2.1.5.4 Oligonucleotides for RNAi clones
Name Sequence (5’->3’) Use
lin-23-RNAi5’ TTTTG A ATTCTCATT AGTTCA AC AT ACTGGC L4440 cloning o f  lin-23 
RNAi clone 2
//>7-2J-RNAi3’ TTTTGAATTCGGAAGATTACAGAGGGTTTG L4440 cloning o f  lin-23 
RNAi clone 2
cul-2-5 TTTTGAATTCTGCAGATTCCAGACGTCAA L4440 cloning o f  cul-2
cul-2-3 TTTTG AATTCTCCAAATCCGTCTCCGATA L4440 cloning o f  cul-2
apr-1-5 ’ GAATCCTGGAAGTGTTATGAC L4440 cloning o f  apr-1
ii GATGATTGGCTTGGGATTCTG L4440 cloning o f  apr-1
wrm-l-5 GGATTGTCAATGCTCTCAGTC L4440 cloning o f  wrm-1
wrm-1-3 TTTTGAATTCGATCATTCTACACGCTGATAC L4440 cloning or wrm-1
bar-1-5 TTTTGAATTCGCAGGATCTCGGAAAACAAA L4440 cloning o f  bar-1
bar-1-3 TTTTG AATTCATTCGTTGCACTTTGGGAAC L4440 cloning o f  bar-1
Table 2.5 RNAi oligonucleotides.
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2.1.6 Strains
2.1.6.1 E. coli strains
Strains were obtained as indicated. CGC (Caenorhabditis Genetics Centre, University of 
Minnesota, Minneapolis, USA), M. Stark (University of Glasgow, Glasgow, UK).
Strain name Use Antibioticresistance Source
AB1157 food source for C. elegans (liquid culture) Strpr
gift from M. 
Stark
OP50 food source for C. elegans, uracil auxotroph Tetr CGC
HB101 food source for C. elegans (liquid culture) Strr Promega
HT115 (DE3)
DE3 lysogen: lacUV5 promoter-T7 
RNA polymerase (IPTG-inducible 
T7 RNA polymerase), RNAse III 
minus; production of double­
stranded RNA for RNAi by feeding
Tetr CGC
Epicurian Coli 
XL 10 Gold 
ultracompetent 
cells
molecular cloning TetR, CamR Stratagene
BL21 Codonplus 
IRL competent 
cells
protein expression from IPTG- 
inducible non-T7 promoters 
(containing lac operators); contains 
rare E. coli tRNA codons: R (AGA, 
AGG), I (AUA), L (CUA)
TetR, CamR Stratagene
Table 2.6 E. coli strains.
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2.1.6.2 C. elegans strains
Strains were obtained from the CGC, I.L. Johnstone (University of Glasgow, Glasgow, 
UK), J. Rothman (UC Santa Barbara, Santa Barbara, USA), O. Hobert (Columbia 
University, New York, USA), P. Askjaer (Seville University, Seville, Spain) and J. White 
(University of Wisconsin, Madison, USA).
Strain name Genotype Source
N2 C. elegans wild-type (Bristol variant) CGC
IA105 unc-76(e911) V; ijls 12[dpy-7::GFP::LacZ, unc- 76(+)J (ectodermal GFP) I.L. Johnstone
JR1838 wls84[pJM66 (elt-2:: GFP::LacZ), pRF4(rol-6 (sul 006dm)] (intestinal GFP) J. Rothman
JR1990 w7s7 7£/pDPMM0 16B unc-119(+), pMW025 (npa-1:: GFP:: LacZ)J J. Rothman
JR1988 w lsl 19[pDPMM016B unc-lJ9(+), pMW025 (npa-1: :GFP:: LacZ)] J. Rothman
JR667 unc-119(e2498::Tcl)III; wIs51[pMFl, pDP#MM106B unc-119(+)] (seam cell GFP) CGC
NL2099 rrf-3(pkl 426)11 CGC
DR439 unc-8(e49) dpy-20(el282)IV CGC
DR96 unc-76(e911)V CGC
IA268 cdc-25.1 (i]48)l I.L. Johnstone
IA123 cdc-25.1 (ij48)I; unc-76(e911) ijIslO[unc-76(+), cpr-5::GFP::LacZ]V  (intestinal GFP) I.L. Johnstone
IA257 lin-62(ij52)IV; ijIslO[unc-76(+), cpr- 5::GFP::LacZ]V  (intestinal GFP) I.L. Johnstone
IA399
cdc-25.1 (nr2036)/dpy-5(e61)unc-l 3(e450)l; 
i]Ex36[cdc-25.1(ij48), wIs84(p3M66 elt- 
2: :GFP:: LacZ, genomic DNA) ]
I.L. Johnstone
OHT1707 [lin-23::GFP, rol-6(d)J 0 . Hobert
CB3514 lin-23 (e l883)/dpy-10 (el 28) 11 CGC
DP38 unc-119(ed3)Ul CGC
IA331 lin-62(i]52)IV I.L. Johnstone
XA3507 unc-119(ed3) qals3507[pie-1 ::GFP::lem-2 unc- 119(+)JIII
P. Askjaer
WH204 unc-119(ed3) II; o jlsl[p ie-1 : :GFP: :beta-tbb-2, 
unc-119(+)J
J. White
Table 2.7 Common C. elegans strains.
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2.1.6.3 C. elegans strains generated in this study
Strain name Genotype
IA521 unc-76(e911)V; i]Ex30]elt-2::LAP::cdc-25.1(+), p76-16B unc-76(+)J
IA522 unc-76(e911)V; ijEx31 [elt-2::LAP::cdc-25.1(+), p76-16B unc-76(+)J
IA523 unc-76(e911)V; ijEx32[elt-2::LAP::cdc-25.1(ij48), p76-16B unc- 76(+)J
IA524 unc-76(e911)V; ijEx33[elt-2::LAP::cdc-25.1(ij48), p76-16B unc- 76(+)]
IA526 lin-62(ij52)IV; wls84[pJM66 elt-2::GFP::LacZ, pRF4 rol-6 (sul 006dm)]
IA530 cdc-25.1 (ij48)I; wls84[pJM66 elt-2::GFP::LacZ, pRF4 rol-6 (sul 006dm)]
IA535 ijIsl6[elt-2::LAP::cdc-25.1(+), p76-16B unc-76(+)]
IA536 ijIsl7[elt-2::LAP::cdc25.1(i]48), p76-16B unc-76(+)J
IA544 lin-62(i]52)IV; w lS l7S/pDPMM016B uncll9(+), pMW025 (npa- 1 ::GFP:: LacZ)]
IA545 lin-62(i]52) dpy20 (el282)lV; wIs84[pM 66 elt2::GFP::LacZ, pRF4 rol-6(su1006dm)]
IA551 lin-23(el883)+/+ dpy-10(e l28)11; unc-119(ed3)UI
IA559 unc-76(e911)V; ijEx34[elt-2::cdc-25.1 (+), p76-16B unc-76(+)]
IA560 unc-76(e911)V; i]Ex35[elt-2::cdc-25.1 (+), p76-16B unc-76(+)]
IA565 lin-23(el883)7+11; wls 119ft>DPMM016B unc-119(+), pMW025 (npa- 1 ::GFP:: LacZ)]
IA568 lin-23 (e l883)/+I; wIs84[pM 66 elt-2: :GFP::LacZ, pRF4 rol-6(su 1006dm)]
IA575 ij Ex 3 6 [cdc-25.1 (i]48), w Is 8 4 [pJM66 elt-2: :GFP:: LacZ, genomicDNA ]
IA577 lin-62(i]52) dpy-20(el282)lV; w/.Syy^/'pDPMMO^B unc-119(+), pMW025 (npa-1 ::GFP::LacZ)J
IA582 unc-119(ed3)III; ijls 18 [lin-23:.FLAG-TY, unc-119(+)]
IA585 lin-62(i]52)dpy-20 (el282)IV; i]Ex36[cdc-25.1(i]48), w ls84[pm 66  elt-2::GFP::LacZ, genomicDNA]
IA589 lin-23 (e l883)11; unc-119(ed3)IIl; ijIS 18 [lin-23:: FLAG-TY, unc- H9(+)J
IA592 lin-23 (e l883)11; ijISIS [lin-23::FLAG-TY, unc-119(+)], w ls84[pM 66  elt2:: GFP:: LacZ, pRF4 rol-6 (sul 006dm)]
IA593 cdc-25.1 (ij 48)1; lin-23 (e l883)11; ijISl 8 [lin-23:: FLAG-TY, unc- 119(+)J, wls84[pJM66 elt2:: GFP:: LacZ, pRF4 rol-6 (sul 006dm)]
Table 2.8 C. elegans strains created in this study.
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2.1.7 Antibodies
2.1.7.1 Primary antibodies
Name Species Antigen Dilution Source
CDC-25.1A rabbit,polyclonal
peptide of aa 495-509 
of C. elegans CDC- 
25.1 (CE11778)
1:150 (IIF) 
1:400 (WB) I.L. Johnstone
CDC-25.1B rabbit,polyclonal
peptide of aa 592-604 
of C. elegans CDC- 
25.1 (CE11778)
1:400 (WB) I.L. Johnstone and this study
CDC-25.1 f.l. rabbit,polyclonal
HIS6::CDC-25.1 
C. elegans (CE11778)
1:600 (WB) 
40 pg (IP) this study
LIN-23 rabbit,polyclonal
GST-LIN23 
C. elegans (CE28600)
1:750 (WB) 
1:600 (IIF) this study
GSK3B
(G4414)
mouse,
monoclonal
recombinant rabbit 
GSK3p, recognises 
C. elegans GSK-3 
(CE21401)
1:500 (WB) Sigma
P-ACTIN
(AC-15,
A1978)
mouse,
monoclonal
peptide of N-terminal 
15 aa of P-ACTIN, 
recognises several 
species including C. 
elegans P-ACTIN
1:2000 (WB) Sigma
GFP
(ab6556)
rabbit,
polyclonal recombinant GFP 4 pg per IP Abeam
UBIQUITIN
(MMS-257P)
mouse,
monoclonal
denatured bovine 
ubiquitin 1:1000 (WB) Covance
GFP
(B-2,sc9996)
mouse,
monoclonal
full-length Aequorea 
victoria 1:300 (WB) Santa Cruz
Table 2.9 Primary antibodies.
2.1.7.2 Secondary antibodies
Name Conjugate Dilution Source
goat anti-mouse 
HRP
horseradish
peroxidase 1:2000 (WB) Promega
donkey anti-rabbit 
HRP
horseradish
peroxidase 1:2000 (WB) Amersham
Alexa Fluor goat 
anti-rabbit Alexa Fluor 594 1:200 (IIF) Invitrogen
Alexa Fluor goat 
anti-mouse Alexa Fluor 488 1:200 (IIF) Invitrogen
Table 2.10 Secondary antibodies.
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2.2 Methods
2.2.1 Standard molecular biology techniques
2.2.1.1 DNA preparation
DNA was amplified using the Plasmid Mini, -Midi or -Maxi kits from Qiagen according to 
the manufacturer’s instruction. Briefly, E. coli strains carrying the desired plasmid DNA 
were grown in liquid culture overnight at 37°C (see 2.2.1.9). In case of low-copy plasmids 
(e.g. pQE-30, pQE-80L) Maxi kits were employed, whereas high-copy plasmids 
(pBluescript) were purified using the Midi kit. The Mini prep kit was utilized for E. coli 
colony screening after transformation of DNA ligation reactions. The culture volume was 
250 ml, 100 ml or 2 ml for Maxi-, Midi- or Mini kit, respectively. To enhance the purity of 
the DNA, the DNA pellet that was precipitated after elution from the columns provided 
with the kit, was further purified. To this end, the DNA pellet was resuspended in 200 pi 
lx TE and spun for 5 min at 13200 g  at room temperature in a microcentrifuge. The 
supernatant was precipitated by addition of 20 pi 3 M sodium acetate pH 5.2 and 600 pi 
100% ethanol, mixed by inversion and immediately spun at 13200 g  for 5 min at room 
temperature in a microcentrifuge. The resulting pellet was resuspended in lx  TE and kept 
at -20°C
2.2.1.2 DNA/ RNA electrophoreses
DNA was routinely separated on 0.8 - 1.5% (w/v) agarose gels in 0.5x TBE. Agarose 
(Invitrogen) was suspended in 0.5x TBE and heated in a microwave until dissolved. The 
mixture was allowed to cool down to around 60°C and ethidium bromide added to a final 
concentration of 1 pg/ml. The gel was poured into a 11 cm or 15 cm gel-tank (GIBCO), 
containing appropriate size combs, and allowed to solidify. The DNA was dissolved in lx 
DNA sample buffer and applied to the wells of the gel. The samples were electrophoresed 
in 0.5x TBE at 10 - 15 V/cm. To obtain highest resolution, large DNA fragments were 
applied to 0.8 - 1% agarose gels whereas small fragments resolved best at high percentage 
(1.5 - 1.8%) agarose gels. The DNA was compared to a known DNA Marker and images 
were taken using a Transilluminator (Bio-Rad) and Quantity One software (Bio-Rad).
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2.2.1.3 PCR
PCR reactions for cloning purposes were performed using PfuTurbo Polymerase 
(Stratagene). However, in some cases TaqPlus Precision Polymerase (Stratagene) had to be 
utilised to generate a product. In each case a 50 pi reaction was set up containing lx 
reaction buffer, 100 ng of each primer, 100 ng of plasmid DNA or 200 ng of C. elegans 
genomic DNA, 400 pM dNTPs and 2.5 units of PfuTurbo Polymerase or 5 units of 
TaqPlus Precision Polymerase. Amplification was performed using a RoboCycler 96 
(Stratagene). Cycling parameters were modified according to the annealing temperature of 
the primer and the length of the fragment to be amplified. A typical starting point is shown 
in (Table 2.11).
Segment Temperature (°C) Time (min) No. of cycles
1 95 1 1
2 95 0.5
50 0.5-1 28
72 2/kb (Pfu) 
1/kb (Taq)
3 72 10 1
Table 2.11 Cycling parameters for PCR amplification. 
2.2.1.4 RT-PCR
RNA isolated as in (2.2.6.2) was employed to generate cDNA using the Stratascript 
FirstStrand synthesis system (Stratagene) according to the manufacturer’s instruction. 
Typically, around 200 - 400 ng of total RNA was annealed with 500 ng of oligo (dT) 
primer in a total volume of 11 pi and incubated at 65°C for 5 min. The reaction was 
allowed to cool to room temperature and lx  FirstStrand buffer, 20 units RNAse Inhibitor, 1 
mM dNTPs and 50 units Stratascript Reverse Transcriptase were added in a final volume 
of 20 pi. The mixture was incubated at 25°C for 10 min, followed by 1 hr at 42°C, and the 
reaction terminated at 70°C for 15 min. Typically, 2 - 4 pi of cDNA were added in a 50 pi 
PCR reaction using 100 ng of gene-specific primers. PCR reactions were performed 
according to (2.2.1.3).
2.2.1.5 Digest and purification of DNA fragments
Purified DNA was digested with restriction endonucleases from New England Biolabs 
(NEB) or Promega. For vector digestion, typically 1.5 pg of vector was digested with 10 
units o f restriction enzyme in a 50 pi reaction containing lx  restriction buffer and 100
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jj.g/ml BSA. The mixture was incubated for 2 hr at the temperature recommended by the 
enzyme manufacturer. The cut vector was separated by agarose gel electrophoreses; the 
band cut out and purified using the Qiaquick gel extraction kit (Qiagen) according to the 
manufacturer. The cut vector was routinely dephosphorylated using 2 units CIP (NEB) in 
reaction buffer 2 (NEB) for 45 min at 37°C. The dephosphorylated vector fragment was 
purified using the Qiaquick PCR purification kit (Qiagen).
Insert fragments were produced by digestion of 8 pg plasmid DNA with 30 - 40 units of 
restriction enzyme in a 100 pi reaction for 2 hr at enzyme-specific temperature. The 
fragments were purified from an agarose gel using the Qiaquick gel extraction kit 
(Qiagen).
PCR fragments were purified after gel electrophoreses using the Qiaquick gel extraction 
kit. Typically, the entire PCR reaction was cut with 30 - 40 units of enzyme in a 200 pi 
reaction for 2 hr (temperature enzyme-specific). The digested PCR fragments were further 
purified using the Qiaquick PCR purification kit.
2.2.1.6 Nucleic acid quantification
Nucleic acids were quantified using a GENOVA spectrophotometer (Jencons, 
http://www.iencons.co.uk/). DNA/RNA was diluted 100 times in dELO and the OD260/280  
determined. An OD2 6 0 /280 ratio of 1.8 and 2.0 indicates good quality DNA or RNA, 
respectively. The nucleic acid concentration was determined using the formula:
Abs2 6o x dilution factor x 50 (DNA) or 40 (RNA) = ng/pl
For visual determination of DNA fragments (typically used for ligations), 2 pi DNA was 
applied on agarose gel together with 500 ng of DNA molecular weight marker. The 
concentration of fragments was estimated according to the following formula:
DNA size (kb) x 500 ng / 80 (kb) = ng/2pl
2.2.1.7 DNA ligation
Ligation reactions were carried out using 10 - 20 ng of digested and dephosphorylated 
vector (see 2.2.1.5) and a 5-fold molar excess of insert-to-vector concentration according 
to the formula:
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i) size of vector (kb) / size of insert (kb) = Y
ii) ng of vector / Y x 5 = ng of insert
Vector and insert were mixed together in lx  T4 DNA ligation buffer (NEB) and 400 units 
T4 DNA ligase (NEB) in a final volume of 20 jul. The sample was incubated at room 
temperature for 1 hr (cohesive-end ligation) or at 16°C overnight (blunt-end ligation).
2.2.1.8 DNA transformation into E. coli
Routinely, 10 pi of a DNA ligation reaction or 0.5 pg of plasmid DNA were transformed 
into XL 10 Gold ultracompetent cells. For protein expression 0.5 pg of plasmid DNA were 
transformed into BL21 CodonPlus cells. In all cases cells were transformed according to 
the manufacturer’s recommendation and plated on LB plates containing the appropriate 
antibiotics (Table 2.12). The plates were incubated overnight at 37°C.
2.2.1.9 E. coli cultures
E. coli strains were grown at 37°C on 9 cm LB plates or liquid culture containing the 
adequate concentration of antibiotics in accordance to the plasmid resistance (Table 2.12).
Concentration
Stock Final
Storage
(stock)
Ampicillin 100 mg/ml in dH20 100 pg/ml -20°C
Chloramphenicol 34 mg/ml in dH20 34 pg/ml -20°C
Kanamycin 25 mg/ml in dH20 25 pg/ml -20°C
Streptomycin 12.5 mg/ml in dH20 12.5 pg/ml -20°C
Tetracycline 12.5 mg/ml in 50% Ethanol 12.5 pg/ml -20°C
Table 2.12 Concentration of antibiotics for selective E. coli growth.
2.2.1.10 Colony screening for positive transformants
Typically, colonies that had grown up overnight, after transformation of a ligation reaction 
into E. coli that were plated on LB plates containing the desired antibiotics, were 
individually picked using a toothpick. 2 ml LB containing the appropriate antibiotics were 
inoculated with individual colonies and cultures grown overnight at 37°C. The following 
day the DNA was extracted using the Plasmid Mini kit (Qiagen) according to the
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manufactures instruction. DNA was digested using restriction endonucleases and the 
fragmented DNA pattern examined for bands of the expected size.
In some cases the DNA in the colony was directly amplified by PCR using two known 
oligonucleotides. Here, the colony was carefully picked, streaked out on another LB plate, 
to maintain the colony, and the rest resuspended into 40 pi dH20. Care was taken to avoid 
contamination with agar pieces. 4 pi of colony mixture was utilised in a 25 pi standard 
PCR reaction containing 100 ng gene-specific primer, lx  reaction buffer, 500 pM dNTPs,
2.5 mM MgCh and 5 units Taq Polymerase (Abgene) and cycling parameters applied 
according to (2.2.1.3).
2.2.1.11 Sequencing
Inserts of newly generated plasmids were routinely sequenced. For one sequencing 
reaction 2 pg of plasmid DNA, as prepared in (2.2.1.1), was precipitated with 1/10 volume 
of 3 M sodium acetate and 2.5 volume 100% ethanol at -20°C for 30 min, followed by 
centrifugation for 20 min at 12900 g  at 4°C. The pellet was washed with 1 ml 70% ethanol, 
dried at room temperature and sent to MWG-Biotech for sequencing with 10 pmol o f the 
desired primer.
2.2.1.12 Plasmid construction
All oligonucleotide sequences utilised for plasmid construction are depicted in (2.1.5).
p A S l (pBS-elt-2::LAP::cdc-25.1(+)) and pAS2 (pBS-elt-2::LAP::cdc-25.1(ij48): PCR
amplification of the 5068 bp elt-2 promoter was done from the pJM69 vector (gift from J. 
McGhee, University of Calgary, Canada) using the Elt-2Xho2 and Elt-2Bam 
oligonucleotides. PCR amplification of a 2569 bp cdc-25.1 genomic DNA fragment was 
done using 25gBam and 25gXba oligonucleotides; this fragment starts at the first codon 
following the cdc-25.1 ATG and includes 478 bp of 3’UTR. The fragments were cut with 
XhoVBamHl {elt-2) and BamHl/Xbal {cdc-25.1) and inserted into pBS-SK that was 
digested with Xhol and Xbal. The resulting vector was subsequently digested with BamHl 
and the LAP tag (GFP-S-tag-TEV cleavage site) inserted in frame as a 1086 bp BamHl 
fragment that was derived from BamHl digestion of the pIC26 vector. For pAS2 the same 
procedure was followed, except genomic DNA from the C. elegans strain IA123 was 
utilised to amplify cdc-25.1 (ij48).
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pAS3 (pBS-elt-2 ::cdc-2 5.1 (+))'. 25.1Notagsen and 25.1Notagas oligonucleotides were 
annealed. The pBS-elt-2::LAP::cdc-25.1 (+) 1 (or for pAS4 cdc-25.1 (ij48)) plasmid was cut 
with BamHl to release the LAP tag cassette and the annealed oligonucleotides ligated into 
the BamHl-cut vector backbone to insert the ATG (performed by A. Coyle). This vector 
contains two additional amino acids following the ATG compared to the wild-type CDC- 
25.1 sequence (R and S insertion).
pAS5 (pQE-30-cdc-25.1 (+)): PCR amplification of a 1815 bp cdc-25.1 cDNA fragment 
using the 25gBam and 25cSac oligonucleotides and insertion of the cdc-25.1 BamHl/Sacl 
fragment into pQE30 (cut with BamHl and Sacl). This results in N-terminal tagging of 
CDC-25.1 with six histidines. (pAS6 [pQE-30-cdc-25.1 (ij48)] was also generated in this 
study, similar to pAS5, but using the cdc-25.1 (ij48) cDNA as a template).
pAS7 (pBS-lin-23 (+)): genomic lin-23 was PCR-amplified using oligonucleotides lin-23- 
5’gen and /m-25-3’gen to clone 2138 bp of upstream promoter, the complete lin-23 gene 
and 766 bp of 3’ UTR. The 5.5 kb fragment was digested with Kpnl and inserted into the 
Kpnl site ofpBS-SK.
pAS8 (pBS-lin-23::FLAG-TY): a 1068 bp fragment was generated using the lin-23lag5 
oligonucleotide with the lin-23-Fig and a 832 bp fragment using oligonucleotide lin-23TY  
and M13rev by PCR amplification using the pBS-lin-23 plasmid as a template. The 
fragments were digested with BamHl and Spel. pBS-lin-23 was digested with BamHl and 
the 1828 bp BamHl fragment removed. The two PCR fragments were inserted in the 
correct orientation into the BamHl-digzsled vector-backbone to generate pBS-/z«- 
23::FLAG-TY. The sequence comprising the tag site generated is: lin-23 (last codon) - 
FLAG tag - Spel restriction site - T Y tag - Stop codon.
pAS9 (pBS-unc-119(+)): a 5.7 kb Hindlll/Xbal fragment, containing the full unc-119 
genomic sequence, was excised from pIC26 and cloned into the Hindlll and Xbal site of 
pBS-SK.
pASlO (pBS-unc-119(+)-lin-23::FLAG::TY): the lin-23:.FLAG-TY sequence of pBS-/z«- 
23::FLAG-TY was excised as a 5.6 kb Kpnl fragment and inserted into the Kpnl site of 
pBS-unc-119. The resulting orientation 5’-> 3’ is: Kpnl - lin-23::FLAG - Spel - TY - Kpnl - 
H indlll - unc-119 - Xbal.
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pA Sll (pGEX-6P-lin-23(+)): the 1995 bp lin-23 cDNA (lacking the endogenous ATG) 
was PCR-amplified using lin-23-GSTfl and lin-23-GSTSTP oligonucleotides. The PCR 
fragment was digested with Smal and inserted in frame into the Smal site of pGEX-6P-l. 
This generates an N-terminal GST fusion of LIN-23. The amino acid sequence comprising 
the fusion 5’->3’: GST tag - Precission Protease site - spacer (LGSPEFPG) - 2. amino acid 
of LIN-23.
pAS12 (p QE-80L-//m-23('+)): pGEX-6P-/w-23 was cut with Smal and the 1.9 kb lin-23 
cDNA fragment excised and inserted in frame into the Swal-linearised pQE80L resulting 
in an N-terminal HIS6 tag fusion. The sequence comprising the fusion site 5’->3’: 6x HIS - 
spacer (GSACELGTPG) - 2. amino acid of LIN-23.
pAS13 (pQE-80L-/m-23A9: pQE80-/m-23 was digested with Pstl and the 5.4 kb vector- 
backbone, containing the 764 bp N-terminal fragment of lin-23, religated. This results in E. 
coli expression of the first 254 amino acids of LIN-23.
pAS14 (pQE-80L-//w-23C): pQE80-/m-23 was cut with BamHl, the 1.2 kb band released 
and the 5.5 kb vector religated. This results in the expression the last 265 amino acids of 
LIN-23 fused to six histidines at the N-terminus. Fusion site: HIS6- codon 401 of lin-23.
2.2.2 Protein biochemistry
2.2.2.1 SDS-PAGE
SDS polyacrylamide gels were either purchased from Bio-Rad with the desired acrylamide 
concentration or prepared according to the following recipe (note for different acrylamide 
concentration the volumes of acrylamide and dH2 0  were changed accordingly):
10% running gel stacking gel
30% Acrylamide/ 
Bisacrylamide (29:1) 17.1 ml 4 ml
10%  SDS 520 pi 200 pi
dH20 21.2 ml 13.1 ml
1.5M Tris pH 8.7 13 ml -
1M Tris pH 6.8 - 2.5 ml
10% Ammoniumpersulfate 500 pi 200 pi
TEMED 50 pi 20 pi
Table 2.13 SDS polyacrylamide gel composition.
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Gels were assembled using the Minigel Cell / Transfer module (Bio-Rad) according to the 
manufacturer’s instructions. Gels were run at 200 V for 45 to 50 min at room temperature.
2.2.1.2 Western blotting
SDS polyacrylamide gels and nitrocellulose membrane (Schleicher & Schuell) were 
soaked in lx  blotting buffer prior to transfer. Gels were assembled into the Minigel 
Transfer module (Bio-Rad), according to the manufacturer’s instructions, and the protein 
transfer performed in lx  blotting buffer at 200 mAmp for 2 hr at 4°C. The membrane was 
subsequently soaked in 1 x Ponceau solution (Sigma) for 2 min and immediately washed in 
lx  PBS-T, before incubation with blocking solution for 1 hr at room temperature. Primary 
antibody was added at the desired concentration (see Table 2.9) in blocking solution either 
for 2 hr at room temperature or overnight at 4°C. Following incubation, the blot was 
washed quickly three times in lx  PBS-T and three times for 10 min in blocking solution 
before addition of secondary antibody (in blocking solution). As secondary antibody either 
anti-rabbit (Amersham) or anti-mouse (Promega) IgG coupled to HRP were used at 1:2000 
concentration for 45 min at room temperature (see Table 2.10). The blots were washed as 
above and after the third wash with blocking solution, rinsed three times in lx PBS and 
subjected to ECL development. 2 ml of a 1:1 ECL solution (Amersham) was applied to 10 
cm nitrocellulose membrane for 2 min at room temperature. The blot was routinely 
exposed to Kodak-film for 10 sec, 30 sec, 1 min, 2 min or 5 min or where necessary up to 
overnight.
2.2.2.3 Coomassie staining
SDS polyacrylamide gels were soaked for 30 min in Coomassie staining solution, washed 
once with dH2 0  and soaked in destaining solution until bands became visible.
2.2.2A Recombinant expression of proteins in E. coli
Exact growth conditions are summarised in (Table 2.14). Typically, 0.5 jug of plasmid 
DNA was transformed into the BL21 Codonplus IRL strain (Stratagene) and the E. coli 
plated overnight on LB plates containing the desired antibiotics and 2% glucose. One 
inoculation loop of freshly grown colonies was scraped off the plate and added to 400 ml 
of liquid LB containing antibiotics and 2% glucose. The cultures were grown at 37°C to an 
OD60o 0.6. One ml of non-induced culture was collected by centrifugation at 13200 g  for 30 
sec at room temperature and the pellet suspended in 100 jul 2x SDS sample loading buffer
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per one OD600 of cells (= non-induced sample). The non-induced sample was heated at 
95°C for 4 min. The remaining culture was induced with IPTG and ethanol added to a final 
concentration of 3% for chaperon induction. Cultures were incubated for 4 hr at 20°C, the 
E. coli collected by centrifugation at 4000 g  for 10 min at 4°C, and the E. coli pellets were 
frozen at -20°C until further usage. A 1 ml sample of the induced fraction was prepared in 
the same way as the non-induced sample. 0.1 OD600 of non-induced and induced sample 
were applied to SDS-PAGE, and protein induction was analysed by Coomassie staining
(2.2.2.3) or Western blot (2.2.2.2).
Fusion protein Plasmid Antibiotics IPTG (mM)
HIS6::CDC25.1 pQE-30-cdc-25.1(+) pREP4
Ampicillin
Kanamycin
Chloramphenicol
0.5
GST::LIN-23 pGEX6P-lin-23(+) AmpicillinChloramphenicol 0.5
HIS6::LIN-23 pQE-80L-lin-23 (+) AmpicillinChloramphenicol 0.5
HIS6::LIN-23N PQE-80L-lin-23N AmpicillinChloramphenicol 0.5
HIS6::LIN23C pQE-80L-lin-23C AmpicillinChloramphenicol 0.5
Table 2.14 Growth conditions for protein expression in E. coli.
2.2.2.5 Purification of soluble fusion proteins from E. coli
The frozen and IPTG-induced E. coli pellets were resuspended on ice in the desired pre­
chilled lysis buffer. Typically, 10 ml lysis buffer per 800 ml of starter culture were used. 
The cells were ruptured using an Ultrasonic Processor with a 5 mm microtip with 10 pulses 
for 10 seconds at 38% amplitude. The homogenate was lysed until it changed to a clear 
appearance. A 100 pi fraction of the homogenate was kept aside for test sample 
preparation. The total homogenate was centrifuged at 15000 g  for 20 min at 4°C. During 
that time the homogenate test sample was centrifuged at 13200 g  for 10 min at 4°C. After 
10 min, 100 pi of 2x SDS sample loading buffer was added to the supernatant (soluble test 
fraction) of the test sample. The test sample pellet (insoluble test fraction) was suspended 
in 100 pi lysis buffer prior to addition of 100 pi 2x SDS sample buffer. Both samples were 
heated at 95°C for 4 min. Soluble and insoluble test fractions were applied to SDS-PAGE 
to estimate solubility of the fusion protein. For soluble proteins, the total supernatant was 
applied to the affinity resin, whereas the pellet was kept for purification of the insoluble 
fraction (see 2.2.2.6). Typically, 300 pi Ni-NTA agarose beads were used (Qiagen) for 10 
ml supernatant of HIS6-tagged fusion protein or 200 pi of Glutathione-Sepharose
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(Amersham Biosciences) for 10 ml of supernatant of GST-tagged fusion protein. However, 
the amount was increased with elevated concentration of expressed fusion protein in the 
extract. Binding was performed using a 50 ml conical for 2 hr at 4°C with continuous end- 
over-end rotation. After 2 hr the beads were poured into a 10 ml Poly-Prep Column (Bio- 
Rad) and washed three times with 10 ml wash buffer. Proteins were eluted from the beads 
using five times one column volume of elution buffer and, where applicable, dialysed in lx 
PBS-G overnight at 4°C.
Buffer HIS6 fusion GST fusion
Lysis
50 mM Tris pH 7.5, 200 mM NaCl, 1 
mM MgCh, 8.7% glycerol, 5 mM beta- 
mercaptoethanol, 15 mM Imidazole pH 
7.5, lx  Protease inhibitor cocktail (PIC), 
0.5 pg/pl Lysozyme
10 mM Tris pH 8, 150 mM NaCl, 
1 mM EDTA, 5% glycerol, 1 mM 
DTT, lx  PIC, 0.5 pg/pl 
Lysozyme, 1% Triton X -100
Wash 50 mM Tris pH 7.5, 200 mM NaCl, 1 mM MgCh, 8.7% glycerol, 5 mM beta- 
mercaptoethanol
lx  PBS, 8.7% glycerol
Elution
50 mM Tris pH 7.5, 200 mM NaCl, 1 
mM MgCh, 8.7% glycerol, 5 mM beta- 
mercaptoethanol, 500 mM Imidazole 
pH 7.5
lx  PBS, 40 mM Glutathione pH 
7.5, 200 mM NaCl, 0.1% NP 40, 
8.7% glycerol
Table 2.15 Buffers for HIS6 and GST fusion proteins.
2.2.2.6 Purification of insoluble fusion proteins from E. coli
Typically, several growth conditions were chosen to improve the solubility of the fusion 
protein, such as different E. coli strains, low growth temperature, different IPTG 
concentrations or addition of ethanol to the culture. However, where only a small fraction 
of the fusion protein remained soluble, under any of the conditions tested, purification of 
the insoluble material was performed. This was the case for all proteins from (Table 2.16). 
After centrifugation of the homogenate from (2.2.2.5), the supernatant was removed and 
the pellet used for purification of the insoluble proteins from inclusion bodies. All further 
steps were carried out at room temperature to avoid precipitation of urea that was used as 
extraction reagent. The exact buffer conditions are summarised in (Table 2.16). 10 ml o f 
lysis buffer was added to the insoluble fraction and sonicated for approximately 20 seconds 
to solubilise all proteins. The sample was clarified by centrifugation at 15000 g  for 20 min 
and the supernatant applied to 300 pg Ni-NTA (Qiagen) per 800 ml starter culture (amount 
was increased for abundantly expressed fusion proteins). The mixture was incubated for 2 
hr on a turning wheel with continuous end-over-end rotation. The sample was subsequently 
poured into a 10 ml Poly-Prep column (Bio-Rad), the beads were washed three times with 
10 ml wash buffer and eluted with five column volumes of elution buffer. Where removal
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of urea was essential, the eluted proteins were dialysed overnight in lx PBS, containing 
22% (v/v) glycerol, followed by a further dialysis step into lx  PBS-G. The dialysed sample 
was snap-frozen in liquid nitrogen and stored at -80°C. However, the dialysis step resulted 
in precipitation of LIN-23 fusion proteins and the precipitation could not be avoided by 
stepwise dialysis or extraction with guanidium chloride.
Fusion protein Lysis buffer Wash buffer Elution buffer
HIS6::CDC25.1
lx  PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol, lx  PIC
lx PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol
lx  PBS, 6 M urea, 
500 mM 
Imidazole, 8.7% 
glycerol
GST::LIN-23
10 mM Tris pH 7.5,4 
M urea, 150 mM 
NaCl, 1 mM EDTA, 
5% glycerol, 1 mM 
DTT, lx  PIC
not done, 
sample applied on 
polyacrylamide gel
not done, 
sample applied on 
polyacrylamide gel
HIS6::LIN-23
lx PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol, lx  PIC
lx  PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol
lx  PBS, 6 M urea, 
500 mM 
Imidazole, 8.7% 
glycerol
HIS6::LIN-23N
lx PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol, lxP IC
lx PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol
lx  PBS, 6 M urea, 
500 mM 
Imidazole, 8.7% 
glycerol
HIS6::LIN23C
lx PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol, lx  PIC
lx PBS, 8 M urea, 200 
mM NaCl, 20 mM 
Imidazole pH 7.5, 
8.7% glycerol
lx  PBS, 6 M urea, 
500 mM 
Imidazole, 8.7% 
glycerol
Table 2.16 Lysis conditions for insoluble proteins.
2.2.2.7 Protein dialysis
Protein buffers were exchanged against the desired buffer (typically lx  PBS-G) overnight 
at 4°C using the Mini dialysis kit (1 kDa cut off, up to 500 pi, Amersham Biosciences) or 
for volumes up to 5 ml the Slide-A-Lyzer 3.5K MWCO dialysis cassettes (Pierce).
2.2.2.8 Peptide antibody production
Anti-LIN-23 peptide antibodies were generated by the company Covalab, according to the 
company’s policy. Two peptides were synthesised by Covalab, according to the company’s 
recommendations, these comprise the LIN-23 amino acids 18 -31 : CLTEGEHDEGKPLSI 
for peptide 1 and amino acids 194 - 207: CIIRDIHNIDNNWKR for peptide 2. Both 
peptides were utilised to immunise two rabbits. However, even after affinity purification of
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the antisera these LIN-23 antibodies did not recognise any specific band on a Western blot. 
For the CDC-25.1 A and CDC-25.1B antibodies see (Clucas, 2003; Clucas et al., 2002).
2.2.2.9 Antibody production against recombinant CDC-25.1 and LIN-23
GST::LIN-23 and HIS6::CDC-25.1 were recombinantly expressed in E. coli. The proteins 
were purified according to (2.2.2.5) and (2.2.2.6). In case of CDC-25.1, one mg of full- 
length protein in lx  PBS-G was sent to SNBTS for immunisation of two rabbits. However, 
in the case of GST::LIN-23, slight modifications were necessary due to the low expression 
level and insolubility of the protein. The protein was first solubilised as in (2.2.2.5). 
However, the pellet was then further purified in a 4 M urea-containing lysis buffer (see 
2.2.2.6), which retained 50% of the expressed protein in the insoluble pellet. This pellet 
fraction was substantially free of other contaminants and diluted in 2x SDS sample buffer. 
The sample was heated for 4 min at 95°C. In total, 500 pg of GST::LIN-23 protein was 
applied to SDS-PAGE (100 pg/gel), the SDS-gel stained with Coomassie and the correct 
size band cut out of the gel. The gel pieces were quick-frozen in liquid nitrogen and 
crushed into very small pieces using a pestle and mortar, lx  PBS-G was added to the 
pieces in order to obtain a thick slurry that was transferred into microcentrifuge tubes and 
concentrated overnight under vacuum pressure. The protein was sent to SNBTS Scotland 
for antibody production in one rabbit and one rat according to the company’s regulations. 
A resulting first test bleed was analysed for expression of protein-specific antibodies by 
Western blotting against HIS6::CDC-25.1 and HIS6:: LIN-23N or HIS6::LIN-23C. For the 
LIN-23 antisera the rabbit serum only reacted to HIS6::LIN-23C, suggesting it contained 
antibodies only against the C-terminus of LIN-23. The rat antibody did not react at all with 
recombinant LIN-23. Sera were affinity purified against recombinant HIS6::CDC-25.1 or 
HIS6::LIN-23C according to (2.2.2.12).
2.2.2.10 Crosslinking of recombinant CDC-25.1 and LIN-23 proteins to 
CNBr-Sepharose
This step was performed to provide an affinity matrix for purification of crude antisera that 
were raised against recombinant LIN-23 or CDC-25.1 as performed in (2.2.2.12). Purified 
recombinant HIS6::LIN-23C and HIS6”CDC-25.1 were dialysed in 4 M urea, 0.1 M 
sodium borate pH 8.3 overnight at 4°C. CNBr-Sepharose (Amersham Biosciences) was 
activated according to manufacturer’s instruction. Briefly, 1 g CNBr-Sepharose 4B was 
added to 50 ml ice-cold 1 mM HC1 in a 50 ml conical and allowed to swell for 2 min. The 
solution was poured into a 20 ml Economo column (Bio-Rad) and washed with an
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additional 200 ml cold 1 mM HC1, followed by one wash with 80 ml wash buffer (100 mM 
sodium borate pH 8.3, 150 mM NaCl). 0.5 g of activated resin was used to immobilise 2.5 
mg (LIN-23C) or 5 mg (CDC-25.1) recombinant protein in a total volume o f 2.5 ml 
binding buffer (4 M urea, 0.1 M sodium borate pH 8.3) by batch-wise incubation for 2 hr at 
room temperature with continuous end-over-end rotation. The beads were spun at 700 g  for 
2 min and the flow-through collected for further analysis. The beads were washed once 
with 10 ml 100 mM sodium borate pH 8.3, 150 mM NaCl and once with 100 mM Tris pH 
8.0, and collected by centrifugation between the washing steps. After the final wash, the 
beads were suspended in 10 ml of 100 mM Tris pH 8.0 and incubated at room temperature 
for 1 hr. Following this incubation, the beads were poured into a 10 ml Poly-Prep column 
(Bio-Rad) and washed with 7 ml of low pH wash buffer (100 mM sodium acetate pH 4, 
150 mM NaCl), followed by an additional wash in 7 ml 100 mM Tris pH 8.0. This step 
was repeated three times and the protein beads were finally washed with 10 ml lx  PBS 
containing 0.01% sodium azide and stored at 4°C. A fraction (equivalent to 0.5 pg protein) 
of input, flow-through and crosslinked beads were analysed by SDS-PAGE to monitor 
binding and crosslinking efficiency of the proteins.
2.2.2.11 Affinity purification of CDC-25.1 and LIN-23 antisera against 
peptides
All peptides used to immunize the rabbits were coupled to Sepharose resin by the company 
Covalab (France) (see (Clucas, 2003; Clucas et al., 2002) for the anti-CDC-25.1A 
antibody, for the anti-CDC-25.1B antibody a peptide against amino acids 592 to 604 was 
used; see (2.2.2.8) for LIN-23). The LIN-23 antisera were affinity purified by Covalab. For 
CDC-25.1 A and B antisera, 5 ml of immune serum was bound to 1 ml of coupled peptide 
resin for 90 min at room temperature. The flow-through was collected, the resin washed 
with 15 ml lx PBS-T, followed by 30 ml lx  PBS. The antibody was eluted with 10 ml of 
elution buffer (0.1 M Glycine / 200 mM NaCl pH 2.2) and 1 ml fractions were collected on 
ice in microcentrifuge tubes containing 200 pi 1 M Tris pH 8.0. The column was re­
equilibrated in lx  PBS / 50 mM Tris pH 8.0 and the flow-through re-bound to the beads. 
This step was repeated twice. A further 10 ml of fresh serum was utilised in case of the 
CDC-25.1B antiserum and purified twice as above. The OD280 was determined for all 
elution fractions and eluates with highest protein concentration were pooled and 
precipitated overnight on ice with 60% ammonium sulfate (ammonium sulfate powder was 
slowly added while stirring on ice). The sample was centrifuged at 4600 g  for 30 min at 
4°C, the pellet suspended in 500 pi lx PBS-G and dialysed in lx  PBS-G for 10 hr at 4°C.
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Protein concentration was determined by spectroscopy (5 pi in 100 pi dP^O at OD28 0) and 
SDS-PAGE analysis (final IgG concentration was 4.8 pg/pl for CDC-25.1 A, 1.2 pg/pl for 
CDC-25.1B). The purified antibodies were kept at -20°C and specificity was analysed by 
Western blotting against C. elegans wild-type, cdc-25.1 RNAi or lin-23 RNAi extracts.
2.2.2.12 Affinity purification of CDC-25.1 and LIN-23 antisera against 
recombinant proteins
5 ml of the anti-CDC-25.1 first test bleed and 10 ml of anti-LIN-23 final bleed were 
diluted with 5 or 10 ml of lx  PBS, respectively. The anti-CDC-25.1 and anti-LIN-23 sera 
were bound to 4 mg HIS6::CDC-25.1 and 1 mg HIS6::LIN-23C proteins (that were 
crosslinked to CNBr-Sepharose as prepared in (2.2.2.10)), respectively. The samples were 
incubated overnight at 4°C in a 15 ml conical with continuous end-over-end rotation. The 
beads were subsequently poured into a 10 ml Poly-Prep column (Bio-Rad) and the flow­
through collected. The antibody, bound to the beads, was washed once with 10 ml wash 
buffer (lx  PBS-T), followed by three washes with 10 ml of lx  PBS. Bound antibody was 
eluted with 10 ml of elution buffer (100 mM Glycine, 200 mM NaCl pH 2.2), and 1 ml 
fractions were collected on ice in 1.5 ml microcentrifuge tubes, containing 200 pi 1 M Tris 
pH 8.0 to neutralise the acidic pH from the elution buffer. The beads were immediately 
neutralised by the addition of 10 ml 50 mM Tris pH 8.0 followed by one wash with 10 ml 
lx PBS. The OD2 80 of all fractions was measured to determine the eluates with highest 
antibody concentration. Fractions with highest OD were kept on ice for further work. The 
flow-through of the serum was re-bound to the beads for 2 hr at room temperature and the 
beads washed and eluted as above. This step was repeated once or until no further antibody 
eluted from the beads. In case of anti-LIN-23 antibody purification, an additional 10 ml of 
fresh serum was added in a further purification step.
The fractions with highest antibody concentrations were pooled and subsequently diluted 
on ice to a final concentration of 50% ammonium sulfate, by slow addition o f a 
concentrated (4.2 M) ammonium sulfate solution. This solution was incubated on ice 
overnight, followed by a centrifugation step at 4600 g  for 30 min at 4°C to pellet the 
antibody. The pellet was suspended in an equal volume of lx  PBS-G and further dialysed 
against lx  PBS-G for 10 hr at 4°C. The antibody concentration was determined by 
spectroscopy (1 pi in 100 pi dH20 at OD2 8 0) and SDS-PAGE analysis against a known 
rabbit IgG standard (Sigma). The final concentration was 5 pg/pl for the anti-CDC-25.1f.l. 
antibody and 1.8 pg/pl for the anti-LIN-23 antibody. The purified antibodies were kept at
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-20°C and the specificity tested by Western blotting against C. elegans extracts with or 
without cdc-25.1 or lin-23 RNAi as required. Additionally, a strain carrying GFP-tagged 
LIN-23 (OHT1707) was employed and the appearance of a high molecular weight band 
was detected with the anti-LIN-23 antibody that was also detected with an anti-GFP 
antibody.
2.2.2.13 Crosslinking of anti-CDC-25.1 and anti-LIN-23 peptide 
antibodies to Protein A-Sepharose
Crosslinking of affinity purified anti-CDC-25.1 and anti-LIN-23 peptide antibodies was 
done using the Seize X Protein A Immunoprecipitation Kit (Pierce), according to the 
manufacturer’s instructions. In brief, 300 pi of Protein A beads suspension (= 150 pg 
beads) was washed in 400 pi lx  PBS and spun at 700 g  using a microcentrifuge. This step 
was repeated three times and the equilibrated beads were added to 300 pg of affinity 
purified antibody, or as control rabbit IgG, in a total volume of 400 pi of lx  PBS (a 
fraction of the input material was kept for SDS-PAGE analysis). The mixture was rotated 
at room temperature for 1 hr and the beads spun down. The supernatant (= flow-through) 
was collected and the protein concentration compared to the input material using Bradford 
assay reagent (Pierce). The beads were washed three times in lx PBS and resuspended in 
400 pi lx PBS, to which 25 pi of freshly dissolved Disuccinimidyl suberate (2 mg / 80 pi 
DMSO) was added. The beads were rotated at room temperature for 45 min, subsequently 
washed three times in lx  PBS and eluted using Pierce elution buffer. A fraction of the 
eluate was kept and the beads washed again three times with lx  PBS. A fraction of the 
input (3 pg protein) was compared to equal volume of flow-through and eluate on a 10% 
SDS polyacrylamide gel, to ensure that all antibody was crosslinked to the beads.
2.2.2.14 Crosslinking of anti-CDC-25.1 and anti-LIN-23 antibodies to
Protein A-Agarose
Crosslinking of anti-CDC-25.1 and LIN-23 affinity purified antibodies (against full-length 
CDC-25.1 and the C-terminus of LIN-23, respectively), as prepared in (2.2.2.12), was done 
using 200 pg Protein A-Agarose (Bio-Rad), essentially as described in (Cheeseman and 
Desai, 2005). The Agarose was washed three times in 1 ml lx PBS-T and 200 pg of 
affinity purified antibody was added in a final volume of 500 pi lx  PBS-G to each resin 
and incubated for 1 hr at room temperature with continuous rotation. The flow-through was 
kept and checked for binding efficiency, the beads were washed three times with 1 ml lx
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PBS-T followed by one wash in 1 ml 0.2 M sodiumborate pH 9.0. The beads were 
resuspended in 900 pi sodiumborate pH 9.0 to which 100 pi of 220 mM 
dimethylpimelimidate (freshly prepared) was added for 30 min at room temperature. This 
step was repeated once using fresh crosslinker, and the crosslinker quenched by washing 
the beads twice with 1 ml 0.2 M ethanolamine / 0.2 M NaCl pH 8.8. The beads were 
incubated in the same buffer for 1 hr at room temperature, followed by three washes with 1 
ml lx PBS and an elution with 500 pi 0.2 M Glycine pH 2.2 to remove any not-crosslinked 
antibodies.
2.2.3 C. elegans culturing and handling
C. elegans strains were grown on NGM plates seeded with a thin layer o f OP50 according 
to standard procedures (Stiemagle, 1999; Sulston and Hodgkin, 1988).
2.2.3.1 Genetic crosses
Seven L4 males were picked onto 3.5 cm NGM plates, and allowed to grow to adulthood 
to mate with two adult hermaphrodites. After two to three days, the FI generation was 
screened for the desired phenotype and the percentage of males recorded, as an indicator 
for mating efficiency. Individual FI animals were transferred onto new plates to either 
observe the F2 generation after self-fertilization or where applicable to cross again into 
another strain.
2.2.3.2 Generation of males by heat shock
Around 80 L4 hermaphrodites were picked to four 3.5 cm OP50-seeded NGM plates, the 
plates sealed with parafilm and incubated at 33°C for 4 hr in a water bath. Occurrence of 
male progeny were scored after three days (typically four to five males were generated 
from 80 hermaphrodites) and backcrossed to hermaphrodites to maintain male progeny.
2.2.3.3 Growth of C. elegans in liquid culture
Growth of large C. elegans liquid cultures was essentially as described by (Cheeseman et 
al., 2004). Worms (for example JR1838 cdc-25.1 (+) or IA530 cdc-25.1 (ij48)) were 
axenized by adding 6 - 1 0  adult hermaphrodites into a drop of bleach solution (a mix of 12 
pL 1 M NaOH and 6 pi 10-20% NaOCl) on the edge of a 5.5 cm OP50-seeded NGM 
growth plate. Cleaned embryos were allowed to hatch and grown until adulthood. 15
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axenized adults were transferred onto 15 OP50-seeded 9 cm NGM growth plates (225 
adults in total) for four further days to increase for LI larvae among the population in 
freshly starved plates. About 5 - 6  plates, enriched with LI larvae, were washed with 5 ml 
lx M9 buffer and LI larvae collected into a 50 ml conical and spun at 1000 g  for 5 min at 
4°C. The worms were washed once with 40 ml lx M9 buffer, collected by centrifugation as 
above and the worm pellet resuspended in 5 ml lx  M9 buffer. The worms were then 
transferred to 500 ml of AB1157-seeded S-medium. This medium was obtained by 
overnight growth of AB1157 (kind gift from Prof. M. Stark, University of Glasgow) in 2 L 
LB, containing 50 |ug/ml streptomycin, and the E. coli collected after centrifugation at 
4000 g  for 10 min at 4°C. The E. coli pellet was then added to a total of 2 L S-medium. 
Liquid worm cultures were grown at 20°C with continuous shaking (150 rpm) in baffled 2 
L culture flasks (Fisher Scientific) to promote aeration of the cultures. Worms were grown 
until a maximum percentage reached adulthood and contained approximately ten embryos 
per hermaphrodite (usually after 3 or 3.5 days).
2.2.3.4 Harvesting embryos from large-scale liquid cultures
Adult worms, grown in liquid culture, were collected through settling them down the 
bottom of the 2 L flask for 1 hour on ice. Under this condition most E. coli remained in the 
supernatant. C. elegans adults were transferred to a 50 ml conical. The worms were 
allowed to settle for 10 min on ice and the worms were washed twice with 50 ml ice-cold 
lx M9 buffer, allowing the worms to settle to the bottom of the tube between the washes. 
After the last wash, the worms were resuspended in 25 ml lx  M9 and 25 ml 60% ice-cold 
sucrose, mixed and spun at 1000 g  for 5 min at 4°C. This step promoted the adult worms to 
float on top of the sucrose cushion, away from unwanted particles in the culture, and 
increased the efficiency of bleaching that subsequently followed. For this step, worms were 
taken from the top of the cushion, up to the 35 ml mark, transferred into a new 50 ml 
conical, washed once with 50 ml lx  M9 buffer and collected by centrifugation as above. 
Worms were resuspended in 10 ml lx M9 buffer and split into 2 conicals to which 15 ml of 
freshly prepared bleach solution was added. Worms were vortexed for approximately 10 - 
15 min until adults were bleached and only embryos remained. Bleaching of adults was 
monitored and stopped as soon as the majority of adults broke open. Embryos were spun at 
4600 g  for 5 min at 4°C, washed two times with 50 ml ice cold dFLO, two times with 1 ml 
lx M9 and resuspended in 100 pi lx M9. Development of the intestine was measured 
under a fluorescence microscope. At this time usually about 50% of the embryos contained 
a fully developed intestine. Embryos were collected and a small fraction applied to a 
OP50-seeded NGM plate to monitor the hatch rate (usually about 70 - 80%). The
remaining embryos were washed in the desired lysis buffer (containing no detergent) and 
then resuspended in equal volume of desired lysis buffer containing 2x Protease inhibitor 
cocktail (Roche) and detergent (typically NP40 or as indicated otherwise). Embryos were 
snap-frozen in liquid nitrogen and kept at -80°C until further usage.
2.2.4 C. elegans transgenesis
2.2.4.1 Generation of C. elegans strains carrying extrachromosomal arrays
Microinjections to generate transformants were essentially done according to (Evans, 
2006; Jin, 1999). pBS-elt-2: :LAP::cdc-25.1 (+), pBS-elt-2::LAP::cdc-25.1 (ij48) or pBS-e//- 
2::cdc-25.1(+) (10 ng/pl final concentration in lx  TE, purified with the Qiagen Maxi kit) 
were mixed with p76-16B unc-76 (100 ng/pl final concentration) and microinjected into 
the gonads of DR96 unc-76(e911). Prior to injection, the DNA mix was centrifuged at 
13200 g  in a microcentrifuge for 15 min at room temperature and loaded into a drawn out 
capillary (Clark Electromedical Instruments, http://www.harvardapparatus.co.uk/) using a 
mouth pipette (Sigma). Injection pads were prepared by adding a drop of liquefied 2% 
agarose in dfEO on a 64 x 22 mm glass coverslip (Thickness 1, Menzel). The agarose was 
flattened through addition of a second coverslip placed on top of the agarose drop. After 
solidification, the top slide was removed and the pads dried in an 80°C oven for 15 min. 
Injection needles from aluminium silicate glass capillaries, containing inner filament 
(GC120F-15, Clark Electromedical Instruments), were pulled using an electrode puller 
(Model 773, Campden Instruments Ltd, http://www.campden-inst.com/).
Five young adult hermaphrodites were transferred to a drop of paraffin oil, placed on the 
injection pad, and allowed to adhere to the pad. Immobilised worms were placed on the 
stage of a Zeiss AxiovertlOO inverted microscope using Nomarski optics and injected into 
their gonads at 400x magnification. The DNA was released into the gonad using nitrogen 
gas as a pressure source. Immediately after injection, the pad was removed to a dissecting 
microscope and a drop of 1 x M9 buffer placed on top o f the oil to release the worms from 
the bottom of the pad. The worms were then transferred to a drop of lx M9 on an OP50- 
seeded NGM agar plate and allowed to recover at 20°C. Rescued animals were identified 
by analysing the FI generation of injected animals for occurrence of non-Unc progeny. To 
maintain rescued animals, a piece of the growth agar containing the worm population was 
excised and placed onto a new plate away from the food source, selecting for wild-type 
animals that can move to the food source as opposed to uncoordinated non-rescued
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animals. Rescued animals were analysed for GFP expression by fluorescence microscopy 
(in case of LAP-tagged CDC-25.1) or indirect immunofluorescence against CDC-25.1.
2.2.4.2 Chromosomal integration of LAP-tagged cdc-25.1
Chromosomal integration using y-radiation was essentially as described in (Evans, 2006; 
Jin, 1999) Briefly, strains carrying an extrachromosomal array with a transmission 
frequency between 30 - 50% were chosen for integration to facilitate identification of 
integrated lines. Two lines were chosen for integration, IA522 elt-2::LAP::cdc-25.1(+) and 
IA524 elt-2::LAP::cdc-25.1(ij48) generating the strains IA535 and IA536, respectively.
Healthy worm cultures, containing a high proportion of L4 animals, were irradiated with 
3800 rad using a 60Co source (performed by Mrs A. Livingstone, Beatson Institute of 
Cancer Research, Glasgow; all subsequent steps were performed by A. Segref). The Po 
worms were allowed to recover for two hours. Eight L4 irradiated worms (for IA535,) or 
five irradiated worms (for IA536) were picked each onto 20 OP50-seeded 9 cm plates (100 
Po for IA536 and 160 Po for IA535) and the worms were allowed to grow to the F2 
generation for six days at 20 degrees. 15 unc-76 rescued worms from each medium plate 
were picked to individual 3.5 cm plates (the total number of F2’s cloned in this case was 
300). Integrated lines were selected from different F2 populations. This screen was 
repeated two times and two independently integrated lines were chosen for further 
analysis. The F2 animals were allowed to self-fertilise and the F3 progeny were screened 
for 100% segregation of the transgene. Individual lines were again selected to ten 3.5 cm 
plates to verify absence of Unc animals.
2.2.4.3 Microparticle bombardment to integrate lin-23::FLAG-TY
Microparticle bombardment was essentially as described in (Praitis et al., 2001) and 
performed by Jane Shingles (Hope laboratory, University of Leeds). As food source for 
liquid culture, the bacterial strain HB101 was grown overnight in 500 ml LB containing 12 
pg/ml streptomycin. The next day the E. coli was pelleted and the pellet resuspended in an 
equal volume of lx  M9 buffer. 3 ml of HB101 pellet was used to inoculate 100 ml S- 
medium containing 50 pg/ml nystatin and 50 pg/ml streptomycin. The strain DP38 unc- 
119(ed3) was freshly grown on five OP50-seeded 6 cm NGM plates at 20°C until 100% 
confluent. The unc-119(ed3) renders worms unable to undergo dauer larvae formation, 
therefore care was taken not to starve the worms in order to prevent survival of rare 
revertants in the unc-119 gene. The worms were collected and added to 100 ml HB101-
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seeded S-medium. One culture was used for one hepta-shot of bombardment, however, 
several cultures were started to ensure that enough worms were available. Worms were 
grown at 200 rpm for four days at 20°C. Worms were collected in 50 ml sterile conicals 
and sedimented at room temperature for 10 min (pellet 1). The supernatant was collected 
and incubated on ice for 20 min to form a second pellet (pellet 2). Pellet 1 was used for 
bombardment, whereas pellet 2 was used to inoculate 100 ml of HB101-seeded S-medium 
to generate a continuous stock of worms for bombardment. The worms in the first pellet 
were kept on ice until further usage.
During this time the DNA was coated to the gold particles. To this end, gold particles were 
prepared by adding 60 mg of particles (0.3-3pm, Chempur) to 2 ml of 70% ethanol, 
vortexed for 5 min and then soaked for a further 15 min at room temperature. The particles 
were spun briefly in a microcentrifuge, the supernatant discarded and the gold particles 
washed three times with sterile water. The final gold pellet was resuspended in 1 ml 50% 
sterile glycerol and stored for up to 2 months at 4°C. 7 pg of Afo/I-linearised plasmid DNA 
(pBS-unc-119-lin-23::FLAG-TY) in 30 pi digestion reaction was added drop-wise to 70 pi 
of gold suspension with continuous vortexing. 300 pi of 2.5 M CaCh and 112 pi of 0.1 M 
spermidine (Sigma) were also added drop-wise and the beads vortexed for a further 5 min 
at room temperature. The beads were centrifuged at 5000 g  for 10 seconds using a 
microcentrifuge, the supernatant removed and the pellet suspended in 800 pi 70% ethanol. 
The beads were re-pelleted and suspended in 70 ml 100% ethanol and vortexed until just 
before use.
A Bio-Rad PDS-1000/He machine was used for the bombardment, according to the 
manufacturer’s instruction. Seven macrocarriers were dipped in isopropanol and placed on 
a paper in the sterile hood to dry. 10 pi DNA gold particles were added to the centre of the 
macrocarriers, allowed to dry and inserted into the holder. Subsequently, the rupture disk 
(1350psi, Bio-Rad) and stopping screen (Bio-Rad) were inserted into the designated 
holder. The carrier containing the DNA was inserted into the top shelf of the Bio-Rad 
chamber. 1 ml of C. elegans pellet (equivalent to 5 x 105 — 1 x 106 young adults) was 
subsequently distributed to seven target spots on a non-seeded 9 cm NGM plate, that were 
aligned to the spacing of the holes in the macrocarrier. The plate was inserted to the second 
shelf (from the bottom) and the worm target spots again adjusted to the exit holes o f the 
macrocarrier. Bombardment was performed using 27 inches Hg according to the 
manufacturer’s instruction. After bombardment 1 ml of lx  M9 buffer was added to the 
plate and the worms allowed to recover for 1 hr. Subsequently, the worms were suspended
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in 4 ml lx  M9 buffer and distributed to seven 9 cm OP50-seeded NGM plates. Worms 
were incubated at 20°C for three to four weeks before screening for integrated non-Unc 
animals that were able to form dauer larvae (screening and selection process was done by 
A. Segref). Four non-Unc larvae were selected from each 9 cm plate and picked to single
3.5 cm OP50-seeded NGM plates to select for 100% transmission rate of non-Unc 
progeny. Subsequently, germline expression of LIN-23 ::FLAG-TY was confirmed by 
indirect immunofluorescence against the TY tag and Western blotting with anti-LIN-23 
antibodies against adult extracts. All strains resulted in high death rates o f embryonic 
progeny, but one strain that clearly displayed a visible correct size band by Western 
blotting was utilised for further experiments (IA582).
2.2.5 C. elegans RNAi
2.2.5.1 Feeding RNAi on NGM plates
RNAi was performed according to the bacterial feeding method (Kamath et al., 2000; 
Timmons et al., 2001). In brief, E. coli strain HT115 (DE3) carrying the T7 IPTG- 
inducible feeding vector L4440 was utilised, containing parts of the relevant target genes 
(Table 2.17) or for control the empty L4440 vector. Production of double-stranded RNA 
was induced overnight at 20°C on standard NGM plates containing 1 mM IPTG and 100 
pg/ml Ampicillin. Ten embryos, LI-staged animals or late L4-to-adult hermaphrodites (see 
Table 2.17) were fed on RNA-induced plates (after hatching when embryos were applied 
on plates) until they reached adulthood (three days when embryos where applied on plates 
and for 24 hr when L4 animals were used). FI embryos were analysed immediately under 
the microscope for the desired phenotype. In parallel, the hatch rate was determined by 
removing adults that had egg-layed on separate plates, and screening for hatched FI 
progeny after 24 hr. When sterility was measured, 20 FI survivors were placed on fresh 
RNAi-seeded plates and incubated at 25°C to avoid starvation. The number of embryos 
present on target RNAi and control RNAi plates was determined after three days of 
incubation at 25°C.
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Gene
(Sequence name)
Target fragment 
relative to genomic
ATG (bp)
Source Stage applied
lin-23 (K10B2.1) 685 - 1811 RNAi library embryo or LI
lin-23 (K10B2.1) 1812 -2686 this study embryo or LI
cdc-25.1 (K06A5.7) 1175 -2049 I. L. Johnstone L4
gsk-3 (Y18D10A.5) 1266-2940 C. Clucas LI or L4
gsk-3 like (C44H4.6) 1319-3018 C. Clucas LI
cullin-1 (D2045.6) 238 - 1234 RNAi library L4
cullin-2 (ZK5204) 1990 -3100 this study L4
skr-1 (F46A9.5) -234 - 785 RNAi library embryo or LI
skr-3 (F44G3.6) -158 - 889 RNAi library embryo
sel-10 (F55B12.3) 796-3010 RNAi library embryo
pop-1 (W10C8.2) 5171 -6847 RNAi library L4
apr-1 (K04G2.8) 2696-4615 this study young adults, injection
urw-7(B0336.1) 1095 -2632 this study young adults, injection
hmp-2 (K05C4.6) 1232 -2349 RNAi library embryo or LI
fo*r-7(C54D1.6) 1465 -2595 this study and RNAi library
embryo or LI, 
young adults in 
case of injections
Table 2.17 E. coli RNAi clones.
2.2.5.2 Feeding RNAi in liquid culture
15 LI animals of the desired strain were each placed on six large OP50-seeded NGM 
plates (or even more plates to ensure that four plates without contamination were available 
for each experiment) and incubated at 20°C for seven days. At this stage the plates were 
depleted of OP50 and contained freshly starved LI animals. One day prior to starvation, 
fresh 100 ml liquid cultures of the E. coli strain HT115 (DE3) carrying a T7-inducible 
feeding vector L4440, containing parts of the gene-specific insert or as control no insert, 
were grown overnight at 37°C in LB containing 100 pg/ml Ampicillin. Only a small 
amount of starting material was chosen for inoculation to avoid overgrowth of the culture. 
The next morning, the cultures were diluted to an OD60o of 0.5 - 1 in a final volume of 400 
ml LB containing 100 pg/ml Ampicillin and 1 mM IPTG (freshly added). After 4 hr 
induction at 37°C, the cultures were harvested by centrifugation at 4000 g  at room 
temperature. The culture supernatant was removed and the pellet resuspended in the 
remaining supernatant. Each pellet was added to 250 ml of S-medium containing 100 
pg/ml Ampicillin and 1 mM IPTG to produce RNAi S-medium. The freshly starved worms 
were collected from four large plates in a 15 ml conical using sterile lx M9 buffer. The 
worms were spun down at 1000 g  at room temperature and washed once in 15 ml lx M9 
buffer. 400 pi of lx  M9 buffer was added to the worm pellet (typically around 600 pi) and
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400 j l a I  of the worm suspension used to inoculate 250 ml RNAi S-medium. The cultures 
were placed at 25°C for three days and embryos harvested according to (2.2.3.4).
2.2.5.3 Double RNAi by feeding
In some cases double RNAi was performed in liquid culture according to (Lehner et al., 
2006). Briefly, 1 ml of non-induced HT115 RNAi overnight culture was mixed with 1 ml 
of the second non-induced HT115 RNAi culture in a final volume of 12 ml and induced 
with 1 mM IPTG for 4 hr at 37°C. Single RNAi, that was necessary for comparison, was 
diluted using the control HT115 RNAi strain. The induced E. coli cultures were collected 
by centrifugation at 4000 g  at room temperature and the pellet added to 10 ml S-medium in 
a 30 ml glass conical. One 3.5 cm plate of starved LI worms was collected in lx  M9 
buffer, quickly spun down using a microcentrifuge and the worm pellet suspended in 400 
pi lx  M9 buffer. 100 pi of worm slurry was added to one 10 ml RNAi culture and 
incubated at 25°C for 3 days with continuous shaking at 200 rpm.
2.2.5.4 RNAi by microinjection
apr-1, gsk-3, bar-1 and wrm-1 RNAi were also performed by microinjection of double­
stranded RNA into the gonads of young adult hermaphrodites. Double-stranded RNA was 
synthesised by in vitro transcription of 5 pg linearised-L4440 vector containing fragments 
of apr-1 (Pstl, Xho\), gsk-3 (SpeI, Ncol), bar-1 (Sail, PvuY) or wrm-1 (Pstl, HindiII). 
Special care was taken to avoid RNAse contamination. After restriction digest, the DNA 
was precipitated with equal volumes of sodium acetate and 2.5 volumes of 100% ethanol at 
-20°C for 30 min, followed by centrifugation at 13200 g  for 30 min at 4°C. The 
precipitated DNA was washed with 75% ethanol, dried and suspended at a concentration of 
1 pg/pl in RNAse free dLLO (Gibco). 5 pg was used to in vitro transcribe the single­
stranded RNA using the T7 RiboMax large-scale RNA production system (Promega) 
according to the manufacturer’s instruction. The RNA was precipitated using one volume 
of sodium acetate, provided with the kit, and 2.5 volumes of 100% ethanol at -20°C for 30 
min. The RNA was pelleted by centrifugation at 13200 g  for 30 min at 4°C, and the pellet 
washed with 75% ethanol, air dried for 15 min at room temperature, and suspended in 50 
pi RNAse free dLLO. 20 pi of each single-stranded RNA was annealed in lx annealing 
buffer (10 mM Tris pH 8.0/20 mM NaCl) for 2 min at 90°C and the mixture slowly cooled 
to room temperature in a heated metal block to produce double-stranded RNA. Single- and 
double-stranded RNA were separated on 1% agarose gels (see 2.2.1.2) to ensure 
production of double-stranded RNA. RNA was injected into the gonads of young adult
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hermaphrodites and phenotypes observed 24 hr post-microinjection. For microinjection 
procedures see (2.2.4.1).
2.2.6 C. elegans molecular biology
2.2.6.1 Isolation of C. elegans genomic DNA
C. elegans genomic DNA was prepared according to (Johnstone, 1999). Mixed staged 
worms were grown on six 9 cm OP50-seeded NGM agarose plates until cultures reached a 
population density of 80 - 90%. Worms were washed off the plates with ice-cold lx  M9 
buffer, collected in 15 ml conicals and allowed to settle on ice for 10 min (reduces E. coli 
contamination). Worms were transferred to a 1.5 ml microcentrifuge tube and spun for 1 
min at 3000 g. The worm pellet was resuspended in five volumes of lx  WLB and 
incubated at 65°C for 1 hr with occasional mixing. The mixture was extracted with 1 
volume of phenol (equilibrated with Tris pH 8.0), mixed carefully (note that vortexing 
would shear the DNA) and spun at 13200 g  for 5 min at room temperature. Any remaining 
DNA that had not extracted at this stage was dissolved by addition of fresh lysis buffer. 
The extracted DNA, present in the top aqueous phase, was extracted two times with one 
volume of phenol/chloroform followed by one extraction with chloroform. The DNA was 
precipitated by addition of 0.1 volume of 3 M sodium acetate pH 5.2 and 0.7 volumes of 
isopropanol and gentle inversion for 5 min at room temperature. The DNA was spun at 
13200 g  for 10 min at room temperature and the pellet washed once with 70% ethanol. The 
DNA was carefully resuspended in 100 pi lx  TE and incubation for 1 hr at room 
temperature with occasional mixing using a 1 ml pipette tip. Subsequently, DNAse free 
RNAseA (Qiagen) was added at a final concentration of 100 pg/ml and incubated at 37°C 
for 1 hr to remove contaminating RNA. This step was followed by addition of 0.1 volume 
of sodium acetate pH 5.2 and 0.7 volume of isopropanol to precipitate the DNA. The DNA 
was dissolved in 20 - 40 pi lx  TE.
2.2.6.2 RNA isolation from C. elegans
To isolate RNA from C. elegans, mixed stage worms were grown on four OP50-seeded 9 
cm NGM agar plates to a population density o f 80 - 90%. Worms were washed off the 
plates using 10 ml chilled lx  M9 buffer, collected in 15 ml conicals and allowed to settle 
on ice for 10 min. The worm pellet (around 100 pi) was transferred to a 1.5 ml 
microcentrifuge tube. Around 30 pi of the worm pellet was lysed in 300 pi RNA lysis 
buffer and incubated at 55°C for 1 hr followed by incubation for 15 min at 95°C.
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RNA was isolated using Total RNA Isolation Reagent TRIR (Abgene). This method is 
based on extraction with guanidine salts, urea and phenol. 750 pi of TRIR was added to 
300 pi RNA lysate and the RNA isolated according to the manufacturer’s instruction with 
slight modifications. In brief, the samples were vortexed, incubated at 4°C for 5 min before 
addition of 200 pi chloroform. The samples were mixed again, kept on ice for 5 min and 
spun at 12000 g  for 15 min at 4°C. After centrifugation, the top phase was selected and the 
RNA precipitated with an equal volume of 100% isopropanol, incubated on ice for 10 min 
and spun at 12000 g  for 10 min at 4°C. The pellet was washed twice with 1 ml 75% ethanol 
and allowed to air dry for 10 min at room temperature. The RNA was resuspended in 20 pi 
RNAse free dH20 and kept at -80°C.
2.2.6.3 Single worm PCR from embryos and adults
Single adult hermaphrodites were picked in 10 pi SWLB, digested at 65°C for 1 hr and the 
Proteinase K subsequently inactivated at 95°C for 15 min. When embryos were to be 
analysed, single embryos were picked into 10 pi SWLB with a mouth-pipette containing 
lx M9 buffer with 1 mg/ml chitinase to remove the eggshell. The 10 pi embryo solution 
was processed in the same way as done for adults. 3 pi of the lysed material was used for a 
25 pi standard PCR reaction containing 100 ng gene specific primer, lx  reaction buffer, 
500 pM dNTPs, 2.5 mM MgCL and 5 units Taq Polymerase (Abgene). PCR parameters 
were according to (2.2.1.3).
2.2.6.4 cdc-25.1 (ij48) restriction site polymorphism
The cdc-25.1 genomic sequence was PCR-amplified from single worms as described in
(2.2.6.3) using oligonucleotides A (5’->3’): TGATGGCTACCACCGGGG and B (5’->3’): 
CGCGCGGATCCTTACACTTCTAACGTTGGAGGAAGTTCAGAATC (provided by C. 
Clucas). These primers amplify a 903 bp cdc-25.1 genomic sequence starting at position -2  
relative to the cdc-25.1 ATG. Additional 11 bp of unrelated sequence is added at the 3’ end 
of the PCR product generating a 914 bp fragment. The Hinfl site present at position 136, 
relative to the first bp of the PCR fragment, is deleted through the ij48 mutation (C to T 
mutation in the Hinfl site 5’GANTC3’, (Clucas, 2003)) and used to detect a restriction site 
polymorphism at the mutation site. Typically, 8 pi of PCR reaction was digested with 1 pi 
of Hinfl in a total volume of 10 pi for 1 hr at 37°C, and the digested PCR fragments were 
applied on 1.8% agarose gel and stained with ethidium bromide. Images of the gel were 
taken using the Biorad Transilluminator and Quantity One software. Wild-type cdc-25.1
81
results in six fragments of 423, 187, 126, 94, 42 and 42 bp, whereas the cdc-25.1(ij48) 
allele produces fragments of 423, 187, 168, 94 and 42 bp. Note that the 42 bp band does 
not resolve well on the 1.8% agarose gel.
2.2.6.5 Iin-23(e1883) restriction site polymorphism
The lin-23 genomic DNA was PCR-amplified from single worms and embryos as 
described in (2.2.6.3) using the oligonucleotides lin-23tag5 and lin-23-GSTSTP (for 
sequence see Table 2.4). These oligonucleotides amplify a 1042 bp genomic sequence 
starting at position +1558 relative to the ATG. Due to the addition of 10 bp in the 3’ 
oligonucleotide a 1052 bp fragment is generated. The lin-23 (e l883) allele creates a TGG to 
TGA mutation (G to A mutant) at 1756 pb relative to the ATG creating a BglW restriction 
site (5’AGATCT 3’) (Kipreos et al., 2000). This generates an additional BglW site at 198 
bp in the amplified PCR fragment. PCR fragments were digested with BglW and processed 
as in (2.2.6.4). Wild-type lin-23 produces fragments of 774 and 278 bp, whereas the 
homozygous lin-23 (e l883) allele produces 199, 278 and 575 bp. When the genomic lin- 
23(el883) allele was screened in the presence of the lin-23:.FLAG-TY allele, the lin- 
2Jcrssgen oligonucleotide was used at the 3’ end to distinguish between lin-23::FLAG-TY 
and endogenous lin-23. This primer hybridises specifically at the 3’ end of the lin-23 
genomic sequence and not the lin-23:.FLAG-TY allele and amplifies 1054 bp of genomic 
lin-23 DNA. After digestion of the amplified PCR fragment with BglW, fragments of 774 
and 280 bp in wild-type lin-23 and 199, 280 and 575 bp in lin-23(el883) are produced.
2.2.7 C. elegans biochemistry
2.2.7.1 Preparation of embryo extracts
Embryos, prepared as in (2.2.3.4), were defrosted on ice and lysed using an Ultrasonic 
Processor with a 5 mm microtip (Jencons) with 10 pulses for 10 sec at 40% amplitude. 
Crude extracts were spun at 30 000 g (unless otherwise indicated in the main text) at 4°C 
for 20 min, and in some cases the supernatants were re-spun at 135000 g  for 20 min at 4°C 
using ultracentrifugation (TLA 100.4 rotor). The protein concentration was measured using 
the Bradford assay. 1 pi of extract was applied to 1 ml Bradford protein assay reagent to 
measure the OD at 595 nm. Extracts were quick-frozen in liquid nitrogen and kept at -80°C 
until further usage or used immediately for immunoprecipitation assays.
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2.2.7.2 Preparation of L4-staged extracts
LI-staged worms were used to inoculate large-scale liquid cultures according to (2.2.3.3). 
Worms were collected before they reached adulthood at the early-to-late L4 stage and 
lysed in the appropriate lysis buffer in the same way as performed on embryos (see embryo 
extracts (2.2.7.1).
2.2.7.3 Preparation of adult worm extracts
For small-scale preparation of adult extracts, four to five OP50-seeded 9 cm NGM plates 
were inoculated with LI-staged worms and grown to adulthood. The worms were collected 
in lx M9 buffer on ice and washed several times. The worms were allowed to settle on ice, 
the supernatant removed and the worm pellet suspended in an equal volume (around 100 
pi) of lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% 
NP40, 1 mM DTT and lx  Protease inhibitor tablet when worm extracts were prepared to 
remove cuticles). The worms were snap-frozen in liquid nitrogen, sonicated using an 
Ultrasonic Processor with a 5 mm microtip (Jencons) with 10 pulses for 10 sec at 40% 
amplitude. Crude extracts were spun at 30 000 g  for 20 min at 4°C and the supernatant 
recovered. The extract was kept at -80°C until further usage.
2.2.7.4 Phosphatase treatment of adult and embryo extracts
Adult C. elegans extracts were prepared as in (2.2.7.3), except the worms were lysed in a 
buffer containing 50 mM Tris pH 7.5, 100 mM NaCl and 2x Protease inhibitor cocktail. 
Embryo extracts were prepared as in (2.2.7.1) and lysed in a buffer containing 50 mM Tris 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.2% NP40, 1 mM DTT and 2 x 
Protease inhibitor cocktail. Typically, 5 pi of extract was incubated for 30 min at 30°C 
with either lx  ^-phosphatase reaction buffer alone (NEB) (final buffer concentration 50 
mM Tris pH 7.5, 100 mM NaCl, 2 mM DTT, 0.1 mM EGTA, 0.01% Brij35, supplemented 
with 2 mM MnCL and lx  Protease inhibitor cocktail) or ^.-phosphatase buffer containing 
800 units of ^ -phosphatase (NEB) in a total volume of 20 pi. The samples were suspended 
in equal volumes of SDS sample buffer, heated for 4 min at 95°C and 12 pg (adult extract) 
or 15 pg total protein (embryo extract) applied to SDS-PAGE analysis using 8% SDS 
polyacrylamide gels (self-poured according to (2.2.2.1). As control the same amount of 
total protein was directly suspended in SDS sample buffer, heated and applied to SDS- 
PAGE.
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2.2.7.5 Immunoprecipitation from embryo and L4 extracts
Unless otherwise stated, around 300 jag of total protein contained in an extract (obtained as 
in (2.2.7.1) and (2.2.7.2)) was diluted to 200 pi in lysis buffer (50 mM Tris pH 7.5, 100 
mM KC1, 1 mM EDTA, 1 mM MgCh, 8.7% glycerol, 1% NP40, 2x protease inhibitor 
cocktail (Roche) and lx  phosphatase inhibitor cocktail I and II (Sigma)). The concentration 
o f KC1 and NP-40 was adjusted in several experiments and this buffer here displays the 
conditions that were used for immunoprecipitation of CDC-25.1 using the newly generated 
CDC-25.1 f.l. affinity purified antibody. 40 pg of affinity purified CDC-25.1 f.l. antibody, 
crosslinked to Protein A-Agarose (according to (2.2.2.14), was added to 200 pi of diluted 
extract in a 1.5 ml Mobicol tube (Mobitec, http://www.mobitec-us.com/) and rotated on a 
turning wheel for 1 hr at 4°C with continuous rotation. As control, rabbit IgG was used 
(Sigma) that had been crosslinked to Protein A-Agarose identical to the CDC-25.1 f.l. 
antibody. During optimisation procedures (as indicated in the Chapter 4, (4.2.1.3)) 
sometimes higher concentrations of antibodies were employed. The beads were spun down 
at 700 g  in a microcentrifuge and the flow-through recovered. The beads were washed 
three times with 400 pi o f lysis buffer and finally eluted using 30 - 40 pi of elution buffer 
(100 mM Glycine, 200 mM NaCl pH 2.2) for 3 min at room temperature. The beads were 
again spun down, the eluate collected and an equal volume of SDS sample buffer was 
added to the flow-through and eluate and incubated at 95°C for 4 min. Samples were kept 
at -20°C.
2.2.7.6 Purification of LAP::CDC-25.1 on S-Protein Agarose
Embryonic extracts were prepared from large-scale liquid cultures of IA535, IA536 and 
JR1838 according to (2.2.7.1). Embryos were collected and lysed in lysis buffer (50 mM 
Tris pH 7.5, 300 mM KC1, 1 mM EDTA, 0.05 % NP40, 1 x Protease inhibitor cocktail 
(Roche) and lx  Phosphatase inhibitor cocktail I and II (Sigma). 60 pg of S-Protein 
Agarose (Novagen) were washed once with 400 pi of lysis buffer. 300 pg of total protein 
in lysis buffer were incubated with the washed S-Protein Agarose in a total volume of 200 
pi. 10 pi was kept aside as input control. The mixture was incubated in a 1.5 ml Mobicol 
tube for 3 hr at 4°C with continuous end-over-end rotation, the flow-through collected, and 
the beads washed three times with 400 pi lysis buffer. The samples were eluted for 3 min 
at room temperature in 60 pi SDS sample buffer followed by 4 min incubation at 95°C. A 
fraction of the input and flow-through was suspended in equal volume of SDS sample 
buffer and heated at 95°C for 4 min. 5 pi of the input and flow-through and 20 pi of the
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eluate were applied to 10% SDS-PAGE to probe against CDC-25.1, GFP or LIN-23. For 
probing of the Western blot against GFP slightly higher volumes had to be applied to SDS- 
PAGE for the LAP-tagged proteins and lower volumes for GFP::LacZ due to the 
difference in expression levels but the ratios of input, flow-through and eluate were kept 
constant.
2.2.8 Microscopy
2.2.8.1 Preparation of living specimen
Microscopy of embryos and worms was according to standard methods (Sulston and 
Hodgkin, 1988). Larvae or adults were mounted on a 4% agarose pad (containing 10 mM 
sodium azide if no real time imaging was performed) and a drop of lx  M9 buffer. Where 
embryos were to be imaged, around 20 adults were transferred to a watch glass that was 
filled with lx  M9 buffer. The adults were cut open using two 18-gauge needles and the 
embryos selected with a mouth pipette (a plastic tubing connected to a drawn out capillary 
glass). Embryos were transferred to a drop of lx M9 buffer. A coverslip was carefully 
added on top of the adults or embryos and sealed with paraffin.
2.2.8.2 Preparation for fixed specimen
Prior to the collection of samples, one drop of 0.1% Poly-L-lysine solution (Sigma) was 
added on the centre of a glass slide and allowed to dry. Where larvae were to be analysed, 
several larvae were selected with a worm pick and placed in one drop of 1 x M9 buffer that 
was added on top of the Poly-L-lysine-coated slide. Embryos were selected as in (2.2.8.1) 
and transferred to a drop of lx  M9 buffer that was placed on the surface of the Poly-L- 
lysine-coated slide. The samples were processed further as in (2.2.8.3).
2.2.8.3 Indirect immunofluorescence
Samples were prepared as in (2.2.8.2). A 22 x 22 mm coverslip (Menzel) was carefully 
added on to of the lx  M9 drop containing larvae or embryos. Excess liquid was removed 
by placing a tissue over the glass. Very slight pressure was applied to the coverslip during 
this procedure, to ensure direct contact of the coverslip and the specimen. The slide was 
immediately placed on top of a cold metal block that had been pre-chilled on dry ice for 
several minutes. Slides were allowed to freeze for several minutes and the coverslip 
quickly removed, with the aid of a scalpel blade, to crack open the eggshell or cuticle of
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the embryo and worm, respectively. The slides were directly immersed in 100% methanol 
(pre-chilled at -20°C) and incubated at -20°C for 10 min before transfer into 100% acetone 
(pre-chilled at -20°C) for 10 min. Slides were removed from the acetone and allowed to air 
dry. 200 pi of lx  PBS/0.2% Tween 20 were added on top of the sample and incubated for 
2 min. The sample was pre-blocked in 200 pi 1% dried milk in lx PBS/0.2% Tween 20 for 
20 min at room temperature. This was followed by an overnight incubation in the same 
blocking buffer containing the primary antibody in a humid chamber at 4°C (for antibody 
dilutions see Table 2.9). The next day, slides were washed quickly three times in 200 pi lx  
PBS/0.2% Tween 20, followed by two 10 min washes in the same buffer, before 
incubation with secondary antibody at 1/200 dilution in lx  PBS/0.2% Tween 20 (for 
secondary antibodies used see Table 2.10). Samples were incubated in a humid chamber 
for 1 hr at room temperature protected from light. Identical wash steps, as done after the 
primary antibody incubation, were performed. The samples were allowed to air dry for 
several minutes, mounted in 10 pi of Vectashield (Vector Laboratories), containing 1.5 
pg/ml DAPI, and sealed with clear nail polish. Slides were stored at 4°C in the dark.
2.2.8.4 Conventional microscopy for fluorescence and Nomarski imaging of 
fixed and living samples
Live or fixed embryos, larvae and adults were viewed using a Zeiss Axioplan 2 microscope 
(Carl Zeiss, http://www.zeiss.co.uk/) with Nomarski optics. For different magnifications 
either a 10x/0.3, 20x/0.5, 40x/0.75 Plan-Neofluar or 63x/1.4 and lOOx/1.4 Plan- 
Apochromat lense were used. GFP, Alexa Fluor 488 or Alexa Fluor 543 fluorescence were 
viewed using a tungsten halogen lamp UV source at 488 or 543 nm, respectively. Images 
were taken with a Hamamatsu C4742-95 digital camera (Hamamatsu Photonics, 
http://www.hamamatsu.co.uk/) and Improvision Openlab 4.0.2. software. Images were 
processed with Adobe Photoshop 8.0 and Adobe Illustrator 12.0 for figure assembly.
2.2.8.5 Confocal microscopy of immunostained samples
Fixed samples were viewed using a Zeiss LSM 510 META Confocal microscope (Carl 
Zeiss) equipped with a Diode (405 nm), Argon 2 (458, 477, 488 and 514 nm), HeNel (543 
nm) and HeNe2 Laser (633 nm). Samples were examined using the 63x/1.4 Plan 
Apochromat lens and two times optical zoom. Images were taken using the LSM 510 Meta 
version 3.2.SP2 imaging software (Carl Zeiss). When desired, the same settings were used 
for comparative imaging according to the manufacturer’s instruction. For double staining 
the pinhole settings for the longer wavelength were adjusted to 1 airy unit and
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subsequently the airy unit of the lower wavelength adjusted in order to keep the same 
optical slice. Typical settings for non-stacked images were: 1012 frame size, line-step: 1, 
maximum scan speed, 12 bit data depth, scan direction: single, mode: line, method: mean 
with average between 2-8 numbers. For comparison of fluorescence intensity, as in the 
case for CDC-25.1 abundance the embryo was first selected in the DAPI channel and the 
numbers of nuclei counted. The embryo was subsequently scanned for anti-CDC-25.1 and 
DAPI fluorescence in the middle focal plane and the images collected. The CDC-25.1 
staining of all nuclei in the embryo was quantified by selection of the whole embryo using 
LSM 510 software tool, the fluorescence intensities extracted and the mean values of 
fluorescence intensities compared. All images were processed for figure assembly using 
Adobe Photoshop 8.0 and Adobe Illustrator 12.0 software.
2.2.9 Statistics
Datasets were analysed for normal distribution with the Normal quantile plot analysis 
function using the JMP 6.0 software. The mean value with standard deviation was 
determined using the average and standard deviation function in the Microsoft Excel (MS 
Office 2000) software. The p-value for the significance that two compared mean values are 
derived from the same mean was determined using the Students t test function in the 
Microsoft Excel (MS Office 2000) software. Where data followed non-normal distribution 
the nonparametric Kruskal-Wallis test (using the JMP 6.0 software) was performed to 
obtain the p-value for the significance whether the datasets were derived from the same 
median value.
2.2.9.1 Statistics for CDC-25.1 indirect immunofluorescence
The fluorescence intensities of anti-CDC-25.1 immunostained embryos were measured as 
described above (2.2.8.5) and analysed using standard statistical techniques by Sokal et al. 
(Sokal, 2000). Note that the staining of CDC-25.1 decreases from early to late stages of 
embryogenesis, which forced the use of different detector gains at different developmental 
stages (but kept identical between the two samples to be compared). Hence, the fold 
difference in staining intensity between for instance CDC-25.1 and CDC-25.1 (S46F) was 
determined at each developmental stage with the help of Dr. Richard Wilson (University of 
Glasgow) and analysed in an Excel spreadsheet as indicated in the example below (see 
Table 2.19). Firstly, all data points were transformed into a log scale. The difference in 
fluorescence intensity of the mutant compared to the wild-type for each individual 
experiment was determined as the difference of the two mean values (Mutant fold increase,
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Table 2.18). The difference between two means on a logarithmic scale corresponds to the 
logarithm of the fold difference of the two means and the fold difference can be obtained 
by back-transformation. The upper and lower confidence level in a 95% interval was 
calculated for each mean (Mutant fold increase, brackets Table 2.18) and the individual p- 
value for a two-tailed distribution determined through the Student’s Mest in order to 
clarify, that the values of each dataset were derived from the same or different mean values 
(p-value). The combined difference (Combined fold increase), at each developmental stage 
from several separate experiments, was determined using the weighted means:
A p lom b \ n \ a + n 2 a j
b *  n 2b 
\ * \ b
\ n \a +  n 2a J
hb *«2A ^
\ n \b + ”
This takes into account the number of embryos underlying each individual difference of 
the mean in order to weight the contribution of each experiment to the overall fold 
difference of the mean. The significance of the combined dataset was obtained using the 
-2lnP:chi-squared method as in Sokal (Sokal, 2000) with one-tailed p-values being 
combined (combined p-value).
Com parison of CDC-25.1 with CDC-25.1(S46F)
Stage No of 
Embryos 
(WTZij48)
Mutant fold 
increase
p-value Combined 
fold increase
Combined
p-value
30 - 40n 14/9
11/7
2.57 (3.62 - 1.83) 
1.75 (2.67 - 1.15)
<0.001
<0.05 2.2 <0.001
Table 2.18 Example of CDC-25.1 fluorescence intensity quantification.
A full Table with all fluorescence intensity quantifications is provided in the Appendix of 
this thesis (Table 8.1). Tables that display the combined fold increase are presented in 
Chapter 3 (Table 3.5 and Table 3.6).
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Excel spreadsheet for CDC-25. fluorescence quantification
WT
Experiment
A
Mutant
Experiment
A
WT
Experiment
B
Mutant
Experiment
B
Values of fluorescence after 
transformation to LOGjo
2 .6 5 4 1 7 7
2 .2 6 7 1 7 2
2 .1 8 1 8 4 4
2 .7 3 3 9 9 9
2 .3 7 4 7 4 8
2 .721811
2 .3 5 0 2 4 8
2 .4 9 5 5 4 4
2 .6 3 9 4 8 6
2 .3 1 3 8 6 7
2 .5 8 8 8 3 2
2 .7 7 4 5 1 7
2 .3 1 5 9 7
2 .5 3 6 5 5 8
2 .8 4 3 2 3 3
3 .0 1 8 7
3 .0 0 8 1 7 4
2 .9 3 1 9 6 6
2 .7 2 3 4 5 6
2 .7 9 0 9 8 8
2 .8 5 9 7 3 9
2 .9 8 0 0 0 3
3 .0 0 2 5 9 8
2 .7 1 5 1 6 7
2 .681241
2 .6 2 0 1 3 6
2 .6 9 0 1 9 6
2 .5 2 7 6 3
2 .7 0 0 7 0 4
2 .7 8 8 8 7 5
2 .7 7 0 8 5 2
2 .3 1 8 0 6 3
2 .5 1 3 2 1 8
2 .6 2 3 2 4 9
2 .6 4 8 3 6
3 .2 0 2 2 1 6
2 .663701
2 .9 66611
3 .0 3 1 8 1 2
2 .606381
3 .0 1 0 7 2 4
n 14 9 11 7
n-1 13 8 10 6
1/n 0.07143 0 . 1 1 1 1 1 0.09091 0.14286
ni*n2 126 77
n]+n2 23 18
N-1
2 > - »
21 16
l/N
0.18254 0.23377
Log Mean ( jli)
2 >
n
2.49634 2.90654 2.63176 2.87569
Log fold difference (A p)
M-mt —P w t
0.41020 0.24393
Fold difference
(backtransformed) 
A jlia 1 0
2.57158 1.75359
Standard Deviation a  (log)
l « * I > 2 - ( 2 » 2
\  n* (rt-1 )
0.19487 0.10680 0.13606 0.23332
Deviation Square SS (log) 
cr2 *(>?-1) 0.49367 0.09125 0.18511 0.32664
Standard error of diff. Means 
SE (log)
h s s
(11N)
0.07130 0.08647
tinv t os 
(0.05, N-1) 2.07961 2.11990
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Excel spreadshee for CDC-25.1 fluorescence quantification
Upper 95% C.L (logscale) 
Ap + (t 0 5 * SE) 0.55848 0.42724
Lower 95% C.L. (logscale) 
Ap - (t os* SE)
0.26191 0.06062
Upper 95% C.L.
(back transformed) 3.61812 2.67446
Lower 95% C.L.
(back transformed) 1.82774 1.14980
p-value
(two-tailed Student’s Ptest) 1.03804 xlO 5 0.01230
p-value (PI)
(one-tailed Student’s Mest) 5.19018 xlO'6 0.00615
ChiSqTerm 
-2ln P\ 24.33749 10.18314
Combined ChiSqTerm % 
-2£lrLPl 34.52063
d.f. 4
Combined p-value
CHIDIST (x2, d.f.) 5.82706xl0'7
Log
(Apc
combined
omb)>
f * >
* \ a  n 2a 
+ n 2 a J
fold increase
f * \
+ ^ h
A + n 2h J 0.33750
/ * \ 
" \ a  " l a
("l« +«2
( * \ , n \h n 2h
U lA  + n 2h
Combined fold increase
( A p c o m b  A l  0 )
2.17522
Table 2.19 Spreadsheet for analysis of CDC-25.1 fluorescence intensities.
2.2.10 Bioinformatics
Wormbase (http://www.wormbase.org/) was preferentially used to acquire C. elegans 
genomic and cDNAs as well as protein sequences. Sequence analysis such as sequence 
similarity searches were performed with Wormbase (http://www.wormbase.org/) or NCBI 
Blast (http://www.ncbi.nlm.nih.gov/BLAST). For identification of phosphorylation and 
other motif sites, NetphosKl.O (http://www.cbs.dtu.dk/services/NetPhosK), the Eukaryotic 
Linear Motif Resource for Functional Sites in Proteins (ELM) (http://elm.eu.org/) or 
PSORTII (http://psort.nibb.ac.ip/form2.html) were utilised. For oligonucleotide design, 
DNA analysis of restriction digests, DNA sequence comparisons as well as multiple 
protein alignments Vector NTI AdvancelO (free version, Invitrogen) was preferentially 
utilised.
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3 Identification of CDC-25.1 regulators
3.1 Introduction
C. elegans embryogenesis offers an attractive system to study the integration of the cell 
cycle with developmental decisions, because all divisions follow a precise pattern that is 
invariant between individual animals. The identification of a cdc-25.1 (ij48) mutant allele 
that causes a S46F mutation in the general cell cycle regulator CDC-25.1 has demonstrated 
the advantages of using this model system (Clucas, 2003; Clucas et al., 2002). 
Identification of this mutant was rather intriguing as it caused a tissue-specific 
hyperproliferation of intestinal cells, albeit removal of cdc-25.1 by RNAi resulted in 
embryonic death (Ashcroft et al., 1999; Clucas, 2003; Clucas et al., 2002; Kostic and Roy, 
2 0 0 2 ) with decreased proliferation of several tissues implicating a general function for 
CDC-25.1 to driving the cell cycle in all or several other embryonic tissues (Clucas, 2003; 
Clucas et al., 2002). CDC25 proteins have been identified in many eukaryotic systems and 
their role as positive regulators of the cell cycle is well established (see Chapter 1).
Consistently, the S46F mutation in C. elegans CDC-25.1 has been proposed to elicit a 
gain-of-function of the CDC-25.1 molecule (Clucas, 2003; Clucas et al., 2002). Hence, this 
suggests the loss of negative regulation of CDC-25.1 through the S46F mutation in CDC-
25.1 ultimately resulting in intestinal hyperproliferation. This strongly argues for the 
presence of a negative regulator acting through S46 in CDC-25.1 possibly in a tissue- 
specific fashion. Deciphering the molecular mechanism underlying the tissue-specific 
phenotype of the CDC-25.1 (S46F) mutant was therefore an important task in order to shed 
light into the tissue-specific regulation of the C. elegans cell cycle.
3.1.1 Conservation of the DSG consensus in CDC-25.1
Apart from the tissue specificity reported for the cdc-25.1 (ij48) allele, no obvious 
differences have been reported that would facilitate the identification of a molecular 
pathway underlying the tissue-specific regulation of the CDC-25.1 protein. 
Immunostaining against CDC-25.1 using anti-CDC-25.1 specific antibodies revealed no 
difference in the CDC-25.1 (S46F) localisation compared to wild-type CDC-25.1. 
Furthermore, no difference for the CDC-25.1 (S46F) protein level was detected as 
compared to CDC-25.1 (Clucas, 2003; Clucas et al., 2002) and see Chapter 1, (1.3.5)). 
Hence, the only clue for a molecular mechanism underlying the cdc-25.1 (ij48) mutation
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was provided by the nature of the S46F mutation site. This serine falls into a conserved 
motif present in C. elegans cdc-25.2 and C. briggsae cdc-25.1 (Clucas et al., 2002). 
Interestingly, sequence conservation of this motif is not restricted to nematode species and 
the similarity to the DSG consensus motif in human p-catenin and CDC25A has been 
previously suggested (Busino et al., 2003; Clucas, 2003).
The DSG motif has been extensively studied and most data arose from the original 
identification of this m otif in p-catenin and the human NFkB pathway (see Figure 3.1, A, 
for an alignment of the DSG motif in C. elegans CDC-25.1 with several DSG motifs found 
in higher eukaryotes). Early studies from several laboratories revealed that a DpSGOXpS 
phosphodegron sequence (where pS denotes serine phosphorylation, any hydrophobic 
residue and X any amino acid) was important for ubiquitin-dependent degradation of IkB 
(Yaron et al., 1997) and human p-catenin (Aberle et al., 1997; Orford et al., 1997). 
Phosphorylation o f the serines has proven important for the ubiquitin-mediated degradation 
of these molecules. Interestingly, phosphorylation of the serine adjacent to the aspartic acid 
in the DSG consensus of p-catenin requires the kinase GSK3P in complex with Axin and 
APC (adenomatous polyposis coli) (Aberle et al., 1997; Hart et al., 1998; Ikeda et al., 
1998; Kitagawa et al., 1999; Liu et al., 2002; Orford et al., 1997).
Intriguingly, inactivating mutations in human APC and in the DSG consensus motif of 
P-catenin have been frequently associated with human primary cancers such as colorectal 
carcinomas (Polakis, 2000). Thus, could this provide a potential link to the tissue-specific 
hyperplasia observed in the C. elegans CDC-25.1 putative DSG phosphodegron mutant 
CDC-25.1 (S46F)? In this chapter I set out to answer this question by identifying whether 
there are common negative regulators that are conserved between C. elegans and higher 
eukaryotes that can regulate S46 in the DSG consensus of C. elegans CDC-25.1. A brief 
introduction into the molecules regulating the DSG consensus in higher eukaryotes is given 
below, and known roles of their respective C. elegans counterparts during C. elegans 
development are highlighted.
3.1.2 Mechanisms of DSG-mediated regulation in higher 
eukaryotes
The DSG motif has been identified in many diverse target genes. Figure 3.1 (panel A) 
depicts an alignment of the DSG site in C. elegans CDC-25.1 with several studied DSG 
motifs in eukaryotic systems (according to (Fuchs et al., 2004; Nakayama and Nakayama,
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2006), details of some target interactions will be discussed below). Original data suggested 
that this motif is important for the degradation of p-catenin (Aberle et al., 1997; Orford et 
al., 1997) and NFkB pathway components such as p i05 and IicBa-e (Yaron et al., 1997). 
However, since there is no indication of the presence of NFkB pathway components in C. 
elegans, this pathway will not be elucidated further here (Manning, 2005; Wang et al., 
2006). What has become evident from many independent studies is that the DSG 
consensus is also present in several cell cycle regulators such as CDC25A, CDC25B, 
WEE1A and EMU and serves as a recognition site for an F-box molecule P-TrCP 
(discussed below). Humans have two P-TrCP genes named P-TrCPl and P-TrCP2 located 
on chromosome 10 and 5, respectively (Fuchs et al., 2004). Since both genes have been 
implicated in the regulation of the DSG consensus, the term P-TrCP will be utilised here 
unless significant differences in their functions require highlighting the specific molecule. 
p-TrCP belongs to a large family of Fbw proteins containing an N-terminal F-box motif 
and a C-terminal WD40 domain. The protein is part of a large multisubunit E3 ubiquitin 
ligase complex SCF named after its members SKIP1, CULLIN1 and the F-box protein. 
The SCF complex mediates the transfer of ubiquitin molecules from the E2 conjugating 
enzymes to the substrate, thereby targeting the substrate for ubiquitin-mediated 
proteasomal degradation ((Pickart and Eddins, 2004) and Chapter 4, (4.1)). The F-box 
molecule P-TrCP interacts via the WD40 domain found in its C-terminus to the 
phosphorylated DSG consensus sequence present in diverse target substrates. In this regard 
the recognition of p-catenin has been extensively studied and will be introduced below, as 
well as the interaction of p-TrCP with known cell cycle related molecules.
3.1.2.1 p-TrCP recognition of p-catenin and other substrates
In the canonical Wnt signalling pathway, secreted cysteine-rich ligands act on cell surface 
receptors, such as Frizzled, which mediate the stabilisation of p-catenin. Stabilised 
p-catenin then moves to the nucleus and binds to the transcription T-cell factor (TCF) 
releasing the transcriptional repression of TCF target genes such as c-myc, c-jun or cyclin 
D1 (Kikuchi et al., 2006; Logan and Nusse, 2004). In the absence o f Wnt signalling 
P-catenin is degraded through the APC/Axin/GSK3p/CKla complex and p-TrCP (for a 
recent review see (Kikuchi et al., 2006)). P-TrCP recognises p-catenin phosphorylated by 
GSK3P on S33, S37 and T41 at the DSG consensus (where S33 represents D(S33)G) 
(Fuchs et al., 2004; Kikuchi et al., 2006; Kitagawa et al., 1999; Liu et al., 2002). 
Phosphorylation of S45 by C K la  is a priming event for the subsequent phosphorylation of 
S33, S37 and T41 by GSK3P (Liu et al., 2002). Thus, binding of P-TrCP to p-catenin
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follows a two-step phosphorylation mechanism on p-catenin mediated by the kinases 
GSK3P and C K la. Interestingly, GSK3p and C K la  exert their function as a multisubunit 
complex. Central to it are the two molecules Axin and APC. In this complex the 
scaffolding molecule Axin binds via its G-protein signalling (RGS) domain to the central 
domain of APC (Behrens et al., 1998; Kishida et al., 1998) and via separate central 
domains to GSK3p, p-catenin (Ikeda et al., 1998; Liu et al., 2002) and C K la  (Liu et al., 
2002). The binding of APC to p-catenin as well as to Axin is necessary for p-catenin 
degradation (Kawahara et al., 2000; Kikuchi et al., 2006).
3.1.2.2 Diverse kinases implicated in DSG phosphorylation
The DSG consensus site is also found in other proteins, for example in HIV Vpu, human 
EMU, human PERIOD and human WEE1A, and is important for p-TrCP-mediated protein 
degradation (Nakayama and Nakayama, 2006). Though HIV Vpu and EMU conform to 
the strict DSG consensus, WEE1A and PERIOD show slight alterations of the DSG motif 
site (Figure 3.1, A). The serine residues within the DSG motif in HIV Vpu and human 
EMU were suggested to be casein kinase 2 (CK2) (Schubert et al., 1994) and polo-like 
kinase 1 (PLK1) (Moshe et al., 2004) target sites, respectively. Similarly, phosphorylation 
of the serine (S53) in the DSG site of WEE1A implicated PLK1 function as revealed by in 
vitro analysis of a peptide comprising this region (Watanabe et al., 2004). Thus, multiple 
kinases have been implicated in phosphorylation of the serine within the DSG motif in 
different target molecules.
3.1.2.3 p-TrCP recognition of CDC25
Interestingly, the DSG motif is also found in human CDC25A, a homologue of C. elegans 
CDC-25.1. As already discussed in the general introduction, CDC25 proteins are 
phosphatases that regulate the cell cycle by dephosphorylating inhibitory phosphates 
present on threonine 14 and tyrosine 15 in cyclin-dependent kinases and thereby stimulating 
cell cycle progression. The fine-tuning of CDC25A protein levels during different stages of 
the cell cycle can therefore mediate a control for cell cycle progression. Hence, CDC25A 
protein levels fluctuate during the mammalian cell cycle, which is the result o f a balance 
between de novo protein synthesis and protein degradation during mitosis and S phase (see 
review by (Busino et al., 2004)). While the anaphase-promoting complex/cyclosome 
(APC/C) orchestrates the degradation of CDC25A at the exit of mitosis (Donzelli et al.,
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2002), S phase degradation of CDC25A is carried out by the SCFp"TrGP complex (Busino et 
al., 2003; Donzelli et al., 2004; Donzelli et al., 2002; Jin et al., 2003).
Binding of P-TrCP to CDC25A has been demonstrated in vivo and it requires 
phosphorylation o f S82 in the DSG consensus site of human CDC25A. Interaction between 
p-TrCP and the DSG consensus of CDC25A is essential for CDC25A degradation during 
the normal cell cycle and in response to DNA damage in human tissue culture cells 
(Busino et al., 2003; Jin et al., 2003). Removal of P-TrCP by RNAi resulted in increased 
CDC25A protein levels during S phase of the cell cycle or in response to DNA damage. A 
double mutation in the DSG consensus site of CDC25A (S82/S88, where S82 is the residue 
adjacent to D in the DSG site) abolished binding of P-TrCP to CDC25A and increased 
CDC25A protein levels (Busino et al., 2003). Similarly, Jin et al. (2003) reported that 
single mutations o f S82 abolished P-TrCP binding in vivo. Phosphorylation o f S76 as well 
as S79 preceding the S82 in the DSG consensus of human CDC25A is also necessary for 
P-TrCP-mediated in vitro ubiquitination (Donzelli et al., 2004; Jin et al., 2003). However, 
S76 is not directly required for binding of P-TrCP to CDC25A. In vivo data revealed that a 
single S76A mutant could still bind to P-TrCP, but a S79A mutant was abolished in p- 
TrCP binding (Jin et al., 2003). Furthermore, a synthetic peptide spanning the BSG region 
(comprising S76, S79 and S82) of CDC25A was able to bind to P-TrCP in vitro when only 
S82 was phosphorylated, but it did not bind to p-TrCP when only S76 was phosphorylated 
(Donzelli et al., 2004; Jin et al., 2003). Single alanine mutations in S76 or S82 resulted in a 
strong decrease o f the CDC25A polyubiquitination rate, whereas mutations of surrounding 
S residues such as S8 8  or S I24 to alanine only caused a slight reduction of CDC25A 
polyubiquitination (Donzelli et al., 2004; Jin et al., 2003). Similarly, S79A abolished 
CDC25A polyubiquitination in vitro (Jin et al., 2003).
Thus, these data indicate that S76, S79 and S82 are the prime target sites of human 
CDC25A interaction with P-TrCP mediated through the DSG motif. Phosphorylation of 
S76 in human CDC25A is mediated by checkpoint kinase 1 (CHK1) in vitro (Hessepass et 
al., 2003). Furthermore, this group showed that UV-induced DNA damage could induce 
S76 phosphorylation in vivo, indicative of an activated CHK1/CHK2 kinase pathway. 
Moreover, CDC25A S76 can be phosphorylated by CHK1 or p38 kinase probably as a 
response to UV-mediated DNA damage and osmotic stress (Goloudina et el., 2003). 
However, during the normal cell cycle knockdown of CHK1 kinase by RNAi did not affect 
the degradation of CDC25A, indicating that in unperturbed cells another kinase is acting 
through this site (Ray et al., 2005). Importantly, the kinases responsible for
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phosphorylation of S79 and S82 have not been identified to date. Thus, P-TrCP-mediated 
degradation of human CDC25A requires a two-step mechanism; phosphorylation of S76 
maybe through CHK1 kinase which is surmised to act as a priming event to phosphorylate 
S82 at the DSG consensus site by an unknown kinase, and subsequent recognition through 
the SCFpTrCP complex (Donzelli et al., 2004; Jin et al., 2003).
3.1.2.4 p-TrCP also recognises DSG-like motifs
Intriguingly, given the high conservation of the DSG motif between C. elegans and human, 
it has recently become apparent that phosphorylation of the strict consensus motif is not 
vital for interaction and degradation of substrates with P-TrCP. A DSG-like motif 
(DDGOXD) present in Xenopus CDC25A and human CDC25B (see Figure 3.1, A) can act 
to recruit P-TrCP in Xenopus egg extracts (Kanemori et al., 2005). Mutational analysis of 
Xenopus CDC25A revealed that within this motif all residues except for the non-conserved 
(X) residue were important to interact with p-TrCP. Alanine mutations of at least two 
residues DDAOXD and DDGOXA resulted in increased CDC25A protein levels and, as 
demonstrated for DDGOXA, a concomitant decrease of the CDC25A polyubiquitination 
rate (Kanemori et al., 2005). Furthermore, these authors demonstrated that a DDAOXA 
mutant present in human CDC25B was unable to bind to p-TrCP, resulting in decreased 
polyubiquitination rate and increased CDC25B stability in Xenopus eggs. Additionally, 
mutational analysis of serine or aspartic acid residues within six to seven amino acids 
upstream of this DDG motif site revealed an important function for negatively charged 
residues as being important for p-TrCP interaction and CDC25A or CDC25B stability.
3.1.3 Conservation of mammalian DSG regulators in C. elegans
In summary, analysis of the general mechanism underlying the control o f DSG motifs in 
higher eukaryotes implicated a central role for the SCF*3'7 1 0  complex in the regulation of 
this target site. Interestingly, several components of the SCFp‘TrGP complex have already 
been identified in C. elegans with CUL-1, the scaffolding protein of the SCF complex 
being the founding member of the human CULLIN family (Kipreos et al., 1996). 
Additionally, out of 326 predicted C. elegans F-box molecules, LIN-23 has been identified 
as the C. elegans orthologue of human P-TrCP, displaying 81-83% identity to P-TrCPl 
and p-TrCP2 in the WD region (Kipreos, 2005; Kipreos et al., 2000; Kipreos and Pagano, 
2000 ). Whereas, of 21 SKP1 related genes (SKR) present in the C. elegans genome, the C. 
elegans SKR-1 displays highest homology to the human SKP1 gene (64% overall identity)
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(Nayak et al., 2002; Yamanaka et al., 2002). Interestingly, analysis of the C. elegans CDC-
25.1 DSG consensus site revealed that it resembles a potential GSK3P phosphorylation site 
similar to the one identified in human P-catenin. The C. elegans genome contains seven 
potential GSK-3 kinases, and recently GSK-3 (previously called SGG-1) was shown to 
display high homology to other eukaryotic GSK3p kinases (Schlesinger et al., 1999). 
Among all members of the C. elegans GSK-3 family, GSK-3 (SGG-1) displays the highest 
homology to human GSK3P (Figure 3.1 (panel B), Ce GSK-3, 71% overall identity), and 
GSK-3 will hereafter refer to this C. elegans GSK-3 kinase. The C. elegans genome 
contains one single APC homologue APR-1, that shares 31% identity to the human APC 
gene in the arm repeat region (Rocheleau et al., 1997). Interestingly, a role for C. elegans 
cell proliferation had already been assigned for LIN-23, CUL-1 and SKR-1, whereas GSK- 
3 and APR-1 play a vital role in the specification of intestinal cells. Hence, these molecules 
could well be involved in the regulation of intestinal cell proliferation.
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Figure 3.1 CDC-25.1 and GSK-3 protein alignm ents. A) A lignm ent o f  the DSG consensus sequence in 
P-TrCP targets. Proteins o f  accession numbers NP 491862, NP 503446, NP 001780, CAB 65556, 
NP 002494, NP 004547, P19838, NP 001895, AAL86610, AAF35359, AAF09263, CAI18849, 
NP 002607, NP 003381 were aligned using the Vector NTI program . B) Top: phylogenetic tree o f  human 
GSK3p (Hs GSK3P, sw issprot accession number: P49841) aligned with C. elegans GSK-3 family 
members. W orm base protein accession num bers are indicated (for Ce GSK-3 in brackets). Bottom: amino 
acid identity (%) o f  the proteins analysed in the top panel. Data are derived from multiple protein 
alignment analysis using the Vector NTI program.
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3.1.3.1 LIN-23 and CUL-1 function during cell proliferation in C. elegans
lin-23 and cul-1 null mutants have recently been characterised by (Kipreos et al., 2000) and 
(Kipreos et al., 1996), respectively. Their proliferation phenotypes are illustrated below. 
Homozygous lin-23 or cul-1 null mutants show hyperplasia of many proliferating tissues 
during their post-embryonic development, indicating that loss of either gene causes a delay 
in cell cycle exit. The onset of the proliferation defect differs slightly, starting at the LI 
larval stage for the lin-23 mutant and at around the L2 larval stage for the cul-1 mutant, 
which is probably caused by the difference of the longevity of maternally provided LIN-23 
and CUL-1. lin-23 and cul-1 heterozygous hermaphrodites proceed normally through 
embryogenesis, suggesting that the half gene-dose from the mother is sufficient for normal 
embryogenesis. Interestingly, lin-23 homozygous null mutants are almost sterile and the 
few embryos produced are not viable. Mosaic analysis of cul-1 null hermaphrodites also 
reveals dying embryos. These embryos arrest without any overt morphogenesis and show 
increased numbers of nuclei as examined by DNA squashes suggesting a 
hyperproliferation defect in the embryo. Thus, maternally provided lin-23 and cul-1 may 
be implicated in restraining normal proliferation of several tissues during embryogenesis.
lin-23 homozygous null hermaphrodites produce the wild-type number of intestinal cells, 
indicating that cells, that have exited the mitotic cycle during embryogenesis remain 
quiescent during post-embryonic development, even without lin-23 present. Unfortunately, 
examination of intestinal cell proliferation during post-embryonic development was 
lacking for the cul-1 mutant. Similarly, the Hobert laboratory recently presented further 
evidence for a proliferative function for lin-23 null mutants during proliferation of post- 
embryonic motor and touch neurons (Mehta et al., 2004). Interestingly, this study 
identified a lin-23(otl) point mutant that showed axonal outgrowth defects of several 
motor and sensory neurons. However, though this point mutation was able to rescue the 
lin-23 null mutant, homozygous lin-23 (oil) showed no proliferation defects of the neurons 
whose proliferation was clearly affected in the homozygous lin-23 null mutant. The otl 
allele results in a P610S mutation in a conserved C-terminal PAPP motif; thus these 
authors concluded that the C-terminus can have distinct roles from the cell proliferative 
function of the N-terminus (comprising the F-box) and the middle domain (comprising the 
WD40 domain).
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3.1.3.2 SKR-1 functions during cell proliferation in C. elegans
Interestingly, SKR-1, the C. elegans SKP1 homologue, has also been shown to display a 
hyperproliferation phenotype. Removal of SKR-1 by RNAi causes hermaphrodites to 
produce dying embryos that arrest between gastrulation and the two-fold stage. DNA 
analysis by DAPI staining revealed a strong increase in the number of nuclei generated in 
those embryos, suggesting that they produce too many cells (Nayak et al., 2002; Yamanaka 
et al., 2 0 0 2 ).
Thus, several C. elegans SCF members, such as LIN-23, CUL-1 or SKR-1, homologous to 
the human SCFp'TrGP complex can be identified. In higher eukaryotes SCFp'TrGP is critically 
involved in the negative regulation of the DSG motif present in many proteins including 
CDC25A. Intriguingly, loss-of-function of lin-23, cul-1 and skr-1 show proliferation 
defects during post-embryonic and maybe embryonic development of several tissues and 
hence their phenotypes fit well with the expected phenotype of a loss of a negative 
regulator during cell proliferation, namely the failure to induce cell cyle exit.
Additionally, GSK-3 and the APC homologue APR-1 have been shown to specify the 
production of intestinal cells in a non-canonical Wnt signalling pathway requiring the 
action of a p-catenin homologue WRM-1. Unlike the canonical Wnt signalling pathway 
GSK-3 is required to activate WRM-1 (rather than down-regulate it as in the absence of the 
canonical Wnt signal of human p-catenin; see Chapter 1 (1.2.2) for details). Nevertheless, 
it is intriguing to note that C. elegans GSK-3 can act in concert with the human APC 
homologue APR-1 to specify intestinal cells. The DSG consensus in CDC-25.1 comprises 
a potential GSK-3 phosphorylation site. Thus, the question whether GSK-3 together with 
APC could act similarly to the canonical Wnt signalling pathway on the stability o f CDC-
25.1 once intestinal cells are bom became apparent. In this case, GSK-3 should be able to 
act together with APR-1 to down-regulate CDC-25.1 through S46 once intestinal cells are 
specified. Unfortunately, so far there were no data regarding the proliferation of intestinal 
cells in embryos that still specify the intestine after removal of GSK-3 (Bei et al., 2002; 
Maduro et al., 2001; Schlesinger et al., 1999) or APR-1 (Bei et al., 2002; Rocheleau et al., 
1997; Rocheleau et al., 1999).
3.1.4 Hypothesis and aims
It was hypothesised in the Johnstone lab that CDC-25.1 is negatively regulated through 
S46, possibly only in intestinal cells during embryogenesis. Possible candidates that might
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act as negative regulators are LIN-23, CUL-1, SKR-1 or GSK-3 and APR-1. Preliminary 
RNAi data obtained in the Johnstone laboratory prior to this study implicated a role for 
LIN-23 and GSK-3 in proliferation of intestinal cells as lin-23 and gsk-3 RNAi caused 
extra intestinal cells (I. L. Johnstone, pers. comm.). Hence, experiments were set up to test 
whether members of the C. elegans SCF complex such as LIN-23, CUL-1 or SKR-1 as 
well as GSK-3 and APR-1 can act as negative regulators on S46 of CDC-25.1 in embryos. 
Removal of the negative regulator was predicted to cause intestinal hyperplasia during 
embryogenesis, similar to the phenotype observed for the cdc-25.1(ij48) allele. To this end, 
RNAi was to be utilised to down-regulate the protein levels of potential candidates in 
embryos. The embryos would then be examined for intestinal hyperplasia. Genes with 
RNAi phenotypes were to be further examined to analyse whether they can act through the 
ij48 allele on cdc-25.1 by comparison of RNAi in wild-type and cdc-25.1(ij48) mutants. In 
order to see whether the negative regulator can act in a tissue-specific fashion, the cell 
numbers of other tissues were to be examined, by utilising strains that express tissue- 
specific GFP markers.
3.1.4.1 Introduction to RNAi in C. elegans
Here, a reverse genetic approach, termed RNA-mediated interference (RNAi), is utilised to 
study negative regulators of CDC-25.1 function during embryonic development. In order 
to facilitate the understanding of the method, a short introduction to the RNAi methods 
utilised in C. elegans is given below. RNAi was first discovered and characterised in C. 
elegans (Fire et al., 1998). It has also been demonstrated to act in a variety of systems 
including plants, fungi, Drosophila and mammalian tissue culture cells (Grishok, 2005). In 
C. elegans Fire et al. first reported that RNA expressed from a transgene could mimic a 
null mutation of that gene (Fire et al., 1991). Subsequently Guo and Kemphues showed 
that both sense or antisense RNA caused downregulation of gene expression in the 
germline (Guo and Kemphues, 1995). Fire et al. termed this mechanism RNAi and 
established that it is induced by double-stranded RNA and that in C. elegans this process is 
systemic and heritable. In C. elegans, RNAi can be applied by injection (Fire et al., 1998) 
or soaking (Tabara et al., 1998) worms with dsRNA, or by feeding worms E. coli that 
expresses double-stranded RNA from an IPTG-inducible T7 promoter (Timmons et al., 
2001; Timmons and Fire, 1998).
It has become evident that RNAi mediates the post-transcriptional silencing of endogenous 
genes. Induction of RNAi in C. elegans by injection of double-stranded RNA caused 
downregulation of a gene downstream of the RNAi target gene present in a single operon.
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RNAi against the target gene resulted in embryonic lethality indicative of a loss-of- 
function phenotype of the downstream gene, whereas a null mutant of the target gene was 
viable. This indicated that RNAi can target pre-mRNA of two genes that are expressed 
from a single transcript (Bosher et al., 1999). The RNAi mechanism has been the object of 
intensive studies from many laboratories, and identification of C. elegans mutant alleles 
defective in RNAi have contributed to our knowledge of how RNAi functions. During 
post-transcriptional gene silencing, double-stranded RNA is cleaved into 21-23 nt short 
interfering RNAs (siRNAs) by the DICER complex, and subsequently endogenous mRNA 
levels are degraded through the RNAi-induced silencing complex (RISC) that utilises a 
single-stranded siRNA as a primer to anneal to the mRNA and induce degradation of the 
mRNA (see (Grishok, 2005) for review).
Interestingly, if RNAi is applied in C. elegans it causes the spread of the RNAi signal 
throughout the animal, thus indicating that RNAi is systemic. Furthermore, when adults are 
subjected to RNAi, an RNAi phenotype can be observed in the treated adult. Besides, a 
transfer of the RNAi signal to their offspring is evident resulting in offspring that can 
display a phenotype indicative of a null mutation or loss-of-function mutation of the target 
gene (Fire et al., 1998). This systemic and heritable RNAi phenotype can be induced by 
exogenous dsRNA independent of the method applied (Fire et al., 1998; Tabara et al., 
1998; Timmons et al., 2001; Timmons and Fire, 1998). However, the strongest phenotypes 
are observed after RNAi by injection when compared to the soaking or feeding method 
(Tabara et al., 1998). Genes involved in the spread of systemic RNAi have been identified 
in C. elegans and involve a transmembrane protein SID-1 which is surmised to act as a 
channel protein facilitating the uptake of cellular dsRNA (Feinberg and Hunter, 2003; 
Winston et al., 2002). Expression of the SID-1 protein in Drosophila cells, that do not 
normally express a SID-1 protein, facilitates the uptake of dsRNA. Interestingly, the 
uptake of dsRNA was increased with target size, indicating that systemic RNAi in C. 
elegans requires at least several hundred base pairs in order to function throughout the 
animal. Consistently, longer dsRNAs were shown to function as preferred substrates for 
systemic RNAi in C. elegans (Feinberg and Hunter, 2003). The precise mechanism of 
systemic RNAi uptake and inheritance signals is still under investigation and is not the 
focus of this study.
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3.2 Results
3.2.1 RNAi to identify negative regulators o f CDC-25.1
In order to determine whether members of the C. elegans SCF complex such as LIN-23, 
CUL-l or SKR-l are involved in the regulation of CDC-25.1, RNAi was performed by 
feeding worms bacteria that express double-stranded RNA against the target genes, 
synthesised from a vector that carries the target gene between two IPTG-inducible T7 
promoters. The exact size and position of the double-stranded target RNAs are displayed in 
(Table 2.17, Chapter 2). As control, bacteria were utilised that contain only the empty 
vector. It was proposed that removal of a negative regulator would result in intestinal 
hyperplasia similar to the phenotype observed with cdc-25.1 (ij48).
Thus, the C. elegans strain JR1838 that carries an intestinal-specific marker was utilised 
for this purpose. JR1838 carries a chromosomally integrated GFP transgene fused to LacZ 
under the expression of the elt-2 promoter (elt-2::GFP::LacZ, termed elt-2::GFP hereafter 
for simplicity). This strain is otherwise like wild-type and induces tight expression of the 
GFP in the nuclei of intestinal cells (when 2 E cells are bom in the embryo until adulthood) 
due to the presence of a nuclear localisation signal present in the GFP (Clucas, 2003; 
Clucas et al., 2002). The C. elegans intestine consists o f 20 cells that are generated in the 
embryo and are manifested in the hatching larva. Cell lineage analysis and the expression 
of an intestinal-specific elt-2: :GFP reporter previously revealed that the cdc-25.1 (ij48) 
gain-of-function allele promotes a tissue-specific hyperplasia of intestinal cells (Clucas, 
2003; Clucas et al., 2002). Thus the elt-2: :GFP transgene can act as an indicator for the 
proliferation of intestinal cells in the embryo.
Interestingly, here it is shown that when worms were fed on plates with bacteria expressing 
double-stranded RNA against lin-23, cul-1 and skr-1, a strong increase in the number of 
intestinal nuclei became evident in the embryos derived from RNAi-fed mothers (Figure 
3.2, Table 3.2). lin-23 RNAi embryos show otherwise no developmental abnormality as 
compared to the control embryos under these RNAi conditions when visualised in 
Nomarski optics. However, embryos depleted for cul-1 and skr-1 arrest at around the 
comma stage, similar to previous results (Kipreos et al., 1996; Nayak et al., 2002; 
Yamanaka et al., 2002). To ensure that the RNAi was specific to the genes investigated, 
several controls were carried out. Firstly, RNAi was performed against close homologues
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of the genes investigated. SEL-10 has been demonstrated to display closest homology to 
LIN-23 (Kipreos et al., 2000). However, when RNAi was performed against sel-10 all 
embryos displayed the wild-type number o f intestinal cells (19.3 ± 1.5 cells, (mean ± s.d.), 
n=50, two independent experiments).
Similarly, RNAi against the cul-1 paralogue cul-2 (Kipreos et al., 1996) resulted in 
embryonic arrest in around 1 0 0  embryos analysed, but none of those embryos showed an 
increase in the numbers of intestinal nuclei (exact numbers of intestinal cells were not 
determined, but were clearly not above 20). Furthermore, when RNAi was performed 
against the skr-1 homologue skr-3, that has been shown to interact with cul-1 in a yeast 
two-hybrid system (Nayak et al., 2002; Yamanaka et al., 2002), embryos showed the wild- 
type number of intestinal nuclei (20.1 ± 0.5, (mean ± s.d.), n=53, one experiment). Thus, 
this indicated that the hyperplasia seen is not due to non-specific knockdown of unrelated 
genes. Another control experiment was carried out that targets a different part of the lin-23 
mRNA. The lin-23 RNAi displayed in Figure 3.2 targets a 1126 bp fragment of the pre- 
mRNA starting at position +685 relative to the genomic ATG. A second lin-23 RNAi clone 
was designed (lin-23 RNAi 2) that targets 874 bp of the pre-mRNA starting at position 
+1812, creating no overlap to the first target lin-23 RNAi. Analysis of embryos derived 
from hermaphrodites treated with lin-23 RNAi or lin-23 RNAi 2 revealed that both 
displayed a similar increase in the number of intestinal cells compared to wild-type 
(intestinal nuclei: 31.4 ± 3.4 for lin-23 RNAi (n=62 embryos), 32.6 ± 4.3 for lin-23 RNAi 
2 (n=81), 19.8 ± 0.8 for control RNAi (n=6 6 ), numbers display mean ± s.d., two 
independent experiments). Thus, it can be concluded that the hyperplasia phenotype 
observed through lin-23 is specific to the lin-23 knockdown.
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Figure 3.2 C. elegans excess endoderm phenotypes. Left panel: GFP fluorescence o f the 
J R 1838 strain carrying the elt-2::GFP transgene, expressed in intestinal nuclei, was analysed 
at the comma stage (control, skr-1, wrm-1), 1.5-fold stage (lin-23), 2-fold stage (apr-1) or 
early arrested embryos (cul-1, gsk-3) after control, lin-23, cul-1, skr-1, gsk-3, apr-1 or wrm-1 
RNAi, right panel: corresponding Nomarski counterparts. For quantification o f  cell numbers 
see Table 3.2. Scale bar: 10 pm.
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To further elucidate the role of gsk-3 to act as a potential kinase negatively regulating 
CDC-25.1, the intestinal cell proliferation phenotype was analysed after gsk-3 RNAi. 
When RNAi was performed by feeding worms on plates with E. coli expressing double­
stranded RNA against the C. elegans gsk-3, a percentage of embryos did not express the 
intestinal-specific GFP marker, indicating that the RNAi was specific to gsk-3 because it 
was previously established that removal of gsk-3 caused a loss of endoderm in RNAi- 
treated embryos (Schlesinger et al., 1999), a phenotype later also observed by (Bei et al., 
2002). However, embryos arresting at an early stage of development and expressing the 
intestinal fate marker showed a mixed number of intestinal cells, with many embryos 
displaying clearly above 20 intestinal cells (Figure 3.2, Table 3.2). In a control experiment 
targeting the closest C. elegans GSK-3 homologue (Figure 3.1, CE08727), all embryos 
displayed wild-type numbers of intestinal cells (2 0 , exact number not determined (n > 
400), two independent experiments).
Thus, this experiment suggested that gsk-3 might be involved in the proliferation of 
intestinal cells once the intestine is specified. Since in the mammalian system, GSK3P can 
act together with APC to phosphorylate p-catenin (see introduction this chapter), the role 
of the C. elegans APC homologue APR-1 in proliferation of intestinal cells was 
investigated. RNAi against apr-1 was performed by microinjection of double-stranded 
RNA targeting the apr-1 mRNA. Microinjection was necessary since feeding resulted in 
only a very mild phenotype. Similar to the gsk-3 RNAi experiments, a percentage of 
embryos did not express the intestinal fate marker elt-2::GFP, suggesting that the RNAi 
was specific to APR-1 since previous experiments had shown that apr-1 is required for 
endoderm specification (Bei et al., 2002; Rocheleau et al., 1997; Rocheleau et al., 1999). 
Interestingly, among those embryos expressing the intestinal fate marker elt-2::GFP 
several embryos displayed excess numbers of intestinal nuclei (Figure 3.2, Table 3.2).The 
precise number of embryos displaying hyperplasia among the total population was not 
quantified since in the experiments a spectrum of the severity of the RNAi phenotype was 
observed ranging from embryos without elt-2::GFP expression, or with elt-2::GFP 
expression in less or more than 20 nuclei. This phenotype was also observed after gsk-3 
and wrm-1 RNAi and in all cases only embryos without elt-2::GFP expression or with an 
elt-2::GFP expression in 20 or above 20 nuclei were counted. The percentage of no E 
expression was derived from all embryos counted. Among the FI escapers of apr-1 RNAi, 
none showed an increase in the number of intestinal nuclei, suggesting that the embryos 
that possess extra nuclei are not viable. In order to identify whether the nuclei analysed 
were the result of extra intestinal cells being bom in the embryo, cell lineage analysis was
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carried out by Dr. J. Cabello using the JR1838 strain and RNAi conditions established in 
this study (for details see (3.2.5)). Several embryos depleted by RNAi against gsk-3 or lin- 
23 were analysed. It was shown that RNAi against both genes resulted in extra cells that 
were generated from extra divisions of the E blastomere in the embryo. Hence, the number 
of intestinal nuclei observed with the expression of the intestinal-specific elt-2::GFP 
marker reflects the number of intestinal cells generated in the embryos and are not 
additional nuclei evolved through extra rounds of karyokinesis. Thus, these data 
established that members of the C. elegans SCF complex LIN-23, CUL-1 and SKR-1 as 
well as GSK-3 and APR-1 are necessary to control the numbers of intestinal cells being 
bom in the embryo, implying they could act to negatively regulate CDC-25.1 in the 
embryo.
3.2.2 lin-23 RNAi mimics the tissue-specific phenotype of cdc- 
25.1 (ij48)
Since embryos derived after lin-23 RNAi seemed to develop relatively normally compared 
to embryos in all other RNAi experiments investigated here, these embryos were examined 
further in order to determine whether the removal of lin-23 would affect proliferation of 
other tissues. RNAi was compared directly in three strains carrying tissue-specific GFP 
markers: JR1838 wls84 carrying the intestinal-specific GFP, JR667 wls51 carrying a seam 
cell reporter GFP and IA105 wls!2  carrying a GFP reporter that is expressed in 
hypodermal nuclei (for strain genotypes see Chapter 2, Table 2.7). Under conditions where 
lin-23 RNAi resulted in a strong hyperplasia of intestinal cells as analysed in embryos that 
reached a stage prior to hatching, no increase in the number of seam cell or hypodermal 
cell nuclei was seen (Figure 3.3, top). It should be noted that lin-23 RNAi resulted in 100% 
of the embryos displaying the intestinal hyperplasia phenotype to a variable degree with 
normal-appearing embryos displaying the milder phenotype. The numbers of GFP-positive 
nuclei were quantified in three-fold stage embryos, and whereas there was a clear increase 
in the number of intestinal nuclei after lin-23 RNAi compared to the control RNAi, no 
increase was observed for the seam cells or hypodermal cell nuclei (see Figure 3.3, 
bottom). All three strains were affected by removal of lin-23, because they displayed a 
similar hatch rate after lin-23 RNAi (Table 3.1).
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%  hatch rate 
control RNAi
% hatch rate 
lin-23 RNAi p-value
mean % 
decrease 
lin-23 RNAi
elt-2:: GFP 98.0 ±2.6
(n=186)
80.7 ±8.9 
(n=198)
<0.05 17.7
scm::GFP 94.1 ±6.1
(n=437)
6 6 . 6  ±10.9
(n=611)
<0.05 29.2
dpy-7::GFP 99.1 ±1.0
(n=415)
73.5 ±5.9 
(n=447)
< 0 . 0 1 25.6
Table 3.1 lin-23 RNAi affects different C. elegans strain backgrounds equally. J R 1 8 3 8  w ls84  
(elt-2::GFP , intestinal G FP ),  J R 6 6 7  wls51  (scm::GFP , s e a m  cell G F P )  a n d  IA105 w ls12  (dpy- 
7::GFP, hy p o d e rm a l  G F P )  a r e  all sens i t ive  to lin-23 RNAi by feed ing  on p la tes ,  m e a n  ± s.d., p- 
value: two-tailed S tu d e n t ’s  f-test, n= n u m b e r  of e m b ry o s  from th re e  in d e p e n d e n t  e x p e r im e n ts .
Hence, around 80% of the animals depleted by lin-23 through RNAi can hatch and have a 
normal body morphology. They are viable and can reach adulthood, although they become 
sterile as adults. FI animals that survived lin-23 RNAi show on average 4.2 ± 3.3% F2 
offspring compared to 1 0 0 % offspring that is produced from FI animals when treated with 
control RNAi when analysed 24 hrs after RNAi-treated FI animals reached adulthood (25 
JR1838 FI each, three independent experiments, the total brood size was not determined). 
However, embryos with a very strong hyperplasia were also observed which did not 
undergo any morphogenesis and probably represent the approximately 2 0 % of embryos 
that are dying (Table 3.1) Thus, it was possible to establish conditions where knockdown 
of LIN-23 from the embryos affected primarily the proliferation of intestinal cells, but cell 
lineages such as the hypodermal and seam cells (depicted in Figure 3.3) remained 
unaffected. Thus, removal of lin-23 by RNAi mimics the tissue-specific hyperproliferation 
phenotype of cdc-25.1(ij48).
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19.4 ± 1.2 
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62.3 ± 7.4 
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Figure 3.3 lin-23 RNAi mimics the cdc-25.1(ij48) intestine-specific hyperproliferation phenotype.
Top: GFP fluorescence phenotypes and corresponding Nomarski counterparts o f  strain JR. 1838 carrying 
elt-2::GFP  expressed in intestinal nuclei (int.), JR667 wls51 carrying a seam cell reporter (seam) and 
1A105 carrying the hypodermal dpy-7::GFP (hyp.) in control or lin-23 RNAi embryos at the three-fold 
stage. Scale bar: 10 pm. Bottom: Quantification o f  GFP-positive nuclei from the experiments performed 
as above (mean ± s.d., in brackets number o f  embryos from two independent experiments).
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3.2.3 SCF members control proliferation of intestinal cells 
through S46 in CDC-25.1
The tissue-specific nature of the lin-23 RNAi phenotype suggested that lin-23 might act 
through S46 in CDC-25.1 to control the proliferation of the intestine. In order to clarify 
this point the following experiment was carried out. If LIN-23 can act through S46 of 
CDC-25.1, it would be anticipated that removal of lin-23 in a cdc-25.1(ij48) mutant 
background would not result in an additional increase of intestinal cells as compared to 
removal of lin-23 by RNAi in a wild-type strain (i.e. the effects of lin-23 RNAi and the 
cdc-25.1 (ij48) mutation would not be additive).
3.2.3.1 Strain generation to visualize intestinal cells
Therefore, a new strain was generated in order to visualize the number of intestinal cells in 
cdc-25.1 (ij48) mutants. This strain was derived by crossing heterozygous IA268 cdc-
25.1 (ij48) males into JR1838 wls84 carrying the intestinal-specific elt-2::GFP transgene. 
GFP-positive F2 progeny displaying strong intestinal hyperplasia were picked and checked 
for homozygosity of the cdc-25.1 (ij48) allele, by single worm PCR and using restriction 
enzyme digestion to check for restriction site polymorphism that is introduced through the 
mutation in cdc-25.1 (data not shown, for an example see Chapter 7, Figure 7.2). The 
resulting strain, IA530 cdc-25.1 (ij48) wls84, was utilised for most applications throughout 
this study.
3.2.3.2 Analysis of intestinal cell numbers
Analysis of the average number of intestinal cells in the embryos of a wild-type strain 
JR1838 compared to IA530 cdc-25.1 (ij48) revealed an increase from 19.7 to 29.5 intestinal 
cells when the control RNAi was applied at 20°C similar to results previously reported 
(Table 3.2) (Clucas, 2003; Clucas et al., 2002). However, at 25°C, on average 19.9 nuclei 
were detected after control RNAi in JR1838, increasing to only 24.1 nuclei in IA530 cdc-
25.1 (ij48), indicating that the cdc-25.1 (ij48) allele is temperature-sensitive. Nevertheless, 
to ensure a visible phenotype the lin-23 RNAi had to be carried out at 25°C. In a control 
experiment, removal of the transcription factor pop-1 was performed. This causes a switch 
of the anterior mesodermal sister-cell (MS) of the intestinal precursor (E) to adopt an E 
fate, such that EMS produces two E cells instead of MS and E (Lin et al., 1995; Thorpe et 
al., 1997). This mechanism is distinct from the mechanism of CDC-25.1-mediated 
proliferation, and thus pop-1 RNAi results in double the numbers of intestinal cells (Table
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3.2). Consistent with the two genes acting in separate pathways, when pop-1 RNAi is 
performed in the cdc-25.1 (ij48) background, a significant 1.2-fold synergistic increase of 
intestinal cells was detected (Table 3.2). In contrast, lin-23 RNAi performed in the wild- 
type strain JR1838 caused on average 36.9 intestinal cells to be bom, but no significant 
difference was detected when lin-23 RNAi was performed in IA530 cdc-25.1 (ij48) (Table
3.2) suggesting that lin-23 may act through the ij48 site of cdc-25.1. Similarly, cul-1 RNAi 
did not result in any synergistic effect on the intestinal cell numbers when combined with 
cdc-25.1 (ij48) (Table 3.2). A slight, but significant increase in the numbers of intestinal 
cells was detected when skr-1 RNAi was performed in a wild-type compared to cdc-
25.1 (ij48) mutant background (Table 3.2). The possible reason for the slight additive effect 
will be discussed below (3.3.1.1). In summary, these data suggest that members of the C. 
elegans SCF complex such as LIN-23 or CUL-1 can act through the ij48 site on cdc-25.1 
because knockdown of these proteins by RNAi does not result in an additive phenotype 
when performed in the cdc-25.1 (ij48) mutant background.
RNAi JR1838 cdc-25.1 (+)
IA530 
cdc-25.1 (ij4 8) p-value
Fold
increase
% Hatch 
(JR1838 / 
IA530)
control
25°C
19.9 ±0 .9  
( n - 176/6)
24.1 ±3 .9  
(n=298/6)
<0.001 1.2 98.8 ±0 .4  98.4 ± 1.5
pop-1 41.9 ± 7.8
( n - 175/3)
49.2 ±11.1
(n= 152/3)
<0.001 1.2 < 1 < 1
lin-23 36.9 ±7.8 (n= 154/4)
35.4 ±6.8 
(n= 156/4)
n.s. 1.0 73.2 ± 10.8 69.8 ± 13.2
skr-1 35.7 ±7.5 
(n= 130/3)
38.6 ±9 .2  
( n - 133/3)
<0.01 1.1 2.9±  1.1 1.2 ± 1.2
cul-1 32.6 ±5.3 
(n= 129/2)
32.9 ±5 .0  
(n= 134/2)
n.s. 1.0 56.0 ±4.2 44.7 ±20.1
gsk-3 27.5 ±5.8
(n= 176/3)
34.6 ±8 .7  
(n=l 87/3)
<0.001 1.3 27.2 ±5 .4  20.8 ± 10.2
control
20°C
19.7 ±0.6
(n=22/l)
29.5 ±3 .2
(n=60/l)
<0.001 1.5 n.d.
apr-1 27.1 ±4 .9  
(n=47/3)
34.9 ±5 .9  
(n=76/3)
<0.001 1.3 n.d.*
wrm-1 23.4 ±5.3 
(n= 146/2)
34.2 ±7 .6  
(n=77/2)
<0.001 1.5 n.d.*
Table 3.2 Quantification of intestinal nuclei in cdc-25.1 (+) (JR1838) and cdc-25.1 (ij48) (IA530) 
strains with or without gene-specific RNAi. RNAi w a s  per fo rm ed  a s  ind icated .  For lin-23 RNAi 
th e  e m b ry o s  d isp lay  th e  mild RNAi phen o ty p e ,  all e m b ry o s  with elt-2::GFP  e x p re s s io n  in a b o v e  19 
nuclei w e r e  c o u n te d  in all c a s e s .  For RNAi by injection (control 20°C, apr-1 a n d  wrm-1): apr-1 RNA 
w a s  very diluted (0.2 pig/pil) c o m p a r e d  to la ter ex p e r im en ts ,  only a  few  e m b ry o s  s h o w e d  a  
p h e n o ty p e  but th a t  w a s  s t ro n g e r  c o m p a r e d  to  la ter  e x p e r im en ts ,  wrm-1 d sR N A  w a s  diluted to 0 .5  
pg/pl prior to injection. For RNAi by injection th e  lo ss  of e n d o d e r m  se rv e d  a s  internal control for 
functional RNAi. * = % no E p h eno type :  17.4 ± 10 a n d  16.0 ± 15.0 for apr-1, 7 4 ,6  ± 7 .5  a n d  6 9 .7  ± 
7 .0  for wrm-1 in J R 1 8 3 8  o r  IA530, respectively .  n.d .= not d e te rm in e d ,  m e a n  ± s.d., p-value: two- 
tailed S tu d e n ts  L te s t  of wild-type c o m p a r e d  to cdc-25.1 (ij48), n.s.: p >0.05, n= n u m b e r  of e m b ry o s  
with elt-2::GFP  e x p re s s io n  in 19 nuclei a n d  a b o v e / in d e p e n d e n t  ex p e r im en ts .
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3.2.4 gsk-3 and apr-1 act independently of cdc-25.1 (ij48)
To determine whether GSK-3 could be the kinase phosphorylating S46 in CDC-25.1, a 
comparison of gsk-3 RNAi in JR1838 compared to IA530 cdc-25.1 (ij48) was performed. 
However, the combination of gsk-3 RNAi and the cdc-25.1 (ij48) lesion was found to be 
additive, with a significant 1.3-fold increase in the number of intestinal cells being evident 
(Table 3.2). This implies that removal of gsk-3 acts independently of the ij48 site of cdc-
25.1. A  similar result was detected for the apr-1 RNAi. This experiment was performed by 
microinjection of apr-1 dsRNA into the gonads of adult hermaphrodites. Offspring were 
analysed after incubation at 20°C for 24 hours. A significant 1.3-fold increase from 27.1 
intestinal cells in JR1838 to 34.9 intestinal cells in IA530 cdc-25.1 (ij48) was detected after 
apr-1 RNAi. Thus, gsk-3 and apr-1 function independently of the ij48 site in cdc-25.1.
3.2.5 Cell lineage analysis (by Dr. J. Cabello)
In order to determine whether the GFP-positive nuclei analysed were indeed the result of 
extra cells being bom in the embryo, a cell lineage analysis was carried out in collaboration 
with Dr. J. Cabello (Prof. Dr. R. Schnabel laboratory, Germany) who performed the 
experiments. The transparency of the C. elegans embryo permits the precise tracking of 
cell divisions of all embryonic cells over time with the aid of four-dimensional microscopy 
(Schnabel et al., 1997). The two strains JR1838 cdc-25.1 (+) and IA530 cdc-25.1 (ij48) 
were analysed (under RNAi conditions established in this study) for the proliferation of the 
E (intestine) and C (hypodermis and body muscle) lineage, and the fate determination of 
intestinal cells was followed by the expression of the elt-2::GFP marker present in both 
strains (indicated by green vertical lines). A representative result is depicted in Figure 3.4 
in each case the two lineages (E (top) and C (bottom) are derived from the same embryo. 
In a wild-type strain (JR1838), the progenitor cell E divides over time, resulting in 16 
intestinal cells that are bom after the fourth division at around 200 minutes post­
fertilisation, of these only four cells undergo a further fifth round of division at about 330 
minutes post-fertilisation generating 20 intestinal cells that all express the intestinal fate 
elt-2::GFP marker (Figure 3.4, Wild-type).
3.2.5.1 Cell lineage after lin-23 RNAi
Interestingly, when lin-23 RNAi was performed in this strain a general shortening of the 
cell cycle was observed such that the fourth and fifth divisions take place at 160 and 250 
minutes, respectively (Figure 3.4, Wild-type, lin-23 RNAi). Unlike in the wild-type, all
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cells bom after the fourth cleavage undergo a further fifth division leading to excess 
intestinal cells. The shortened cell cycle and hyperplasia is indistinguishable from that 
previously shown for the cdc-25.1 (ij48) allele (Clucas, 2003; Clucas et al., 2002). 
However, lin-23 RNAi causes a more robust failure to exit the cell cycle than the variable 
effect previously observed for the cdc-25.1(ij48) allele. The embryo analysed here displays 
a strong lin-23 RNAi phenotype because the embryo does not undergo morphogenesis (J. 
Cabello pers. communication). In this embryo lin-23 RNAi causes a fate-change in Cp, the 
posterior daughter of C, which develops ectopically as endoderm expressing elt-2::GFP 
fate (Figure 3.4, Wild-type, lin-23 RNAi bottom). Note that the timing of the Cp divisions 
is enhanced compared to a wild-type E lineage. The cdc-25.1 (ij48) mutant does not 
enhance the effect of lin-23 RNAi when lin-23 RNAi is performed in a cdc-25.1(ij48) 
mutant background; both the timing and numbers of E and the Cp-transformed E cells 
appear indistinguishable from the lin-23 RNAi alone (cdc-25.1 (ij48), lin-23 RNAi). Thus, 
removal of lin-23 causes a true hyperplasia of endodermal cells through a shortening of the 
cell cycle and a cell cycle exit defect after the fourth division. Under strong RNAi 
conditions a Cp to E fate switch is observed, that is not apparent in embryos with mild 
RNAi phenotype that undergo morphogenesis and display only hyperplasia of E (J. 
Cabello, pers. comm.).
3.2.5.2 Cell lineage after gsk-3 RNAi
A similar lineage analysis was carried out to study gsk-3 function, gsk-3 RNAi causes Ea, 
the anterior daughter of E, to develop with non-endodermal fate (cells do not express the 
elt-2::GFP marker), while Ep, the posterior daughter develops as endoderm (Figure 3.4) 
similar to previous reports (Bei et al., 2002; Schlesinger et al., 1999). But no lineage data 
was available previously. Interestingly, whereas in the wild-type a lengthened cell cycle is 
incorporated when Ea and Ep divide (Figure 3.4, see first to second division in Wild-type), 
after gsk-3 RNAi the first cleavage of Ep is faster than in the wild-type (see first to second 
division in wild-type, gsk-3 RNAi) and the first long cell division occurs after Ep divides 
(Figure 3.4, see second to third division in Wild-type, gsk-3 RNAi). Furthermore, after gsk- 
3 RNAi all cells undergo further divisions in subsequent cleavages and in the embryo 
recorded no exit of the cell cycle was observed. Thus, gsk-3 RNAi results in an aberrant Ep 
lineage with more cells bom than in wild-type. Also, in more severe cases it was observed 
that Epl developed as non-endoderm with only Epr developing as endoderm. However, 
unlike for lin-23 RNAi, no severe shortening of the cell cycle was observed. Interestingly, 
the Cp cell develops with endodermal fate after removal of gsk-3. A similar result was 
previously demonstrated but no cell lineage analysis was performed in those studies
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(Maduro et al., 2001; Schlesinger et al., 1999). Intriguingly, the cell cycle length in the Cp 
to E transformed lineage is comparable to the cell cycle length of a wild-type E lineage 
(Figure 3.4, compare Wild-type E with Wild-type, gsk-3 RNAi in C). Clearly, this cell 
cycle length is different from the shortened Cp to E transformed lineage after lin-23 RNAi 
(Figure 3.4, compare Wild-type, lin-23 RNAi with gsk-3 RNAi in C). Significantly, when 
gsk-3 RNAi is performed in the cdc-25.1 (ij48) mutant, a further shortening of the cell cycle 
is observed for both the E and the Cp to E transformed lineage as compared to gsk-3 RNAi 
in the wild-type (Figure 3.4).
3.2.5.3 Cell lineage summary
Hence, these data provide significant evidence for a lin-23 function to restrain proliferation 
of intestinal cells. Most cells undergo a fifth or sometimes even sixth (not shown) division 
through a major shortening of the cell cycle that is mediated through cdc-25.1 (ij48), since 
no additive effect has been observed in the mutant background, consistent with lin-23 
acting through the site of the ij48 lesion. Removal of gsk-3 causes a phenotype different 
from that observed by loss of lin-23. GSK-3 knockdown causes a shortening of the first 
cell cycle length in E, a phenotype not observed after LIN-23 knockdown. However, 
subsequent cell divisions of both the E and the Cp to E transformed lineage are similar to a 
wild-type E lineage, but all cells expressing endodermal-fate fail to exit the cell cycle after 
the fourth cleavage. The cell cycles of both lineages remain sensitive to the presence of the 
cdc-25.1 (ij48) mutant causing a further shorting of the cell cycle when combined with gsk- 
3 RNAi. Thus, gsk-3 does not promote cell cycle transition through the ij48 lesion of cdc-
25.1.
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3.2.6 gsk-3-mediated extra intestinal cells requires wrm-1
Since knockdown of GSK-3 and APR-1 caused an additive effect when RNAi was 
performed in cdc-25. l( ij48) mutants, it suggested that GSK-3 and APR-1 cause extra 
intestinal cells through a pathway independent of CDC-25.1. During the specification of 
intestinal cells via a non-canonical Wnt signalling pathway, these two genes act in concert 
on wrm-1, the C. elegans homologue of human p-catenin (Rocheleau et al., 1997). In this 
pathway, WRM-1 levels are required in E in order to specify intestinal cells. However, it 
remained to be established whether proliferation of intestinal cells, once specified, requires 
the presence of wrm-1. Interestingly, wrm-1 RNAi results in 74.6% of embryos not 
expressing the intestinal fate marker elt-2::GFP (Table 3.3). However, embryos that do 
express the intestinal fate show a variable number of intestinal cells, including embryos 
with excess endoderm phenotype (Figure 3.2). Similar to gsk-3 RNAi, wrm-1 RNAi caused 
a significant 1.5-fold increase of intestinal cells in JR1838 compared with IA530 cdc- 
25. I(ij48) (Table 3.2, only embryos with extra intestinal cells were counted).
A combined approach of RNAi was performed in order to test whether gsk-3, apr-1 and 
wrm-1 act independently to promote the increased numbers in intestinal cells. Here, 
dsRNA against a single gene or two genes was injected at equal concentrations into the 
gonad of adult hermaphrodites, and the FI embryos examined after 24 hours of incubation 
at 20°C and only embryos with more than 19 intestinal cells were counted. Although all 
RNAi resulted in extra intestinal cells, no significant increase could be detected for any of 
the combinations tested (Table 3.3). Hence, gsk-3 appears to act together with wrm-1 and 
apr-1 to induce extra intestinal cells.
RNAi Num ber of E p-value %  no E
gsk-3 24.2 ±3 .9  (n= 141) n.s. 18.5 ± 1.7
wrm-1 23.4 ±5.3 (n=146) n.s. 74.6 ±7.5
apr-1 23.2 ±3 .0(n=182) n.s. 12.6 ± 5.1
wrm-1 gsk-3 23.3 ±4.5(n=126) n.s. 74.0 ± 4.2
gsk-3 apr-1 23.4 ±2 .7  (n-103) n.s. 21.7 ± 1.8
wrm-1 apr-1 23.6 ±4 .7  (n=98) n.s. 70.9 ±2 .2
Table 3.3 gsk-3 double RNAi with apr-1 and wrm-1 in a cdc-25.1(+) (JR1838) strain. RNAi w a s  
per fo rm ed  by injection of d s  RNA a g a in s t  th e  ind icated  g e n e s .  d sR N A  w a s  diluted to 0 .5 ng/pl 
{wrm-1) a n d  2 pg/pl {gsk-3, apr-1) prior to injection, two in d e p e n d e n t  e x p e r im e n ts  for e a c h  doub le  
RNAi, th re e  in d e p e n d e n t  e x p e r im e n ts  for e a c h  s ing le  RNAi. m e a n  ± s.d .,  n= n u m b e r  of e m b ry o s  
ex p re s s in g  elt-2::GFP  in m o re  th a n  19 cells, p-value: Kruskal-Wallis test ,  n.s.: p > 0.05.
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To validate this experiment further, RNAi was carried out against the two other wrm-1 
homologues bar-1 and hmp-2 (Eisenmann et al., 1998; Natarajan et al., 2001). RNAi 
against bar-1 resulted in no visible embryonic phenotype when applied by feeding (Table 
3.4) or microinjection of dsRNA (data not shown). A weak decrease in the embryonic 
hatch rate was observed and several mothers displayed a post-embryonic ruptured-vulva 
phenotype when observed under the microscope, similar to previous reports, indicating that 
the RNAi was indeed targeting bar-1 (Kamath et al., 2003; Simmer et al., 2003). However, 
RNAi against hmp-2 caused a strong embryonic lethality (Table 3.4), similar to previous 
reports (Fraser et al., 2000; Lehner et al., 2006; Piano et al., 2002; Sonnichsen et al., 2005) 
and indicating that the RNAi is functioning. However, all embryos analysed exhibited a 
wild-type number of intestinal cells and hmp-2 RNAi did not suppress the gsA;-3-mediated 
extra intestinal cells (Table 3.4). Knockdown of GSK-3 by RNAi in some animals results 
in birth of additional intestinal cells, and in others there is a loss of intestinal cells. But no 
significant difference was detected when gsk-3 RNAi was combined with bar-1 or hmp-2 
(Table 3.4). Thus, the increase in intestinal cells caused through RNAi o f gsk-3 does 
require wrm-1 and is independent of the ij48 lesion in cdc-25.1.
RNAi num ber of E p-value %  no E %  hatch
gsk-3 26.1 ±8 .6  (n=369) - 15.8 ±4.3 0
bar-1 19.3 ± 1.5
(n= 121)
- 0 87.7 ± 1.8
hmp-2 19.8 ± 1.3
(n=96)
- 0 21.0 ± 13.4
bar-1 gsk3 26.4 ± 9.2 
(n=128)
n.s. 14.6 ±0 .6 0
hmp-2 gsk-3 25.6 ±7 .9
(n= 119)
n.s. 20.2 ± 0.2 0
Table 3.4 gsk-3 double RNAi with bar-1 and hmp-2 in a cdc-25.1 (+) (JR1838) strain. Double  
RNAi w a s  p er fo rm ed  by feed ing  w o rm s  in liquid cu l tu res ,  s e e  C h a p te r  2, (2.2.5.3).  U n d er  t h e s e  
cond it ions  only two m a jo r  p h e n o ty p e s  w e re  o b se rv e d ,  lo ss  of intestinal cells  or e x p re s s io n  of th e  
elt-2::GFP  m a rk e r  in a t  le a s t  18 intestinal cells. Tw o in d e p e n d e n t  e x p e r im e n ts  e a c h  (six in c a s e  of 
gsk-3  RNAi), m e a n  ± s.d .,  p-value: two-tailed S tu d e n ts  f-test c o m p a r e d  to gsk-3  RNAi only, n= 
n u m b e r  of e m b ry o s  e x p re s s in g  th e  elt-2::GFP  m arker,  n.s.: p> 0.05.
3.2.7 CDC-25.1 protein levels in the embryo are dependent on S46
It had become evident through the experiments above that removal of lin-23 and cul-1 
seemed to act on S46 in CDC-25.1, and lin-23 RNAi primarily affected proliferation of 
intestinal cells as compared to other tissues. These observations posed the question 
whether LIN-23 in complex with CUL-1 could act on the CDC-25.1 protein levels in the 
embryo. It was decided to focus the efforts on LIN-23 as in an SCF complex this protein 
would be expected to act as the direct binding partner of CDC-25.1. Previous experiments
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by Dr. C. Clucas revealed no difference for the CDC-25.1 protein levels compared to 
CDC-25.1(S46F) in protein extracts from whole animal cultures (Clucas, 2003; Clucas et 
al., 2002); however the cdc-25.1 (ij48) allele causes aberrant proliferation in the embryo 
suggesting that the protein malfunction should be evident in embryos.
Thus, embryos were analysed for the amount of CDC-25.1 protein levels. In C. elegans a 
relatively pure embryo preparation can be obtained by treating adult worms grown in large 
liquid cultures in a standard bleach solution, which removes the rest of the worms, but does 
not penetrate the embryos due to the presence of the eggshell. Interestingly, when 
embryonic extracts were prepared of the strain IA530 cdc-25. l( ij48) derived from control 
RNAi-treated worms an increase in the CDC-25.1(S46F) protein levels can be detected on 
a Western blot compared to CDC-25.1 (Figure 3.5, A, compare lane 2 with 4). The 
antibody utilised to detect CDC-25.1 was previously developed and demonstrated to 
specifically recognise CDC-25.1 in immunocytochemistry and Western blotting (Clucas, 
2003; Clucas et al., 2002). For clarity, this antibody will be referred to as anti-CDC-25.1A 
antibody throughout this study and is characterized in more detail in Chapter 4. Equal 
amounts of protein were loaded on the SDS-polyacrylamide gel as examined by p-ACTIN 
protein levels.
Furthermore, an increase of CDC-25.1 protein levels can be detected in embryos derived 
from mothers that were fed with dsRNA against lin-23 (Figure 3.5, A, lanes 1 and 2). 
Removal of the LIN-23 protein was evident by probing the Western blots with a newly 
generated antibody against LIN-23 (this antibody is further characterised in Chapter 4, 
(4.2.3). The samples were separated multiple times on SDS polyacrylamide gels, and since 
CDC-25.1 and LIN-23 protein run at almost identical size, they were probed independently 
(including p-ACTIN as internal control). Only one typical representative for each sample 
loading and the internal control is depicted here and in subsequent figures that required 
double probing of CDC-25.1 and LIN-23. Importantly, no increase in CDC-25.1(S46F) 
mutant protein was detected after lin-23 RNAi as compared to the control (Figure 3.5, A, 
compare lanes 3 and 4). Thus, consistent with the results above, LIN-23 may act through 
S46 to control the CDC-25.1 protein levels in embryos. In contrast, gsk-3 RNAi does not 
increase CDC-25.1 protein levels in embryos (Figure 3.5, B, compare lanes 1 with 2). 
However, a decrease is detected in CDC-25.1 protein levels, which could be due to the 
high lethality rate evident after gsk-3 RNAi as compared to lin-23 RNAi (Table 3.2). 
Nevertheless, a difference between the CDC-25.1 and CDC-25.1(S46F) protein levels is 
still apparent after gsk-3 RNAi (Figure 3.5, B, compare lanes 1 and 3), indicating that 
removal of gsk-3 does not act to stabilise CDC-25.1 through S46. Knockdown of the GSK-
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3 protein was confirmed with a commercial anti-GSK3p antibody, that recognises the 
correct size band (40.9 kDa) on the Western blot.
3.2.8 CDC-25.1 (S46F) protein levels are increased in all early 
embryonic blast cells
Previous work had established that CDC-25.1 is maternally provided to the embryo and 
that the protein levels decrease and become undetectable after the 28-cell stage (Ashcroft 
et al., 1999; Kostic and Roy, 2002) or the 100-cell stage (Clucas, 2003; Clucas et al., 2002) 
during embryogenesis. The increase of CDC-25.1(S46F) protein levels compared to CDC-
25.1 in early embryos by Western blotting strongly argues that CDC-25.1 abundance is 
regulated through S46. This could be due to an increase in the longevity of CDC- 
25.1(S46F) in only intestinal cells, or an increase in CDC-25.1(S46F) abundance in all 
blast cells. In order to address this point, indirect immunofluorescence was carried out 
using the anti-CDC-25.1A antibody which has been previously demonstrated to 
specifically recognise CDC-25.1 (Clucas, 2003; Clucas et al., 2002). However, unlike in 
the previous work, the primary antibody was used at a slightly lower concentration 1:150 
instead of 1:50 (for dilutions see also Chapter 2, Table 2.9) to prevent saturation of the 
signal. Furthermore, confocal microscopy was utilised to facilitate quantification of the 
signal. As can be seen in Figure 3.6 (panel A), CDC25.1 protein levels decrease from early 
to late stages of embryogenesis. The cell stage of the embryo was determined by counting 
the numbers of nuclei after DAPI staining. Note that the signal detected here is rather an 
under-representation of the fast decline of CDC-25.1 protein levels. In order to keep the 
signal linear for quantification purposes, each developmental stage was imaged at the 
appropriate detector gain (kept identical between wild-type and mutant for each stage). 
Interestingly, CDC-25.1(S46F) protein levels are increased at the early stages of 
development as compared to CDC-25.1. However, both protein levels decrease at later 
stages and become almost undetectable when the embryo contains between 100 and 200 
blast cells (Figure 3.6, A).
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Figure 3.5 lin-23 but not gsk-3 RNAi enhances CDC-25.1 stability in C. elegans 
em bryos. A) Embryonic extracts derived from adult strains J R 1 838 (WT, lanes 1 and 2) or 
IA530 cdc-25. / (ij48) (S46F. lanes 3 and 4) that were grown in liquid culture at 25°C after 
control (-) or lin-23 (+) RNAi. The same amount o f  total proteins for each sample were 
applied to SDS-PAGE followed by Western blotting. The blots were cut and individually 
probed against C D C -25.1 (anti-CDC-25.1 A), LIN-23 (this study) or p-ACTIN (Sigma) as 
loading control. B) Essentially as (A) but RNAi was performed against gsk-3 followed by 
Western blotting against CDC-25.1, GSK3p (Sigma) and P-ACTIN.
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Figure 3.6 Elevated CDC-25.1 protein levels in the early embryo. A) Indirect immuno­
fluorescence o f  CDC-25.1 using CDC-25.1 A antibodies (red panels) with corresponding DAPI 
counterparts (blue panels) in JR1838 (WT) or IA530 cdc-25.I(ij48) (S46F) at approximately the 
4-, 30-. 60- or 200-cell stage. Scale bar: 10 pm. B) Indirect immunofluorescence as in (A) at the 
40-cell stage o f  J R 1838 (WT) or 1A530 cdc-25. Uij48) (S46F) after control, tin-23, cut-1 or gsk-3 
RNAi. Note that each gene-specific RNAi is compared with its corresponding control RNAi. 
Scale bar: 10 pm.
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A quantification of the signal was carried out (for a detailed description of this method 
please see Chapter 2, (2.2.8.4)). The fluorescence signal of early and late embryos derived 
from strain JR1838 and IA530 cdc-25. l(ij48) was quantified in individual embryos. Here, 
the developmental stage of the embryo was determined by DAPI staining through counting 
the number of nuclei present in the embryos (Table 3.5, Stage). The fold increase in 
fluorescence intensity was determined according to statistical methods that are described in 
detail in (Chapter 2, (2.2.9.1). The overall fold increase was calculated by combining 
several individual datasets and the statistical significance was revealed by the 
determination of the p-value for the overall fold increase (Table 3.5, p-value). 
Interestingly, analysis from several experiments showed that CDC-25.1(S46F) protein 
levels were significantly increased between the 10- to 60-cell stage of embryogenesis 
(Table 3.5). However, at later stages no significant increase was detected between CDC-
25.1 and CDC-25.1(S46F) (Table 3.5).
Stage (nuclei) Embryos
CDC-25.1
Embryos 
CDC-25.1(S46F)
CDC-25.1 
(S46F) fold 
increase
p-value
1 0 -2 0 22 (3) 22 (3) 1.4 <0.001
3 0 -4 0 25 (2) 16(2) 2.2 <0.001
5 0 -6 0 24 (3) 24 (3) 1.9 <0.001
100 - 200 19(3) 19(3) 1.4 n.s.
Table 3.5 Comparative analysis of CDC-25.1 protein levels in the early embryo by 
immunostaining. A v e ra g e  fold in c re a s e  of CD C -25.1  levels  w a s  d e te rm in e d  by indirect 
im m u n o f lu o re sc e n c e  in e m b ry o s  of th e  wild-type s train  J R 1 8 3 8  c o m p a r e d  to IA530 cdc-25.1(ij48). 
Em bryos: n u m b e r  of em b ry o s  (experim en ts) ,  p-value: two-tailed S tu d e n t ’s  f-test, n.s.: p -va lue  > 
0.05.
As an independent approach to validate the statistics, the individual fluorescence intensities 
determined from single experiments were directly compared for CDC-25.1 and CDC- 
25.1(S46F) without any sophisticated calculations. Figure 3.7 (top panel) displays an 
example of the comparisons of CDC-25.1 and CDC-25.1(S46F) at the 30- to 40-cell stage 
when raw fluorescence intensities from all individual experiments were combined. Clearly, 
there is an increase in the CDC-25.1(S46F) protein levels compared to CDC-25.1. In 
summary, here it is shown that the CDC-25.1(S46F) protein levels remain at higher levels 
compared to CDC-25.1 in all early blast cells of the embryo, but both proteins are 
eventually degraded and become undetectable at later stages of development.
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Figure 3.7 Q uantification of CDC-25.1 fluorescence in em bryos after indirect im m unostaining against 
CDC-25.1. Combined raw data o f  CDC-25.1 fluorescence intensities (FI) for immunostaining experiments 
at the 30- to 40-cell stage o f  J R 1838 (CDC-25.1) and 1A530 (CDC-25.1(S46F)) alone or after control (ctrl) 
or gene-specific RNAi, as indicated. Each point represents one embryo and fluorescence intensities (FI) were 
plotted by rank. Two (lin-23 RNAi), three (without and cul-1 RNAi) and four (gsk-3 RNAi) independent 
experiments.
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3.2.9 LIN-23 and CUL-1 regulate CDC-25.1 abundance in all blast 
cells through S46
The protein levels of CDC-25.1 in the strain JR1838 were compared by indirect 
immunofluorescence after control and lin-23 RNAi treatment. Quantification revealed a 
significant increase in CDC-25.1 protein levels after lin-23 RNAi (Table 3.6). At later 
stages the signal became too weak for the CDC-25.1 control experiment, and therefore 
quantification was omitted at later stages. Figure 3.7 depicts an example of the comparison 
at the 30- to 40-cell stage after analysis of the raw data and demonstrates the clear increase 
observed for the protein levels after lin-23 RNAi compared to the control RNAi. 
Importantly, CDC-25.1 protein levels are elevated in all blast cells similar to CDC- 
25.1(S46F) (Figure 3.6, B). Additionally, knockdown of LIN-23 was performed in the 
IA530 cdc-25.1(ij48) strain, lin-23 RNAi did not cause any significant increase in the 
CDC-25.1(S46F) protein levels (Table 3.6, see also Figure 3.7 for analysis o f raw data and 
Figure 3.6, (panel B) for immunostaining picture). Hence, knockdown of LIN-23 from the 
early embryo increases CDC-25.1 but not CDC-25.1(S46F) protein levels in all blast cells. 
Since cul-1 RNAi showed no synergism for the number of intestinal cells in a wild-type 
compared to cdc-25. l( ij48) allele, it was surmised that depletion of CUL-1 would result in 
a similar stabilisation of the CDC-25.1 protein. Consistently, comparison of CDC-25.1 
protein levels after cul-1 and control RNAi revealed a significant increase in CDC-25.1 
protein levels (Table 3.6). However, no significant increase of CDC-25.1(S46F) in all blast 
cells was detected when cul-1 RNAi was compared to control RNAi (Table 3.6). See also 
Figure 3.6 (panel B) for a staining image and comparison of the raw data. In summary, 
LIN-23 and CUL-1 can act through S46 in CDC-25.1 to control the protein abundance in 
all blast cells in the early embryo.
3.2.10 GSK-3 does not stabilise CDC-25.1 through S46
Detection of CDC-25.1 by Western blotting suggested that GSK-3 does not act to stabilise 
CDC-25.1 through S46. However, a small decrease in the CDC-25.1 protein levels was 
detected after gsk-3 RNAi. This could be due to an increased death rate of the overall 
embryo population. Thus, CDC-25.1 protein levels were also quantified by 
immunostaining of embryos at the 30- to 40-cell stage after control or gsk-3 RNAi. The 
CDC-25.1 protein levels remain similar in the control and gsk-3 RNAi-treated sample 
(Table 3.6). A similar result was obtained when gsk-3 RNAi was performed in the cdc- 
25.1(ij48) strain (Table 3.6). Analysis of the raw data clearly demonstrates that all
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fluorescence intensities measured are derived from similar readings (Figure 3.7) and no 
increase of CDC-25.1 or CDC-25.1(S46F) was detected in the 30- to 40-cell stage (Figure 
3.6). Thus, GSK-3 does not act to regulate the stability o f CDC-25.1 through S46 in early 
embryos.
RNAi Stage
(nuclei)
CDC-25.1 Em bryos
control /gene-specific 
RNAi
Fold
increase
p-value
lin-23 10-20 WT 15/18(2) 1.7 <0.001
lin-23 3 0 -4 0 WT 19/18(2) 2.8 <0.001
lin-23 5 0 -6 0 WT 13/15(2) 2.3 <0.001
lin-23 10-20 S46F 15/16(2) 1.1 n.s.
lin-23 3 0 -4 0 S46F 16/ 9(2) 1.0 n.s.
lin-23 5 0 - 6 0 S46F 14/16(2) 1.0 n.s.
cul-1 3 0 - 4 0 WT 46/39 (3) 2.2 <0.001
cul-1 3 0 - 4 0 S46F 40/33 (3) 1.1 n.s.
gsk-3 3 0 - 4 0 WT 56/35 (3) 0.9 n.s.
gsk-3 3 0 - 4 0 S46F 56/42 (4) 1.1 n.s.
Table 3.6 CDC-25.1 protein levels by immunostaining after gene-specific RNAi compared to 
control RNAi. CD C-25.1  protein levels  w e re  c o m p a r e d  by indirect im m u n o f lu o re sc e n c e  in the  
JR 1 8 3 8  strain (WT) or in IA530 cdc-25.1(ij48) (S 46F )  a f te r  g en e -sp ec if ic  RNAi c o m p a r e d  to control 
R N Ai-treated e m b ry o s .  Em bryos: n u m b e r  of em b ry o s  (experim en ts) ,  p-value: two-tailed S tu d e n t ’s  
f-test, n.s.: p -va lue  > 0.05.
3.3 Discussion
Based on information on DSG motifs present in higher eukaryotes it was hypothesised that 
the DSG motif in C. elegans CDC-25.1 is regulated through members of the C. elegans 
SCF complex. Furthermore, the S46 residue within the CDC-25.1 DSG consensus could 
possibly resemble a GSK3p phosphorylation site and thus implicate the C. elegans GSK-3 
and APR-1 in phosphorylation of this residue. Here, data are presented showing that LIN- 
23 and CUL-1 act to negatively regulate CDC-25.1 through S46 in all blast cells of the 
early C. elegans embryo. Interestingly, GSK-3 and APR-1 are not involved in the 
regulation of CDC-25.1 through S46, though knockdown of both proteins causes a 
hyperproliferation of intestinal cells. Several experiments were performed that reinforce 
this conclusion and are discussed below.
3.3.1 lin-23 and cul-1 act through the cdc-25.1(ij48) allele
RNAi against LIN-23, SKR-l and CUL-l resulted in a hyperproliferation of intestinal cells 
in the C. elegans embryo. This clearly implicated a role for these proteins in the negative 
regulation of cell cycle exit in intestinal cells during C. elegans embryogenesis. The result 
fits well with previous studies that show that a few dying embryos generated in lin-23
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(Kipreos et al., 2000) and cul-1 (Kipreos et al., 1996) null hermaphrodites show an 
increased number of embryonic nuclei, possibly representing embryonic hyperplasia of 
unknown origin. Similarly, skr-1 RNAi was shown to cause embryonic arrest with 
increased numbers of nuclei (Nayak et al., 2002; Yamanaka et al., 2002). Interestingly, 
here it is shown that when the RNAi was performed in a cdc-25. l(ij48) mutant background 
compared to wild-type cdc-25.1(+), no synergistic increase for the number of intestinal 
cells was detected when LIN-23 or CUL-1 were removed. This proposed that knockdown 
of either protein causes the hyperplasia by the same pathway as CDC-25.1(S46F). 
Specificity of the experiments was evident by the fact that no RNAi effect was seen after 
control RNAi or when SEL-10, the close homologue of LIN-23, was targeted. Most 
importantly, a second RNAi experiment, targeting a separate part of the lin-23 mRNA, 
resulted in an identical hyperplasia phenotype. Furthermore, the LIN-23 protein 
knockdown in embryos was clearly demonstrated by Western blotting. Here, the expected 
75.9 kDa band is deleted after lin-23 RNAi as detected using a newly synthesised anti- 
LIN-23 antibody (this antibody is also characterised in Chapter 4, (4.2.3)) and compared to 
an internal protein loading control. Additionally, an RNAi experiment against the cul-1 
paralogue cul-2 displayed no intestinal hyperproliferation phenotype. Thus, it can be 
concluded that the RNAi against cul-1 and lin-23 is specific for both genes. This was also 
strengthened by the fact that RNAi against skr-1, another member of the SCF complex, 
also resulted in hyperplasia of the intestine. Furthermore, RNAi against skr-3, a homologue 
of skr-1 but no member of the SCF complex, did not reveal this phenotype.
Thus, targeting of three molecules with homology to known SCF components resulted in 
an identical hyperproliferation of the intestine, suggesting that all molecules can act as one 
entity in the negative control of the proliferation of the intestine. In fact, physical 
interaction of SKR-1 with CUL-1 has been demonstrated by two independent groups 
(Nayak et al., 2002; Yamanaka et al., 2002). Furthermore, one study reported that binding 
of LIN-23 to SKR-1 and the paralogue SKR-2 was detected using the yeast two-hybrid 
assay (Nayak et al., 2002). This is highly indicative of a ternary complex formation 
including LIN-23, SKR-1 or SKR-2 and CUL-1.
3.3.1.1 skr-1 RNAi is synergistic to the cdc-25.1(ij48) allele
Surprisingly, when skr-1 RNAi was performed in a cdc-25. l(ij48) mutant background 
(compared to cdc-25.1 (+)) a slight synergism in the number of intestinal cells was evident 
after removal of skr-1. One possible reason is that skr-1 is highly homologous to skr-2 
(83% nucleotide identity), and thus it is likely that the skr-1 RNAi is targeting both genes
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at the same time as previously suggested (Nayak et al., 2002; Yamanaka et al., 2002). 
However, two-hybrid analysis revealed that SKR-2 interacts with CUL-1 and LIN-23 as 
well (Nayak et al., 2002; Yamanaka et al., 2002), thus making it unlikely that the slight 
additive effect is mediated through additional downregulation of SKR-2 in complex with 
CUL-1. Knockdown of SKR-2 should then also mimic the RNAi phenotype of CUL-1 
knockdown. But cul-1 RNAi does not cause an additive effect when performed in a cdc- 
25. l(ij48) strain. However, it remains to be established whether both SKR-1 and SKR-2 
binding is specific to CUL-1 only. The experiments performed previously were mainly 
based on yeast two-hybrid assays and may not reflect the natural binding properties of both 
proteins.
Consistently, it was demonstrated that the human homologue SKP1 could act 
independently of CUL-1 to down-regulate P-catenin levels (Matsuzawa and Reed, 2001). 
There is no evidence so far for a secondary target interaction of SKR-1 or SKR-2 
independent of CUL-1. Nevertheless, if SKR-1 or SKR-2 were able to negatively regulate 
a factor involved in intestinal cell proliferation independently of CUL-1, this would 
explain the additive effect when skr-1 RNAi is performed in a cdc-25. l( ij48) mutant 
background.
In order to identify whether skr-1 RNAi targets skr-1 and skr-2, the mRNA levels could be 
analysed by RT-PCR. However, measurement of mRNA levels is not always an indicator 
for the protein levels, as proteins can have a long half-life and be supplied maternally to 
the embryo. Specific peptide antibodies could be employed to distinguish between SKR-1 
or SKR-2 downregulation by Western blotting. Additionally, pull-down of SKR-1 or SKR- 
2 from C. elegans embryos and analysis of their binding partners could serve to identify 
additional regulatory molecules and decipher between SKR-1- and SKR-2-mediated 
phenotypes. These are major experiments and would require either the preparation of 
protein-specific antibodies or the expression of tagged versions of SKR-1 and SKR-2 in C. 
elegans embryos. None of the experiments have been attempted here, because the primary 
focus was directed towards identifying the physical interaction between CDC-25.1 and its 
possible direct binding partner LIN-23.
In summary, it is concluded that LIN-23 together with CUL-1 and possibly SKR-1 or 
SKR-2 regulates the proliferation of intestinal cells during C. elegans embryogenesis 
through S46 in CDC-25.1.
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3.3.2 lin-23 RNAi mimics the cdc-25.1(ij48) allele
Intriguingly, whereas cul-1 RNAi resulted in a robust early embryonic arrest similar to a 
previous report (Yamanaka et al., 2002), a high percentage of embryos derived from lin-23 
RNAi-treated mothers (80%) did hatch with no obvious morphological defects. Analysis 
for the intestinal-specific elt-2::GFP marker revealed that almost all lin-23 RNAi embryos 
analysed displayed a strong hyperplasia of the intestine. This was also confirmed by a cell 
lineage analysis that revealed additional numbers of E cells being bom that express the 
GFP marker in embryos that undergo normal morphogenesis. Cell divisions of the C 
lineage, giving rise to hypodermis, body muscle and neurons appeared normal in those 
embryos (J. Cabello, pers. comm.). In this study, quantification of intestinal nuclei in 
embryos at the three-fold stage revealed about 32-36 intestinal nuclei. The difference in 
numbers between independent experiments is probably due to the difference in batches of 
IPTG being used, consistent with the notion that lowering IPTG concentrations can lead to 
less severe RNAi phenotypes (Kamath et al., 2000). Thus, each experiment was analysed 
with its internal control on its own. Importantly, abnormal looking embryos with many 
intestinal cells (up to around 60) were also detected, which most likely represent the 20% 
dying embryos. Indeed cell lineage analysis carried out by Dr. Cabello confirmed that lin- 
23 RNAi-treated embryos that do not undergo morphogenesis (and probably die) have a 
strong hyperplasia of endodermal cells and additionally the neighbouring C lineage (in 
particular Cp) expressed the intestinal fate elt-2::GFP marker in those embryos. These 
differences in phenotype are probably caused through differences in the severity of the 
RNAi effect. Such an effect has been reported previously and it was suggested that 
embryos can escape the severity of the RNAi depending on their developmental stage 
when the RNAi is applied (Clucas et al., 2002; Grishok et al., 2000; Tijsterman et al., 
2004; Timmons et al., 2001; Timmons and Fire, 1998). Mild RNAi affected embryos are 
able to reach adulthood, whereas severely affected lin-23 RNAi embryos, probably 
representing the almost complete knockdown of the LIN-23 protein, arrest during their 
embryogenesis. This is also consistent with the fact that embryos derived from lin-23 null 
mutants are not viable, whereas embryos from heterozygous lin-23 mutants grow up to 
adulthood and produce a sterile phenotype (Kipreos et al., 2000). This is probably due to 
the presence of maternal LIN-23 product coming from heterozygous lin-23 mothers (the 
maternal function of lin-23 is discussed in Chapter 5). Consistently, lin-23 RNAi escapers 
analysed here reach adulthood and produce a 100% sterile phenotype, phenocopying a lin- 
23 null mutant.
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3.3.2.1 Mild lin-23 RNAi affects primarily intestinal cell proliferation
Intriguingly, unlike the severe cul-1 RNAi phenotype, it was possible to generate 
conditions for lin-23 RNAi that resulted in embryos displaying only an intestinal-specific 
phenotype. Given the role of both proteins, LIN-23 is assumed to confer target specificity 
due to its homology to known F-box proteins (Kipreos et al., 2000; Kipreos and Pagano, 
2000). CUL-1 however is surmised to act as a scaffolding protein, possibly mediating the 
regulation of many target genes unrelated to CDC-25.1 (Kipreos, 2005; Kipreos et al., 
1996). Quantitative analysis of other tissues through expression of tissue-specific markers 
in embryos with mild lin-23 RNAi phenotype revealed that those tissues were unaffected 
by lin-23 RNAi under conditions where the intestine displayed a strong hyperplasia. It was 
evident that all strains were targeted by lin-23 RNAi because they showed a similar 
decrease in their hatch rate after LIN-23 knockdown.
Thus, knockdown of LIN-23 affects primarily the proliferation of intestinal cells and 
mimics the cdc-25.1 (ij48) phenotype. Cell lineage analysis revealed that knockdown of 
LIN-23 resulted in increase of intestinal cells by two mechanisms: and a severe shortening 
of the cell cycle in cells expressing the intestinal fate marker and a robust failure to exit the 
cell cycle after the fourth division. These phenotypes are similar to the lineage described 
for cdc-25.1(ij48), though the failure to exit the cell cycle is more variable in this mutant 
(Clucas, 2003; Clucas et al., 2002). Intriguingly, when lin-23 RNAi was performed in a 
cdc-25. l( ij48) background, no further shortening of the cell cycle in cells expressing 
endodermal fate such as the E and even a Cp to E transformed lineage was detected by cell 
lineage analysis consistent with the fact that LIN-23 acts through S46 in CDC-25.1 
described in this study.
3.3.2.2 LIN-23 regulates CDC-25.1 protein levels through S46
In agreement with the results above, lin-23 RNAi causes elevated CDC-25.1 protein levels 
during early embryonic development in all tissues in accordance with the nature of the cdc- 
25. l(ij 48) allele (discussed below). This was examined by Western blotting and indirect 
immunostaining against CDC-25.1. Consistent with the action of LIN-23 through S46 in 
CDC-25.1, no increase in protein abundance was detected when lin-23 RNAi was 
performed in the cdc-25. l(ij48) strain. This result was confirmed by RNAi against cul-1 
and thus complements the lin-23 RNAi phenotype. The results reinforce the importance for 
the LIN-23 and CDC-25.1 interaction in C. elegans embryos and suggest that abrogation of
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the interaction through knockdown of LIN-23 or mutation of a possible LIN-23 binding 
site in CDC-25.1 primarily affects proliferation of the intestine.
3.3.3 CDC-25.1 (S46F) is elevated in all embryonic blast cells
Novel data presented here establish that CDC-25.1(S46F) protein levels are elevated 
compared to CDC-25.1 during early stages of embryogenesis as examined by Western 
blotting and indirect immunofluorescence. This conclusion contradicts previous work that 
did not detect any differences in CDC-25.1(S46F) abundance by Western blotting and 
indirect immunofluorescence (Clucas, 2003; Clucas et al., 2002). The discrepancy in the 
data obtained is explained by the difference in the methodology applied. In this study 
Western blotting was performed using purified embryonic extracts reflecting the stage 
when CDC-25.1(S46F) exerts its cell-proliferative effects. The previous studies however 
examined an adult worm culture where the majority of CDC-25.1(S46F) protein might be 
reflecting the protein expressed in the germline, which is differentially regulated. Data 
supporting this idea are presented in Chapter 5. Thus, in adult cultures the embryonic 
CDC-25.1 protein levels might be underrepresented. Additionally, here indirect 
immunostaining against CDC-25.1 was performed using less primary antibody though the 
same antibody preparation as used by (Clucas, 2003; Clucas et al., 2002) was employed. 
Down-titration of the antibody ensured less saturation of the signal, and confocal 
microscopy facilitated the fast scanning and therefore less bleaching of the signal.
In summary, from the data presented in this study it can be concluded that CDC- 
25.1(S46F) protein levels are elevated in all blastomeres during the 10- to 60-cell stage of 
embryogenesis. In accordance with this conclusion, a CDC-25.1(G47D) mutant was 
demonstrated to persist longer in all blast cells in C. elegans embryos (Kostic and Roy, 
2002). This mutant was demonstrated to exhibit a similar intestinal hyperplasia phenotype 
as compared to CDC-25.1(S46F). The authors concluded that CDC-25.1 protein levels 
become undetectable after the 28-cell stage of embryogenesis, whereas CDC-25.1(G47D) 
longevity is increased up to the 100-cell stage. However, previous work (Clucas, 2003; 
Clucas et al., 2002) and data presented here clearly show that CDC-25.1 is present up to 
the 100-cell stage of embryogenesis. This elementary difference is probably the result of 
different antibodies employed in the studies.
Importantly, the immunostaining results presented here argue strongly that CDC- 
25.1(S46F) protein is elevated compared to CDC-25.1 at a time when CDC-25.1 would 
also normally be present. This conclusion differs from the statement by Kostic and Roy
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(2002) who proposed that CDC-25.1(G47D) persists longer at a time when CDC-25.1 
would not normally be present in the embryo (i.e. after the 28-cell stage) (Kostic and Roy, 
2002). This would suggest that the presence of CDC-25.1 in cells that would normally be 
depleted from this cell cycle regulator remain sensitive to the presence of CDC-25.1 
following an all or nothing principle. However, the data here argue that intestinal cells 
normally still possessing CDC-25.1 protein levels are more sensitive to slightly elevated 
CDC-25.1 protein levels when degradation of CDC-25.1 is reduced.
3.3.4 CDC-25.1 S46 regulation is not tissue-specific
3.3.4.1 Is a downstream molecule limiting in non-intestinal tissues?
Intriguingly, the CDC-25.1(S46F) protein increase is not restricted to intestinal cells, but 
affects all tissues, similar to the CDC-25.1(G47D) phenotype (Kostic and Roy, 2002). It is 
conceivable that a downstream regulator such as a cyclin-dependent kinase becomes 
limiting in non-intestinal cells as compared to the intestine. The C. elegans genome 
contains twelve genes related to cyclin-dependent kinases (Manning, 2005) and at least 
seven show embryonic lethality in RNAi screens (Fernandez et al., 2005; Gonczy et al., 
2000; Kamath et al., 2003; Lehner et al., 2006; Maeda et al., 2001; Piano et al., 2002; Rual 
et al., 2004; Simmer et al., 2003; Sonnichsen et al., 2005). Furthermore, at least ten cyclin- 
related genes are present in the C. elegans genome and for seven of those an embryonic 
lethal phenotype has been described in RNAi screens (Kamath et al., 2003; Maeda et al., 
2001; Piano et al., 2002; Rual et al., 2004; Simmer et al., 2003; Sonnichsen et al., 2005). In 
particular cyclin E could be of potential interest as it has recently been implicated as a 
downstream partner of CDC-25.1 in embryos (Kostic and Roy, 2002). In other metazoans, 
CDK2 interacts with cyclin E (van den Heuvel, 2005). By sequence homology, C. elegans 
has one putative cdk-2 gene that is required during embryogenesis (Boxem et al., 1999) 
and could be another downstream target of CDC-25.1. However, in the (Kostic and Roy, 
2002) study no cyclins that may act at distinct cell cycle stages and which have known 
implications for early embryonic development were tested (such as B type cyclins that 
would be surmised to act at the G2/M transition). This is particularly important given the 
fact that intestinal cells are the primary cells in the embryo that initiate a G2 phase. During 
intestinal development, after the first intestinal Ea to Ep division a first G2 phase is 
initiated (Edgar and McGhee, 1988), thus indicating that factors acting at this cell cycle 
stage might become important downstream targets of CDC-25.1. Further indications that 
CDC-25.1 may also be able to act at the G2/M transition are given by the fact that the G2/M 
phase kinase CDK-1 is expressed in the early embryo (Boxem et al., 1999). Furthermore,
knockdown of CDK-1 results in embryonic lethality (Boxem et al., 1999) and a cdk-1 
mutant produces excess endoderm through aberrant C specification; however E cell 
proliferation was not analysed (Shirayama et al., 2006). Thus, it remains to be elucidated 
whether cdk-1 might also be functioning in the intestine.
Another downstream candidate of CDC-25.1 could be cyclin D (cyd-1), because a cyd-1 
loss-of-function mutant was previously shown to produce only 16 intestinal cells (Boxem 
and van den Heuvel, 2001). This could indicate that at least the final four divisions of 
intestinal cells might require cyd-1 function. However, this phenotype was not observed by 
cyd-1 RNAi, indicating that cyd-1 RNAi is not effective in the embryo under the 
conditions examined. A previous study by (Kostic and Roy, 2002) proposed that CDC-25.1 
does not act through CYD-1 because cyd-1 RNAi could not suppress CDC-25.1(G47D) 
mediated hyperplasia, but it remains to be established whether the cyd-1 loss-of-function 
allele can suppress the intestinal hyperplasia of cdc-25. l(ij48) or cdc-25.1 (rr31).
3.3.4.2 Identification of CDC-25.1 downstream partners
Hence, if a downstream regulator of CDC-25.1 becomes limiting in other tissues but not 
the intestine, removal of that factor might primarily result in abrogation of the cell cycle in 
tissues other than the intestine (see Figure 3.8). Removal of kinases for which an 
embryonic lethal phenotype has been described (cdk-1, cdk-2, cdk-5, cdk-7, cdk-9, B0285.1 
or B0495.2) or a cyclin (cyb-1, cyb-2.1, cyb-2.2, cyb-3, cye-1, cyh-1, cyl-1) (Fernandez et 
al., 2005; Gonczy et al., 2000; Kamath et al., 2003; Lehner et al., 2006; Maeda et al., 2001; 
Piano et al., 2002; Rual et al., 2004; Simmer et al., 2003; Sonnichsen et al., 2005) with 
priority given to the cdk-1, cdk-2 and cyb and eye genes (see above) could be performed in 
strains expressing tissue-specific GFP markers as done for lin-23 RNAi in this study. 
Unfortunately, this experiment would not be easily performed with cyd-1 because cyd-1 
RNAi is not very effective (see above). However, for the other genes analysed this would 
reveal whether it is possible to obtain conditions where removal of any kinase or cyclin 
affects proliferation of other tissues more easily. Such tissue might be more sensitive due 
to its limiting pool of the kinase or cyclin and thus would be more sensitive to depletion. 
Such experiments would establish whether the ‘limiting pool’ theory could indeed be true. 
Any candidate could be further tested for suppression of the cdc-25. l(ij48) phenotype, thus 
implicating it as a downstream target for cdc-25.1. Overexpression of any candidate could 
then be performed in the cdc-25. l(ij48) mutant, to determine whether it triggers a 
hyperplasia of that tissue.
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F igure 3 .8  T he ‘lim iting p o o l’ m odel.
The downstream target o f  CDC-25.1 is limiting in other tissues compared to the intestine. The circle 
represents the pool o f  the cyclin-dependent kinase (CDK) or cyclin. Under normal conditions, CDC-25.1 
activates (arrow) a certain pool o f  its downstream kinase. Overexpression o f CDC-25.1 through S46F 
mutation results in increase o f the levels o f  active kinase in the intestine but not other tissues, because other 
tissues do not possess more molecules that can be activated.
3.3.4.3 Are additional negative regulators present in non-intestinal tissues?
As an alternative model, the amounts of downstream target might not be limiting but an 
additional negative regulator might be missing from intestinal cells (for a model see 
Chapter 7, Figure 7.1). In that regard the observation that CDC-25.1(S46F) (this study) as 
well as CDC-25.1(G47D) (Kostic and Roy, 2002) render cells sensitive to the protein 
levels once E is specified is rather intriguing. Removal of the transcription factor pop-1 by 
RNAi causes the progenitor of endoderm, the EMS blastomere, to produce two E cells 
rather than MS and E (Lin et al., 1995; Thorpe et al., 1997), probably due to the release of 
endoderm repression in MS. A hyperplasia of the MS to E transformed cells was detected 
when pop-1 RNAi was performed in cdc-25. l( i j48) (this study) or cdc-25.1(rr31) (Kostic 
and Roy, 2002) mutant backgrounds, resulting in a synergistic increase of intestinal cells. 
This suggests that zygotic transcription might be important to confer the enhanced 
sensitivity of intestinal cells to increased CDC-25.1 levels. This could be achieved either 
by de novo synthesis of additional negative regulators in non-intestinal tissues but not 
transcribed in E. Alternatively, de novo synthesis of a downstream molecule in E that is not 
expressed in MS or other tissues could account for the tissue-specific phenotype (see 
limiting pool theory above). If an additional negative regulator is present in non-intestinal 
tissues, a combination of an inactivating mutation in a negative regulator, present in other 
tissues but not in the intestine, with cdc-25.1 (ij48) might result in hyperproliferation of 
other tissues and cause embryonic lethality. A genome-wide RNAi screen could identify 
negative regulators that enhance the CDC-25.1(S46F) phenotype (details on how to 
perform such experiment are described in the Chapter 7, (7.1.1)).
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3.3.5 GSK-3 is not the kinase acting on S46 in CDC-25.1
The experiments performed in this chapter suggest that GSK-3 acts independently of S46 
in CDC-25.1. Firstly, gsk-3 RNAi results in a synergistic increase of intestinal cells when 
performed in the cdc-25. l(ij48) strain. Secondly, cell lineage analysis (by J. Cabello) 
demonstrated that knockdown of GSK-3 caused no shortening of the cell cycle, a 
phenotype that was observed after LIN-23 knockdown or in the cdc-25.1 (ij48) mutant. 
When the gsk-3 RNAi was performed in the cdc-25.1(ij48) mutant, a further shortening of 
the cell cycle was observed compared to gsk-3 RNAi in the cdc-25.1(+) background. This 
was evident for intestinal cells expressing the elt-2::GFP marker generated from Ep and 
Cp. Hence, the shortening of the cell cycle mediated through cdc-25. l(ij48) is additive to 
the removal of gsk-3 and thus might reflect the further increase in the number of intestinal 
cells observed in this study. Thirdly, RNAi against gsk-3 does not increase CDC-25.1 
protein levels, either on Western blot or as examined by indirect immunofluorescence in 
embryos. Clearly, GSK-3 is depleted under these conditions as examined by Western 
blotting against GSK-3. Furthermore, the fact that around 15 - 18% of the embryos fail to 
express intestinal cells is consistent with the down-regulation of GSK-3 (Bei et al., 2002; 
Schlesinger et al., 1999).
3.3.5.1 gsk-3 RNAi phenotype is novel
The extra intestinal cell phenotype detected in these and preliminary experiments (earlier 
performed in the Johnstone lab) is novel, since previous reports mostly addressed the 
specification of intestinal cells (Bei et al., 2002; Schlesinger et al., 1999). None of the 
studies analysed the expression of an intestinal-specific marker. Furthermore, the cell 
lineage demonstrated that the posterior E cell Ep generates at least 16 intestinal cells (thus 
six more than it would normally do). Here, knockdown of GSK-3 causes Ea to express 
non-endodermal fate, suggesting a fate switch similar to a previous report that 
demonstrated that E in isolation is able to express a pharyngeal marker after gsk-3 RNAi 
(Schlesinger et al., 1999). Furthermore, cell lineage analysis revealed that the Cp 
blastomere produces intestinal cells, in agreement with previous reports showing that Cp or 
P2 in isolation can produce intestinal cells after gsk-3 RNAi (Maduro et al., 2001; 
Schlesinger et al., 1999). Interestingly, lin-23 RNAi also causes a Cp to E transformation, 
which could suggest that both GSK-3 and LIN-23 might have a common function in the 
suppression of endodermal fate in C. However, the fate specification was not the primary 
focus of this study. To sum up, the intestinal cells that are quantified after gsk-3 RNAi are 
the results of more cells generated in Ep and Cp.
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3.3.5.2 apr-1 and wrm-1 RNAi induce extra intestinal cells similar to gsk-3 
RNAi
Interestingly, apr-1 and wrm-1 RNAi show a similar phenotype to GSK-3 knockdown. 
During the non-canonical Wnt signalling pathway, the development of the intestine 
requires the action of gsk-3 (Bei et al., 2002; Schlesinger et al., 1999), apr-1 and wrm-1 
(Bei et al., 2002; Rocheleau et al., 1997; Rocheleau et al., 1999). Thus, the hyperplasia 
generated through apr-1 and wrm-1 RNAi might be by the same mechanism as gsk-3 
RNAi, because when RNAi was performed in combination no synergism could be 
detected. However, without a lineage analysis after apr-1 or wrm-1 RNAi it is unclear 
whether the intestinal cells are derived from the same tissues as those obtained after gsk-3 
RNAi. It is interesting to see that the wrong specification of E results in excess numbers of 
intestinal cells. A possible reason could be that gsk-3 RNAi can delay the specification of 
the E blastomere and therefore the terminal differentiation of the intestine, such that E 
behaves as EMS and can give rise to a MS and E complement (with Ea generating MS and 
Ep generating a complete E lineage; I. L. Johnstone pers. comm.). The fact that GSK-3 
knockdown results in a shortened cell cycle when the putative Ep cell divides for the first 
time compared to wild-type is also in agreement with this hypothesis. In this case the fifth 
division indicated after gsk-3 RNAi would be comparable to the fourth division in the 
wild-type, due to the delay of E specification for one cell cycle. One way to test if the E 
cell has retained an EMS potential for another division (such that E is actually EMS) 
would be to isolate the EMS blast cell after gsk-3 RNAi in the four-cell stage embryo, but 
prior to P2 signalling. In the wild type, EMS loses its ability to react to the P2 derived 
signal if the contact is provided less than three minutes prior to EMS cytokinesis 
(Goldstein, 1995). Placing the EMS blastomere in contact with P2 after it has divided will 
identify, if the posterior cell can induce endoderm by elt-2::GFP expression. If so, than E 
has retained the EMS potential.
Unfortunately, it is presently unknown whether all of the intestinal cells after gsk-3 RNAi 
undergo one further division or if only four cells continue dividing. Importantly, the gsk-3 
RNAi phenotype seems different from the cell proliferative function of LIN-23 or CDC-
25.1 in the intestine. It will be interesting to determine whether a cell lineage analysis of 
apr-1 or wrm-1 RNAi-treated embryos results in an identical phenotype to the gsk-3 RNAi. 
However, cell lineage analysis of wrm-1 RNAi-treated embryos is quite difficult to 
perform due to the high percentage of embryos lacking endoderm.
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Most importantly, here it is shown that the gs£-5-mediated extra intestinal cells are not 
generated through the same mechanism as the hyperplasia mediated through cdc- 
25.1(ij48). In fact, the synergism observed by gsk-3 RNAi in cdc-25.1(ij48) shows clearly 
that both phenotypes are caused by separate mechanisms. Together, these data suggest that 
the C. elegans GSK-3 does not act through S46 in CDC-25.1. Nevertheless, it does not 
exclude the possibility that another member of the C. elegans GSK-3 family is able to 
negatively regulate this site or that GSK-3 may be able to act on another site of CDC-25.1.
3.3.6 Conclusion
Novel data presented in this chapter provide significant insight into the mechanism 
underlying the cdc-25. l( ij48) mutant phenotype. For the first time LIN-23 is shown to act 
as a negative regulator of CDC-25.1, mediating its effect through S46 and thus controlling 
the intestinal cell proliferation in a whole model organism. LIN-23 is necessary in the C. 
elegans embryo to restrain CDC-25.1 protein levels in all blast cells during early 
embryogenesis. In human tissue culture experiments an interaction between CDC25A or 
CDC25B and p-TrCP is necessary to control progression of the cell cycle under normal 
conditions and in response to DNA damage (see Introduction to this chapter, (3.1.2.3)). 
Thus, the data displayed here exemplify the high conservation of the regulation of the DSG 
consensus of CDC25 from C. elegans to humans. Phosphorylation of S46 is not achieved 
through the closest GSK3P homologue GSK-3. But interestingly, GSK-3 influences the 
number of intestinal cells in a mechanism distinct from S46 in CDC-25.1.
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4 CDC-25.1 S46 is crucial for LIN-23 binding
4.1 Introduction
The work presented in Chapter 3 clearly delineates a role for LIN-23 in the regulation of 
CDC-25.1 through the S46 residue in the DSG consensus sequence. In mammalian cells 
the LIN-23 orthologue P-TrCP forms part of the E3 ubiquitin ligase complex, termed SCF 
(SKP1, CULLIN1, F-box), and participates in the ubiquitination of target substrates. 
Ubiquitin-mediated delivery to the substrates is a multistep process requiring the E l, E2 
and E3 enzymes. The activating enzyme El utilises ATP to transfer ubiquitin to the E2 
conjugating enzyme. The E2 enzyme then transfers the ubiquitin to the target substrate 
with the aid of the E3 ubiquitin ligase. In the SCF ligase complex the transfer o f ubiquitin 
occurs directly from the E2 ligase to the substrate. Ubiquitination is achieved by the 
covalent attachment of ubiquitin between the C-terminal glycine of ubiquitin and the s- 
amino group of the lysine in the target protein or another ubiquitin. Attachment of multiple 
ubiquitins to the lysine-48 or lysine-29 residue of ubiquitin results in proteasome- 
dependent degradation of the target substrate (Nandi et al., 2006; Pickart and Eddins,
2004).
In the E3 ligase SCF complex the CULLIN1 (also termed CUL1 hereafter) protein acts as 
a scaffold molecule whose C-terminus binds the RING finger (Really Interesting New 
Gene) molecule RBX1 that is bound to the E2 ubiquitin conjugating enzyme. The N- 
terminus of CUL1 interacts with the SKP1 protein bound to the F-box region of the 
substrate recognition particle such as p-TrCP. Association of the SCF core subunit with 
multiple F-box molecules allows for the distinct targeting of substrate molecules for 
ubiquitin linkage. The F-box molecule P-TrCP interacts via its C-terminal WD40 domain 
with the phosphorylated DSG consensus sequence present in diverse target substrates and 
positions the substrate to the ubiquitin conjugating enzyme E2, which covalently attaches 
ubiquitin to the lysine residues on the substrate molecule (Ang and Wade Harper, 2005).
4.1.1 C. elegans SCF components
Based on homology searches members of the C. elegans SCF complex have been 
identified (Kipreos, 2005). The C. elegans genome contains 326 F-box molecules 
compared to only 68 in humans. These are subdivided into several distinct categories based 
on their motif domain in their C-terminus. The FBXW proteins contain the WD40 motif,
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FBXL proteins the leucine rich repeats (LRR) and FBXO denotes proteins with another or 
no other motif (Kipreos and Pagano, 2000). Common to all these molecules is an 
approximately 50 residue F-box motif that has been demonstrated to bind to the SKP1 
protein and was named after its presence in cyclin F (Bai et al., 1996). Only three 
members, LIN-23, SEL-10 and the so far unnamed protein WP:CE02308 (Wormbase 
accession number) form the FBXW family of proteins in C. elegans as compared to five 
family members in humans (Kipreos and Pagano, 2000). Furthermore, 21 SKP-related 
(SKR) proteins have been identified in C. elegans compared to a single SKP1 gene in 
humans. Seven of the SKR genes (SKR-1,-2,-3,-7,-8,-9 and 10) were found to interact with 
the C. elegans CULLIN1 orthologue CUL-1 (Nayak et al., 2002; Yamanaka et al., 2002). 
An interaction of LIN-23 with CUL-1 and SKR-1 and SKR-2 has been reported making it 
likely that LIN-23, CUL-1 and SKR-1 or SKR-2 form a SCF complex in C. elegans 
(Nayak et al., 2002). So far only BAR-1, another C. elegans homologue of human 
p-catenin (Eisenmann et al., 1998; Natarajan et al., 2001), has been identified as a 
downstream target of LIN-23 during C. elegans post-embryonic development (Dreier et al.,
2005). Dreier et al. demonstrated binding of LIN-23 to BAR-1 in mammalian tissue culture 
cells and the dependence of the BAR-1 ubiquitination state on LIN-23 function in C. 
elegans.
In the previous chapter it was established that LIN-23 and CUL-1 influence the stability of 
CDC-25.1 through residue S46 in C. elegans embryos. However, it remained to be 
determined whether this is due to a direct effect on CDC-25.1 or caused through a 
secondary effect on the stability of another molecule. Since LIN-23 is surmised to act as a 
direct binding partner of CDC-25.1 its function was further elucidated. The LIN-23 protein 
consists of 665 amino acids (Kipreos et al., 2000; Mehta et al., 2004). The F-box domain 
comprises amino acids 87 to 127, whereas the WD40 domain is found between amino acid 
207 to 500 (Kipreos et al., 2000; Mehta et al., 2004). High mRNA levels were detected in 
embryos and the germline of gravid adults, indicating that the LIN-23 protein might be 
expressed at higher levels during these developmental stages (Kipreos et al., 2000).
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Substrate
SKP1
RBXl
CULLIN1
Figure 4.1 Schematic representation of  the SCF complex. Adapted from (Kipreos, 2005, Pickart and 
Eddins, 2004). The N-terminus o f  CUL1 (CULLIN1) binds the adaptor SKP1 (SKR in C. elegans), while the 
C-terminus binds RBXl in complex with the E2 ubiquitin-conjugating enzyme. The F-box-containing protein 
P-TrCP (LIN-23 in C. elegans) binds via its F-box domain to SKP1 and its WD40 domain to the target 
substrate. Ubiquitin (Ub) is directly transferred from E2 to the substrate.
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4.1.2 Hypothesis and aims
Since LIN-23 function is required to restrain CDC-25.1 protein levels in the early C. 
elegans embryo, I surmised that LIN-23 might physically interact with CDC-25.1 in the C. 
elegans embryo. Furthermore, the interaction may be disrupted through the S46F mutation 
in CDC-25.1. To address these questions binding studies were to be employed to determine 
whether CDC-25.1 physically interacts with LIN-23 in C. elegans embryos and whether 
this binding is reduced in CDC-25.1(S46F) mutant embryos. To this end, a biochemical 
system that utilises embryonic extracts to analyse the binding between CDC-25.1 and LIN- 
23 was to be set up. The principle of this methodology is rather straightforward.
However, the C. elegans system is not as simple as other purification systems such as 
human tissue culture cells or Xenopus eggs where the harvesting of samples can be 
performed at distinct cell cycle stages when the interaction between SCF components and 
CDC25 is maximal (Jin et al., 2003; Kanemori et al., 2005). Additionally, in C. elegans 
obtaining sufficient material from embryos to undertake several experiments is not 
straightforward and requires growth of large-scale cultures that can take several weeks 
(discussed below). Due to the multicellular nature, the C. elegans embryos comprise 
several tissues that are found at different cell cycle and developmental stages and cell cycle 
synchronisation is not an option. A previously developed method is to feed adults a 
deoxynucleoside analogue fluorodeoxyuridine that can block the development of the 
embryos at the 200-cell stage (Mains, 1999). But as demonstrated in the previous chapter, 
the interaction between CDC-25.1 and LIN-23 occurs at a narrow time window during C. 
elegans embryogenesis (between the 10- to 60 -cell stage) and it is therefore difficult to 
enhance for embryos that are present at these early developmental stages. Additionally, the 
LIN-23 interaction with CDC-25.1 may be rather dynamic. Once CDC-25.1 is bound to 
LIN-23 the protein will be released and degraded by the proteasome after addition of 
sufficient ubiquitin moieties. The transient nature of the binding may therefore be difficult 
to detect. Finally, the methodology for obtaining embryos that can be utilised for binding 
studies is tricky. Many adults have to be harvested to generate enough embryos that allow 
purification of cellular components. Adult worms containing sufficient amounts of 
embryos have to be treated with a solution containing sodium hypochloride and sodium- or 
potassium-hydroxide (Mains, 1999; Sulston and Hodgkin, 1988). Bleaching o f the adults 
has to be sufficient enough to release all embryos and remove the surrounding adult 
worms. However, extended incubation with bleach solution can ultimately penetrate the 
eggshell of the embryo and therefore destroy them.
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Thus, C. elegans culture conditions were to be set up to enhance for adult worms and a 
relatively pure and healthy embryo population in order to perform purification assays. 
Experiments were set up to precipitate endogenous CDC-25.1 and determine the binding of 
LIN-23. To this end, the anti-CDC-25.1A antibody utilised for indirect 
immunofluorescence and Western blotting in previous work (Clucas, 2003; Clucas et al.,
2002) and this study was to be used in order to identify conditions to pull down 
endogenous CDC-25.1 or CDC-25.1(S46F) from embryonic extracts. Furthermore, a new 
antibody against LIN-23 was required in order to detect LIN-23 and to analyse binding of 
CDC-25.1 to endogenous LIN-23. However, in other systems overexpression studies of 
tagged proteins were frequently used to detect binding between P-TrCP and CDC25, 
indicating that it may be difficult to detect physical interaction between the endogenous 
molecules, because either of them may be limiting in abundance (Busino et al., 2003; Jin et 
al., 2003; Kanemori et al., 2005; Ray et al., 2005). Hence, as a second approach the 
expression of a LAP-tagged version of CDC-25.1 was to be employed in order to enrich 
for the substrate molecule. CDC-25.1 was to be fused under the control of the elt-2 
promoter allowing expression of CDC-25.1 in the intestine. This promoter enriches for 
CDC-25.1 in the tissue that is of primary interest, since overexpression in all tissues may 
lead to an increase in embryonic lethality. The elt-2 promoter allows expression of the 
CDC-25.1 protein starting from the 2E cell stage that persists until adulthood. Thus, the 
CDC-25.1 is present at a time when most of the endogenous CDC-25.1 is no longer 
expressed because endogenous CDC-25.1 is degraded after the 100-cell stage and is not 
expressed in the adult intestine (Ashcroft et al., 1999; Clucas, 2003; Clucas et al., 2002; 
Kostic and Roy, 2002). The CDC-25.1 protein was to be tagged using the previously 
established LAP tag method (localisation and affinity purification) (Cheeseman and Desai, 
2005; Cheeseman et al., 2004). Here, a GFP tag is fused to a TEV cleavage site followed 
by an S-peptide tag, which allows a tandem purification of the fusion protein. As a first 
purification step an anti-GFP antibody bound to a Sepharose resin can be used, the protein 
cleaved off the beads using TEV protease and subsequently purified on S-Protein Agarose 
through the S-peptide tag. The advantage of this double system is the purity o f the resultant 
eluate compared to single-step purifications. The experiments will allow to determine 
whether CDC-25.1 physically interacts with LIN-23 and whether this interaction is 
weakened or abolished in the cdc-25.1 (ij48) mutant background.
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4.2 Results
4.2.1 Characterisation of CDC-25.1 A and B antibodies
Previous work had established that the anti-CDC-25.lA antibody raised against peptide 
495 - 509 of CDC-25.1 utilised in the lab detects endogenous CDC-25.1 on Western blots 
and in indirect immunofluorescence (Clucas, 2003; Clucas et al., 2002). A second anti­
peptide antibody raised against amino-acids 592 - 604 and thus the very C-terminus of 
CDC-25.1 (termed CDC-25.IB hereafter) had also been generated in our laboratory but the 
specificity not tested. In order to determine whether either or both antibodies could 
precipitate CDC-25.1 from C. elegans embryos, both antibodies were first affinity purified 
against the corresponding peptide and analysed for specificity by Western blotting. The 
experiments were performed side by side to ensure a correct purification procedure by 
utilising the CDC-25.1 A antibody as a positive control.
Whole adult worms were lysed, sonicated, the cuticles removed by centrifugation and the 
soluble fraction applied to SDS-PAGE. Indeed, both the newly affinity purified anti-CDC-
25.1 A antibody as well as the previously established one recognise a specific band of 
around 83 kDa on Western blots that is depleted when adult worms were fed with RNAi 
against cdc-25.1 (Figure 4.2, A, lanes 1 and 2, only one condition is depicted for 
simplicity). The similar size band was also detected with the CDC-25.IB antibody that was 
run side by side (although to a much lesser extent) that disappeared after cdc-25.1 RNAi 
(Figure 4.2, A, lanes 4 and 5, note that due to the weak signal a different exposure had to 
be utilised for figure assembly). Thus, both antibodies can recognise CDC-25.1 by Western 
blotting of proteins extracted from adult hermaphrodites.
4.2.1.1 Setting up healthy embryo preparations
To determine whether this band could be detected in embryos, adult worms were grown in 
liquid cultures and the embryos harvested by the bleach method. To obtain enough healthy 
embryos new growth conditions were set up. Here, C. elegans worms were fed with the 
AB1157 strain that is not uracil auxotroph compared to the regular OP50 strain and can be 
grown to high densities in order to avoid starvation o f worms in the culture which could 
result in dauer larvae formation. Growth conditions were optimised to obtain the maximum 
number of adults that carry enough embryos. Several bleach methods were also tested in 
order to define the optimal condition that could be utilised for further studies. The amount 
of embryonic viability obtained was therefore tested each time when embryos were
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extracted and under optimal conditions found to be around 70 to 80%. The final conditions 
used are summarised in (Chapter 2, (2.2.7.1)).
4.2.1.2 CDC-25.1 is phosphorylated in embryos
As depicted in Figure 4.2 (panel A), both antibodies recognise the 83 kDa band in 
embryos. Interestingly, the size of this band does not correlate with the predicted molecular 
weight of 67.9 kDa (WormBase, 2007). When the samples were applied to 8% SDS-PAGE 
and electrophoresed for a longer time (70 min) to obtain a higher resolution, it was obvious 
that the original band detected in adult worms (and also in embryos, see Figure 4.2, E) was 
in fact derived from at least three distinct bands with slightly different molecular weights 
(Figure 4.2, A lanes 1 and 2 bottom). Thus, it became apparent that CDC-25.1 could be a 
target of post-translational modifications or alternative splicing. Previous work established 
the presence of only a single cdc-25.1 mRNA transcript (Ashcroft et al., 1999) and in other 
model systems CDC25 proteins are the target of extensive phosphorylations (for a review 
see (Busino et al., 2004)).
Hence, the phosphorylation state of CDC-25.1 was determined in C. elegans adults and 
embryos. Treatment of embryonic extracts with lambda phosphatase results in downshift of 
all bands to one lower migrating form at around 70 to 75 kDa (Figure 4.2, B, compare 
lanes 1 and 5). The same result was obtained when adult extracts were analysed (data not 
shown). This result was obtained in a wild-type and in the cdc-25. l( ij48) mutant 
background (compare lanes 2 and 6), indicating that there is no difference in 
phosphorylation detectable between CDC-25.1 and CDC-25.1(S46F). Note that due to 
differences in signal intensity the top CDC-25.1 band is not visible at this exposure. A 
partial downshift o f the three bands was also apparent when the extracts were incubated 
with buffer alone, probably reflecting the endogenous phosphatase activity in the extracts 
(Figure 4.2, B, compare lanes 1 and 2 with 3 and 4). Thus, CDC-25.1 and CDC-25.1(S46F) 
protein levels are highly phosphorylated in embryos (and adults). At this resolution there 
was no consistent difference detectable between CDC-25.1 and CDC-25.1(S46F) when 
different extracts were analysed. Note however that in accordance with the results in the 
previous chapter, an increase in the CDC-25.1(S46F) protein levels compared to CDC-25.1 
is clearly detectable (Figure 4.2, B). Interestingly, removal of lin-23 by RNAi results in an 
increase of all three detectable phosphorylation forms (Figure 4.2, E, compare lanes 1 and 
2).
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Figure 4.2 Characterisation of CDC-25.1 and LIN-23 antibodies. A) Extracts o f  wild-type adults (lanes 
1, 2, 4 and 5) or embry os (lanes 3 and 6) with (+) or without (-) cdc-25.1 RNAi (lanes 1, 2, 4 and 5) were 
applied to 10% SDS-PAGE and Western blotted with anti-CDC-25.1 A or anti-CDC-25.1B antibodies, 20 gg 
o f  total protein were applied per lane, bottom: same as top lanes 1-2 but samples were applied to 8% SDS- 
PAGE. B) CDC-25.1 is regulated through phosphorylation in embryos. Embryonic extracts from wild-type 
JR1838 (WT) or IA530 cdc-25.1(ij48) (S46F) strains were either suspended in SDS sample buffer (lanes 1,
2), incubated at 30°C in phosphate buffer (lanes 3, 4) or in phosphate buffer containing 800 U o f  X- 
phosphatase (lanes 5, 6) and 15 gg  total protein applied to 8% SDS-PAGE followed by Western blotting 
against CDC-25.1 (anti-CDC-25.1 A). C) Immunoprecipitation o f  CDC-25.1 from embryonic extracts using 
anti-CDC-25.1 A, or B antibodies or rabbit IgG. Input and flow-through represent 3%, the eluate 30% o f  the 
total fraction. The Western blot was probed against C D C -25.1 using anti-CDC-25.1 A. D) Similar to (A), but 
the anti- CDC-25. lf.l. antibody was used, 100 adults were lysed in sample buffer and applied per lane, 2.5 
gg  of  embryos were lysed in an equal volume o f  sample buffer and applied per lane, Ponceau staining to 
show equal loading of  proteins (bottom). E) Embryonic extract o f  J R 1838 strain (WT) or IA530 (S46F) with 
(+) or without (-) lin-23 RNAi were applied to 8% or 10% SDS-PAGE (same amount as D) and probed 
against CDC-25.1 (anti-CDC-25.1 A) or LIN-23, Ponceau staining to show equal protein loading, (same 
samples as Chapter 3). Two (A, B. D, E lin-23 RNAi) and three (E, (-) lin-23 RNAi) independent experi­
ments each.
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4.2.1.3 Characterisation of anti-CDC-25.1 antibodies for 
immunoprecipitation
Western blotting confirmed that both anti-peptide antibodies A and B raised against CDC-
25.1 could recognise CDC-25.1 and CDC-25.1(S46F). However, the signal intensity 
derived of the A antibody was slightly higher on Western blots (also when almost identical 
antibody concentrations were tested). However, this result could suggest that the B 
antibody shows a lower affinity to the target peptide under denaturing conditions, but it 
might be able to recognise the native CDC-25.1. Conditions were set up to purify 
endogenous CDC-25.1 from embryonic extracts.
To this end, lysis conditions were to be established, to allow purification of the CDC-25.1 
protein from embryos. As a starting point a lysis buffer was utilised that closely resembles 
the conditions previously published for CDC-25.1 (Ashcroft et al., 1999) or P-TrCP 
purifications (Busino et al., 2003; Donzelli et al., 2002). However, ionic detergents were 
omitted and a low concentration of non-ionic detergent was utilised in order to start with 
mild buffer conditions. Firstly, embryos were lysed in 50 mM Tris, 100 mM NaCl, 1 mM 
EDTA, 10% glycerol, 0.2% NP40, 1 mM DTT and 1 x protease inhibitor cocktail. 50 pg of 
affinity purified anti-CDC-25.1 antibody A or B were crosslinked to Protein A-Sepharose 
and incubated with the embryo extract (Table 4.1, 1). As seen in Figure 4.2 (panel C), only 
antibody B precipitated CDC-25.1 as compared to rabbit IgG that was used as negative 
control (compare lane 6 and 7) under this experimental condition. However, the amount 
precipitated was minor compared to the amount present in the flow-through (bottom band 
lanes 2-4). Thus, the flow-through (FT) was utilised to determine whether the antibody was 
limiting. Increasing the antibody concentration and lowering the amount of total protein 
did not precipitate more CDC-25.1 (Table 4.1, FT1, a), indicating that the antibody was not 
limiting. Additionally, different salt and non-ionic detergent conditions were utilised to 
precipitate the FT with antibody B only (Table 4.1, FT1, b-d). None of these conditions 
purified more CDC-25.1 protein, though the initial control conditions remained positive. 
Thus, the remaining CDC-25.1 protein was not extractable with different salt conditions. 
New extracts were generated and extracted with a buffer with constant salt concentration 
and slightly higher centrifugal force applied to further clarify the supernatant (Table 4.1, 2- 
5).
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Experiment Salt (mM) Detergent
(% )
Centrifugal 
force (g)
Antibody
(ftg)
Total protein
1 100 NaCl 0.2 NP40 30000 50 (A/B) 3200
FT la 100 NaCl 0.2 NP40 30000 100 (A/B) 600
FT lb 100 KC1 0.05 NP40 30000 50(B) 600
FT lc 300 KC1 0.05 NP40 30000 50 (B) 600
FT Id 300 KC1 0.2 NP40 30000 50 (B) 600
2 300 KC1 0.1 NP40 30000
135000
75 (B) 600
3 300 KC1 0.1 NP40 30000
135000
75 not
crosslinked
(B)
700
4 300 KC1 1 NP40 
0.5 DOC 
0.1 SDS
30000
135000
75(B) 500
5 300 KC1 1 NP40 
0.5 DOC
30000
135000
75 (B) 500
Table 4.1 Various experimental conditions to precipitate endogenous CDC-25.1 from 
embryonic extracts using anti-CDC-25.1A or B antibody.
The precipitation efficiency of CDC-25.1 was compared with and without crosslinking of 
the B antibody (2 and 3) and DTT omitted to ensure that the crosslinking or the DTT did 
not inactivate the antibody, but no difference to the initial binding was obtained. 
Furthermore, more stringent lysis conditions using higher NP40 concentrations, SDS or 
sodium deoxycholate did not increase the binding.
Thus, it was concluded that the antibodies A and B available in the laboratory were not 
suitable for precipitation studies to analyse for potential binding partners such as LIN-23. 
Only a minor fraction of the total CDC-25.1 protein could be precipitated. Though given 
the anticipation that not all the protein might interact with LIN-23, this amount was clearly 
not enough.
4.2.2 Generation of a new anti-CDC-25.1 antibody
Since the CDC-25.1A and B antibodies were not able to precipitate sufficient amounts of 
CDC-25.1 a new antibody against CDC-25.1 was generated. I decided to generate an 
antibody that can recognise multiple epitopes of the full-length protein and might provide a 
better tool for immunoprecipitation studies. To this end, conditions were set up to express 
and purify HIS6-tagged CDC-25.1. The cdc-25.1 cDNA was cloned into the pQE-30 
expression vector allowing the N-terminal fusion of six histidines to CDC-25.1. After 
initial difficulties in obtaining any expressed protein, conditions were finally established 
that produced reasonable amounts of CDC-25.1 protein (600 pg/400 ml culture was 
obtained after purification from the insoluble fraction and protein dialysis). This protein
was utilised to immunise one rabbit (performed by SNBTS) and the obtained serum 
affinity purified against recombinant CDC-25.1. The affinity purified antibody was tested 
against wild-type adult extracts and recognises multiple specific bands of around 83 kDa 
on Western blot that are reduced after cdc-25.1 RNAi (Figure 4.2, D, lanes 1 and 2). The 
same bands are detected in C. elegans embryonic extracts and are increased in embryos 
derived from the cdc-25. l(ij48) strain, similar to the result obtained with the anti-CDC-
25.1 A antibody (Figure 4.2, D, lanes 3 and 4). The exact conditions for protein expression 
and affinity purification of the serum are depicted in (Chapter 2, (2.2.2.5), (2.2.2.6) and 
(2.2.2.12)). Consequently, the new antibody generated against CDC-25.1 (hereafter named 
CDC-25.lf.l.) specifically recognises both CDC-25.1 and CDC-25.1(S46F) on Western 
blots.
4.2.3 Generation of anti-LIN-23 antibodies
Novel antibodies against LIN-23 were also generated in this study, because no antibody 
against LIN-23 was available. Firstly, Dr. I. L. Johnstone produced one antibody with the 
aid of the company Covalab. This peptide antibody was raised against two peptides in the 
N-terminus of the LIN-23 protein according to the company’s recommendation (aa 18-31  
and aa 194 - 206). Antisera and affinity purified antibodies from two rabbits were provided 
by Covalab and tested in this study against C. elegans strains that were treated with or 
without lin-23 RNAi, but it was impossible to obtain any specific band.
Thus, I decided to raise new antibodies that could recognise multiple epitopes on the LIN- 
23 protein. The complete lin-23 cDNA was cloned into the pGEX-6P-l vector that allows 
E. coli expression of the full-length LIN-23 protein with an N-terminal GST tag. 
Expression of LIN-23 in E. coli was rather difficult, because the protein was expressed at 
low levels and insoluble. Removal of the N-terminus containing the F-box motif did not 
improve the solubility. Additionally, expression under several different growth conditions 
and in different E. coli strains did not improve the solubility of the protein. Finally one 
rabbit and one rat were immunised with GST::LIN-23 excised from an SDS- 
polyacrylamide gel. The rabbit serum obtained was affinity purified against the 
recombinant HIS6-tagged C-terminus of LIN-23, because the full length HIS6::LIN-23 was 
only poorly expressed and the serum did not recognise the N-terminal portion of the LIN- 
23 protein when expressed in E. coli. The final conditions used for protein expression and 
affinity purification are summarised in (Chapter 2, (2.2.2.5), (2.2.2.6), (2.2.2.12)).
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The affinity purified anti-LIN-23 antibody was tested for specificity towards LIN-23 by 
Western blotting against embryonic extracts derived from hermaphrodites that were 
subjected to lin-23 or control RNAi. The antibody recognises a specific band around 80 
kDa in the control RNAi-derived samples that was absent after lin-23 RNAi (Figure 4.2, E, 
compare lanes 1 and 2 or 3 and 4). This is consistent with the expected molecular weight of 
75.9 kDa (WormBase, 2007). Additionally, the LIN-23 protein levels were analysed by 
Western blotting of lin-23 null hermaphrodites compared to lin-23 heterozygotes or a lin- 
23 wild-type strain. This revealed the presence of the 80 kDa band in the wild-type strain 
that was reduced in a lin-23 heterozygote strain and completely absent in a lin-23 null 
background (see Chapter 5, Figure 5.1). The antibody was also tested in 
immunoprecipitation studies and was able to precipitate endogenous LIN-23 from C. 
elegans embryonic extracts. But the affinity of the antibody to the protein was extremely 
weak and resulted in the loss of the protein after the first wash of the immunoprecipitate. 
Washing of the eluates only once in binding buffer resulted in too much background 
binding and thus no further attempts were made to utilise this antibody for 
immunoprecipitation studies. Nevertheless, the novel anti-LIN-23 antibody generated in 
this work has proven extremely valuable to recognise endogenous LIN-23 on Western 
blots and in immunocytochemistry (illustrated in Chapter 5, Figure 5.1 and Chapter 6, 
Figure 6.1).
4.2.4 Generation of tagged CDC-25.1 in intestinai cells
For use in a second purification approach, tagged versions of CDC-25.1 and CDC-
25.1 (S46F) were generated. The CDC-25.1 or CDC-25.1(S46F) genomic sequences were 
fused under the control of the elt-2 promoter and tagged at their N-terminus with the LAP 
tag (GFP followed by a TEV cleavage site and the S-peptide). Several strains carrying the 
LAP-tagged CDC-25.1 or CDC-25.1(S46F) on an extrachromosomal array were generated 
by microinjection of the plasmid pBS-elt-2::LAP::cdc-25.1(+) or pBS-elt-2::LAP:.cdc- 
25.1(ij48) into the gonad of the DR96 strain. This strain is mutated for the unc-76 gene and 
a wild-type unc-76 gene co-injected with the LAP-tagged cdc-25 plasmids served as a 
rescue marker (for details on microinjection and transgenesis procedures see Chapter 2,
(2.2.4)). Analysis of the intestinal numbers by DAPI staining of adult worms revealed an 
increase in the number of intestinal nuclei as compared to the N2 Bristol wild-type strain 
(Table 4.2). An example of an adult worm carrying elt-2::LAP::cdc-25.1 (+) or elt- 
2::LAPv.cdc-25.1(ij48) is depicted in Figure 4.3, (panel A). The increase in intestinal
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nuclei suggested that the constructs could potentially cause intestinal hyperplasia and were 
therefore functional.
Strain*(for precise genotype see 
Chapter 2, Table 2.8)
Intestinal
nuclei
(D A P I, adults)
Strain*
Intestinal
nuclei
(G F P , em bryos)
N2 Bristol 31.7 ± 3.6 
( n = l l )
- -
IA123 cdc-25. l(ij48)1 60.5 ± 11.6
(n=18)
- -
IA521 ijEx30
[elt-2:: LAP:: cdc-25.1 (+)]
49.1 ±5 .6  
(n=13)
- -
IA522 ijEx31
[elt-2:: LAP:: cdc-25.1(+)]
45.6 ±9.1 
(n=16)
IA535 ijls l6  
[elt-2:: LAP ::cdc- 
25.1(+)]
24.4 ± 4.0
(n=21)
IA523 ijEx32
[elt-2: .LAP:: cdc-25.1 (ij48)]
40.0 ±9 .0  
(n=23) - -
IA524 ijEx33
[elt-2: :LAP:: cdc-25.1 (i[48)]
39.0 ±5 .9  
(n=24)
IA536 ijlsl7  
[elt-2::LAP::cdc25.1
ami
25.8 ±3 .7
(n=23)
IA560 i[Ex35 
[elt-2:: cdc-25.1(+)]
46.4 ±4 .9
(n=21) - -
IA559 i[Ex34 
[elt-2:: cdc-25.1(+)]
49.3 ± 5.4
(n=22)
IA559 FI embryos 
containing wls84 
[elt-2: :GFP::LacZJ
24.3 ±4.1
(n=9)
Table 4.2 Intestinal cell number (mean ± s.d.) of C. elegans strains zygotically expressing 
cdc-25.1.
Hence, it was decided to integrate the plasmids stably into the genome by gamma 
irradiation. For this procedure one strain was chosen for each construct. The strains 
generated were outcrossed four times against wild-type N2 to remove unwanted mutations 
introduced through the gamma irradiation. This produced the strains IA535 ijlsl6[elt- 
2::LAP::cdc-25.1(+)] and IA536 ijIsl7[elt-2::LAP::cdc-25.1(ij48)] (for full genotype see 
Chapter 2, Table 2.8). In Figure 4.3 (panel B), the JR1838 strain expressing elt- 
2::GFP::LacZ in intestinal nuclei is depicted. By comparison LAP::CDC-25.1 and 
LAP::CDC-25.l(S46F) also localise to intestinal cells. Interestingly, the localisation of 
LAP::CDC-25.l(S46F) was found to be mainly in the nuclear compartment, whereas 
LAP::CDC-25.l was present in both the nucleus and the cytoplasm, indicating that both 
molecules may be differentially regulated. This localisation did not differ from the original 
non-integrated strains and thus was not caused through the integration of the plasmids.
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*** :
WT cdc-25.l(ij 48)
LAP: :cdc-25.J (+)
n \
LAP:: cdc-25.
% »
GFP::LacZ
LAP::CDC-25.1
LAP::
CDC-25.1(S46F)
Nomarski
anti-GFP anti-CDC-25.1
MW WT S46F GFP- GFP+ WT S46F GFP- GFP+
- GFP::LacZ
- LAP::CDC-25.1
}CDC-25.1
Figure 4.3 Expression of  elt-2:: LAP:: cdc-25.1 in C. elegans adults and embryos. A) DAPI staining o f  
wild-type strain N2 (WT), cdc-25. l(ij48) or IA522 carry ing elt-2::LAP::cdc-25.1(+) or elt- 
2::LAP::cdc-25.1 (ij48) (IA523) on extrachromosomal arrays. Some intestinal nuclei are indicated by 
arrows. Scale bar: 50 pm. B) GFP fluorescence and corresponding Nomarski counterparts o f  the strain 
JR1838 carrying intestinal-specific elt-2::GFP (GFP::LacZ) or IA535 elt-2:.LAP::cdc-25.1 (+) 
(LAP::CDC-25.1), IA536 elt-2::LAP::cdc-25.1(ij48) (LAP::CDC-25.1(S46F)) after chromosomal 
integration. Only one focal plane is shown. Scale bar: 10 pm. C) Embryonic extracts (15 pg total protein/ 
lane) o f  CDC-25.1 strains from (B), N2 Bristol (GFP-) and J R 1838 (GFP+) were applied to 8% SDS- 
PAGE followed by Western blotting against GFP or CDC-25.1 (anti-CDC-25.1 A). Two independent 
experiments for (C).
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Western blotting of embryonic extracts, derived from IA535 elt-2:: LAP:: cdc-25.1(+) and 
IA536 elt-2::LAP::cdc-25.1(ij48) integrated strains, revealed the expression of the correct 
size bands of around 100 kDa (due to the insertion of additional 304 amino acids) with a 
GFP antibody. These bands were also recognised with the anti-CDC-25.1 A antibody but 
absent in wild-type extracts or extracts carrying elt-2::GFP::LacZ, indicating that the 
proteins were full-length (Figure 4.3, C). Interestingly, the proteins were highly 
overexpressed compared to endogenous CDC-25.1 (Figure 4.3, C, lanes 5 and 6). Analysis 
of the intestinal nuclei through GFP expression revealed an increase in the number of 
nuclei (Table 4.2). Thus, the increase in intestinal nuclei observed in the non-integrated 
adults by DAPI staining is the result of extra-nuclei that are bom in the embryo. It is 
concluded that the LAP::CDC-25.1 or LAP::CDC-25.1(S46F) constructs when expressed 
in C. elegans can cause extra intestinal nuclei to be bom during embryonic development.
4.2.4.1 Zygotic expression of untagged cdc-25.1 causes extra intestinal 
nuclei
Since the tagged versions of CDC-25.1 augmented the numbers of intestinal nuclei in the 
embryo, the possibility remained that the tag, and not the overexpression of CDC-25.1 
could interfere with the normal regulation of the protein. Hence, a new plasmid was made 
(pBS-elt-2::cdc-25.1(+)) that allows expression of the untagged CDC-25.1 in intestinal 
cells. Transgenic strains were generated with this construct by microinjection together with 
the unc-76 gene into DR96 unc-76(e911)V and selection for unc-76 rescue. Two non-Unc 
strains (IA559 and IA560) carrying elt-2::cdc-25.1(+) on an extrachromosomal array were 
analysed for the numbers of intestinal cells by DAPI staining and display elevated numbers 
of intestinal nuclei (Table 4.2). To analyse the number of intestinal cells in the embryo, elt- 
2::GFP was crossed into the IA559 strain. For this purpose, males of the IA559 strain were 
generated by heat shock and crossed into JR1838 hermaphrodites that carry the elt-2::GFP 
transgene. Several hermaphrodites carrying the elt-2::GFP transgene showed extra 
intestinal nuclei in their FI embryos as examined by fluorescence microscopy, indicating 
that they also carried the elt-2::cdc-25.1(+) (a wild-type JR1838 strain never displays extra 
intestinal nuclei) (Table 4.2, 24.3 nuclei, and Figure 4.4, A). Indirect
immunocytochemistry of embryos using the CDC-25.1 A antibody confirmed that CDC-
25.1 was strongly expressed in intestinal nuclei during a stage when the surrounding cells 
contain almost no more CDC-25.1 protein (Figure 4.4, A). In summary, zygotic expression 
of wild-type CDC-25.1 results in a hyperplasia of the intestine as examined by the 
increased number of intestinal nuclei in the embryo.
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elt-2:: cdc-25. l(+)
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elt-2:: cdc-25. I ( a
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lin-23:: FLAG-TY
Figure 4.4 Expression of  untagged cdc-25.1 or a lin-23::FLAG-TY  allele cause hyperplasia of  the 
intestine. A) IA559 carrying elt-2::cdc-25.1(+) on an non-integrated extrachromosomal array is analysed 
by DAPI staining o f  adult hermaphrodites (left). To the right: expression o f  elt-2::GFP::LacZ in embryos 
carry ing elt-2::cdc-25.1(A) on an extrachromosomal array (non integrated) compared to a strain J R 1838 
(WT) that carries only elt-2::GFP::LacZ. Scale bar: 50 Jim for adult, 10pm for embryos. Bottom: immunos- 
taining against CDC-25.1 in an embryo expressing e/t-2::CDC-25.1 (anti-CDC-25.1 A) with corresponding 
DAPI image. Scale bar: 10 pm. B) 1A592 strain containing lin-23::FLAG-TY  in a lin-23 null background 
(for genotype see Chapter 2, Table 2.8) show hyperplasia o f  the intestine as examined by GFP::LacZ  expres­
sion in intestinal nuclei. Scale bar: 10 pm.
154
4.2.4.2 LAP-tagged CDC-25.1 interacts with LIN-23 in the embryo
Purification of the LAP-tagged CDC-25.1 proteins was attempted by several means. 
Firstly, several commercial antibodies against the GFP tag were utilised to pull down 
LAP::CDC-25.1 and LAP::CDC-25.1(S46F) from embryonic extracts compared to extracts 
that are derived from the JR1838 and thus express the GFP::LacZ fusion in intestinal 
nuclei. Multiple commercially available antibodies were incapable to purify any of the 
GFP-tagged proteins. Only one antibody was able to purify 90% of the GFP::LacZ fusion 
protein (that was expressed in intestinal nuclei like CDC-25.1) but the LAP-tagged CDC-
25.1 proteins could not be precipitated under these conditions tested.
Therefore, I decided to purify the CDC-25.1 proteins via the S-peptide tag using S-Protein 
Agarose. Several conditions were tested and it was possible to specifically bind 
LAP::CDC-25.1 but not the control protein GFP::LacZ to the S-Protein Agarose (Figure 
4.5, A, compare lanes 7 with 9). Interestingly, probing the samples with an anti-LIN-23 
antibody revealed specific binding of LIN-23 to LAP::CDC-25.1 but not to the control 
resin, indicating that zygotically overexpressed CDC-25.1 physically interacts with LIN-23 
in embryos.
Results obtained in the previous chapter suggested that the binding of LIN-23 to CDC- 
25. 1(S46F) might be abolished. To address this point, a direct comparison of the LIN-23 
bound to purified LAP::CDC-25.1 and LAP::CDC-25.1(S46F) was necessary. 
Unfortunately, binding of the LAP::CDC-25.1(S46F) to S-Protein Agarose was not 
obtained under conditions when LAP::CDC-25.1 specifically bound to the resin. 
LAP::CDC-25.1(S46F) remained in the flow-through as compared to 90% depletion from 
the flow-through of LAP::CDC-25.1 (Figure 4.5, A, compare lanes 4 with 5 and 7 with 8). 
This was also the case when new extracts were prepared. A direct comparison between 
these two molecules was therefore not possible. It should be noted that both molecules 
show slightly differential distribution in intestinal cells (discussed in Chapter 6, (6.3.1.1)) 
implying that the epitope may be masked in case of LAP::CDC-25.1(S46F) due to 
differential complex formation or protein folding. Nevertheless, it became apparent that a 
physical interaction between overexpressed CDC-25.1 and endogenous LIN-23 is evident 
in C. elegans embryos.
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Figure 4.5 CDC-25.1(S46F) is crucial for LIN-23 interaction in C. elegans embryos. A) Immunoprecipita­
tion of  c//-2-expressed LAP::CDC-25.1 (WT), LAP::CDC-25.1(S46F) or GFP::LacZ (ctrl) from embryonic 
extracts using S-Protein Agarose. Input and flow-through represent 1.25% and the eluate 30% (50% in case 
o f  S46F) o f  the total fraction. Samples were applied to 10% SDS-PAGE followed by Western blotting against 
GFP (top panel) or LIN-23 (bottom panel). B) Immunoprecipitation o f  CDC-25.1 from embryonic extracts 
using anti-CDC-25.1 f.l. antibodies from JR1838 (WT) and 1A592 expressing LIN-23::FLAG-TY in a lin-23 
null background (+TAG). Samples were similar to A) except only input (lanes 1 and 2) and eluates (lanes 3-6) 
are displayed. Western blots were probed against LIN-23 (top panel) or CD C -25.1 (using the anti-CDC-25.1A 
antibody). Note the 2.4 kDa shift of  L1N-23::FLAG-TY compared to wild-type (compare lanes 1 and 2, or 
lanes 3 and 5). Rabbit IgG was used as negative control (lanes 4 and 6). C) Embryonic extracts from JR1838 
(WT, lane 1), 1A530 cdc-25.1(ij48) (S46F, lane 2), 1A592 lin-23 null expressing LIN-23::FLAG-TY (WT, lane
3) or IA593 cdc-25.1(ij48) (S46F, lane 4) a lin-23 null strain co-expressing CDC-25.1(S46F) and LIN- 
23::FLAG-TY were applied to 10% SDS-PAGE and Western blot perfonned as indicated. 10 |ig of  total 
protein was applied per lane, the samples were separated multiple times (5 and 10 pg total protein) by SDS- 
PAGE. D) Immunoprecipitation o f  CDC-25.1 from JR1838 (WT) or 1A530 cdc-25.1(ij48) (S46F) using the 
anti-CDC-25.1 f.l. antibody (lanes 3 and 5) or rabbit IgG as control (lanes 4 and 6). Samples were applied to 
SDS-PAGE similar to B), but 0.5% o f  the total fraction was loaded for input (lanes 1 and 2) and 30 and 25% 
o f  the eluate (lanes 3-6) for anti-LIN-23 (middle), anti-CDC-25.1 (bottom, anti-CDC-25.1 A antibodies) and 
ubiquitin (top) blots, respectively. Small inset: weak exposure o f  input lanes o f  anti-LIN-23 blot to show equal 
protein loading. Two independent experiments each.
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4.2.5 CDC-25.1 physically interacts with LIN-23 in embryos
The binding observed between LAP-tagged CDC-25.1 and LIN-23 encouraged me to 
undertake further attempts to immunoprecipitate endogenous CDC-25.1 using the new 
anti-CDC-25.1 f.l. antibody generated in this study. Several experimental conditions were 
tested in a manner similar to the experiments performed with anti-CDC-25.1 A and B 
antibodies. The eluates were probed by Western blotting with anti-CDC-25.1 A antibody to 
ensure specificity of the signal to CDC-25.1. Importantly, conditions were identified that 
could precipitate sufficient amounts (around 50%) of endogenous CDC-25.1 from 
embryonic extracts. Intriguingly, specific binding of endogenous LIN-23 was detected in 
eluates derived from precipitation of CDC-25.1 as compared to control eluates using rabbit 
IgG (Figure 4.5, B, compare lanes 3 and 4).
As a second control, CDC-25.1 was precipitated from worms that express a tagged version 
of LIN-23 (LIN-23 ::FLAG-TY) in a lin-23 null background. This strain was generated in 
this study by microparticle bombardment of the pBS-unc-119-lin-23::FLAG::TY plasmid 
into the DP38 strain. This method was utilised because it results in low-copy integration of 
the plasmid into the genome and permits expression of the transgene in the germline 
(Praitis et al., 2001). The FLAG and TY tag were chosen because they are relatively small 
and therefore reduce the chance of interference of the tag with the protein function. The tag 
was inserted in the C-terminus because previous work had identified that a C-terminal 
GFP-tagged version of LIN-23 was able to rescue a lin-23 mutant allele (Mehta et al., 
2004). However, the GFP-tagged LIN-23 utilised in their study was only expressed after 
gastrulation due to silencing of high-copy extrachromosomal arrays in the germline (Kelly 
et al., 1997), and thus could not be utilised here. The resulting DP38 lin-23::FLAG-TY 
strain was crossed into a lin-23 null background to generate the strain IA592 that stably 
expresses LIN-23::FLAG::TY in a lin-23 null background (for strain generation see 
Chapter 5, (5.2.3), for genotype Chapter 2, Table 2.8).
Importantly, when CDC-25.1 was precipitated in this strain background the LIN-23 band is 
shifted to a slightly higher molecular weight due to the presence of the tag and this band is 
not present in the IgG control (Figure 4.5, B, compare lanes 3 and 5 for the shift and 5 and 
6 for the specific binding). Thus, endogenous CDC-25.1 physically interacts with 
endogenous LIN-23 in C. elegans embryos.
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4.2.5.1 The lin-23::FLAG-TYallele causes elevated CDC-25.1 levels and
hyperplasia
Interestingly, when CDC-25.1 was precipitated from embryos expressing only the LIN- 
23 ::FLAG-TY protein, a strong decrease in LIN-23 binding was observed (Figure 4.5, B, 
compare lanes 3 with 5) though similar amounts of LIN-23 ::FLAG-TY compared to 
endogenous LIN-23 is present in these embryos (Figure 4.5, B, compare lanes 1 and 2, or 
C, compare lanes 1 and 3). Thus, LIN-23::FLAG-TY displays a reduced binding to CDC-
25.1. Intriguingly, CDC-25.1 protein levels are strongly elevated in the LIN-23::FLAG-TY 
background compared to wild-type levels (Figure 4.5, B, lanes 1 and 2, or C, lanes 1 and 
3). When this strain was analysed for the numbers of intestinal nuclei, through expression 
of the intestinal-specific elt-2::GFP marker, an increased number of intestinal nuclei was 
observed (Table 4.3 and Figure 4.4, B).
IA592 lin-23(el883)11; 
ijls l8  [lin-23 ::FLAG-TY]; 
elt-2:: GFP::LacZ
IA593 cdc-25.1 (ij48)I; 
lin-23 (e l883)11; 
ijls l8  [lin-23 ::FLAG-TY]; 
elt-2:: GFP::LacZ
p-value
Fold
increase
34.6 ±8 .6  
(n=62)
38.5 ±8.3 
(n=69)
< 0 .01 1.1
Table 4.3 Hyperplasia of the intestine caused by the lin-23::FLAG-TY allele. M ean  ± s.d .,  p- 
value: two-tailed S tu d e n t ’s  f-test, n= n u m b e r  of em b ry o s .
These results suggested that the reduced binding of LIN-23::FLAG-TY to CDC-25.1 
causes elevated CDC-25.1 protein levels and hence hyperplasia in the embryo. To 
determine, whether this phenotype is synergistic with CDC-25.1(S46F) or mediated by 
separate means, the cdc-25. l(ij48) allele was inserted into the lin-23::FLAG-TY 
background.
This was achieved by crossing heterozygous IA589 lin-23 (e l883)11; unc-119(ed3) ijlsl8  
[lin-23:.FLAG-TY, unc-119(+)J males with IA530 hermaphrodites and selection for GFP- 
positive F2 worms that carry the homozygous lin-23 (el 883) null allele, the homozygous 
lin-23::FLAG-TY allele and were homozygous for the cdc-25. l( ij48) allele. The presence 
of these alleles was examined by single worm PCR and restriction enzyme digestion to 
check for restriction site polymorphism that is introduced through the mutations in cdc- 
25.1(ij48) or lin-23 (el 883). (Details on the restriction site polymorphism are in Chapter 2,
(2.2.6.4) and (2.2.6.5) and the IA589 generation in Chapter 5, (5.2.3)).
The resulting strain (IA593) was analysed for the numbers of intestinal nuclei. A 
significant increase in the numbers of intestinal nuclei was evident when the lin-
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23:.FLAG-TY  allele was combined with the cdc-25.l(ij48) allele (Table 4.3). Comparison 
of the protein levels in embryonic extracts revealed a decrease in the LIN-23 ::FLAG-TY 
protein levels in the IA593 strain expressing CDC-25.1(S46F) compared to IA592 
expressing CDC-25.1. The reason for the decrease in the LIN-23::FLAG-TY protein levels 
is not clear. However, it might explain the synergistic increase in the intestinal cell 
numbers when combined with the cdc-25. l(ij48) mutant. Several attempts were undertaken 
to precipitate LIN-23 ::FLAG-TY in order to analyse for association of endogenous CDC-
25.1 using either anti-FLAG resin (Sigma) or an anti-TY antibody that was available in Dr. 
Johnstone’s laboratory. However, only tiny amounts of LIN-23 could be precipitated, 
under any condition tested, suggesting that the epitope is masked and therefore not 
accessible to the antibody. In conclusion, the lin-23::FLAG-TY allele causes hyperplasia of 
the intestine through elevated CDC-25.1 protein levels.
4.2.6 CDC-25.1 S46 is crucial for UN-23 binding in embryos
Binding of LIN-23 to CDC-25.1 and CDC-25.1(S46F) was compared from embryonic 
extracts derived from the strain JR1838 cdc-25.1(+) and IA530 cdc-25.1 (ij48) after 
immunoprecipitation of endogenous CDC-25.1. As depicted in Figure 4.5, LIN-23 
associates specifically with CDC-25.1 because the LIN-23 protein is not present in the IgG 
control (Figure 4.5, D, lanes 3 and 4). Due to the elevated CDC-25.1(S46F) protein levels 
in embryos a considerably greater amount of CDC-25.1(S46F) is precipitated compared to 
CDC-25.1 (compare lanes 3 and 5). Importantly, a strong reduction of LIN-23 protein 
levels in the CDC-25.1(S46F) eluate is evident as compared to the amount precipitated 
with CDC-25.1. The relative amount of LIN-23 protein levels bound to CDC-25.1 are very 
little as compared to the input lanes (compare lanes 1 and 2 with 3 or 5), suggesting that 
only a very small subfraction of LIN-23 is bound to CDC-25.1. The same amount of input 
material was loaded (as indicated by the small inset that displays weak exposure of the 
blot) in both cases.
This experiment demonstrates that endogenous LIN-23 shows decreased binding to CDC- 
25. 1(S46F) as compared to CDC-25.1 in embryonic extracts under this experimental buffer 
conditions. It should be noted that this difference was not observed when 1% NP40 was 
omitted from the binding buffer. To determine whether the reduced binding influences the 
ubiquitination state of CDC-25.1(S46F), the samples were re-examined by SDS-PAGE and 
probed with an antibody that recognises poly- and mono-ubiquitin. Only the 
polyubiquitinated fraction is depicted here. A decrease of polyubiquitinated CDC- 
25. 1(S46F) is detected as compared to CDC-25.1 (compare lanes 3 and 5). Importantly, the
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result acquired here emphasizes that CDC-25.1(S46F) shows reduced physical association 
to LIN-23 and a concomitant decrease in its polyubiquitination state.
4.3 Discussion
I hypothesised that CDC-25.1 can physically interact with LIN-23 in C. elegans embryos 
and that the binding is abolished through the S46F mutation in CDC-25.1. Here, a 
biochemical system was set up gathering novel data that provide strong evidence for a 
physical interaction of CDC-25.1 to LIN-23 in C. elegans embryos. Furthermore, CDC- 
25.1(S46F) binding to LIN-23 is weakened and there is decreased polyubiquitination of 
CDC-25.1(S46F) compared to CDC-25.1.
4.3.1 Setting up the biochemical assay to study CDC-25.1 
interaction to LIN-23
4.3.1.1 Testing of anti-CDC-25.1 peptide antibodies
A biochemical system was established to purify a CDC-25.1 LIN-23 complex from C. 
elegans embryonic extracts. An elaborate set of experiments was performed in order to 
obtain this essential information. Firstly, several attempts were undertaken to purify 
endogenous CDC-25.1 using anti-CDC-25.1 peptide antibodies (A and B) but were 
unsuccessful under several binding conditions. A weak affinity of the antibody to the 
protein or an intra-or inter-molecularly masked epitope, due to the folding of the protein 
within itself or within a complex, may provide the reason for this observation. It is clear 
that the A antibody is able to specifically detect CDC-25.1 in its denatured form on 
Western blots. The B antibody raised against the last 12 amino acids of CDC-25.1 could 
pull down little CDC-25.1 protein, similar to a previous report (Ashcroft et al., 1999), and 
recognised CDC-25.1 weakly on Western blots. This suggests that antibody A detects the 
denatured CDC-25.1 better than the non-denatured form. It could be possible that the C- 
terminal epitope is masked through binding to other proteins. The C-terminus of the 
eukaryotic CDC25 family contains a cyclin binding domain that is conserved from yeast to 
humans (Uto et al., 2004). Alignment o f this motif reveals no strong homology to the C. 
elegans CDC-25.1 protein, however the very conserved (R, K), XKXX (T, S) core domain 
(where R denotes arginine, K lysine, T threonine, S serine and X any amino acid) present 
in all molecules is also found in C. elegans CDC-25.1. In CDC-25.1 it comprises amino 
acids 505 to 510 (RPKWYS), suggesting that this domain could be involved in interaction
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of C. elegans CDC-25.1 with cyclins. Consistently, the anti-CDC-25.1 A antibody was 
raised against amino acids 495 to 509 and is thus overlapping with the putative cyclin 
binding domain, suggesting that cyclin binding may interfere with the recognition of the A 
antibody to CDC-25.1. However, whether this domain is indeed involved in CDC-25.1 
binding to cyclins remains to be elucidated.
4.3.1.2 Purifications of LAP-tagged CDC-25.1
As an alternative purification approach, overexpression of LAP-tagged CDC-25.1 in 
intestinal cells was utilised. Purification with a commercial anti-GFP antibody was not 
possible though purification of a GFP::LacZ fusion protein expressed in the same 
compartment was. This would suggest that the GFP epitope is buried in the CDC-25.1 
proteins. Nevertheless, the LAP::CDC-25.1 protein was able to efficiently bind to S- 
Protein Agarose indicating that the S tag is exposed. However, a comparison between 
LAP::CDC-25.1 compared to LAP::CDC-25.1(S46F) was not possible because the mutant 
protein did not bind to the resin. This finding was rather surprising and could suggest that 
the N-terminus of the LAP::CDC-25.1(S46F) mutant might fold differently than the wild- 
type leaving the epitope masked. One way to examine this would be to boil the extracts in 
SDS to completely denature the proteins, and analyse whether binding to the S-Protein 
Agarose is increased. However, this would not solve the purification problem and the 
experiment was therefore omitted.
A difference in the localisation state of LAP::CDC-25.1 and LAP::CDC-25.1(S46F) was 
noticed in this study, indicating that both molecules are differentially regulated. This could 
suggest that LAP::CDC-25.1 is present in a different complex compared to LAP::CDC- 
25.1(S46F) and therefore not able to be precipitated in the same manner as the wild-type to 
the S-Protein resin, due to differential epitope masking. This observation in itself is rather 
intriguing. Purification of the extracts on gel filtration columns and following the presence 
of CDC-25.1 with an anti-GFP antibody could resolve this question. The difference in the 
molecular weight of the LAP::CDC-25.1(S46F)-containing complex compared to the 
LAP::CDC-25.1 would allow predictions of differential complex formations.
4.3.1.3 Purification strategies to pull down LIN-23
Additionally, a strain was generated that expresses a FLAG-TY-tagged LIN-23 in a lin-23 
null background in C. elegans embryos and utilised for pull down studies. Furthermore, 
immunoprecipitation of LIN-23 using a newly synthesised anti-LIN-23 antibody was
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attempted. However only a newly generated CDC-25.1 antibody was able to purify CDC-
25.1 and CDC-25.1(S46F) and could be utilised for comparative interaction studies of 
LIN-23 to CDC-25.1 and CDC-25.1(S46F). This was due to the fact that the anti-LIN-23 
antibody showed a weak affinity to CDC-25.1 in immunoprecipitation assays and the LIN- 
23 ::FLAG-TY could not be precipitated with antibodies against the FLAG or TY tag.
Together, these difficulties reflect the unpredictability of the biochemical purification 
assays. A peptide might be masked in a complex or within the protein itself. As alternative 
purification strategies placing the tag to different domains of either protein is another 
option. In this work several alternative methods were used to place a tag on the N-terminus 
of CDC-25.1 or the C-terminus of LIN-23 and different antibodies utilised against the C- 
terminus of CDC-25.1 and the N- and C-terminus of LIN-23. Generation of antibodies is 
an elaborate method and tagging of proteins in C. elegans is not as easy as in other systems 
such as E. coli or mammalian tissue culture cells. Generating and testing transgenic strains 
can take several months, thus I decided to continue my efforts on the reagents that are 
functional and provide robust data. A combination of approaches was employed to 
underpin the specificity of the interaction of CDC-25.1 to LIN-23 in C. elegans embryos, 
and they are discussed below.
4.3.2 CDC-25.1 interacts with endogenous LIN-23 in C. elegans 
embryos
In this study, overexpressed LAP-tagged CDC-25.1 in intestinal cells could be purified on 
S-Protein Agarose. This protein showed clear binding to endogenous LIN-23 as examined 
by Western blotting using a novel LIN-23 antibody. As a second approach endogenous 
CDC-25.1 was immunoprecipitated from embryonic extracts using a novel anti-CDC-25.1 
antibody that was raised against the full-length CDC-25.1 protein and specifically detects 
CDC-25.1. Importantly, LIN-23 is present in the eluate of CDC-25.1 immunoprecipitates 
and CDC-25.1 thus associates with LIN-23 in embryos.
As another experiment to verify specificity of the interaction, a tagged version of LIN-23 
was able to interact with endogenous CDC-25.1 in the absence of untagged LIN-23, 
resulting in an approximately 2 kDa LIN-23 shift. Thus, the endogenous LIN-23 band 
present in the CDC-25.1 eluate is specific for LIN-23 and no artefact of the experiment. It 
is presently unclear, whether this interaction is direct or mediated by a bridging molecule. 
The direct binding between the DSG peptide of (3-catenin and p-TrCP in vitro (Wu et al.,
2003) suggests a direct interaction of C. elegans LIN-23 to the DSG consensus of CDC-
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25.1. One way to examine whether the CDC-25.1 binding to LIN-23 is direct would be to 
develop an in vitro assay between the two molecules that are expressed in E. coli. This is 
not straight forward, because CDC-25.1 is highly phosphorylated in embryos as illustrated 
in this study and prior phosphorylation of at least the DSG motif and possibly other 
residues, as demonstrated for human CDC25A (Donzelli et al., 2004; Jin et al., 2003; 
Kanemori et al., 2005; Ray et al., 2005), may be important for LIN-23 interaction. 
Recombinant E. coli expressed CDC-25.1 could be purified through a tag, in vitro 
phosphorylated with several recombinant kinases, re-purified and added to E. coli in vitro 
translated and radiolabelled LIN-23 to assay for binding.
Importantly, the data obtained here show that CDC-25.1 and LIN-23 form a complex in 
vivo. Consequently, these data illustrate that binding of LIN-23 is specific to CDC-25.1 by 
several means. Endogenous CDC-25.1 binds to endogenous LIN-23, as examined by 
immunoprecipitation using an anti-CDC-25.1 antibody. Tagged CDC-25.1 binds to 
endogenous LIN-23 as examined by pull downs of CDC-25.1 through the LAP tag. 
Additionally, in the absence of wild-type LIN-23, the LIN-23 band that shifts to a LIN- 
23::FLAG-TY band in a CDC-25.1 immunoprecipitate. However, only a small amount of 
the total LIN-23 is associated with CDC-25.1. This is not entirely surprising since the 
complex is expected to be of a transient nature and only present at a distinct stage of 
embryonic development (probably mainly the 10- to 60-cell stage). Furthermore, only a 
subfraction of the total CDC-25.1 may be associated with LIN-23 and vice versa. LIN-23 
may be involved in targeting a wide range of substrates, as identified for its the human 
orthologue P-TrCP, and thus only a small fraction of it may associate to CDC-25.1. It is 
thus rather intriguing that it was possible to set up conditions to detect the steady state 
interaction between these two endogenous molecules.
4.3.3 CDC-25.1 S46 may be crucial for LIN-23 binding
Based on the specificity of LIN-23 binding to CDC-25.1, experiments were conducted to 
test whether the interaction o f LIN-23 with CDC-25.1(S46F) was affected. 
Immunoprecipitation of endogenous CDC-25.1 compared to CDC-25.1(S46F) using the 
newly synthesised CDC-25.1 f.l. antibody revealed that LIN-23 binding to CDC- 
25. 1 (S46F) is weakened as compared to CDC-25.1. Furthermore, the polyubiquitination of 
CDC-25.1(S46F) is reduced compared to CDC-25.1. Thus, these results suggest that the 
S46F mutation affects the binding of LIN-23 to CDC-25.1. Both extracts contain similar 
amounts of LIN-23 protein as assayed in the small inset (Figure 4.5, D lanes 1 and 2), but 
in this experiment no p-ACTIN loading control is present. However, in other experiments
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performed previously the amount of LIN-23 protein was found to be similar in the embryo 
when the same strains were utilised (Figure 3.5, A, lanes 2 and 4). It is possible that the 
amount of LIN-23 protein that can associate to CDC-25.1 is limiting and that only a 
subfraction of LIN-23 can ever associate to CDC-25.1 in the extract. However, in these 
experiments performed (using 1% NP40 in the binding assay) the amount o f LIN-23 bound 
to CDC-25.1(S46F) is clearly reduced compared to LIN-23 binding to CDC-25.1. A 
possible explanation of these data is that most of the CDC-25.1(S46F) is in a separate 
compartment and thereby unavailable for LIN-23 binding. Thus, a differential localisation 
of CDC-25.1(S46F) might escape LIN-23 association. This differential LIN-23 association 
to the CDC-25.1 and CDC-25.1(S46F) is only observed under high amounts of detergent 
for reasons that remain unresolved. Ultimately, it would be desirable to compare the 
binding of the CDC-25.1 and CDC-25.1(S46F) to LIN-23 in an in vitro assay, where the 
total amounts of each protein can be directly compared. This could be done by in vitro 
translation of the CDC-25.1 protein, which could be assayed for binding to recombinant 
LIN-23 either in a band-shift assay or by pulldown analysis.
In the in vivo assay obtained here clearly, the binding of LIN-23 is not abolished but 
probably reduced. In mammalian cells the single mutation of analogous S82 in the DSG 
consensus of CDC25A was reported to abolish P-TrCP binding in vivo (Donzelli et al., 
2004; Jin et al., 2003). This apparent inconsistency can be explained by the difference in 
methodology applied. Assuming LIN-23 binding was not limiting, the assay system 
described here purifies much higher amounts of endogenous CDC-25.1(S46F) protein 
compared to CDC-25.1, whereas in the experiment by Donzelli et al. similar amounts of 
FLAG-tagged CDC25A were pulled down or loaded on the gel (it should be noted that 
they also used 1% NP40 in their assay system). An adjustment of the CDC-25.1 protein 
levels was not performed in this study in order to keep all parameters identical. It is highly 
unlikely that LIN-23 protein levels could still be detected if far less CDC-25.1(S46F) 
eluate was applied on the gel. Furthermore, (Jin et al., 2003) utilised a truncated version of 
CDC25A (aa 1 - 100) for their studies, which might lack additional binding sites important 
to stabilise CDC25A interaction to p-TrCP.
In accordance with the potentially reduced binding, a decrease in the polyubiquitination 
state has been identified for CDC-25.1(S46F). Similarly, an in vitro ubiquitination assay 
revealed that the polyubiquitination of CDC25A is reduced by about 50% in the human 
CDC25A S82A mutant (Donzelli et al., 2004). In contrast, (Jin et al., 2003) concluded that 
this mutant is abrogated in P-TrCP-mediated polyubiquitination, but the initial
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ubiquitination signal was very low and no quantification was provided in that study, and it 
is therefore possible that stronger exposure times would unravel residual ubiquitination of 
CDC25A S82A.
In essence, the experiments conducted here suggest that the binding of CDC-25.1(S46F) to 
LIN-23 may be reduced and a decrease in polyubiquitinated CDC-25.1(S46F) is observed. 
This result fits well with the elevated CDC-25.1 protein levels that are detected for CDC- 
25. 1 (S46F) by Western blotting and indirect immunofluorescence and suggests that the 
kinetics of CDC-25.1 degradation are reduced when S46 is mutated. Accordingly, CDC- 
25.1(S46F) protein levels are undetectable at later stages of development, suggesting that 
the protein is degraded eventually. Thus, S46 is essential for LIN-23 interaction and 
similar to other vertebrate systems, such as for example P-TrCP binding to p-catenin and 
CDC25; phosphorylation of this residue may be important for LIN-23 interaction.
4.3.3.1 CDC-25.1 is phosphorylated in embryos
Western blot analysis using two independent antibodies revealed that multiple CDC-25.1 
bands are detected by SDS-PAGE that migrate at higher molecular weight than predicted. 
All bands shift down to a smaller molecular weight that corresponds to the estimated 
molecular mass on addition of lambda phosphatase to the extracts. Multiple 
phosphorylation of CDC25 had been reported for the vertebrate counterparts. Initial studies 
using the Xenopus system revealed that Xenopus CDC25C (Izumi et al., 1992; Kumagai 
and Dunphy, 1992) is extensively phosphorylated upon entry into mitosis and exhibits a 
severe migrational retardation on SDS polyacrylamide gels. Subsequently, several 
phosphorylation sites were identified in all three vertebrate CDC25 proteins. 
Phosphorylation of Xenopus CDC25C on the N-terminal region was described that is 
required for CDC25 activity (Kumagai and Dunphy, 1992) and comprises phosphorylation 
of several residues (T48, T67, T138, S205 and S285) (Izumi and Mailer, 1993). S285 
corresponds to S214 and S307 in human CDC25C and CDC25B, and phosphorylation of 
both residues has been shown to inhibit S216/S309 phosphorylation (Bulavin et al., 
2003b). Furthermore, several phosphorylation sites have been identified in CDC25A. In 
mitosis, human CDC25A is phosphorylated on S I8 and SI 16 resulting in stabilisation of 
CDC25A (Mailand et al., 2002). During S and G2 phase of the cell cycle, human CDC25A 
is phosphorylated on multiple residues (S76, S82, S88, S I24, S I78, S279 and S293) 
contributing to the rapid turnover o f CDC25A in unperturbed cells and in response to DNA 
damage (Busino et al., 2003; Falck et al., 2001; Goloudina et al., 2003; Hassepass et al.,
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2003; Ray et al., 2005; Sorensen et al., 2003). In human cells, S82 in the DSG consensus 
sequence is phosphorylated by an as yet unknown kinase.
Thus, it can be anticipated that S46 of CDC-25.1 is phosphorylated in C. elegans embryos. 
No robust difference in the appearance of the three more slowly migrating bands was 
observed between the CDC-25.1 and CDC-25.1(S46F) on SDS polyacrylamide gels, 
suggesting that these bands reflect multiple phosphorylation on CDC-25.1. Similarly, 
knockdown of LIN-23 by RNAi stabilised all phosphorylated forms and not only one. The 
exact residues that are phosphorylated and the individual mechanism of phosphorylation 
remain to be identified. It is presently unclear whether S46 is phosphorylated in embryos. 
A comparison of CDC-25.1 and CDC-25.1(S46F) by two-dimensional SDS-PAGE could 
be employed to obtain a higher resolution of the CDC-25.1 phosphorylation forms. 
Importantly, this result demonstrates that in C. elegans embryos CDC-25.1 is 
phosphorylated similar to vertebrate CDC25.
4.3.4 Overexpression of CDC-25.1 causes hyperplasia
4.3.4.1 Zygotic expression of CDC-25.1
During the course of this work it became evident that zygotic overexpression of tagged and 
untagged CDC-25.1 resulted in intestinal hyperplasia in the embryo as evident by an 
increased number of intestinal nuclei. Overexpression of the CDC-25.1 proteins was 
confirmed by Western blotting (LAP::CDC-25.1) or indirect immunostaining (CDC-25.1). 
The hyperplasia was examined by DAPI staining of adult worms or the expression of the 
intestinal-specific elt-2::GFP. In a wild-type strain, 34 intestinal cells are present during 
post-embryonic development due to an additional nuclear division of the 14 most posterior 
cells at the LI lethargus (Sulston and Horvitz, 1977). Here, on average 31.7 nuclei were 
counted by DAPI staining, probably due to difficulties in clearly distinguishing the small 
nuclei in the tail of the worm from the nuclei of surrounding tissues. A cdc-25. l( ij48) 
mutant analysed shows on average 60.5 nuclei in the adult. However, worms zygotically 
overexpressing tagged or untagged CDC-25.1 show an average of 40 to 50 nuclei, thus 
indicating that the tag is not causing malfunction of the protein. Consistent with previous 
reports on chromosomally integrated cdc-25. l(ij48) (Clucas, 2003; Clucas et al., 2002) or 
cdc-25.1(rr31) (Kostic and Roy, 2002), these nuclei are generated in the embryo as 
examined by the expression of the elt-2::GFP transgene. An average increase to 24 - 25 
nuclei are evident after CDC-25.1 expression in the embryo correlating with the average of 
40 - 50 nuclei in the adult worm if the four most posterior nuclei undergo no nuclear
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division during post-embryonic development as in the wild-type. It maybe possible that in 
some cases the posterior nuclei undergo one nuclear division leading to a slight increase in 
the post-embryonic numbers of nuclei. Cell lineage studies of the cdc-25. l( ij48) mutant 
revealed that the expression of the elt-2::GFP in intestinal nuclei correlates with the 
number of intestinal cells bom (Clucas, 2003; Clucas et al., 2002). Thus, it is highly 
suggestive that the intestinal nuclei in the embryos observed, by zygotic overexpression of 
CDC-25.1, represent the number of intestinal cells. Thus, this experiment complements the 
data obtained in Chapter 3 that identified that high CDC-25.1(S46F) protein levels are 
detected in the embryo and thus emphasises that merely high expression levels of CDC-
25.1 can result in hyperplasia of the intestine.
4.3.4.2 Developmental timing and severity of CDC-25.1 effects
Interestingly, a small difference in the severity of the intestinal cell number is evident 
between the chromosomally integrated cdc-25. l( i j48) and the zygotically overexpressed 
CDC-25.1. Analysis of protein extracts by Western blotting showed an approximately 10- 
fold difference in the LAP-tagged protein abundance as compared to endogenous CDC- 
25.1. Only a four- to five-fold difference of endogenous CDC-25.1(S46F) compared to 
CDC-25.1 was observed in this and the previous chapter. However, elt-2 promoter 
expression commences at the 28-cell stage of embryogenesis after the first two intestinal 
cells are bom (Fukushige et al., 1998). This promoter allows the ectopic expression of 
CDC-25.1 at a time when the endogenous CDC-25.1 or CDC-25.1(S46F) protein levels are 
undetectable. Thus, it is possible that the delayed timing of CDC-25.1 expression from the 
elt-2 promoter can cause the difference in severity of intestinal hyperplasia. In accordance 
with this assumption, a narrow time window at the 10- to 60-cell stage o f embryogenesis 
shows upregulated CDC-25.1(S46F) protein levels in the cdc-25. l( ij48) mutant. It is 
possible that the CDC-25.1 protein levels need to reach a certain threshold level at this 
early stage of development in order to cause hyperplasia. Comparative analysis of the 
CDC-25.1 (S46F) protein levels with elt-2:.CDC-25.1 by immunostaining of merely 
intestinal cells could be performed in order to detect whether CDC-25.1(S46F) protein 
levels are significantly higher at early embryonic stages.
Intriguingly, zygotic overexpression of CDC-25.1 does not seem to increase the 
hyperplasia during post-embryonic development as the number of cells in the embryo 
correlate with the expected number in the adult worm. This result has already been 
obtained previously for the cdc-25.1(1)48) allele (Clucas, 2003; Clucas et al., 2002), 
however, CDC-25.1(S46F) levels eventually diminish and are undetectable after the 100-
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to 200-cell stage. In contrast, elt-2::CDC-25.1 is expressed throughout embryonic 
development and post-embryonically (as observed for the e//-2::LAP::CDC-25.1), which 
suggests the presence of a mechanism that distinguishes mitotic from post-mitotic 
intestinal cells. This could be due to the lack of a CDC-25.1 downstream target such as a 
cyclin-dependent kinase or cyclin. An interesting experiment would be to determine 
whether post-mitotic expression of CDC-25.1 causes an increase in intestinal cells during 
post-embryonic development. CDC-25.1 could be placed under the control o f the cpr-5 
promoter allowing expression in the C. elegans intestine during larval and adult stages 
(Larminie and Johnstone, 1996) and analysed for elt-2::GFP expressing intestinal nuclei.
4.3.4.3 A chromosomally integrated lin-23 transgene causes hyperplasia of 
the intestine
During this study, a lin-23 partial loss-of-function allele was obtained by generation of 
FLAG-TY tagged lin-23 under the control of its authentic promoter. This allele can 
complement the sterility of the lin-23 null allele but causes strong embryonic lethality (for 
details see Chapter 5, (5.2.3)). Thus, the lin-23::FLAG-TY allele is partially 
complementing the lin-23 null phenotype. During the course of this study, a weakened 
binding of LIN-23::FLAG-TY to CDC-25.1 was evident in embryos. Interestingly, the 
CDC-25.1 protein levels are elevated in a lin-23 null mutant that expresses only the lin- 
23::FLAG-TY allele and results in the hyperplasia of the intestine as examined by elt- 
2::GFP expression.
These data complement the lin-23 RNAi experiments that show that knockdown of LIN-23 
produces elevated CDC-25.1 protein levels and intestinal hyperplasia. The enhanced levels 
of intestinal hyperplasia observed in a strain co-expressing the cdc-25. l( ij48) and lin- 
23:: FLAG-TY however seems inconsistent with the previous data showing that CDC-25.1 
is regulated by LIN-23 through S46. However, protein analysis revealed that the CDC- 
25.1(S46F) protein level is not enhanced in this strain compared to the cdc-25.1 (ij48) 
strain. Thus, the lin-23:.FLAG-TY allele does not cause the enhanced hyperplasia through 
S46 in CDC-25.1. However, the LIN-23::FLAG-TY protein levels are greatly reduced in 
the cdc-25.1 (ij48) mutant background compared to the wild-type. Thus the reduction of 
LIN-23 protein may act on proteins independent o f CDC-25.1. Cell lineage analysis 
performed by Dr. J. Cabello revealed that under strong lin-23 RNAi conditions, the Cp 
lineage expresses the intestinal fate marker elt-2::GFP. Thus, lin-23 is required in Cp to 
suppress the intestinal fate. The extra intestinal cells observed when CDC-25.1(S46F) is 
combined with low levels of LIN-23::FLAG-TY may represent additional cells derived
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from the Cp lineage. Only a cell lineage analysis between the lin-23::FLAG-TY allele in a 
cdc-25.1(+) or cdc-25. l(ij48) background will ultimately resolve this question. This 
methodology is not available in our laboratory and requires the collaboration with Dr. 
Cabello.
4.3.5 Conclusion
The data here provide vital information on the functional conservation of CDC25 
regulation between C. elegans and human. Notably, for the first time the significance for 
physical interaction of LIN-23 through S46 in CDC-25.1 to regulate the tissue-specific 
proliferation during the embryonic development of a multicellular model organism has 
been illustrated in a biochemical approach. S46F mutation in CDC-25.1 results in reduced 
binding of LIN-23 to CDC-25.1 and a decrease in the CDC-25.1 polyubiquitination rate. 
This is consistent with the data presented in Chapter 3 that detect elevated CDC- 
25.1(S46F) protein levels in the early embryo, thus demonstrating that a decrease in the 
CDC-25.1(S46F) degradation rate in all tissues, through abrogated LIN-23 interaction, 
results in the hyperplasia of the intestine. Accordingly, overexpression of zygotic CDC-
25.1 in intestinal cells results in hyperplasia of the intestine emphasising that merely 
enhanced wild-type CDC-25.1 protein levels are responsible for the proliferation 
phenotype. Moreover, a LIN-23::FLAG-TY protein shows decreased binding to CDC-25.1 
and elevated CDC-25.1 levels resulting in intestinal hyperplasia.
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Chapter 5 
CDC-25.1 tissue specificity
5 CDC-25.1 tissue specificity
5.1 Introduction
As previously reported, the maternally acting cdc-25. l(ij48) gain-of-function allele triggers 
a hyperplasia in the embryo that is mediated in a tissue-specific fashion and only perturbs 
the proliferation of intestinal cells (Clucas, 2003; Clucas et al., 2002). Cell lineage analysis 
of homozygous cdc-25. l(ij48) embryos revealed that the intestinal precursor (E) gives rise 
to 1 5 -2 0  additional intestinal cells in the embryo, whereas proliferation of a neighbouring 
blastomere (D) was evidently unaffected. Similarly, expression of tissue-specific GFP 
markers revealed no increase in the proliferation of at least two other tissues in the embryo 
and the cdc-25. l(ij48) homozygous hermaphrodites are otherwise healthy and viable with 
no obvious post-embryonic defects. A comparable intestine-specific proliferation 
phenotype has been identified for the cdc-25.1 (rr31) gain-of-function mutant, and the 
encoded CDC-25.1(G47D) protein has been illustrated to display a prolonged lifetime in 
all embryonic blast cells (Kostic and Roy, 2002). In contrast, removal of CDC-25.1 by 
RNAi causes embryonic lethality with severe mitotic division defects and a decrease in the 
proliferation of several tissues (Ashcroft et al., 1999; Clucas, 2003; Clucas et al., 2002). 
Hence, CDC-25.1 function is required in all embryonic blast cells to drive cell 
proliferation.
In the previous chapters, data are presented that depict the important role of LIN-23 in the 
regulation of CDC-25.1 through S46 in the embryo. Binding of LIN-23 to CDC-25.1 
regulates the stability of CDC-25.1 in all early embryonic blast cells and the mutant CDC- 
25. 1(S46F) escapes this negative regulation causing elevated protein levels in all blast 
cells. Thus, the negative regulator LIN-23 does not act in a tissue-specific fashion, which is 
consistent with the previous lack of phenotype for tissue-specific differences in the CDC- 
25.1(S46F) (Clucas, 2003; Clucas et al., 2002) or CDC-25.1(G47D) (Kostic and Roy, 
2002) mutant protein levels or localisation in early embryos.
It is intriguing to note that the cell cycle exit in distinct embryonic blast cells differ in their 
sensitivity to the elevated presence of the CDC-25.1 protein. It will therefore be 
challenging but equally fascinating to decipher the mechanism underlying the differential 
sensitivities for this cell cycle regulator in different tissues. The identity of LIN-23 as the 
negative regulator of CDC-25.1 provides a significant step towards elucidating the 
temporal and spatial control of CDC-25.1 regulation during C. elegans development,
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particularly because the expression and function of cdc-25.1 and lin-23 is not temporally 
restricted to the early embryo when the fine-tuning of the interaction between both 
molecules is crucial to sustain normal embryogenesis.
5.1.1 cdc-25.1 and lin-23 function during germline development
Previous work from several laboratories revealed that cdc-25.1 and lin-23 are expressed in 
the C. elegans proliferating germline and embryos and the evidence supporting these 
findings is introduced below. Northern blotting for cdc-25.1 revealed high RNA expression 
levels in proliferating germlines that diminish during larval stages (Ashcroft et al., 1999), 
whereas high lin-23 RNA levels were detected in the germline and embryos by Northern 
blotting and in situ hybridisation (Kipreos et ah, 2000). In accordance with the high RNA 
levels, CDC-25.1 protein levels have been detected in the germline and in early embryos 
by indirect immunofluorescence against CDC-25.1 (Ashcroft et ah, 1999; Clucas, 2003; 
Clucas et ah, 2002; Kostic and Roy, 2002).
Detailed immunolocalistation studies by (Ascroft et ah, 1999) revealed that, in the adult 
hermaphrodite, CDC-25.1 protein is mainly expressed in the germline and present in the 
nuclei of the oocytes with diffuse staining in the pachytene nuclei of the distal gonad, 
which becomes more apparent in the diakinetic nuclei of the proximal gonad arm. Some 
cytoplasmic signal becomes evident in older oocytes but is reduced at fertilisation. After 
fertilisation the signal becomes mainly nuclear in both the sperm and oocyte pronucleus 
and is mainly nuclear in the interphase and prophase of all early embryonic blast cells. 
Thus, the presence of CDC-25.1 protein in the germline suggests a requirement for its 
function during this developmental stage. Indeed, RNAi against cdc-25.1 revealed that 
RNAi escapers developed into sterile adults because they probably obtained sufficient 
maternally provided CDC-25.1 to complete embryogenesis (Ashcroft and Golden, 2002; 
Ashcroft et al., 1999; Clucas, 2003; Clucas et al., 2002). Similarly, homozygous cdc-
25.1 (nr2036) null mutants are sterile and their empty gonads contain only a few non-viable 
germ cells that do not develop into oocytes indicating a zygotic role for CDC-25.1 during 
germline proliferation (Ashcroft and Golden, 2002).
Immunolocalisation has been lacking for LIN-23 to date. Expression of GFP 
transcriptional and translational reporter constructs revealed ubiquitous embryonic 
expression of LIN-23 starting at gastrulation in the cytoplasm of all embryonic blast cells 
and in the cytoplasm of several neurons, the hypodermis and muscle cells o f the adult 
hermaphrodite (Mehta et al., 2004). Lack of GFP expression in the germline is probably
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due to germline silencing of these constructs that were injected as extrachromosomal 
arrays, which are known to be subject to silencing in the germline (Kelly et al., 1997). A 
maternal and zygotic function for lin-23 has been previously reported through the analysis 
of lin-23 null mutants (Kipreos et al., 2000). In heterozygote progeny, post-embryonic 
development is reported to appear like wild-type as the animals develop into fertile adults. 
In contrast, homozygous mutant progeny of heterozygous mothers proceed through 
embryogenesis with no reported defects, but develop a variety o f post-embryonic defects 
including sterility as adults. Homozygous lin-23 null mothers produce only very few non- 
viable embryos that arrest with excess numbers of nuclei. Thus, this indicates that maternal 
LIN-23 products derived from a heterozygote mother are sufficient to sustain normal 
embryogenesis and the zygotic LIN-23 product is vital for germline development. In 
contrast to the lack of germline proliferation obtained in the cdc-25.1 null mutant, lin-23 
null hermaphrodites produce the wild-type number of germ cells but show somatic defects 
including extra gonad arms and distal tip cells probably due to post-embryonic 
proliferation defects. The causative nature for the lin-23 sterility has not been investigated 
to date.
However, these data clearly depict a zygotic role for both CDC-25.1 and LIN-23 in the 
development of the C. elegans germline whereas a maternal function of both proteins is 
required for normal embryogenesis. Interestingly, the difference in the germline 
proliferation phenotype of null alleles of each gene suggests that both genes act via 
separate mechanisms in the C. elegans germline as opposed to their common function in 
early embryos. Since CDC-25.1 is required for germ cell proliferation, removal of LIN-23 
would be anticipated to result in hyperproliferation of the germline if it was negatively 
regulating CDC-25.1, but no hyperproliferation in lin-23 null mutants was observed 
recently (Kipreos et al., 2000). Accordingly, cdc-25. l( ij48) mutant animals show normal 
proliferation of the germline and the cdc-25. l(ij48) allele can complement the sterile 
phenotype of the cdc-25.1 (nr2036) null mutant (Clucas, 2003; Clucas et al., 2002) 
indicating that LIN-23 function is not required to control CDC-25.1 through S46 during 
germline proliferation.
5.1.2 Hypothesis and aims
Due to the scientific evidence portrayed above, I anticipated that zygotic LIN-23 might not 
regulate zygotic CDC-25.1 during C. elegans germline proliferation. Experiments were 
designed in order to test this hypothesis. Firstly, the zygotic versus maternal function of 
LIN-23 during C. elegans intestinal cell proliferation was further investigated. As
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described earlier, homozygous lin-23 null mutant embryos derived from heterozygous 
mothers have been reported to proceed normally through embryogenesis, as examined with 
Nomarski optics, thus suggesting that maternally provided LIN-23 from the heterozygous 
mother is sufficient to drive normal embryogenesis (Kipreos et al., 2000). However, no 
intestinal-specific marker was utilised in those experiments and proliferation defects of the 
intestine may have been missed. RNAi experiments performed here, which reduce both the 
maternal and zygotic LIN-23, indicate that lowered LIN-23 maternal protein levels can 
cause intestinal hyperplasia in the embryo. However, the contribution of the zygotic 
genotype for the intestinal cell proliferation phenotype has not been examined and was 
therefore investigated.
Since lin-23 null embryos from heterozygous lin-23 mothers proceed normally through 
embryogenesis and develop into fertile adults, it was decided to investigate whether 
lowering the lin-23 gene-dose would result in embryonic intestinal defects in homozygous 
lin-23 embryos derived from heterozygous mothers. Hyperplasia in zygotic null embryos 
would show that the intestinal phenotype is determined by the zygotic genotype. To this 
end, the lin-23 null mutant strain was to be crossed into intestinal-specific GFP marker 
strains such as JR1838 wls84 [elt-2::GFP:LacZ] permitting GFP expression in the 
intestinal nuclei of embryos and a second marker strain JR1988 w ls ll9  [npa- 
1 ::GFP::LacZ] allowing GFP expression in intestinal nuclei from late embryonic 
development that persists during post-embryonic development.
Secondly, though a zygotic role has been described for lin-23 during C. elegans germline 
development and elevated mRNA levels were detected at this stage, the LIN-23 protein 
expression levels and localisation in the C. elegans germline remained elusive. Thus, 
indirect immunofluorescence against LIN-23 using the novel LIN-23 antibody was to be 
carried out. Furthermore, the regulation of CDC-25.1 through S46 in the germline was 
compared to the regulation in embryos by Western blotting of CDC-25.1 and CDC- 
25.1(S46F) in germline and embryo extracts. Finally, immunoprecipitation of endogenous 
CDC-25.1 from germline extracts would reveal whether any LIN-23 could interact with 
CDC-25.1 in a similar manner as in embryos.
174
5.2 Results
5.2.1 LIN-23 maternal function during intestinal cell proliferation
A lin-23(el883) null mutant was employed to investigate the extent of maternal versus 
zygotic lin-23 requirement for the proliferation of intestinal cells in the C. elegans embryo. 
The lin-23(el883) allele comprises a G to A point mutation in the lin-23 sequence resulting 
in a conversion of W450 into a stop codon (Kipreos et al., 2000). This allele showed an 
identical phenotype to lin-23 (rh294) that terminates at amino acid position 12, due to the 
mutation into a nonsense codon, and that is therefore a molecular null allele. Thus, it was 
surmised that the e!883 allele also constitutes a strong loss-of-function allele of lin-23. To 
analyse the number of intestinal cells during post-embryogenesis, a new strain was 
generated to combine the lin-23 (el 883) allele with an intestinal-specific post-embryonic 
GFP marker. To this end, heterozygous JR1988 npa-1: :GFP::LacZ males were crossed 
with CB3514 lin-23(el883)/dpy-10(e 128)11. The GFP positive FI generation was analysed 
for the presence of 25% Lin animals in their F2 brood to create the strain IA565 lin- 
23(el883)/+ II; w lsll9 . This strain was utilised to observe the number of intestinal cells 
by examining the GFP fluorescence in the adult worm.
As depicted in Figure 5.1 (panel A), lin-23 heterozygote animals are evidently wild-type 
for their numbers of intestinal nuclei. However, homozygous lin-23(el883) 
hermaphrodites contain excess numbers of small intestinal nuclei (the precise numbers 
were not counted). The presence of the lin-23 mutant or wild-type allele was confirmed by 
single worm PCR and restriction site polymorphism that is introduced through the 
mutation (Figure 5.1 B and see Chapter 2 (2.2.6.5) for PCR details). The extra intestinal 
nuclei could have been produced during embryonic or post-embryonic development. 
Therefore, the number of intestinal nuclei was examined through the elt-2:: G F P L a c Z  
transgene. To this end, heterozygous CB3514 lin-23(el883)/+ //m ales were crossed with 
JR1838 wls84 hermaphrodites. GFP-positive FI animals were checked for the presence of 
25% homozygous Lin phenotype in their brood and the resulting strain IA568 lin- 
23(el883)/+  /  wls84 utilised to examine the intestinal nuclei in the embryo. Single 
embryos were analysed under the fluorescence microscope and their genotype confirmed 
by single embryo PCR and restriction site polymorphism similar to Figure 5.1, B. The 
result is summarised in Table 5.1.
175
Numbers analysed Embryo genotype Em bryo phenotype
24 lin-23 +/+ 20.0 ±0.9
19 lin-23 +/- 20.0 ± 1.0
7 lin-23 -/- 20.7 ± 1.3
Table 5.1 Comparison of genotype with phenotype of IA568 embryos.
All embryos analysed exhibited the wild-type number of intestinal nuclei, indicating that 
the zygotic genotype of the embryo does not influence the phenotype and the extra 
intestinal nuclei observed in the adult hermaphrodite are generated during post-embryonic 
development. Thus, reduction of the lin-23 gene-dose by half in the mother is sufficient to 
drive normal embryogenesis in the homozygous offspring, with respect to intestinal cell 
number.
In order to test if the LIN-23 protein product is reduced in lin-23 heterozygous animals, the 
amounts of LIN-23 product derived from wild-type, lin-23 heterozygote and lin-23 null 
animals were examined. The amount of LIN-23 was analysed by Western blotting of 
CB3514 lin-23(el883)/dpy-10(el 28)11 animals. Here, phenotypically Dpy adult
hermaphrodites (lin-23 +/+) were compared to phenotypically Lin {lin-23 -/-) and wild- 
type {lin-23 +/-) hermaphrodites by SDS-PAGE analysis using the novel anti-LIN-23 
antibody. A specific band of 80 kDa is evident in wild-type animals, reduced to 47 +/- 7% 
in lin-23 heterozygotes and absent in lin-23 null hermaphrodites ((Figure 5.1 (panel C), 
two independent experiments, samples were applied multiple times and the signal 
quantified by densitometry, compared to P-ACTIN as internal control). Thus, a reduction 
of LIN-23 protein levels by 52% in heterozygous lin-23 mothers is sufficient for normal 
embryogenesis in their zygotically wild-type, lin-23 heterozygote and lin-23 null mutant 
progeny.
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Figure 5.1 lin-23 null mutant adults exhibit extra intestinal nuclei during postembryogenesis. A)
Offspring derived from C. elegans strain IA565 carrying the intestinal-specific GFP marker npa- 
1 ::GFP::LacZ (for genotype see Chapter 2, Table 2.8) was analysed for the numbers o f  intestinal nuclei 
(GFP) in lin-23 null (lin-23 -/-), lin-23 heterozygote (lin-23 +/-) or lin-23 wild-type (lin-23 +/+) young 
adults. Scale bar: 50 |Ltm. B) The genotype o f  adults was confirmed by single worm PCR and restriction site 
polymorphism. C) Western blot analysis o f  LIN-23 protein levels o f  50 (lin-23 + /+  and lin-23 + / - )  or 100 
{lin-23 -/-) adult hermaphrodites compared to (3-ACT1N, c = cross-reacting band o f  the anti-LIN-23 antibody. 
Two independent experiments for C.
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5.2.2 LIN-23 post-embryonic localisation
The data above strongly suggested that maternally provided LIN-23 can sustain cell cycle 
exit during proliferation of intestinal cells in the embryo, whereas zygotic LIN-23 is 
required for appropriate control of intestinal nuclear divisions during post-embryonic 
development. Thus, indirect immunofluorescence, using the anti-LIN-23 antibody, was 
performed to examine whether LIN-23 protein levels could be detected in the adult 
intestine and germline. Weak expression of LIN-23 was detected in the cytosol of intestinal 
cells in wild-type adult hermaphrodites as compared to a lin-23 null strain (Figure 5.2). 
Furthermore, strong LIN-23 expression was detected in the adult germline and was 
evidently missing in the lin-23 null hermaphrodite (Figure 5.2). In the germline a mainly 
cytosolic staining was observed in the meiotic region (depicted to the bottom right), the 
pachytene (loop) and diakinetic region (top right) of the germline and in newly generated 
oocytes. Strong staining was also observed in other postembryonic tissues (no detailed 
analysis on the tissue identity was performed in this study) and in the embryo (embryonic 
LIN-23 localisation is discussed in Chapter 6). Thus, in accordance with LIN-23 function, 
the protein is localised in the intestine and germline of the adult hermaphrodite.
5.2.3 A lin-23::FLAG-TYallele rescues lin-23 germline defects
During the course of this study, a partially functional lin-23 allele (lin-23::FLAG-TY) was 
generated. This transgene was integrated into the genome of the strain DP38 unc- 
119(ed3)III by microparticle bombardment and rescue of the unc-119 mutation. Four 
independently integrated lines that were non-Unc were generated indicating that they 
contained the unc-119 wild-type copy potentially together with the lin-23::FLAG-TY 
allele. All strains were analysed for the expression of LIN-23 ::FLAG-TY by 
immunocytochemistry against the TY tag and showed similar cytosolic staining in the 
germline (data not shown). Interestingly, it was observed that all strains, which evidently 
contain the endogenous wild-type copy of lin-23 and the lin-23::FLAG-TY allele, showed a 
high degree of embryonic lethality of on average 50% in their offspring, which could be 
due to the lin-23::FLAG-TYallele or through the bombardment procedure.
One strain (IA582) that showed detectable expression of LIN-23::FLAG-TY on Western 
blot and the lowest frequency of embryonic lethality was chosen to determine whether the 
lin-23::FLAG-TY allele was fully functional and could complement the lin-23(el883) null 
allele. Hence, this strain was crossed into the lin-23 null strain to analyse rescue of sterility. 
To this end, homozygous males of IA582 unc-119(ed3)III; ijlsl8  [lin-23::FLAG-TY, unc-
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119(+)] were crossed into IA551 lin-23(el883 )+/+ dpy-10(e l28)11; unci 19(ed3)III 
hermaphrodites. Due to the presence of the homozygous unc-119(ed3) mutation in the 
background of both strains, the presence o f homozygous lin-23::FLAG-TY, co-injected 
with the unc-119 gene, could be followed by rescue of the Unc phenotype. If lin-23 (e l883) 
was on a separate chromosome as lin-23::FLAG-TY by Mendelian segregation, 50% of the 
FI generation would be expected to be lin-23 (e l883)/+ II; lin-23:: FLAG-TY unc-119(+)/+ 
+, unc-119(ed3)III. An Unc FI hermaphrodite with this genotype would be expected to 
segregate 25% sterile animals due to the presence of the homozygous lin-23(el883) allele. 
Thus, F2 populations were screened for the presence of sterile animals, indicating that the 
lin-23(el883) allele was present. Non-Unc animals containing the lin-23::FLAG-TY allele 
were picked and screened for the presence of homozygous lin-23(el883) by single worm 
PCR. Offspring of mothers with that genotype were selected for the presence of 
homozygous lin-23:: FLAG-TY to generate the strain IA589 lin-23 (e l883)11; 
unci 19(ed3)III; ijISIS [lin-23::FLAG-TY, unc-119(+)J. Thus, this strain contains the lin- 
23:: FLAG-TY allele in a lin-23 null background (for an example of the lin-23 PCR see 
Figure 5.1). Since it was possible to obtain this strain, it was obvious that the lin- 
23::FLAG-TY allele could rescue at least to some considerable extent the sterility of the 
lin-23 null mutant. This was examined in detail.
As seen in Figure 5.3 (panel A), the lin-23::FLAG-TY allele was able to fully complement 
the sterility of the lin-23 (e l883) mutant, but, on average approximately 70% of the 
embryos produced were not viable (Figure 5.3, B). The death rate differed between 
individual populations between 55% and up to 94%. The PCR analysis for genotyping of 
this strain (according to Chapter 2, (2.2.6.5)) is not depicted because two other strains that 
were generated by combining the elt-2::GFP transgene with or without the cdc-25. l(ij48) 
allele were derived from this strain after crossing IA589 males with IA530 hermaphrodites 
generating IA592 and IA593 (IA592 was generated in same way as IA593 except worms 
were selected for the cdc-25.1(+) allele; details on IA593 generation are depicted in 
Chapter 4, (4.2.5)). As illustrated in Chapter 4, both strains express only the tagged version 
of LIN-23 ::FLAG-TY and no endogenous lin-23 as determined by Western blotting and an 
example for the analysis of the lin-23 (e l883) genotype PCR is given in Figure 5.1 (panel 
B). Analysis o f the intestinal cells in those strains revealed intestinal hyperplasia in the 
embryos and elevated CDC-25.1 protein levels (see Chapter 4, 4.2.5). Thus, the LIN- 
23 "FLAG-TY protein can fully rescue the sterility o f the lin-23 null mutant, but it can only 
partially rescue the embryonic function.
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a  LIN-23 DAPI
Figure 5.2 Localisation of  LIN-23 in the adult hermaphrodite. Immunofluorescence staining 
o f  LIN-23 in wild-type ( lin-23 + /+ )  or lin-23 (el883) (lin-23 -/-) hermaphrodites with DAPI 
counterparts; only the anterior part o f  the intestine is depicted (anterior to the left), arrows indicate 
the position o f  intestinal cells. Dissected gonads are shown (germline) in the bottom. Scale bar: 
50 pm.
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Figure 5.3 A lin-23::FLAG-TY  allele rescues lin-23 null sterility and causes embryonic death. A)
Number o f  FI embryos in N2 Bristol (N2), IA589 lin-23 (e l883)11; uncll9(ed3)lll\ ijls l8  [lin-23-FLAG - 
TY, unc-119+] {lin-23::FLAG-TY) and lin-23(el883)ll. B) Percent hatch rate o f  N2 Bristol (N2) and IA589 
{lin-23::FLAG-TY), (N2, three experiments), {lin-23::FLAG-TY, six experiments).
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5.2.4 LIN-23 does not regulate CDC-25.1 in the germline
The data illustrated above, suggested two separable functions of LIN-23 during C. elegans 
post-embryonic and embryonic development. Maternally provided LIN-23 is vital for 
regulated proliferation of the intestine during embryonic development, whereas zygotic 
LIN-23 is important for proper germline function. It has become evident that LIN-23 is 
required to restrain CDC-25.1 protein level through S46 in the early embryo in order to 
promote accurate cell proliferation of the intestine. Thus, these data suggested that 
zygotically acting LIN-23 does not regulate CDC-25.1 protein levels through S46 in the 
germline. In order to address this point, CDC-25.1 and CDC-25.1(S46F) protein levels 
were compared in the C. elegans germline. As described previously, CDC-25.1 is mainly 
expressed in the proliferating germline and embryos of the adult hermaphrodite (Ashcroft 
and Golden, 2002; Ashcroft et al., 1999). Thus, worms were grown in liquid culture and 
staged until they reached the L4 developmental stage, when they only contain a 
proliferating germline and no embryos, and CDC-25.1 protein levels were analysed by 
Western blotting. As depicted in Figure 5.4 (panel A), CDC-25.1(S46F) protein levels are 
similar to CDC-25.1 in L4 hermaphrodites as compared to the internal P-ACTIN loading 
control, but a substantial increase in CDC-25.1(S46F) protein levels was detected when 
embryos were examined in a parallel experiment. Thus, the CDC-25.1 protein level is not 
regulated through S46 in L4 hermaphrodites possibly representing the protein present in 
the germline.
Finally, the binding of LIN-23 to CDC-25.1 was analysed in L4 extracts and compared to 
the original binding in embryonic extracts. A similar amount of CDC-25.1 was precipitated 
with the CDC-25.lf.l. antibody and LIN-23 was bound to CDC-25.1 in embryonic extracts. 
In contrast, no LIN-23 binding was observed in L4 extracts (Figure 5.4, B). Thus, LIN-23 
does not regulate CDC-25.1 stability in L4-staged animals.
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Figure 5.4 LIN-23 does not control CDC-25.1 protein levels in the C. elegans germline.
A) Comparison o f  CDC-25.1 protein levels from L4-staged hermaphrodites, mainly expressing 
CDC-25.1 in the germline (lanes 1 and 2), with the protein levels in embryos (lanes 3 and 4). Similar 
amount o f  total proteins derived from extracts o f  the C. elegans strain J R 1838 (WT) and IA530 cdc- 
25.1 (ij48) (S46F) were applied to 10% SDS-PAGE and blotted with anti-CDC-25.1A and as loading 
control (3-ACTIN antibodies. B) Immunoprecipitation o f  CDC-25.1 with the anti-CDC-25.If.l.  
antibody from extracts o f  L4-staged hermaphrodites (lane 1) or embryos (lane 3) o f  the strain JR1838 
as compared to rabbit IgG as control (lanes 2 and 4, respectively). Eluates were applied to 10% SDS- 
PAGE followed by Western blotting against LIN-23 (top) and CDC-25.1 (anti-CDC-25.1 A, bottom). 
Two independent experiments each.
183
5.3 Discussion
It was hypothesised that LIN-23 may not regulate CDC-25.1 through S46 in the germline, 
mainly because loss of zygotic cdc-25.1 function caused germline proliferation defects 
(Ashcroft and Golden, 2002). However, no proliferation phenotype was identified after 
loss of lin-23 in the germline (Kipreos et al., 2000), suggesting two independent functions 
of both proteins in the germline. Data are presented here that argue that LIN-23 does not 
control CDC-25.1 protein levels in the germline when L4-staged animals were analysed. 
Firstly, two developmentally separable functions were identified for LIN-23 during post- 
embryonic germline development and embryonic development of the intestine, as 
illustrated by the analysis of a lin-23 partial loss-of-function allele. This allele can rescue 
the sterility o f a lin-23 null mutant but causes embryonic death, suggesting that the allele 
can function normally in the germline but not in embryos. Hence it may regulate different 
targets in the germline as compared to the embryo. Furthermore, biochemical evidence is 
presented that corroborates the conclusion that LIN-23 does not bind and regulate the 
abundance of CDC-25.1 in the L4-staged hermaphrodite where most of the CDC-25.1 
protein resides in the germline.
5.3.1 Zygotic versus maternal lin-23 function
Analysis of the lin-23(el883) null allele previously revealed a zygotic role for lin-23 in the 
development of the C. elegans germline (Kipreos et al., 2000). Furthermore, a maternal 
contribution of lin-23 during embryonic cell proliferation had been identified in that study. 
A few homozygous null embryos derived from homozygous mothers displayed additional 
nuclei in the embryo indicating proliferation defects in the embryo. However, homozygous 
embryos of heterozygous mothers proceeded normally through embryogenesis, thus 
demonstrating that maternally provided LIN-23 from the heterozygous mother was 
sufficient to drive embryogenesis.
Here, analysis of intestinal-specific GFP markers revealed that homozygous lin-23 null 
mutants that are derived from heterozygote mothers show no proliferation defects of the 
intestine during embryogenesis. Thus, the zygotic genotype of the embryo does not 
determine the intestinal cell proliferation phenotype and maternally provided LIN-23 
protein derived from the mother is sufficient to produce normal embryos. However, these 
embryos hatch and show extra intestinal nuclei during their post-embryonic development. 
This is in agreement with a previous report illustrating a contribution of LIN-23 to restrain
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endoreduplication in the C. elegans larva (Kipreos et al., 2000). During the LI larval stage 
only the 14 most posterior nuclei (int-3 to int-9) undergo one round of nuclear division 
(Sulston and Horvitz, 1977) that is followed by an endoreduplication cycle o f all nuclei at 
each larval stage (Hedgecock and White, 1985). In homozygous lin-23 null worms 
however, the endoreduplication cycle at the LI lethargus is converted to a second nuclear 
division, such that each intestinal cell (int-3 to int-9) obtains four intestinal nuclei with a 
16N instead of a 32N content. In this study, GFP expression revealed multiple smaller 
nuclei in the intestine of the lin-23 null adult hermaphrodite, which are probably derived 
by the conversion of the endoreduplication cycle into a nuclear division. The molecular 
nature underlying this defect is not known and is not the focus of this study.
Importantly, maternal LIN-23 protein is required during embryonic proliferation of the 
intestine but not during proliferation of the germline. Interestingly, heterozygous lin-23 
mothers only produce on average 50% of the LIN-23 protein levels as compared to the 
wild-type worm; thus 50% of LIN-23 protein levels that are deposited to the embryo from 
a heterozygote mother are sufficient to drive normal proliferation of the intestine. 
Similarly, RNAi against lin-23, that decreases maternal as well as zygotic lin-23 function, 
revealed that 80% of the embryos are still viable but show hyperproliferation of the 
intestine. Thus, it is possible that a certain threshold level below 50% of maternal LIN-23 
depletion has to be obtained in order to create an intestinal cell proliferation phenotype. 
When RNAi was performed in liquid cultures, depleting more than 90% of the LIN-23 
protein as examined by Western blotting (Chapter 3, Figure 3.5), none of the embryos was 
viable (data not shown). Thus, maternal LIN-23 function may first become limiting during 
intestinal cell proliferation when a reduction below 50% protein levels is reached. The 
increase in embryonic lethality by further LIN-23 knockdown suggests that LIN-23 must 
have also other functions in the embryo.
In agreement with two separable functions of lin-23 during postembryogenesis and 
embryogenesis, a lin-23::FLAG-TY allele was identified in this study that can rescue the 
lin-23 sterility but results in embryonic lethality. The LIN-23::FLAG-TY protein shows 
decreased binding to CDC-25.1 in the embryo with concomitant hyperproliferation of the 
intestine (Chapter 4, (4.2.5)). It is clear that the lin-23::FLAG-TY allele is able to 
complement the normal lin-23 function in the germline, but it is impaired in its proper 
function in the embryo. It is possible that this allele has lost the ability to regulate correctly 
other factors in the embryo, especially because high embryonic lethality has been 
observed. Importantly, this result emphasises that the function of LIN-23 can be attributed 
to two independent mechanisms in the germline and embryo and altogether shows that at
185
least 50% maternal LIN-23 protein, derived from the mother, is required to promote 
normal embryogenesis. It will be extremely valuable to analyse the total protein expression 
levels in embryos derived from the lin-23::FLAG-TY strain compared to wild-type 
embryos by 2D-gelelectrophoreses. This will reveal additional downstream targets that are 
negatively regulated through LIN-23 in the embryo. Furthermore, a similar proteomics 
approach could be performed by analysis of germline proteins in the adult hermaphrodite 
with or without lin-23 RNAi, which will provide powerful insight into the identification of 
proteins that are regulated through LIN-23 in the germline.
5.3.2 LIN-23 localisation
Immunolocalisation using the anti-LIN-23 antibody revealed for the first time that LIN-23 
protein is expressed mainly in the cytosol of the adult germline and in the intestine. Thus, 
this expression is in agreement with the proposed LIN-23 function during post-embryonic 
development of the germline and intestine. In the germline, the localisation of LIN-23 is 
differing from the CDC-25.1 localisation, which was evidently nuclear as opposed to the 
cytosolic localisation of LIN-23 (Ashcroft et al., 1999). Thus, it may be possible that the 
spatial localisation of both proteins in the germline prevents these two proteins from 
interacting and thus renders them functionally independent. Artificially restricting the 
CDC-25.1 localisation to the germline cytosol could reveal whether it makes CDC-25.1 
more sensitive to LIN-23 function. This could be achieved by blocking the nuclear import 
of CDC-25.1. An RNAi experiment against the C. elegans nuclear import receptors ima-2 
(Askjaer et al., 2002) or ima-3 (Geles and Adam, 2001; Segal et al., 2001) could be 
performed in order to test whether CDC-25.1 localisation can be shifted to the germline 
cytosol. If so, extracts from L4 staged animals with normal or cytosol restricted CDC-25.1 
could reveal whether the CDC-25.1 protein levels are decreased in the germline and remain 
stable through CDC-25.1(S46F).
5.3.3 LIN-23 does not regulate CDC-25.1 in the germline
Biochemical analysis demonstrated that CDC-25.1 protein levels remain constant in the 
germline even in the presence of the S46F mutation in CDC-25.1. Thus, the S46 residue is 
not important to control CDC-25.1 protein levels in the germline as compared to its 
essential function in the embryo. This result is consistent with previous work that did not 
find an increase in CDC-25.1(S46F) protein levels when adult extracts were analysed by 
Western blotting and compared to the wild-type (Clucas, 2003; Clucas et al., 2002). In this 
work, staged L4 to young adult animals were analysed, which contain CDC-25.1 in their
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proliferating germline but do not produce embryos yet. Thus, the CDC-25.1 protein levels 
measured are derived mainly from the germline. In the previous study by Clucas et al., 
adult animals were examined that contained CDC-25.1 in their germline and in their 
embryos that are produced at that stage. Hence, this suggests that in adult worms, that 
produce both germline and embryonic CDC-25.1, the majority of CDC-25.1 protein 
analysed by Western blotting of whole worms is derived from the germline and the 
temporal difference of the protein levels in the embryo (as detected by analysis in 
embryonic extracts in this study) is therefore missed in that experiment. Thus, CDC-25.1 
abundance is not regulated through S46 in the germline. Accordingly, immunoprecipitation 
of CDC-25.1 from the germline revealed no association of LIN-23 whereas the binding in 
the embryo is still observed. In summary, LIN-23 does not regulate the CDC-25.1 
abundance in the germline.
Apart from the differential localisation of both molecules, it is possible that the kinase that 
phosphorylates CDC-25.1 on S46 is not present or active in the germline as opposed to the 
embryo. A similar contribution of kinase activity marking a transition between oocyte 
maturation and embryonic regulation of the OMA-1 (Oocyte maturation defective) protein 
has been previously established (Shirayama et al., 2006). Identification of the kinase that is 
necessary for phosphorylation of CDC-25.1 S46 in the embryo will provide a significant 
step towards answering this question. As discussed in Chapter 3 (3.1.2), the S46 site 
provides a potential target site for a GSK3P kinase. In this study, removal of the closest 
GSK3p homologue did not enhance CDC-25.1 stability through S46, indicating that this is 
not the kinase responsible for acting through this site, but the possibility remains that 
another member of the GSK-3 family is performing this function. Furthermore, sequence 
motif analysis for potential kinase sites using the NetphosKl.O and ELM server revealed 
that S46 in CDC-25.1 could be part of a potential PICA (RX(S,T); RDS) (Shabb, 2001) or 
CK1 (S(P)xx(S,T); SRDS) (Flotow et al., 1990) kinase target site. The C. elegans genome 
contains 2 PKA and 78 CK1-related kinases (Manning, 2005). Thus, identification of the 
crucial kinase involved in phosphorylation of this residue may prove challenging due to 
potential functional redundancy of the kinases.
5.3.4 Conclusion
In summary, novel data evolved in this work demonstrate a spatially and temporally 
restricted interaction of LIN-23 and CDC-25.1 to the early embryo, thus providing a 
further insight into the tissue-specific regulation of CDC-25.1 during C. elegans
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development. A certain threshold amount of maternally provided LIN-23 is necessary to 
restrain intestinal cell proliferation in the embryo via regulation of CDC-25.1 abundance. 
Furthermore, zygotic LIN-23 function is not required for intestinal cell proliferation in the 
embryo, and is thus restricted to post-embryonic development. However, during post- 
embryonic development, LIN-23 does not regulate CDC-25.1 protein levels in the 
germline. It is therefore possible that the spatial localisation of both molecules, or the 
spatial and temporal regulation of the kinase negatively regulating CDC-25.1 through S46, 
is responsible for the differential requirement for LIN-23 interaction between post- 
embryonic and embryonic development.
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Chapter 6
LIN-23 localisation in the early embryo
6 LIN-23 localisation in the early embryo
6.1 Introduction
Evidence presented in the previous chapters established a physical interaction of LIN-23 
and CDC-25.1 through the S46 residue in the early embryo. The maternal function of both 
proteins is required for correct proliferation of intestinal cells, thus implying that intestinal 
cell cycle control results from the interaction of the two maternally provided proteins. 
CDC-25.1 protein levels have been reported in the germline (Ashcroft et al., 1999; Clucas, 
2003; Clucas et al., 2002) and the early embryo (Ashcroft et al., 1999; Clucas, 2003; 
Clucas et al., 2002; Kostic and Roy, 2002). The CDC-25.1 protein levels decline in all 
blast cells during later stages of embryogenesis, at least in part as a result of LIN-23 
interaction with CDC-25.1. However, though high LIN-23 RNA levels have been reported 
in embryos (Kipreos et al., 2000), no published data were available that demonstrate the 
expression of LIN-23 protein in the early embryo. Expression of a transcriptional and 
translational lin-23: :GFP transgene revealed ubiquitous expression in the cytoplasm of all 
embryonic blast cells after gastrulation (Mehta et al., 2004). As demonstrated in Chapter 5, 
the LIN-23 protein is detected in the germline, indicative of a maternal contribution of 
LIN-23 to the embryo. However, no information about the endogenous LIN-23 expression 
and localisation in the early embryo was available.
6.1.1 Hypothesis and aims
It was anticipated that the LIN-23 protein would be expressed in all early embryonic blast 
cells until later stages of embryogenesis. Therefore, immunocytochemistry, using the anti- 
LIN-23 antibody, was to be performed in wild-type or lin-23 RNAi-treated embryos in 
order to analyse for the presence of LIN-23 during embryogenesis.
6.2 Results
6.2.1 LIN-23 is ubiquitously expressed in embryos
Indirect immunofluorescence was performed in order to examine the expression of LIN-23 
in the embryo. Staining with the anti-LIN-23 antibody and fluorescent analysis by 
conventional microscopy revealed expression of LIN-23 in all blast cells from early to late 
embryogenesis (Figure 6.1). This staining was specific since embryos that were treated
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with lin-23 RNAi did not show any staining under identical experimental conditions 
(Figure 6.1, see bottom). The majority of LIN-23 is localised in the cytosol of all blast 
cells. Intriguingly, some LIN-23 protein was evident in the vicinity of the DNA in AB 
descendants in two- or four-cell stage embryos, indicating that LIN-23 can shuttle between 
different compartments in at least some blast cells. Thus, this experiment demonstrates that 
LIN-23 protein is ubiquitously expressed in all embryonic cells from early to late 
embryogenesis.
6.2.2 UN-23 embryonic localisation is dynamic
Since differences in the localisation of LIN-23 were observed in some early blastomeres, it 
became apparent that LIN-23, though mainly cytosolic, might be able to move between 
distinct cellular compartments in some or all blast cells. This differential localisation could 
be the result of LIN-23 redistribution at various cell cycle stages in some or all blastomeres 
or differential localisation of LIN-23 in certain blastomeres throughout the cell cycle. 
Thus, confocal microscopy was carried out using two GFP marker strains to facilitate 
identification of the cell cycle stage in individual blast cells and the cellular localisation of 
LIN-23. The GFP::LEM-2 strain was utilised as a marker for nuclear envelope formation, 
because LEM-2 encodes for an inner nuclear membrane protein (Galy et al., 2003). This 
protein surrounds the DNA during interphase, redistributes into the endoplasmatic 
reticulum surrounding the spindle at prometaphase, and only fully disassembles during 
mid-to-late anaphase. During telophase, the nuclear envelope reforms around the 
chromatin building two nuclear envelopes (Lee et al., 2000; Oegema, 2006). As a second 
marker GFP::p-TUBULIN was employed to label for microtubule assembly (Strome et al., 
2001). During the cell cycle, the two centrosomes move to opposite sites of the nucleus at 
prophase and start to build a spindle connecting to the kinetochores of the DNA at 
prometaphase. Chromosomes that align at the metaphase plate between the two spindle 
poles are pulled apart during anaphase and the kinetochore microtubules disappear during 
telophase (Scholey et al., 2003; Strome et al., 2001).
Double immunostaining was performed using anti-GFP and anti-LIN-23 antibodies 
together with DAPI staining, thus co-labelling the nuclear envelope or the microtubules 
with LIN-23 and the DNA. As observed before, the majority of LIN-23 localises to the 
cytosol in all embryonic blast cells (Figure 6.2). Interestingly, some LIN-23 concentrates 
to the vicinity of the DNA during prometaphase to metaphase transition. Figure 6.2 (panel 
A) shows LIN-23 association around the condensed DNA during late prometaphase in the 
posterior PI blastomere of a two-cell stage embryo at the point when the nuclear envelope
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starts to break down and some LEM-2::GFP is surrounding the spindle poles (arrow 
indicates LIN-23, two stars point out the position of the spindle poles). However, during 
telophase LIN-23 is excluded from the nucleus. Figure 6.2 (panel A) depicts the exclusion 
of LIN-23 from the telophase nuclei of the anterior AB blastomere and in panel B the 
telophase exclusion from the just dividing EMS blastomere is shown in a four-cell stage 
embryo. Additionally, the AB descendants in this embryo exhibit nuclear exclusion of 
LIN-23 during interphase and LIN-23 is excluded from the prophase nucleus of P2 (Figure 
6.2, B).
Co-staining of embryos with LIN-23 and the tubulin marker confirmed this result. LIN-23 
is detected around the newly forming spindle of the anterior AB cell in late prophase to 
prometaphase and excluded from the prophase nucleus of PI (Figure 6.2, C). A fraction of 
LIN-23 is concentrated at the vicinity of the centrosomes in all blast cells of the four-cell 
stage embryo at interphase-to-mitosis transition and is excluded from all nuclei (Figure 6.2, 
D, yellow merged areas indicate co-staining). In the four-cell stage embryo staining of 
LIN-23 is evident in the vicinity of the metaphase spindle poles in the AB descendant (note 
the poles are visualised from the top, thus this staining likely represents LIN-23 protein 
wrapping around the DNA visualised from the top), whereas LIN-23 is excluded from the 
interphase nucleus of the EMS blastomere (Figure 6.2, E). Intriguingly, the protein is 
found surrounding the DNA of the metaphase EMS cell (Figure 6.2, F arrow), but does not 
co-localise with the entire spindle apparatus (arrowhead). Some protein is still enriched in 
the area surrounding the DNA in the anaphase ABp cell. In some later embryos (around the 
28-cell stage) this metaphase staining o f LIN-23 was also observed, indicating that the 
redistribution might not be restricted to early embryos (data not shown).
In summary, LIN-23 localisation is rather dynamic during the cell cycle stage in all early 
blastomeres analysed. Figure 6.2 is representative for multiple embryos examined in three 
independent experiments. No obvious differences in the staining pattern were observed 
between various blast cells. It can be concluded that at least a fraction of LIN-23 enters the 
nuclear area during prometaphase, where it surrounds the DNA in metaphase maybe by 
associating to the central spindle apparatus and leaves the DNA periphery during anaphase, 
such that all LIN-23 is found in the cytosol during telophase and interphase.
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Figure 6.1 LIN-23 localisation during C. elegans em bryogenesis. Indirect immunofluorescence o f  
LIN-23 using the anti-LIN-23 antibody (this study) with corresponding DAPI and Nomarski counterparts in 
early (2- to 28-cell stage) and late stages o f  embryogenesis before hatching. The bottom panel depicts a four­
cell stage embryo after lin-23 RNAi to demonstrate specificity o f  the staining. Anterior is depicted to the left. 
The blast cells are indicated at the early stages. Scale bar: 10 pm.
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Figure 6.2 LIN-23 localisation changes during the cell cycle in early em bryos. Indirect immuno- 
staining o f  embryos carry ing GFP::LEM-2 (A, B) or GFP::(3-TUBUL1N reporter (C-F) with anti-GFP 
and anti-LIN-23 antibodies. A) LIN-23 shuttles to the nucleus during prometaphase (arrow) when the 
nuclear envelope absorbes into the ER (indicated by stars) in PI, it is excluded from the chromatin in AB 
(telophase) during NE reformation. B) LIN-23 is mainly cytosolic and excluded from chromatin in 
telophase o f  the newly formed MS and E nuclei (arrow) and is cytosolic in interphase o f  the AB descend­
ants. C) LIN-23 moves to the vicinity o f  the newly formed AB spindle during prometaphase at the two­
cell stage (arrow) and is exluded from the PI prophase nucleus. D) LIN-23 is mainly cytosolic in 
interphase-to-mitosis transition during the four-cell stage, weak co-staining is visualised at the centro- 
somes. E) LIN-23 localises to the vicinity o f  the spindle poles in AB descendants at the four-cell stage. 
White dot indicates the spindle pole visualised from the top. F) LIN-23 wraps around the chromatin 
(arrow) in metaphase o f  the EMS spindle (triangle). Anterior is depicted to the left, scale bar: 10 pm.
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6.2.3 LIN-23 influences the CDC-25.1 localisation
The ubiquitous expression of LIN-23 in all blast cells is in agreement with the general 
control of CDC-25.1 through LIN-23 in probably all blast cells o f the embryo. Previous 
data established that CDC-25.1 is localised mainly to the nucleus in interphase and 
prophase cells but moves to the cytoplasm following nuclear envelope breakdown in all 
early blast cells (Ashcroft et al., 1999). Because CDC-25.1 is nuclear during interphase and 
prophase whereas some LIN-23 localises to the vicinity of the DNA during prometaphase 
to early anaphase, it suggests that the LIN-23 interaction to CDC-25.1 might occur in the 
cytoplasm. Since cytoplasmic co-staining experiments are rather difficult to interpret, a 
separate approach was carried out to identify the influence of LIN-23 on CDC-25.1 
localisation. Here, the strains IA535 ijls l6  and IA536 ijls l7  carrying LAP::CDC-25.1 and 
LAP::CDC-25.1(S46F), respectively, were utilised. These strains express CDC-25.1 or 
CDC-25.1(S46F) only in intestinal cells starting from the 2E-cell stage (see Chapter 4 
also). The localisation of CDC-25.1 was visualised through live fluorescence imaging due 
to the presence of the GFP tag at the N-terminus of CDC-25.1. Intriguingly, LAP::CDC-
25.1 is localised in the cytosol and nucleus of intestinal cells (Figure 6.3), whereas 
LAP::CDC-25.1(S46F) displays a mainly nuclear localisation in intestinal cells. This 
differential localisation was not observed in embryos during gastrulation (between 150 — 
330 minutes post-fertilisation). Removal of LIN-23 promoted a shift of LAP::CDC-25.1 
localisation to the nucleus and was not observed for LAP::CDC-25.1(S46F) (which was 
already nuclear prior to LIN-23 removal). This effect was only detected after gastrulation 
and maintained at least until the three-fold stage (only one focal plane of comma stage 
embryos are depicted in Figure 6.3). Thus, LIN-23 activity can influence the localisation of 
zygotically expressed LAP::CDC-25.1 by promoting its cytosolic localisation.
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Figure 6.3 LAP::CDC-25.1 localisation is dependent on S46 and LIN-23. C. elegans strains 1A535
elt-2::LAP::cdc-25.1(+) and IA536 elt-2::LAP::cdc-25.1(ij48) expressing LAP::CDC-25.1 and 
LAP::CDC-25.1(S46F) in intestinal cells, respectively were analysed for protein localisation through 
GFP fluorescence after control or lin-23 RNAi. Scale bar: 10 pm.
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6.3 Discussion
It was anticipated that LIN-23 is expressed in all embryonic blast cells from early to late 
stages of embryogenesis. In this chapter indirect immunofluorescence against LIN-23 
validates this hypothesis. Moreover, it provides a platform to speculate further functions of 
LIN-23 for the regulation of CDC-25.1 and maybe other embryonic proteins, because 
removal of LIN-23 affects CDC-25.1 localisation. Furthermore, LIN-23 itself is 
redistributing between distinct cellular compartments during the cell cycle and thus may 
contribute to separate cell cycle functions.
6.3.1 LIN-23 expression in embryos
The ubiquitous expression of LIN-23 in all embryonic blast cells correlates with the 
phenotype of CDC-25.1 regulation. The CDC-25.1 (S46F) protein level is elevated in all 
embryonic blast cells and not only in the intestine. Thus, the interaction between LIN-23 
and CDC-25.1 takes place in probably all cells of the early embryo. Interestingly, LIN-23 
is mainly localised to the cytosol in interphase, whereas a previous report (Ashcroft et al., 
1999) and experiments performed in this study show that the main pool of CDC-25.1 
localises to the nucleus at this stage. Thus, during interphase the majority of both proteins 
are separated into two distinct cellular compartments, however both proteins may be 
constantly shuttling between the nuclear and cytoplasmic compartment. CDC-25.1 leaves 
the nucleus during prophase. At this stage the majority of LIN-23 is still localised in the 
cytosol and a fraction of the protein wraps around the DNA in prometaphase, where it 
surrounds the DNA at the metaphase plate. Since no accumulation of CDC-25.1 at the 
metaphase DNA was previously reported, it is anticipated that the LIN-23 interaction with 
CDC-25.1 might take place in the cytosol, where the majority of LIN-23 is present 
throughout the cell cycle.
It is increasingly recognised in other systems that the localisation of the E3 ligase 
determines the site of protein degradation (Pines and Lindon, 2005). For example, in 
mammalian cells mitotic exit requires the presence of the anaphase-promoting complex or 
cyclosome (APC/C) at the central spindle where it regulates the degradation of its 
substrates like PLK1 (Kraft et al., 2003; Lindon and Pines, 2004; Tugendreich et al., 1995). 
Similarly, in yeast the SCFGDC4 complex is localised to the nucleus where is degrades the 
cyclin-dependent kinase inhibitor FARlp. In response to pheromones, FARlp leaves the
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nucleus and is stabilised in the cytoplasm where it contributes to actin polarization 
(Blondel et al., 2000).
6.3.1.1 LIN-23 influences zygotically expressed CDC-25.1 localisation
Here, it is demonstrated that zygotically overexpressed and tagged CDC-25.1 shows 
differential localisation in intestinal cells that is dependent on S46 and the interaction with 
the E3 ligase LIN-23. S46F mutation in CDC-25.1 or LIN-23 knockdown cause nuclear 
accumulation of CDC-25.1, whereas in the presence of LIN-23 wild-type CDC-25.1 is 
present in both the nuclear and cytosolic compartment. This result suggests that LIN-23 
interaction traps some CDC-25.1 in the cytosol and that in the absence of LIN-23, more 
CDC-25.1 protein is able to move to the nucleus. A similar mechanism has been reported 
for p-catenin, where overexpression of a dominant negative p-TrCP mutant, lacking the F- 
box domain, results in nuclear accumulation of p-catenin in human tissue culture cells 
(Sadot et al., 2000). Though the mutation does not abrogate p-TrCP interaction to the 
substrate (as is the case for the CDC-25.1 (S46F) binding to LIN-23) but to the remaining 
SCF complex. In the case of CDC-25.1, it remains to be determined whether solely the 
binding to LIN-23 sequesters some portion of CDC-25.1 in the cytoplasmic compartment, 
or whether the downstream ubiquitination event is part of the cytoplasmic sequestration. 
Overexpression of a dominant negative LIN-23 mutant that retains its interaction with 
CDC-25.1 but lacks the F-box motif, and therefore would be impaired to target CDC-25.1 
for ubiquitination in intestinal cells, could be performed by expression under the elt-2 
promoter. This allele could be combined with the elt-2::LAP::cdc-25.1 (+) allele and the 
CDC-25.1 protein distribution analysed by live fluorescence imaging.
Nevertheless, it should be noted that here the ectopically overexpressed LAP::CDC-25.1 is 
analysed at a developmental stage when most of the endogenous CDC-25.1 is already 
degraded. It is therefore not clear to what extent this reflects the endogenous CDC-25.1 
distribution. The majority of endogenous CDC-25.1 is localised to the nucleus in the 
interphase embryo (Ashcroft et al., 1999; Clucas, 2003; Clucas et al., 2002; Kostic and 
Roy, 2002). Furthermore, in the early embryo no difference in the localisation of 
endogenous CDC-25.1 (S46F) and CDC-25.1 were observed. It is possible that, because 
early blast cells are in different stages of the cell cycle, changes in endogenous CDC-25.1 
protein localisation might be difficult to detect.
The change in zygotic LAP::CDC-25.1 localisation was however only evident after the 
comma stage, around 450 minutes post-fertilisation when most intestinal cells have exited
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the mitotic cycle (Sulston et al., 1983). Thus, it is possible that more cytoplasmic 
LAP::CDC-25.1 is only evident in post-mitotic cells than in mitotic cells. Though, 
importantly the staining pattern is sensitive to the presence and binding of LIN-23. Work 
in Chapter 4 has demonstrated that LAP::CDC-25.1 is still able to interact with LIN-23. 
Thus, the possibility remains that the endogenous interaction between LIN-23 and CDC-
25.1 does occur in the cytosol.
6.3.1.2 How to set up a system to analyse the localisation of a LIN-23/CDC-
25.1 complex
It is difficult to prove whether the binding between the LIN-23 and CDC-25.1 happens in 
the nucleus or in the cytosol. Cytosolic co-staining experiments may not prove very 
significant and have therefore been omitted. Generation of nuclear and cytoplasmic 
extracts is possible in embryos but requires some technical expertise to disrupt the eggshell 
sufficiently but not the nuclei (S. Kuersten pers. comm.). Additionally, the interaction 
between endogenous LIN-23 and CDC-25.1 is very weak and might be lost by further 
fractionation of the extracts. It would probably be more straightforward to co-express 
fluorescently tagged versions of LIN-23 and CDC-25.1 in human tissue culture cells, 
examine their temporal distribution throughout the cell cycle by real time imaging, and 
biochemical complex formation in nuclear and cytoplasmic extracts. This would allow 
testing mutants of CDC-25.1 that can be kept in the nuclear or cytoplasmic compartment of 
the cells and thus examine the influence of CDC-25.1 compartmentalisation on the 
complex formation between CDC-25.1 and LIN-23.
The CDC-25.1 protein contains several nuclear localisation sequences (NLS). NLS 
sequences are identified by a cluster of basic amino acids that resemble similarity to the 
monopartite NLS (B 4 , PQ3 3 X), P(XXB3X) or B3 (H/P); where B stands for lysine or 
arginine, P for proline, H for histidine and X for any amino acid) or the bipartite NLS 
(B B X 10B3X 2 ) driving transport of proteins into the nucleus (Macara, 2001). At least one 
putative monopartite NLS (aa 457 KKKR) and one putative bipartite NLS (aa 128 
KRVMSERPTDNHRKRTS) are present in the CDC-25.1 sequence. Nuclear export of 
proteins is achieved by the presence of a leucine rich nuclear export signal in substrate 
molecules that are recognised by the nuclear export receptor (CRM1). A canonical nuclear 
export signal has been identified through analysis of a variety of substrate molecules and 
comprises the sequence LX?/3(FIVLM)Xi ? ^LXIIVL) (L= leucine, F= phenylalanine, V= 
valine, M= methionine, X= any amino acid), however alterations of this signal have also 
been identified (Macara, 2001). CDC-25.1 contains one putative nuclear export signal in
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its C-terminus (aa 553 IVQLGLQV), thus indicating that the protein might be actively 
exported to the cytoplasm.
Thus, mutational analysis of the putative NLS or NES sequence in CDC-25.1 could be 
performed and the localisation of the mutants studied in human tissue culture cells. This 
would determine whether it is possible to restrict CDC-25.1 to the nuclear or cytoplasmic 
compartment. The relevance of these experiments to the C. elegans system could be further 
tested. C. elegans could be microinjected with a GFP tagged version of an NLS or an NES 
mutant under the control of the end-1 promoter. This allows temporal expression of CDC-
25.1 in intestinal cells at a restricted time interval when the first E cell is generated until 
four intestinal cells are bom (Maduro et al., 2007; Zhu et al., 1997). Real-time imaging 
could be performed to see whether the CDC-25.1 NLS and NES mutant are also localised 
to the cytoplasm and nucleus, respectively in C. elegans embryos. If so, the half-life of the 
nuclear or cytoplasmically restricted protein could be analysed in vivo by real-time 
imaging and quantification of the fading nuclear versus cytoplasmic GFP signal of CDC- 
25.1. This experiment would reveal two important points: firstly, whether the degradation 
of CDC-25.1 requires a nuclear/cytoplasmic shuttling in the C. elegans embryo. Secondly, 
it would determine, whether in C. elegans the majority of CDC-25.1 is degraded in the 
nuclear or the cytoplasmic compartment. Together with biochemical evidence of pull down 
experiments from nuclear and cytoplasmic tissue culture extracts (as proposed above), this 
would reveal substantial information whether the interaction between CDC-25.1 and LIN- 
23 occurs in the nucleus or rather in the cytosol as implied in this study. These experiments 
constitute a completely new part of the project and due to time restrictions have not been 
performed yet.
6.3.2 LIN-23 localisation is dynamic during the cell cycle
For the first time, a dynamic localisation of LIN-23 during the cell cycle in C. elegans 
embryos has been reported here. Previous reports analysing a LIN-23 ::GFP reporter 
suggested an overall cytoplasmic localisation for LIN-23 (Mehta et al., 2004), however 
movement of LIN-23 to the prometaphase nuclear compartment and association of LIN-23 
to the metaphase plate has not been reported to date. But, the presence of a putative NLS in 
the LIN-23 sequence at the N-terminus (aa 160 - 174) was already proposed previously 
(Kipreos et al., 2000). However, it remains to be established whether this sequence in fact 
resembles a nuclear localisation signal or whether LIN-23 localisation to the vicinity of the 
DNA is due to passive diffusion and retention on the spindle apparatus at the time of 
nuclear envelope breakdown during prometaphase. The nuclear exclusion during telophase
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and interphase might be the result of nuclear export through an NES signal in LIN-23. 
Bioinformatic analysis (according to the ELM server) reveals the presence of two putative 
NES signals in LIN-23 (aa 91 LVELILFNV, aa 177 LDQLILMHV) and it thus remains to 
be determined whether either of them contributes to the nuclear export of LIN-23.
6.3.2.1 Further LIN-23 functions in the embryo?
The dynamic behaviour of LIN-23 is intriguing, since it does not seem to correlate with the 
CDC-25.1 staining. No identical CDC-25.1 localisation on the centrosomes and metaphase 
plate has been reported and it implies the presence of maybe at least one other LIN-23 
target substrate independent of CDC-25.1 in the C. elegans embryo. The human orthologue 
P-TrCP 1 has been demonstrated to localise mainly in the nucleus with some cytoplasmic 
signal by overexpression studies (Davis et al., 2002; Lassot et al., 2001) and 
immunoblotting of the endogenous protein in nuclear and cytoplasmic extracts of human 
tissue culture cells (Davis et al., 2002). However, the human p~TrCP2 protein localises 
mainly to the cytoplasm in tissue culture cells when overexpressed (Davis et al., 2002). 
Unfortunately, data regarding the p-TrCP distribution during the cell cycle remain lacking. 
Furthermore, it remains to be elucidated whether overexpression studies in tissue culture 
cells accurately reflect the localisation of endogenous P-TrCP 1/2 in a multicellular 
organism. Nevertheless, the data suggest that LIN-23 might have retained the ability to 
fulfil several cellular functions that later in evolution have diversified to two separate 
genes.
6.3.2.2 Does LIN-23 function during centrosome duplication?
In this study, a slight concentration of LIN-23 around the centrosome in interphase cells 
has been identified. This finding is not entirely surprising, since the pericentrosomal area 
has been reported to act as proteolytic centres within the eukaryotic cell. Treatment of 
proteasome inhibitors in mammalian cells resulted in accumulation of ubiquitinated 
proteins in the centrosomal area (Wojcik, 1997; Wojcik et al., 1996) and purification of 
centrososome preparations have been demonstrated to contain active proteasomes 
(Fabunmi et al., 2000; Wigley et al., 1999). At the onset of mitosis centrosome duplication 
takes place, the centrosomes subsequently move around the nucleus in order to establish 
two separate spindle poles from which the bipolar spindle originates during prometaphase 
(Scholey et al., 2003). The Drosophila LIN-23 orthologue, termed SLIMB, has been 
demonstrated to play a role during centrosome duplication. A hypomorphic slimb mutant 
has been reported to display centrosome duplication defects, but spindle formation is
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otherwise normal (Wojcik et al., 2000). Similarly, mouse embryonic fibroblasts derived 
from P-TrCP 1 knockout mice show centrosome overduplication, and formation of 
multipolar spindles that nucleate from these centrosomes (Guardavaccaro et al., 2003). The 
molecular mechanism underlying these defects remains to be identified but might involve 
the APC/C inhibitor EMI1 (Early Mitotic Inhibitor) as proposed by Guardavaccaro et al., 
because EMI1 is a target of (3-TrCP and overexpression of EMI 1 results in centrososome 
overduplication. Unfortunately, data describing whether removal of EMI 1 could rescue the 
overduplication of P-TrCP 1 null fibroblasts was lacking in that study and thus other targets 
such as cyclins, CDKs or CDC25 could be involved in this process.
Real-time imaging and analysis of the spindle formation using the GFP::P-TUBULIN 
strain after lin-23 RNAi showed no overt spindle formation defects in the early one- to 
four-cell stage embryo (data not shown). It remains therefore to be elucidated whether lin- 
23 RNAi results in centrosome duplication defects in C. elegans. This could be performed 
by observing centrosome duplication in a GFP::y-TUBULIN marker strain (Strome et al., 
2001) after lin-23 RNAi.
6.3.2.3 Does LIN-23 function during metaphase-to-anaphase transition?
Interestingly, a portion of LIN-23 associates to the vicinity of the DNA during 
prometaphase and wraps around the metaphase plate, indicating that a fraction of the 
protein may participate at the metaphase-to-anaphase transition. The eukaryotic cell cycle 
requires the function of the anaphase-promoting complex/cyclosome (APC/C) at 
prometaphase in order to separate two aligned chromatids and progress into anaphase 
(reviewed in (Yu, 2002)). Members of the APC/C complex have also been identified in C. 
elegans and shown to be implicated in mitotic divisions (reviewed in (Yeong, 2004)). One 
mechanism of APC/C inactivation is through the binding of the EMI1 protein in 
mammalian cells (Hsu et al., 2002; Miller et al., 2006; Reimann et al., 2001a; Reimann et 
al., 2001b). P-TrCP plays a role in degradation o f EMU, thereby contributing to the 
activation of the APC/C complex (Hansen et al., 2004; Margottin-Goguet et al., 2003). 
However, no obvious EMU homologue is evident in the C. elegans genome by BLAST 
search analysis, suggesting that, either this process is not conserved or another downstream 
target is responsible for this action. Should this pathway be conserved, knockdown of LIN- 
23 would be expected to result in increased anaphase arrest due to the stabilisation of an 
‘EMI 1-like’ molecule. However, real-time imaging of a strain carrying GFP labelled 
HISTONE and [3-TUBULIN showed no apparent defects in early one- to four-cell stage
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embryos after lin-23 RNAi (data not shown). Thus, this could reveal that LIN-23 is not 
involved in analogous pathway in the early C. elegans embryo or that LIN-23 function is 
redundant and can be performed by any of the remaining 326 F-box proteins present in the 
C. elegans genome.
The timely localisation of LIN-23 to the periphery of the metaphase plate resembles strong 
similarity to the staining of C. elegans proteins that are involved in the spindle checkpoint 
response. The proteins BUB-1 (Desai et al., 2003; Encalada et al., 2005; Oegema et al.,
2001), SAN-1 (Nystul et al., 2003), MDF-1 and MDF-2 (Kitagawa and Rose, 1999; Nystul 
et al., 2003) have been localised to the metaphase plate in early embryos. BUB-1, MDF-1 
and MDF-2 have been demonstrated to prevent delay of anaphase onset under conditions 
of spindle defects (Encalada et al., 2005) and similarly MDF-2 and SAN-1 knockdown by 
RNAi cause defects in metaphase arrest during anoxia but not under normal conditions 
(Nystul et al., 2003). Thus, LIN-23 could act to regulate the degradation of a factor 
involved in the metaphase-to-anaphase transition in response to cellular stress or spindle 
abnormalities. Accordingly, lin-23 RNAi has not revealed any obvious defects in 
metaphase-to-anaphase transitions in the early embryo when examined for chromosome 
segregation and spindle formation under normal conditions (data not shown). Thus, 
analysis of lin-23 RNAi in spindle defect mutants or by treatment of the embryos with a 
microtubule depolymerising agent as performed in a previous study (Encalada et al., 2005) 
could reveal whether LIN-23 is required to restrain the metaphase-to-anaphase transition or 
can result in chromosome segregation defects under such conditions. Importantly, the 
dynamic localisation of LIN-23 displayed in this work unravels a potentially new function 
of LIN-23 during embryogenesis, but further work is required to substantiate this 
hypothesis.
6.3.3 Conclusion
Endogenous LIN-23 protein is localised to the cytosol of all embryonic blast cells from 
early to late stages of embryogenesis. Zygotic CDC-25.1 protein localisation to the nucleus 
is enhanced in the absence of LIN-23, thus suggesting that LIN-23 retains a portion of 
CDC-25.1 in the cytosol. During the cell cycle, a fraction of LIN-23 associates to the 
vicinity of the centrosomes and the protein enters the nuclear space at prometaphase to 
surround the DNA on the metaphase plate, proposing a potential function of LIN-23 during 
the metaphase-to-anaphase transition of the C. elegans embryonic cell cycle.
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Chapter 7 
LIN-62 and CDC-25.1 interaction
7 LIN-62 and CDC-25.1 interaction
7.1 Introduction
One interesting conclusion that has arisen from my studies is the fact that global elevation 
o f CDC-25.1 protein levels in all blast cells at a defined stage of embryogenesis (namely 
between the 10- to 60-cell stage) results in the tissue-specific hyperproliferation of 
intestinal cells. Previous data established that the cdc-25.1(ij48) allele causes a tissue- 
specific hyperplasia o f the intestine, which is in stark contrast to RNAi results that revealed 
that depletion of cdc-25.1 from the embryo resulted in embryonic death (Ashcroft et al., 
1999; Clucas, 2003; Clucas et al., 2002; Kostic and Roy, 2002) with concomitant decrease 
of proliferation in additional tissues (Clucas, 2003; Clucas et al., 2002) indicating that 
CDC-25.1 function is required in all blast cells of the early embryo. CDC-25.1 protein 
analysis as detected by anti-CDC-25.1 immunofluorescence showed no obvious difference 
for the CDC-25.1 protein levels or protein distribution (Clucas et al., 2002).
In this study, it has become apparent that the cdc-25.1 (ij48) allele results in a global 
increase of CDC-25.1 (S46F) in all blast cells during the 10- to 60-cell stage of 
embryogenesis as compared to the wild-type levels by escaping the negative regulation of 
LIN-23 (see Chapter 3 and 4). This phenotype is consistent with previous data on the cdc-
25.1 (ij 48) allele, however the general increase of the CDC-25.1 protein levels in all blast 
cells does still not explain the tissue-specific nature of the cdc-25.1 (ij48) allele.
Hence, I hypothesised that during C. elegans embryogenesis non-intestinal tissues might 
possess additional negative regulators of the cell cycle that restrain proliferation of such 
tissues. This might imply that the mechanism underlying intestinal cell proliferation is 
simpler than that of non-intestinal tissues, making the intestinal cells more susceptible to 
respond to increased CDC-25.1 protein levels than other tissues. This could be explained if 
a negative regulator is simply more active in non-intestinal tissues or a negative regulator 
is missing in intestinal cells. One way to determine whether such a scenario might in fact 
be the case, is to analyse whether mutations of factors that regulate proliferation of other 
tissues are lethal when combined with the cdc-25.1 (ij48) mutant. This would imply that 
factors, such as negative regulators of the cell cycle in other tissues become crucial for 
proliferation only when combined with cdc-25.1 (ij48). Such a factor might on its own 
exhibit a hyperproliferation phenotype when mutated, or it may only exhibit a proliferation 
phenotype when combined with cdc-25. l(ij48) (see Model in Figure 7.1).
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Intestine Other tissues
CDC-25.1 CDC-25.1
F igure 7.1 M odel for tissu e-sp ecific  cell cycle  regu lation .
Intestinal cell proliferation (circle) is dependent on CDC-25.1 activity and under the control o f  a negative 
regulator (blocked arrow). The same pathway is found in surrounding tissues, but those have at least one 
more negative regulator to restrain proliferation. A gain-of-function mutation in cdc-25.1 would affect 
proliferation o f intestinal cells only by overriding a single negative regulator, whereas it would not affect 
other tissues due to the presence o f  a second negative regulator. Mutation in the negative regulator common 
to intestinal and other tissues, may affect intestinal cell proliferation but not proliferation o f  other tissues 
when mutated on its own. Co-mutation o f  cdc-25.1 and the common negative regulator may be sufficient to 
overcome the second negative regulation and induce hyperproliferation o f the intestine and other tissues.
Interest was thus drawn to lin-62(ij52), a mutant allele that had recently been discovered in 
the same mutant screen that identified altered numbers of intestinal nuclei in the cdc- 
25.1(ij48) mutant and displayed a similar phenotype (Clucas, 2003; Clucas et al., 2002). 
This allele has previously been suggested to act as a negative regulator of the cell cycle and 
was proposed to potentially play a role in regulation of intestinal cell proliferation but 
maybe also proliferation of non-intestinal tissues, which would be consistent with model 
described above (Figure 7.1).
The lin-62(ij52) allele had not been cloned at the start of this study, but its phenotype was 
partially characterised and is introduced below according to (Clucas, 2003; Clucas et al.,
2002). Like cdc-25. l( ij48) mutants, lin-62(ij52) mutants exhibit extra numbers of intestinal 
nuclei. Immunostaining of intestinal cell boundaries as well as cell lineage analysis 
revealed that the extra intestinal nuclei observed during post-embryonic development in 
the initial screen, were the result of additional cell proliferations during embryonic 
development of the intestine, similar to cdc-25. l( i j48). However, unlike the semi-dominant 
maternal effect mutation of cdc-25.1 (ij48), the lin-62(ij52) allele is recessive over wild- 
type and acts zygotically. This was demonstrated by the fact that when homozygous lin- 
62(ij52) mutants were crossed with wild-type males, all outcrossed FI offspring exhibited
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the wild-type phenotype. Furthermore, lin-62(ij52)/+ hermaphrodites produced a 
Mendelian 1:2:1 frequency of the Lin phenotype in their offspring. Homozygous lin- 
62(ij52) however, do not show a 100% penetrance of the Lin phenotype. Germline 
proliferation appears to be unaffected and is thus similar to cdc-25. l( ij48) mutants, but lin- 
62(ij52) homozygotes display a strong tail morphology defect that becomes apparent 
during post-embryonic development. Thus, LIN-62 might be regulating proliferation of 
other tissues apart from the intestine. Although cell lineage analysis illustrates proliferation 
defects of the intestine, other tissues were not examined for lineage defects in that 
experiment.
The position of this allele had been mapped to around +3.3 on chromosome IV based on 
STS and multi-factor crosses. STS mapping placed lin-62(ij52) into close proximity of the 
sequence polymorphism stP44 which is found on position +3.27 (WormBase, 2007). 
Further refinement of the position using multi-factor crosses placed the allele to position + 
3.37 between bli-6 (+3.19) and unc-24 (+3.52). Positioning was confirmed by crossing the 
allele over several deficiencies. Only progenies derived from crosses with stDf7 and stDf8 
covering the regions +2.48 - +3.40 and +2.48 - +3.39, respectively displayed Lin 
phenotypes in their brood indicating that lin-62(ij52) must be contained within these 
deficiencies. The recessive action of the Un-62(ij52) allele to the wild-type and the fact that 
loss of lin-62 function when placed over a deficiency display hyperplasia, demonstrated 
that lin-62(ij52) is a hypomorphic allele. Continued propagation of the lin-62(ij52)/stDf7 
and Un-62(ij52)!stDf8 heterozygotes proved problematic and a new phenotype of dead 
larvae was observed amongst the FI progeny of the crosses, indicating that lin-62(ij52) 
may not be a null allele (Clucas, 2003).
Hence, these results suggested a negative function for lin-62 during cell proliferation of the 
intestine and maybe additional tissues. As such lin-62 could be an auxiliary negative 
regulator o f the cell cycle found in the intestine and maybe other tissues. Nevertheless, the 
similar hyperplasia phenotype of lin-62 (ij 52) and the cdc-25.1 (ij 48) mutant could also 
suggest that lin-62 may regulate cdc-25.1 through the site of the ij48 lesion. As described 
in the previous chapters, the site of the ij48 lesion introduces a serine to phenylalanine 
substitution in a conserved DSG consensus site of CDC-25.1 and abrogates binding of 
CDC-25.1 to the F-box molecule LIN-23, the C. elegans homologue of mammalian p- 
TrCP. This results in the escape of CDC-25.1(S46F) from proteasomal degradation 
mediated through LIN-23. In mammalian systems phosphorylation of the serine residue 
within this motif is essential for P-TrCP recognition and the kinases involved in this 
process differ between different target molecules (see Chapter 3, (3.1.2.2)). Although the
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S46 in CDC-25.1 falls within a putative GSK-3 consensus, the data presented in this study 
argue strongly that GSK-3 is not the kinase involved in the regulation of S46 in CDC-25.1. 
Removal of the kinase acting through the site of S46 would be expected to enhance CDC-
25.1 protein levels due to the escape of CDC-25.1 from the negative regulation of LIN-23. 
However, no increase in CDC-25.1 protein levels was obtained when GSK-3 was depleted 
from the embryo by RNAi (see Chapter 3, (3.2.10)). Thus, identification o f the kinase that 
can modify the site of the ij48 lesion is an important task.
7.1.1 Hypothesis and aims
The similar intestinal hyperproliferation phenotype of lin-62(ij52) and cdc-25. l(ij48) 
suggests that LIN-62 might negatively regulate CDC-25.1 either through S46 or 
independent of S46, or that LIN-62 might regulate the cell cycle independent o f CDC-25.1 
in intestinal cells.
In the case that LIN-62 acts on S46 in CDC-25.1 a combination of the lin-62 (ij 52) and cdc- 
25. l(ij 48) mutant alleles would be predicted to display no synergism in their phenotypes. 
Furthermore, mutation of lin-62(ij52) would result in a CDC-25.1 protein increase similar 
to CDC-25.1(S46F). In order to determine whether lin-62 can enhance the cdc-25.1 (ij48) 
proliferative effect in the intestine or other tissues, or whether it regulates cdc-25.1 on the 
site of the ij48 lesion, a double mutant of the cdc-25.1 (ij48) and lin-62(ij52) was to be 
employed and further attempts undertaken to clone the Un-62(ij52) allele. Additionally, it 
became apparent that establishing a genetic system for future investigations that would 
facilitate the genome-wide identification of genes that show strong synergism, or even 
synthetic lethality only when combined with the cdc-25. l(ij48) allele, would be of 
extremely high value. It would allow the identification of further negative regulators in 
other tissues that are only sick or lethal when combined with the cdc-25.1 (ij48) mutation, 
but not on their own. This could be achieved by creating a strain that contains the intestinal 
elt-2::GFP together with the cdc-25.1 (ij48) allele on a complex free array, allowing 
expression of the allele in the germline. Thus, the presence of the cdc-25. l( ij48) allele 
would be ‘labelled’ with the GFP marker. Due to the maternal cdc-25.l(ij48) function all 
FI progeny containing the free array will display the hyperplasia phenotype. However, 
some animals that will have lost the array and will therefore not contain the cdc-25. l(ij48) 
allele and the GFP marker could be analysed at the same time. If a genome-wide RNAi 
screen was to be carried out at later times, it would allow to select for worm populations 
that propagate GFP-negative and thus wild-type animals, but contain dead GFP-positive 
and thereby cdc-25.1 (ij48) containing embryos in their brood. Thus, this would allow
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identification of maternal or zygotically acting genes that negatively regulate the cell cycle 
independent from cdc-25. l(ij48).
In order to test whether this system could be utilised to detect any additive phenotype, a 
strain carrying cdc-25. l( ij48) and elt-2:: GFP::LacZ on a complex free array was generated 
and utilised here to determine its genetic interaction with lin-62(ij52). Furthermore, 
Western blots were carried out in a lin-62 (ij52) mutant compared to wild-type in order to 
determine whether lin-62(ij52) can act to stabilise CDC-25.1.
7.2 Results
7.2.1 Iin-62(ij52) and cdc-25.1 (ij48) genetic interaction
To test for a genetic interaction between cdc-25. l(ij48) and lin-62(ij52) a new lin-62(ij52) 
marker strain was generated that allowed identification of the lin-62(ij52) allele 
independent of the lin-62 (ij 5 2) phenotype. This strain (IA577 see Table 7.2) carries a post- 
embryonic intestinal-specific GFP marker in order to differentiate it from the elt-2::GFP 
that was subsequently to be employed to ‘label’ the presence of the cdc-25. l( ij48) allele in 
the cross. To generate the Un-62(ij52) marker strain the strain IA331 lin-62(ij52), derived 
from a frozen stock that had been outcrossed three times after EMS mutagenesis against a 
wild-type N2 Bristol, was crossed with the strain JR1990 w ls l l8  containing npa- 
1 ::GFP::LacZ. This marker displays GFP expression in intestinal nuclei starting during 
late embryonic development and is easily visible during post-embryonic development. The 
presence of lin-62(ij52) was determined by the hyperplasia of the intestine in the F2 brood. 
Only homozygous lin-62(ij52) animals display hyperplasia of the intestine as examined by 
fluorescence of the intestinal GFP reporter w lsl 18 in this strain (data not shown). Since the 
lin-62(ij52) allele is not yet cloned but the mutation mapped to approximately position +
3.3 on chromosome IV, a second mutation was introduced on chromosome IV to create a 
chromosomal marker strain. dpy-20(el282) was utilised because it localises to position + 
5.18 on chromosome IV and gives animals a dumpy (Dpy) appearance when homozygous; 
a phenotype easily scored under a dissecting microscope. Homozygosity of the Un-62(ij52) 
allele could be followed by the hyperplasia that is caused through this mutation only when 
homozygous (Clucas et al., 2002).
Embryonic death in this strain (IA577) was analysed after backcrossing with an N2 Bristol 
strain in order to examine whether any reciprocal translocation could have been introduced 
through the GFP allele integration or the additional dpy-20(1282) cross and could result in
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aneuploidy of the offspring. However, this strain appeared to be relatively healthy as it 
produced on average 4.4% embryonic death (Table 7.1).
Strain %  death
IA577 lin-62(ij52) dpy-20(el282)IV; 
w lSl 18 (in F2 coming from N2 cross)
4.4 ± 5.0 (1.3 - 7.4) (n=364, 13 FI)
IA575 ijEx36[cdc-25.1(ij48), wls84] in FI 11.7 ± 13.4(2.8 - 20.9) (n= 410, 11 P0)
Table 7.1 Embryonic lethality of IA577 and IA575. M ean  ± s .d . (95%  u p p e r  a n d  low er co n f id e n ce  
interval), p-value; n.s., one- ta i led  S tu d e n t ’s  t test.
To test for a genetic interaction between cdc-25.1 and lin-62, heterozygous lin-62(ij52) 
dpy~20(1282)/++ IV  males were crossed into wild-type hermaphrodites carrying a cdc- 
25.1(ij48) and elt-2::GFP::LacZ reporter on a complex free array. This array had 
previously been reported to partially complement a cdc-25.1(nr2036) null allele (Clucas,
2003) and the strain used here was derived by outcrossing the cdc-25.1 (nr2036) null allele 
from the original strain and selecting for GFP-positive hermaphrodites expressing cdc- 
25.1(ij48) on a complex array (IA575). The complex array was utilised, because genes 
expressed from a repetitive array are often silenced in the germline and thus would not 
allow to analyse for the maternally acting cdc-25.1 effects (Kelly et al., 1997). The IA575 
strain displays robust early onset of the elt-2:: GFP ::LacZ that is switched on at the two E- 
cell stage and becomes strongly visible under the microscope when about 10 E cells are 
bom and is clearly distinguishable from the late expression of the npa-1 ::GFP::LacZ 
expression present in the lin-62(ij52) marker strain. All animals carrying the array were 
GFP-positive due to the expression of the elt-2::GFP transgene and displayed intestinal 
hyperplasia evident for the maternal effect of CDC-25.1(S46F). Thus, due to the maternal 
function of cdc-25.1 (ij48) all FI animals possessed intestinal hyperplasia and could 
potentially show lethality in combination with the heterozygous lin-62(ij52) allele.
Only GFP-positive FI animals that displayed strong hyperplasia and were thereby positive 
for the cdc-25(ij48) transgene were analysed for the presence o f the lin-62 (ij 52) dpy- 
20(el282) allele in their offspring. A strain was generated that segregated 18% Dpy 
phenotype in the F2 generation (Table 7.2). The GFP-positive Dpy animals, thus carrying 
the cdc-25.1 (ij 48) array and the homozygous lin-62 (ij 52) allele were examined further. 
The presence of the ij48 allele in GFP-positive hermaphrodites was confirmed by single 
worm PCR and analysis of a restriction site polymorphism that is introduced through the 
mutation (Figure 7.2, A). To analyse whether there is an enhanced lethality between 
maternally provided cdc-25(ij48) and homozygous Un-62(ij52) all Dpy animals were 
analysed for the occurrence o f GFP in their offspring and the lethality determined. Thus, if 
Dpy animals lost the cdc-25(ij48) allele at higher frequency than the non-Dpy animals it
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would indicate a degree of lethality. This was not the case, on average 80.8% of the 
animals retain the GFP among the Dpy animals whereas the original cdc-25. l( ij48) strain 
keeps the GFP at a frequency of 75% (p-value: n.s., one-tailed Student’s t test, Table 7.2) . 
An average death rate for GFP-positive animals was found to be 26.7%, whereas Dpy 
animals that had lost the array and were homozygous for the lin-62 mutation were 
segregating 19% death (p-value: n.s., one-tailed Student’s t test, Table 7.2).
IA577 lin-62(ij52) dpy-20 (el282) w lsl 18 fnpa-l::GFP::LacZJ x IA575 N2 [cdc- 
25(ij48) elt-2::GFPr.LacZ]
% Dpy in F2 1 8 (n=73)
% embryonic death among Dpys 
in F4
29.2 ± 16.7 (19.1 -  39.3) (n=679, 13 F3)
% GFP+ in Dpys 80.8 ± 10.4 (n=442, 15 F3, all F3 contain cdc- 
25.1 (ij 48) confirmed by single worm PCR)
% Lin in GFP+ 98.8 ± 15.2 (n=335, 15 F3)
lin-62(ij52) dpy-20(el282) (GFP “ F3 from cross) x JR1990 w ls l 18 [npa- 
1:: GFPr.LacZ]
% segregating Dpy/Lin 100 (20 FI)
% Dpy/Lin/F2 22 ±5.3
% Lin among Dpys 100
lin-62(ij52) dpy-20 (e l282) (GFP " F3 from cross)
% embryonic death in FI 19.7 ± 10.7 (11.4 -  27.9) (n=279, 9 F3)
IA575 ijEx36[cdc-25.1 (ij48), w!s84[elt-2::GFP::LacZ]
% GFP+ in FI 75.4 ± 15.1
Table 7.2 A genetic cross between Iin-62(ij52) and cdc-25 .1  (ij48). M ean  ± s.d. (95%  u p p e r  an d  
lower c o n f id e n c e  interval), p -value for em bryon ic  lethality of G F P + v e r s u s  G F P '  Dpy an im als:  > 0 .05  
(one-ta i led  S tu d e n t ’s  t- test).
To eliminate the possibility that a recombination event created a lin-62 (ij 52) dpy- 
20(el282)/+ dpy-20(el282) animal (i.e. an animal that has dumpy appearance but is 
heterozygous for the lin-62 (ij52) allele) GFP-negative animals from the F3 Dpy brood 
were selected to ensure loss of the cdc-25(ij48) allele and crossed into the npa- 
1::LacZ::GFP intestinal-specific GFP marker strain JR1990 w lsl 18 (Table 7.2). Since the 
Un-62(ij52) allele acts recessively and zygotically, if no recombination event had occurred 
F2 generations should contain 25% Dpy animals in their brood that are also lin- 
62 (ij52)/lin-62(ij52) (which can be observed by the presence of intestinal hyperplasia). Of 
20 F 1 broods analysed, all segregated on average 22% Dpy in their F2 brood and were also 
Iin-62(ij52)/lin-62(ij52) due to the fact that they all displayed intestinal hyperplasia (Table 
7.2). Hence, it was possible to obtain a strain that is homozygous for lin-62(ij52) and 
carries the cdc-25. l( ij48) on a complex free array indicating that there is no synthetic 
lethality between cdc-25. l(ij48) and lin-62(ij52) in this genetic context.
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This result suggested that lin-62 may act through the ij48 lesion on cdc-25.1. This was 
determined by testing whether there is an accumulative effect in the lin-62(ij52) dpy- 
20(el282)llin-62(ij52) dpy-20(el282) strain that also carries cdc-25(ij48). Intestinal 
numbers of nuclei were counted by examining the expression of the embryonic elt-2::GFP 
marker only in embryos displaying intestinal hyperplasia. The lin-62(ij'52) dpy-20(el282) 
strain IA545 resulted in an almost identical number of intestinal cells as compared to the 
IA526 lin-62(ij52) strain on its own (Table 7.3), indicating that no additional mutation was 
introduced through the recombination of lin-62(ij52) with dpy-20(el282) that could 
generate additional intestinal nuclei. Intriguingly, a significant increase in the lin-62 (ij 5 2) 
cdc-25. l( ij48) double mutant compared to each single mutant lin-62 (ij52), cdc-25.1(ij48) 
(Table 7.3) was detected, indicating that lin-62 can act independently of the ij48 allele in 
cdc-25.1.
Strain Intestinal 
nuclei/ embryo
p-value vs. 
lin-62 (ij52)
p-value vs 
cdc-25.1(ij48)
IA526 Un-62(ij52)
wls84[elt2:: GFP: :LacZ, rol-6(su
1006dm)]
29.4 ±4.1
(n=69)
- -
IA545 lin-62(ij52) dpy-20 (el282)IV  
wls84[elt2:: GFP: :LacZ, rol-6(su 
1006dm)]
30.0 ±4 .2  
(n=69)
- n.s.
IA575 N2 [cdc-25. l(ij48) elt- 
2: .GFPr.LacZ]
28.9 ±4.1
(n=92)
n.s. -
IA585 lin-62(ij52) dpy-20 (el282)IV  
[cdc-25(ij48) elt-2::GFP::LacZ]
37.2 ±4.8
(n=79)
<0.001 <0.001
Table 7.3 Comparison of intestinal nuclei of Iin-62(ij52) and cdc-25.1 (ij48) single and double 
mutants. Intestinal n u m b e rs  w e re  a n a ly s e d  afte r  incubation  of th e  s t ra in s  a t  20°C. Two-tailed 
S tu d e n t ’s  f-test.
7.2.2 Iin-62(ij52) does not affect the stability of CDC-25.1 in 
embryos
The additive effect on the number of intestinal nuclei seen through the combination of lin- 
62 (ij 52) with cdc-25. l(ij48) suggested that lin-62(ij52) may act on the cell cycle 
independent of the ij48 lesion in cdc-25.1. Previous data however had revealed that lin- 
62 (ij 52) cannot bypass the cdc-25.1 function. This was illustrated by the fact that when 
RNAi against cdc-25.1 was performed in the Un-62(ij52) mutant background compared to 
a wild-type strain, no increase was observed for the intestinal cell numbers (Segref and 
Johnstone, 2004). This result could suggest that lin-62(ij52) requires the prior function of 
cdc-25.1 within another stage of the cell cycle or that lin-62 (ij 52) acts on cdc-25.1.
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Since the molecular mechanism underlying the ij48 mutation in cdc-25.1 has only become 
apparent in this study, it allowed me to perform another simple test to examine, whether 
lin-62(ij52) acts as a negative regulator through the ij48 lesion in cdc-25.1. As illustrated in 
previous chapters, cdc-25.l(ij48) mutants show an increase in the CDC-25.1(S46F) protein 
levels as compared to CDC-25.1 in the early embryo. The site o f the ij48 mutation 
introduces a serine to phenylalanine substitution in the conserved DSG consensus site 
which acts as a scaffold for the protein degradation machinery and is recognised by LIN- 
23. Phosphorylation of the serine is a prerequisite for p-TrCP interaction in higher 
eukaryotes and thus, the possibility remains that lin-62 might be involved in 
phosphorylation of S46 in CDC-25.1 (see 7.1). Thus if LIN-62 phosphorylates CDC-25.1 
on S46, removal or mutation of LIN-62 would be predicted to enhance CDC-25.1 protein 
levels similar to the enhanced protein levels of CDC-25.1(S46F).
To test this possibility, embryonic extracts from C. elegans strains derived from the wild- 
type strain JR1838 wls84 and IA526 lin-62(ij52) wls84 were prepared and CDC-25.1 
protein levels compared by Western blotting. As can be seen in Figure 7.2 (panel B), equal 
amounts o f total protein were applied to 10% SDS-PAGE as determined by Western 
blotting against P-ACTIN as loading control. However, CDC-25.1 protein levels remain 
similar in both cases. The protein extraction was only performed once and protein samples 
loaded repeatedly on a 10% SDS polyacrylamide gel, only one sample loading is depicted 
(Figure 7.2, B) for simplicity. This result is rather clear and controlled in itself through p- 
ACTIN comparison and compared to embryonic extracts of a cdc-25. l( ij48) allele (see 
Chapter 3, Figure 3.5) that consistently show a high increase in CDC-25.1(S46F) protein 
levels. Thus, it can be concluded that lin-62(ij52) is not acting on the stability of CDC-25.1 
through S46.
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Figure 7.2 Analysis o f lin-62(ij52) cdc-25.1(ij48) mutants. A) Single worm PCR and 
restriction site polymorphism to detect the presence o f  the cdc-25.1 (ij48) allele in GFP 
-positive F3 hermaphrodites coming from the IA577 lin-62(ij52) dpy-20(el282) cross 
with 1A575 [cdc-25.1(ij48), elt-2::GFP::LacZ]. DNA o f  GFP-positive Dpy animals 
containing cdc-25.1 (ij48) with elt-2::GFP on a complex array (GFP+, lanes 1 and 2) 
were analysed on a 1.8% agarose gel next to DNA o f  animals that were Dpy but had lost 
the complex array (GFP-, lane 3) or as a positive control IA530 containing the 
integrated homozygous cdc-25.1(ij48) allele (ij48, lane 4). A 126 pb band present in 
GFP-negative, thus cdc-25.1 animals, is shifted to 168 bp in a homozygous cdc- 
25. I(ij48) or GFP-positive hermaphrodites as indicated by arrows. For precise informa­
tion on restriction fragment sizes see Chapter 2 (2.2.6.5). B) Embryo extracts derived 
from the strain J R 1838 (WT) or IA529 lin-62(ij52) were applied to 10% SDS-PAGE 
followed by Western blotting against CDC-25.1 (anti-CDC-25.1A) and P-ACTIN.
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7.2.3 Iin-62(ij52) mapping
Attempts were made to further map the precise position of the lin-62(ij52) mutant. 
Previous mapping studies using a combined approach of three-factor- and STS mapping 
(Clucas, 2003)) have placed the mutation at the approximate position of +3.3 between bli-6 
(+3.19) and unc-24 (+3.52) on chromosome IV. In order to verify these data and refine the 
position further, the recombination events between lin-62 (ij5 2), unc-8(e49) (+3.29) and 
dpy-20(el282) (+5.18) were examined. This was achieved by crossing hermaphrodites of 
the newly generated strain IA526 lin-62 (ij 5 2) IV; wls84 [elt-2: .GFPr.LacZ rol-6(su!006)J 
into heterozygous DR439 unc-8(e49) dpy-20(el282)IVmales and observing segregation of 
lin-62(ij52) phenotype in Dpy-non-Unc recombinant animals of the F3 generation. During 
the cross it became apparent that is was almost impossible to determine the Lin phenotype 
when the rol-6(sul006) mutation (introduced through the elt-2::GFP marker of the initial 
lin-62(ij52) strain IA526) was combined with unc-8(e49). However, Dpy recombinants 
allowed a very clear discrimination between Lin and wild-type phenotypes even in the 
presence of the rol-6 mutation. Thus, Dpy-non-Unc recombinant animals were screened. 
Out of 36 recombinant animals, all segregated the Lin phenotype, which strongly argues 
that the lin-62(ij52) allele must be either to the left (centromeric) or in close proximity of 
unc-8(e49). Preliminary STS mapping results (Clucas, 2003) had revealed that lin-62(ij52) 
was in close proximity of the polymorphism stP44 which is found at the approximate 
position of +3.27 between him-3 and pgl-1 (WormBase, 2007). This result suggests that 
the lin-62 (ij 52) allele might be in close proximity of unc-8(e49).
Recombinant class Recombinants 
segregating lin- 
62 (ij52) phenotype
Recombinant not 
segregating lin- 
62(ij52) phenotype
Total number of 
recombinants
Dpy-non-Unc 36 0 36
Table 7.4 Three-factor mapping of Iin-62(ij52) with unc-8(e49) dpy-20(e1282).
In order to further refine the location of lin-62, the elt-2::GFP transgene that was 
integrated with the rol-6(sul006) mutant background was replaced with a post-embryonic 
GFP marker to facilitate the identification of the Lin phenotype in Unc animals. To this 
end, the lin-62(ij52) dpy-20(el282)IV  strain carrying the elt-2::GFP and rol-6(sul006) 
transgene (IA545) was crossed into JR1990 w lsl 18 males. Dpy-Lin F2 progeny were 
selected on the basis of the expression of the intestinal GFP marker and subsequently 
animals that had lost the embryonic elt-2:: GFP, but retained post-embryonic GFP 
expression through the presence of w ls ll8  npa-1 ..GFPr.LacZ  were selected. This 
produced the strain IA577 Un-62(ij52) dpy-20 IV; w lsl 18 (Table 7.1). At this point during
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the studies it became evident that the work discussed in previous chapters required 
increased attention and this project was continued by a postdoc in our laboratory who is 
currently using the strains generated in this study to further clone the Un-62(ij52) allele.
7.3 Discussion
It was hypothesised that LIN-62 can either act through S46 to regulate CDC-25.1 or cause 
hyperplasia in a mechanism independently o f CDC-25.1. The data displayed in this chapter 
clearly show, that LIN-62 does not act through S46 in CDC-25.1 to generate intestinal 
hyperplasia.
7.3.1 lin-62 mapping
In this chapter cloning of lin-62 was further undertaken and new strains were generated 
that are currently being used for mapping purposes. The mapping data using unc-8 and 
dpy-20 as marker strains show that lin-62 must lie to the left or in the close proximity of 
unc-8 at position +3.29 on chromosome IV. This result fits well with the previous report 
that placed lin-62 between bli-6 (+3.2) and unc-24 (+3.52) in close proximity to the stP44 
polymorphism at +3.27 (Clucas, 2003). Altogether the data suggest a map position for lin- 
62 between bli-6 (+3.19) and in the close proximity of unc-8 (+3.29).
7.3.2 Iin-62(ij52) is synergistic to cdc-25.1 (ij48)
The data presented here argue strongly that there is a synergism between cdc-25. l(ij48) 
and lin-62(ij52). This was mostly demonstrated by the fact that a combined strain that is 
homozygous for lin-62 (ij 52) and carries cdc-25. l(ij 48) on a complex array displays an 
additive number o f intestinal cells. Twenty intestinal cells are produced in a wild-type 
strain. This number is increased by 10 (to 30) in the case of a homozygous lin-62(ij52) 
mutant and by 8 (to 28) when cdc-25.1 (ij48) is supplied on an complex extrachromosomal 
array. However, when homozygous lin-62 (ij 5 2) animals carry the cdc-25. l(ij 48) on a 
complex array an addition of both single alleles is obtained creating 17 more intestinal 
cells (to 37). Hence, this shows that Un-62(ij52) and cdc-25.1 (ij48) cause the intestinal 
hyperplasia by two independent mechanisms.
A slight but statistically significant increase in the embryonic lethality of the double 
mutant compared to each single mutant was identified. However, when Dpy animals of this 
cross were analysed after they lost the cdc-25.1 (ij48) array they showed no statistically
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significant difference in their embryonic lethality compared to animals that were 
homozygous for both alleles. This would suggest that the slight additive effect in 
embryonic lethality might be independent of the combination of lin-62(ij52) and cdc- 
25.1(ij48). The data obtained above are derived from a strain that carries the cdc-25. l( ij48) 
on a complex extrachromosomal array. This allows expression of cdc-25.1 (ij48) in the 
germline as repetitive arrays can be silenced in the germline (Kelly et al., 1997). 
Nonetheless, it remains to be established whether a chromosomally integrated cdc- 
25.1(ij48) would display a similar phenotype when combined with lin-62(ij52). Partly, 
because the cdc-25. l( ij48) allele might be supplied in different copy numbers in the 
germline, since arrays usually form from many gene copies (Mello et al., 1991) and thus 
partial silencing might result in differential CDC-25.1(S46F) expression levels. It will 
therefore be important to repeat the cross with one of the newly synthesised lin-62(ij52) 
strains. For example, IA545 lin-62(ij52) dpy-20(21282)IV; wIs84[elt-2::GFP::LacZJ could 
be crossed into IA268 cdc-25. l(ij48) and progeny followed by Dpy appearance for lin- 
62 (ij 5 2) and restriction site polymorphism for the cdc-25. l( ij48) allele. This would allow 
us to identify whether single copies of both genes result in a more severe additive 
phenotype as displayed in this study.
7.3.3 UN-62 does not stabilise CDC-25.1
The synergistic increase in the number of intestinal nuclei observed when lin-62(ij52) is 
combined with cdc-25.1 (ij48) indicates that lin-62 acts independently of the ij48 site in 
cdc-25.1 (as described above). This result is further supported by the observation that no 
increase in CDC-25.1 protein levels is detected in a lin-62 (ij 5 2) strain compared to a wild- 
type strain. Should LIN-62 be the kinase acting to phosphorylate CDC-25.1 on S46 and 
thereby targeting CDC-25.1 for LIN-23-mediated proteasomal degradation, removal or 
mutation of LIN-62 would cause a similar increase in the CDC-25.1 protein levels as 
observed for the CDC-25.1(S46F) mutant. However, as displayed in this chapter the ij52 
mutation in lin-62 does not stabilise CDC-25.1. Hence, LIN-62 is not the kinase to 
phosphorylate CDC-25.1 on S46.
7.3.3.1 Possible functions of LIN-62
It remains possible that lin-62 may exert its function by acting on another site in cdc-25.1. 
This is supported by previous experiments that showed that lin-62 could not bypass cdc-
25.1 RNAi (Segref and Johnstone, 2004). Though, taken into account that cdc-25.1 is a
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general cell cycle regulator, this RNAi result is not too surprising and could suggest that 
LIN-62 requires the prior function of CDC-25.1 at a different stage of the cell cycle.
Alternatively, LIN-62 could negatively regulate CDC-25.1 function on another site in the 
CDC-25.1 protein independently of S46. The mapping data places the lin-62 allele between 
+3.19 and +3.29 to a 840 Kbp region on chromosome IV, which comprises approximately 
190 genes with five predicted kinases and twelve predicted phosphatases (WormBase, 
2007), suggesting that lin-62 could potentially be a kinase or a phosphatase that may act on 
CDC-25.1 in order to negatively regulate its function.
Such negative regulations of CDC25 are evident in vertebrate systems. 14-3-3 proteins 
have been shown to bind to a critical phosphoserine residue in Xenopus CDC25C (S287) 
(Duckworth et al., 2002; Kumagai et al., 1998) and human CDC25C (S216) (Bulavin et al., 
2003a; Bulavin et al., 2001; Peng et al., 1998; Peng et al., 1997). CDC25C is 
predominantly cytoplasmic in interphase, but lack of 14-3-3 binding, through non- 
phosphorylatable (S287A/S216A) mutations in CDC25C, can induce its shuttling to the 
nucleus, and thus release the protein from cytoplasmic retention (Graves et al., 2001; 
Kumagai and Dunphy, 1999; Yang et al., 1999). The cytoplasmic retention acts as a 
negative regulatory mechanism, because release from 14-3-3 binding can increase the 
CDC25C mitosis-promoting activity in Xenopus (Yang et al., 1999) and human cells (Dalai 
et al., 1999; Dalai et al., 2004; Graves et al., 2001; Karlsson et al., 1999; Peng et al., 1997). 
Similarly, 14-3-3 binding to an analogous phosphoserine residue has been reported for 
human CDC25B (Bulavin et al., 2003a; Bulavin et al., 2001). Lack of 14-3-3 binding 
causes CDC25B redistribution to the nucleus (Giles et al., 2003; Lindqvist et al., 2004; 
Uchida et al., 2004) and induces premature mitosis (Lindqvist et al., 2004).
Thus, LIN-62 could act as a kinase by negatively regulating CDC-25.1 function similar to 
the vertebrate system. Alternatively, LIN-62 could be negatively regulating CDC-25.1 
function through dephosphorylation of CDC-25.1. Such a mechanism was reported in 
Xenopus eggs, where dephosphorylation of a threonine residue (T138) in CDC25C by the 
PP2A phosphatase, was found to enhance 14-3-3 binding, thereby negatively regulating 
CDC25C mitosis-promoting activity (Margolis et al., 2006). Hence, if LIN-62 encodes for 
a kinase or a phosphatase acting on CDC-25.1 by a similar negative regulation as detected 
for the vertebrate CDC25s, then the lin-62(ij52) allele might affect the nuclear-to- 
cytoplasmic ratio of CDC-25.1 in the embryos. This would correlate with the fact that there 
is no increase of the CDC-25.1 protein detected by Western blotting because it would 
imply a differential localisation of CDC-25.1 in lin-62(ij52) embryos. To this end, indirect
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immunostaining against CDC-25.1 in embryos could be employed to determine the nuclear 
and cytoplasmic ratio of CDC-25.1 in lin-62 (ij 5 2) mutants compared to wild-type.
7.3.4 Conclusion
In summary, the data displayed here provide strong evidence that the intestinal hyperplasia 
caused through mutations in cdc-25. l( ij48) and lin-62 (ij52) are the result of two 
independent mechanisms and that LIN-62 is not a negative regulator of S46 in CDC-25.1. 
The cdc-25.1 (ij48) strain utilised to analyse the combinatorial effects of cdc-25.1(ij48) and 
lin-62(ij52) is a valuable tool to set up a genome-wide screen to expand the search to 
identify negative regulators of the cell cycle that can act independently of S46F in CDC-
25.1 in the intestine or other tissues and address further the tissue-specific nature of the 
cdc-25.1 (ij48) allele.
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Chapter 8 
Final discussion
8 Final discussion
8.1 Summary of Results
The research presented in this thesis advances the understanding of how the tight negative 
control of CDC-25.1 contributes to maintenance of tissue-specific regulation of cellular 
proliferation during embryonic development of the multicellular organism C. elegans. A 
combination of reverse genetics and biochemical approaches successfully revealed that the 
interaction between the E3 ubiquitin ligase component LIN-23 through S46 in CDC-25.1 is 
vital to restrain cellular divisions of intestinal cells, specifically during embryogenesis.
8.1.1 UN-23 controls intestinal cell proliferation through S46 in 
CDC-25.1 in the embryo
Firstly, removal of SCF components such as LIN-23, CUL-1 or SKR-1 caused excess 
intestinal cells, indicating that the SCF complex is involved in regulation of intestinal cell 
proliferation. Removal of LIN-23 and CUL-1 showed no synergism for the number of 
extra intestinal cells when combined with the recently identified cdc-25. l( i j48) allele 
(Clucas, 2003; Clucas et al., 2002), suggesting that they cause the excess intestinal cells 
through the same pathway as cdc-25. l(ij48). In agreement with this result, partial 
inhibition of LIN-23 by RNAi primarily affects proliferation of intestinal cells, when 
compared to other tissues, similar to the previously reported phenotype of the cdc- 
25. l(ij48) allele (Clucas, 2003; Clucas et al., 2002). Zygotic lin-23 expression in the 
embryo does not influence the proliferation of the intestine, because lin-23 zygotic null 
embryos show no proliferation defects of the intestine, indicating that maternally provided 
LIN-23 is important to control cell divisions of intestinal cells.
Embryos derived from heterozygous lin-23 mothers, that obtain half the amount of LIN-23 
protein levels, show normal proliferation of intestinal cells. Thus, a 50% protein level of 
LIN-23 provided by the mother is sufficient to drive normal development of the intestine. 
Lowering these threshold levels of LIN-23 by RNAi primarily affects proliferation of the 
intestine because lin-23 RNAi-treated embryos show intestinal hyperproliferation, but the 
majority of embryos hatch and grow to adulthood (when they become sterile).
Unique biochemical data are presented that unravel the endogenous complex formation of 
LIN-23 and CDC-25.1 in early embryos, providing compelling evidence for the physical
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interaction between both molecules. Intriguingly, the S46 mutation in CDC-25.1 decreases 
LIN-23 binding to CDC-25.1, reduces the CDC-25.1 polyubiquitination state, and 
increases CDC-25.1 protein levels. Elevated CDC-25.1 (S46F) protein levels are not 
restricted to the intestine and have been detected in the majority of blast cells o f the early 
embryo, a phenotype that was also evident for CDC-25.1 after LIN-23 or CUL-1 
knockdown by RNAi. LIN-23 protein levels are detected in all blast cells of the early 
embryo, which is in accordance with the general regulation of its target CDC-25.1 in 
probably all blast cells of the embryo. Intriguingly, LIN-23 protein is also detected in the 
germline. Although, it does not regulate CDC-25.1 through the S46 residue in the 
germline, because LIN-23 does not bind CDC-25.1 in the germline and the CDC-
25.1 (S46F) mutant protein levels are not up-regulated in the germline. Thus, this suggests 
the presence of a third key-player, possibly a kinase that can restrain CDC-25.1 S46 
phosphorylation to a tight window during C. elegans early embryonic development.
8.1.2 gsk-3, apr-1 and wrm-1 RNAi cause extra intestinal cells 
independently of the cdc-25.1(ij48) allele
Data provided in this work clearly demonstrate that the potential kinase GSK-3 is not 
involved in regulation of CDC-25.1 through the S46 residue. Intriguingly, knockdown of 
GSK-3 also results in excess intestinal cells. However, the mechanism causing the extra 
intestinal cells is clearly distinct from the mechanism caused by abrogated LIN-23/CDC-
25.1 interaction.
GSK-3 knockdown causes additive numbers of intestinal cells, when combined with the 
cdc-25.1(ij48) allele, indicating that GSK-3 and the CDC-25.1 (S46F) mutant act in 
separate pathways. Furthermore, CDC-25.1 protein levels are not increased after GSK-3 
knockdown, which contrasts with the data obtained by LIN-23 knockdown, and 
emphasises that GSK-3 does not negatively regulate the stability of CDC-25.1 through 
S46. Additionally, APR-1 and WRM-1 knockdown cause extra intestinal cells, which were 
found to be synergistic to the extra intestinal cell phenotype caused by the cdc-25.1(ij48) 
allele. However, no synergism was observed when apr-1, wrm-1 and gsk-3 RNAi were 
combined, suggesting that gsk-3, apr-1 and wrm-1 RNAi might cause the extra intestinal 
cells by a similar mechanism, but not through the cdc-25.1(ij48) allele.
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8.1.3 Iin-62(ij52) does not act through the ij48 site in cdc-25.1
The recently identified Un-62(ij52) allele (Clucas, 2003; Clucas et al., 2002) was an 
interesting candidate to regulate cdc-25.1 through the ij48 lesion due to its similar 
proliferation defect in the intestine. However, here it is shown that LIN-62 is not the kinase 
that regulates CDC-25.1 through S46, because the combination of the lin-62(ij52) and cdc-
25.1 (ij 48) allele was found to be additive with respect to intestinal cell number, an 
indication that both alleles act through separate pathways. Furthermore, the lin-62(ij52) 
mutant does not stabilise the CDC-25.1 protein in embryos.
8.2 Discussion
8.2.1 CDC-25.1 overexpression causes hyperplasia
Perturbation of the CDC-25.1 interaction with LIN-23, either by RNAi against lin-23 or 
through a CDC-25.1(S46F) mutant, causes elevated CDC-25.1 protein levels in the early 
embryo, ultimately resulting in intestinal hyperplasia. Intriguingly, zygotic expression of 
wild-type CDC-25.1 in the embryo, through expression of the elt-2::cdc-25.1(+) 
transgene, was shown to induce extra intestinal cells. This indicates that solely high CDC-
25.1 protein levels, and not the CDC-25.1 (S46F) mutation per se, can stimulate the 
production of extra divisions. The additional cell divisions after lin-23 RNAi (this study) 
appear to be a result of a shortening of the cell cycle and a failure to exit the cell cycle after 
the fourth division (as evidenced by cell lineage analysis, J. Cabello) as previously also 
observed for the cdc-25.1 (ij48) allele (Clucas, 2003; Clucas et al., 2002).
The C. elegans CDC-25.1 (G47D) mutant was proposed to display a similar shortening of 
the cell cycle during C. elegans intestinal development, but a detailed lineage analysis was 
not performed in that study (Kostic and Roy, 2002). It has been shown that this mutant 
protein persists longer in the embryo, but given the fact that this mutation also perturbs the 
DSG motif in CDC-25.1, it is conceivable to expect a similar degradation defect of the 
CDC-25.1 protein under identical experimental conditions as performed for CDC-
25.1 (S46F). The overexpression data presented here are also in agreement with previous 
observations in mammalian tissue culture cells, where overexpression of the CDC25A 
protein can accelerate S phase entry (Blomberg and Hoffmann, 1999) and induce 
premature entry into mitosis (Mailand et al., 2002; Molinari et al., 2000). Similarly, 
overexpression of human CDC25B (Baldin et al., 2002; Gabrielli et al., 1996; Karlsson et
223
al., 1999), and to a lesser extent CDC25C, can induce premature entry into mitosis 
(Karlsson et al., 1999). Furthermore, overexpression of human CDC25A induces 
hyperplastic changes in mouse mammary glands (Ray et al., 2007).
Thus, the data presented here show that solely the elevated CDC-25.1 protein levels are 
enough to complete the extra cellular divisions of the intestine, indicating that CDC-25.1 is 
the driving force o f the early embryonic cell cycle at least regarding the divisions of 
intestinal cells. This is in agreement with the detailed study by (Ashcroft et al., 1999) who 
reported a primary role for CDC-25.1 during embryogenesis. RNAi against cdc-25.1 
resulted in embryonic lethality that was slightly enhanced after simultaneous co-depletion 
of all four cdc-25 counterparts through concomitant RNAi. cdc-25.3 and cdc-25.4 RNAi 
did not show any obvious embryonic defects and cdc-25.2 RNAi resulted in penetrant 
larval defects. Thus, it appears that in C. elegans, multiple CDC-25 forms can drive the 
cell cycle in the embryo, but CDC-25.1 is the primary factor driving proliferation in 
embryos, whereas CDC-25.2 might be involved in larval development. The use of tissue- 
specific GFP markers will establish to what extent other CDC-25 family members are 
important for proliferation of certain tissues in the embryo. In mammalian tissue culture 
cells, all three human CDC25 forms can cooperate at different cell cycle stages to drive 
cellular divisions (reviewed in (Boutros et al., 2006)). However, it remains to be 
established to what extent this accurately reflects the function of each form in a 
multicellular organism. For example, a recent study in mice revealed a major function of 
only one CDC25 isoform (CDC25A) that is sufficient to drive normal cell divisions in cells 
derived from mice that lack both CDC25B and CDC25C (though the female mice are 
sterile) (Ferguson et al., 2005). Accordingly, here it is demonstrated that overexpression of 
the single CDC-25.1 protein in C. elegans embryos can act to solely control proliferation 
of at least one entire tissue.
8.2.2 S46 is vital for CDC-25.1 regulation
Novel data produced in this study revealed that CDC-25.1 contains a predicted DSG motif 
in its N-terminus that is important for the regulation via LIN-23, the C. elegans orthologue 
of the human E3 ligase p-TrCP that specifically binds to DSG phosphodegron motifs. LIN- 
23 acts as a vital negative regulator through S46 within the predicted DSG m otif of CDC-
25.1, highlighting the conservation of this interaction from C. elegans to human.
Previous data revealed that S82 in the DSG motif of human CDC25A is important for P- 
TrCP-dependent binding and polyubiquitination (Busino et al., 2003; Donzelli et al., 2004;
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Jin et al., 2003). In vivo studies with single serine (82) to alanine mutants uncovered that 
this residue is particularly important for the interaction o f CDC25A with p-TrCP (Donzelli 
et al., 2004; Jin et al., 2003). Furthermore, S82 is vital for the P-TrCP-mediated 
degradation of CDC25A in mammalian tissue culture cells (Busino et al., 2003; Ray et al., 
2005). Deletion of P-TrCP by RNAi abrogates the intra-S-checkpoint response in human 
tissue culture cells in a CDC25A-dependent way (Busino et al., 2003).
In summary, these findings provide substantial information for the importance of the 
CDC25A interaction with P-TrCP to sustain a functional division cycle in cultured cells. 
Unfortunately, it could not delineate a picture for the consequences o f this interaction when 
cells are dividing within the context of a complete tissue or organism. Here, it is suggested 
that the single serine within the putative DSG motif of CDC-25.1 is important for the 
complex formation of CDC-25.1 with LIN-23 and resulting in the degradation of CDC-
25.1. Mutation of this serine has detrimental effects for the embryonic development, 
resulting in tissue-specific hyperplasia of the intestine.
8.2.2.1 gsk-3 and Iin-62(ij52) do not act through cdc-25.1 (ij48)
The kinase regulating the phosphorylation o f the S46 residue in CDC-25.1 is presently 
unknown. Of potential GSK-3 kinases with homology to human GSK3p, the closest 
homologue was found not to act through S46. Similarly, the lin-62(ij52) allele is not acting 
through the (ij48) lesion (S46F) in cdc-25.1. According to bioinformatic analysis, S46 falls 
also into a potential CK1 or PKA phosphorylation site. However, the C. elegans genome 
contains many different CK1 isoforms (Manning, 2005), and this could hamper the 
identification of the specific molecule involved in S46 phosphorylation. It should be 
emphasised that the data displayed here do not exclude the possibility that another member 
of the GSK-3 family can act to regulate S46.
Interestingly, in human CDC25A the S76 and S79 upstream of the DSG motif are also 
important for P-TrCP-mediated polyubiquitination (Donzelli et al., 2004; Jin et al., 2003). 
S76 was suggested to encompass a potential CHK1 kinase site (Donzelli et al., 2004; 
Goloudina et al., 2003; Hassepass et al., 2003). While the S residue equivalent to S79 is 
conserved in C. elegans CDC-25.1 (S43), analysis of the CDC-25.1 sequence reveals an 
aspartic acid (D40) at the position analogous to S76. D40 might be able to mimic 
constitutive phosphorylation of this residue and thus can uncouple CDC-25.1 regulation 
from the potential action of the CHK-1 kinase that is also functioning in the early embryo 
(Kalogeropoulos et al., 2004).
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8.2.3 Tissue specificity
An intriguing question that remains to be resolved is: why does global elevation of the 
CDC-25.1 protein level in all blast cells primarily affect the proliferation of the intestine? 
As discussed in Chapter 3 (3.3.4) and Chapter 7 (7.1), it could be anticipated that the cell 
cycle in intestinal cells is somehow more sensitive to elevated CDC-25.1 protein levels. 
This would imply that the intestinal cell cycle might lack some cell cycle control 
mechanism that is present in other cells.
However, in the intestine the Ea and Ep cells are the first cells in the embryo that acquire a 
G2 phase into their cell cycle, compared to other embryonic cell cycles that switch between 
mitosis and S phase (Edgar and McGhee, 1988). Additional data proposed that the final 
stages of intestinal divisions acquire also a G] phase, because the Gi type cyclin D (cyd-1) 
is required for the final four intestinal divisions (Boxem and van den Heuvel, 2001). It is 
presently unclear at what developmental stage other embryonic tissues acquire a gap phase 
into their cell cycle. The insertion of gap phases into the intestinal cell cycle rather 
suggests that intestinal cell cycles are more tightly controlled than cell cycles of 
surrounding tissues, and thus appears to contradict the findings here that intestinal cells are 
more sensitive to perturbations of CDC-25.1 protein levels. It is possible that other 
negative regulators are present to control CDC-25.1 activity only in the intestine leading to 
the long cell cycle in intestinal cells compared to other tissues.
Nevertheless, it is also possible that in intestinal cells additional gap phases have evolved 
because these cells lack other negative regulators that are present in non-intestinal tissues. 
Thus, the intestine might utilise additional gap phases as another means to restrain cellular 
proliferation. It will be fascinating to determine whether there are other negative regulators 
that are present in other tissues but not in the intestine.
8.2.3.1 Are negative regulators of the cell cycle limiting in the intestine?
WEE1/MYT1 proteins are interesting candidates to negatively regulate the cell cycle in 
non-intestinal tissues, because they negatively regulate the activity of CDKs through 
phosphorylation and thereby inhibit mitosis. The C. elegans genome contains three WEE1 
like genes {wee-1.1, wee-1.2 and wee-1.3) (Wilson et al., 1999). The wee-1.2 gene was 
found to be a pseudogene because no cDNA transcript has been identified to date. In situ 
hybridisations detected wee-1.1 transcript in the nucleus of the E blast cell and later in the 
nucleus of eight AB descendants at the 16-cell stage embryo. No transcript was found
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before or after that stage (Wilson et al., 1999). Thus, wee-1.1 might not be a crucial 
negative regulator in other tissues because it is also present in the intestine. However, 
suppressor mutants of a wee-1.3 gain-of-function allele have recently been identified and 
shown to result in embryonic lethality (Lamitina and L'Hemault, 2002). A wee-1.3 
promoter-fusion to GFP was expressed in all early embryonic tissues, which might suggest 
that wee-1.3 is vital for proliferation of many or all tissues in the embryo (Lamitina and 
L'Hemault, 2002). RNAi experiments previously failed to determine if wee-1.3 also acts in 
the intestine, due to sterility of RNAi-treated mothers (Clucas, 2003). The wee-1.3 
suppressor mutant (Lamitina and L'Hemault, 2002) could be analysed for the numbers of 
intestinal cells by crossing the intestinal-specific elt-2::GFP marker into this strain and 
examining the numbers of intestinal nuclei. The absence of intestinal hyperplasia would 
suggest that wee-1.3 could be an additional negative regulator in other tissues, but not in 
the intestine.
Other negative regulators of the cell-cycle are cyclin-dependent kinase inhibitors (CKI) 
that can bind cyclin/CDK complexes and thereby inactivate the activity of the kinase 
(Schafer, 1998; van den Heuvel, 2005). In C. elegans two cki genes have been identified 
and named cki-1 and cki-2 (Feng et al., 1999; Hong et al., 1998). Interestingly, a recent 
study revealed a role mainly for cki-1 in mediating the proliferation of several embryonic 
tissues, including the intestine (Fukuyama et al., 2003). Thus, cki-1 and cki-2 appear not to 
be responsible for the tissue-specific proliferation defect of the intestine.
8.2.4 Function of cdc-25.1, gsk-3 and lin-23 in the endoderm
This thesis has identified a new function for lin-23, gsk-3, apr-1 and wrm-1 in regulating 
intestinal cell proliferation. The number of intestinal cells is elevated through abrogation of 
the CDC-25.1/LIN-23 interaction or by GSK-3, APR-1 or WRM-1 knockdown. However, 
the mechanism underlying the excess intestinal cells after gsk-3, apr-1 and wrm-1 RNAi is 
distinct from that of the cdc-25.1 (ij48) allele. Interestingly, cell lineage analysis performed 
in collaboration with Dr. Cabello confirmed the findings that lin-23 functions through cdc-
25.1 (ij 48) and gsk-3 does not. lin-23 RNAi causes a shortening of the cell cycle and a 
failure o f cell cycle exit, similar to the previously identified cdc-25.1 (ij48) allele (Clucas, 
2003; Clucas et al., 2002). However, gsk-3 RNAi causes no general shortening of intestinal 
cell divisions and the cell cycle length is sensitive to the presence of the cdc-25.1 (ij48) 
allele. When gsk-3 RNAi is performed in a wild-type background all cells expressing 
endodermal fate undergo a further division after the fourth cleavage, which is possibly the 
result o f a delayed E specification after gsk-3 RNAi (as discussed in Chapter 3, (3.3.5.2)).
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gsk-3, wrm-1 and apr-1 RNAi do not cause a synergistic increase for the numbers of 
intestinal cells. Given the known role of gsk-3, wrm-1 and apr-1 in the specification of 
endoderm (see Chapter 1, (1.2.2)), it is feasible to suggest that their RNAi phenotypes 
cause extra intestinal cells by the same mechanism. However, ultimately a cell lineage 
analysis will have to be employed to determine, whether the extra cells detected after 
WRM-1, APR-1 or GSK-3 knockdown are derived from the same precursor.
8.2.5 Is cyclin D involved in cell cycle exit?
It is interesting to see that lin-23 RNAi and the previously identified cdc-25.1 (ij48) allele 
(Clucas, 2003; Clucas et al., 2002) cause a failure to exit the cell cycle after the fourth 
cleavage. It is presently unclear what causes the four intestinal cells to undergo a further 
cleavage in the wild-type background as compared to the other twelve intestinal cells that 
cease cell division. Intriguingly, a cyclin D (cyd-1) loss-of-function mutant was shown to 
result in a failure of the final four intestinal divisions (Boxem and van den Heuvel, 2001). 
Additionally, a cell lineage analysis after cki-1 RNAi revealed that all cells divide once 
more after the fourth division, but there is no shortening of the cell cycle (Fukuyama et al.,
2003). Binding of CYD-1 to CKI-1 was previously detected by two-hybrid analysis 
(Boxem and van den Heuvel, 2001). Thus, CKI-1 might counteract the function of CYD-1 
during the fourth intestinal division. These data encourage the speculation that abrogation 
of CDC-25.1 regulation through LIN-23 results in shortening of the cell cycle, and 
probably a mis-segregation of genetic determinants such as factors responsible for cyd-1 
expression, forcing variable cleavages of the cells into fifth or sometimes even sixth 
divisions. A recent report by (Ray et al., 2007) demonstrated that mammary tumours in 
mice with induced overexpression of CDC25A show abnormal chromosome numbers and 
chromosomal deletions compared to tumours that did not overexpress CDC25A, indicating 
that high levels of CDC25A can promote genomic instability.
Thus, it remains to be established whether the loss-of-function mutation in cyd-1 can 
antagonise cdc-25.1(ij48), lin-23 or gsA:-3-mediated excess endodermal cells. Previous 
work revealed that the cdc-25.1 (rr31) mutation does not act through cyd-1 in the intestine. 
However, those experiments were done after cyd-1 RNAi (Kostic and Roy, 2002), which is 
apparently not very effective to study cyd-1 function in embryos (Boxem and van den 
Heuvel, 2001).
Most importantly, the combination of genetics and biochemical data illustrated in this 
thesis (as well as cell lineage analysis) demonstrate clearly that the hyperplasia caused
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through knockdown of LIN-23 is mediated through the S46 residue in CDC-25.1, whereas 
this is not the case after GSK-3 knockdown.
8.2.6 Role of CDC25 in human malignancies
8.2.6.1 Overexpression of CDC25 in human malignancies
In C. elegans, high CDC-25.1 protein levels result in hyperplasia of the endoderm, thus 
illustrating that elevated CDC-25.1 protein levels are potentially oncogenic. A recent 
comprehensive study, that analysed the role of CDC25 phosphatases in human 
malignancies, revealed that overexpression of CDC25A and B was frequently associated 
with many human primary cancers, such as hepatocellular, colorectal and pancreatic 
carcinoma, prostate, breast and lung cancer or non-Hodgkins lymphoma (for a review see 
(Kristjansdottir and Rudolph, 2004)). These data correlate well with the previously 
proposed oncogenic effect of CDC25A and B, but not CDC25C, in mouse fibroblasts 
(Galaktionov et al., 1995) and the enhanced proliferative activity caused by CDC25A 
overexpression in mouse mammary tumors (Ray et al., 2007).
In C. elegans, CDC-25.1 protein levels are regulated through the interaction with LIN-23 
via the CDC-25.1 DSG motif, illustrating the importance of this interaction in a whole 
model organism. Intriguingly, the human LIN-23 orthologue p-TrCP regulates the 
abundance of human CDC25A through the DSG motif in human tissue culture cells 
(Busino et al., 2003; Donzelli et al., 2004; Jin et al., 2003; Ray et al., 2005) and it controls 
human CDC25A and B and Xenopus CDC25A abundance through the recently discovered 
DDG motif when analysed in Xenopus eggs (Kanemori et al., 2005). Taken together, these 
data correlate well with the elevated CDC25A and B levels in primary cancers, and suggest 
that an abrogated interaction in human p-TrCP, and CDC25A/B might have a pivotal role 
for the transforming activity of CDC25A/B during human malignancies.
Elevated CDC25A or CDC25B mRNA or protein levels have been detected in the majority 
of primary cancers analysed (Kristjansdottir and Rudolph, 2004). Unfortunately, a 
correlation between both mRNA and protein levels, which would provide additional 
information for the mechanism underlying CDC25 overexpression in those cancers, has not 
received much attention. Interestingly, several carcinomas such as colorectal carcinoma 
(Hernandez et al., 2001) as well as non-Hodgkins lymphoma (Hernandez et al., 2000) 
revealed elevated CDC25A protein levels that did not correlate with the amount o f mRNA 
present in those cancers. This suggests that, in some tumours, crucial post-transcriptional
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mechanisms account for differences in CDC25 protein levels. Similarly, a decrease in the 
CDC25A degradation rate was proposed to causs elevated CDC25A protein levels in 
human breast cancer cell lines (Loftier et al., 2005). These data highlight the importance 
for post-transcriptional control of CDC25 phospha:ases, possibly through the degradation 
pathway, during normal development and in human malignancies.
8.2.6.2 p-TrCP/CDC25 in human malignancies
The work in this thesis highlights that a balanced interaction of LIN-23 with CDC-25.1 is 
essential to restrain cellular proliferation during the development of a multicellular 
organism. This leads to the attractive hypothesis that inactivating mutations in human p- 
TrCP or the DSG motif in CDC25 might be associated with human malignancies. 
Interestingly, mutations in P-TrCP have rarely been found in primary tumours (for a 
review see (Fuchs et al., 2004)). A 96 bp deletion was found in a prostate cancer xenograft 
that generates a stop-codon in P-TrCP 1 at position 212, resulting in a truncated protein 
lacking the WD40 domain. A second mutation is a 169 bp deletion in a human prostate 
cancer cell line that leads to an in-frame deletion of residues 1 7 - 7 3  preceding the F-box 
motif o f P-TrCP 1 (Gerstein et al., 2002). Other p-TrCP mutations include a F462S point 
mutation at the seventh WD40 repeat domain of p-TrCP2 that was identified in a gastric 
cancer cell line (Saitoh and Katoh, 2001). Additionally, a recent study revealed five 
heterozygous missense mutations in p-TrCP 1 o f 95 human gastric cancers that were 
analysed (A99V, G260E, C206Y, H342Y and H425Y) (Kim et al., 2007). Two of these 
mutations are in the WD40 domain (H342Y and H425Y) whereas one (C206Y) is present 
in the F-box domain of P-TrCP. It will be interesting to determine whether these P-TrCP 
mutants abolish CDC25A/B binding.
Surprisingly, a variety of human malignancies and cancer cell lines possess elevated p- 
TrCP protein or mRNA levels (Gerstein et al., 2002; Koch et al., 2005; Muerkoster et al., 
2005; Ougolkov et al., 2004). However, the protein levels of the proto-oncogene p-catenin 
(the downstream target of P-TrCP) are also often up-regulated in those primary cancers 
with elevated P-TRCP protein levels, such as colorectal carcinomas (Ougolkov et al.,
2004) or hepatoblastomas (Koch et al., 2005). This is most likely the result o f DSG 
mutations in p-catenin, which would be expected to escape p-TrCP downregulation, or 
inactivating mutations of the tumour suppressor APC in the tumours and cell lines that 
were investigated. Mutations in the DSG motif o f CDC25A would be expected to also 
escape P-TrCP regulation in such cancers by a similar mechanism. It remains to be
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established whether these cancer cells also show elevated CDC25 protein levels and 
mutations in the DSG motif.
Intriguingly, a combined analysis of mutations in P-TrCP, p-catenin and APC in prostate 
cancers revealed that they were mutually exclusive; suggesting that all three genes may act 
in the same pathway in these tumours and that other mutations in separate pathways may 
contribute to their oncogenic effects in these tissues (Gerstein et al., 2002). Work in this 
thesis suggests that additive mutations in the DSG motif of CDC25A or maybe the DDG 
motif of CDC25B may result in an enhanced oncogenic potential. This is because in C. 
elegans, removal of Wnt pathway genes, such as GSK-3 or APR-1, causes a synergistic 
increase in the numbers of intestinal cells when combined with the CDC-25.1 DSG mutant.
Given the vast amount of evidence for the oncogenic effects of CDC25, and the established 
role for P-TrCP in down-regulation o f CDC25A during the normal cell cycle and in 
response to DNA damage, it is astonishing that the interplay between both proteins in 
human malignancies has received only little attention to date.
A first link between P-TrCP and CDC25A has been demonstrated in human lung cancer 
(He et al., 2005). Several human lung cancer cell lines show a decrease in P-TrCP 1 protein 
levels by an as yet unknown mechanism. Re-expression of P-TrCP 1 in one lung cancer cell 
line decreased the tumour size and reduced cell invasiveness when cells were injected in 
nude mice, implicating P-TrCP 1 function as vital for tumour growth and motility in mice. 
A direct interaction between p-TrCP 1 and CDC25A in non-small lung cancer cells was 
demonstrated, and knockdown of CDC25A by RNAi was shown to decrease cell 
invasiveness. Unfortunately, a comparison of the CDC25A mRNA and protein levels in 
primary lung tumours was missing in this study. Thus, it remains to be elucidated whether 
CDC25A protein levels are up-regulated in those primary human cancers and whether the 
mechanism described in the cell invasion assay correlates with a potential o f CDC25 to 
cause tumours in mice and human lung cancer. Importantly, it is the first study that reveals 
an interaction between P-TrCP 1 and CDC25A in human lung cancer cells (He et al., 2005).
These findings correlate with data presented in this thesis that suggest a vital role for a 
balanced interaction between CDC-25.1 and the C. elegans p-TrCP orthologue LIN-23 to 
restrain proliferation during C. elegans embryonic development. Mutational analysis of the 
CDC25 DSG or DDG motifs in human malignancies, which has unfortunately been 
lacking in the majority of cancer studies to date, should shed light on the question of
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whether the enhanced oncogenic potential of certain tissues is the consequence o f a 
dysregulated CDC25/p-TrCP interaction.
It remains to be established whether the tissue-specific defects, seen in C. elegans, are 
restricted to this model system. The fact that perturbations in P-TrCP and CDC25 protein 
levels have been identified in cancers of diverse tissue types (though many of endodermal 
origin) in humans might suggest a general role for the importance of the interactions of 
both proteins in humans. Further studies to discover additional negative regulators, acting 
in non-intestinal C. elegans tissues or on CDC-25.1 in the intestine, might identify whether 
the tissue-specific phenotype is conserved from C. elegans to humans. Alternatively, a 
limited pool of downstream regulators in other tissues compared to the intestine, such as 
cyclin-dependent kinases or cyclins, could cause the tissue-specific phenotype observed in 
this model system (as discussed in Chapter 3, (3.3.4.1)).
8.3 Future Perspectives
The work provided in this thesis has opened a wide spectrum of possibilities for further 
research investigation. Single experiments are described in the discussions of the 
individual chapters. But many exciting possibilities could represent the start of new 
projects and a broad outline of the most interesting perspectives is suggested below.
8.3.1 Does the intestinal cell cycle exit depend on cyclin D?
It will be interesting to determine whether the cyd-1 loss-of-function allele (Boxem and 
van den Heuvel, 2001) can abrogate the extra intestinal cells caused by either the cdc-
25.1 (ij48) allele, lin-23 or gsk-3 RNAi. The elt-2::GFP marker could be crossed into the 
cyd-1 (lof) strain to determine the numbers of intestinal cells when combined with the cdc-
25.1 (ij 48) allele or after lin-23 or gsk-3 RNAi. Cell lineage analysis would reveal whether 
the cyd-1 (lof) allele affects the shortening of the cell cycle in cdc-25.1 (ij48) or after lin-23 
RNAi. Or if it only affects the cell cycle exit o f the intestinal cells after the fourth division 
in the cdc-25.1 (ij48) mutant and after lin-23 RNAi as compared to gsk-3 RNAi.
8.3.2 Identification of negative regulators of non-intestinal tissues
A RNAi screen can be performed utilising the strain IA575, generated in this study, that 
carries cdc-25.1 (ij48) and elt-2::GFP on an extrachromosomal array. It would permit 
screening for animals that produce embryonic lethality (i.e. green dying embryos) only in
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combination with the cdc-25.1 (ij48) allele. Thus, this screen would allow the identification 
of negative regulators, possibly also in non-intestinal tissues, whose function becomes 
crucial when combined with the cdc-25.1 (ij48) gain-of-function allele.
8.3.3 Identification of the kinase that regulates S46 in CDC-25.1
A new strain could be generated that expresses CDC-25.1 tagged with GFP under the 
control of its own promoter. RNAi screening of potential kinases, such as CKI or PKA, 
could then be performed by examining embryos with increased GFP fluorescence, that are 
impaired in CDC-25.1 degradation. The identification of the kinase would answer the 
question whether the kinase is only active in the embryo and not in the germline, as 
suggested in this study.
8.3.4 Discovery of novel LIN-23 targets
A  lin-23: .FLAG-TY allele has been generated in this study. This allele can rescue the 
sterility of a lin-23 null allele, but some embryos are dying. This suggests that maybe other 
targets o f LIN-23 might be elevated in those embryos. Embryonic extracts of the lin- 
23 v.FLAG-TY allele could be compared to wild-type extracts using 2-dimensional gel 
electrophoresis. Proteins that are elevated in the mutant, but not in the wild-type, could be 
analysed by mass spectrometry. Potential targets could be further examined for the 
presence of a DSG motif by sequence analysis, and their function in the embryo could be 
studied by RNAi.
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Appendices
Stage No. of 
embryos
Fold increase p-value Combined 
fold increase
Combined
p-value
A) Comparison of CDC-25.1 with CDC-25.1 (S46F)
10-20n 11/10
4/7
7/5
1.71 (2.53 - 1.15) 
0.62 (0.93 -0.41) 
2.17(3.33 - 1.41)
<0.01
<0.05*
<0.01
1.4 <0.001
30-40n 14/9
11/7
2.57 (3.62 - 1.83) 
1.75 (2.67 - 1.15)
<0.001
<0.05 2.2 <0.001
50-60n 14/10
4/5
6/9
2.19 (3.07- 1.57) 
1.31 (2.69-0.64) 
2.00 (3.39- 1.17)
<0.001
n.s.
<0.05
1.9 <0.001
100-200n 6/9
5/2
5/8
1.72 (4.89-0.60) 
1.13 (2.46 -0.52) 
1.19(1.82 -0.77)
n.s.
n.s.
n.s.
1.4 n.s.
B) CDC-25.1 comparison lin-23 and control RNAi
10-20n 6/12
9/6
2.42 (3.48 - 1.68) 
1.16(2.61 -0.51)
<0.001
n.s. 1.7 <0.001
30-40n 8/11
11/7
3.62 (4.99 - 2.62) 
2 .16(4.56- 1.02)
<0.001
<0.05 2.8 <0.001
50-60n 6/7
7/8
3.14 (5.33 - 1.84) 
1.73 (3.45 -0.86)
<0.001
n.s. 2.3 <0.001
C) CDC-25.1 S46F) comparison lin-23 and control RNAi
10-20n 6/7
9/9
0.95 (2.00 - 0.45) 
1.15 (1.63 - 0.82)
n.s.
n.s. 1.1 n.s.
30-40n 4/3
12/6
0.56(1.26 - 0.25) 
1.32 (1.83 - 0.95)
n.s.
n.s. 1.0 n.s.
50-60n 5/4
9/12
0.47 (0.94 - 0.23) 
1.43 (1.93 - 1.05)
n.s.
n.s. 1.0 n.s.
D) CDC-25.1 comparison cul-1 and control RNAi
30-40n 23/10
12/18
11/11
2.07 (3.00- 1.43) 
1.46(1.94- 1.1) 
4.02 (5.73 -2.81)
<0.001
<0.05
<0.001
2.2 <0.001
E) CDC-25.1 S46F) comparison cul-1 and control RNAi
30-40n 13/7 
12/8 
15/18
1.18 (1.74-0.80) 
1.35 (1.83 - 1.00) 
1.03 (1.14-0.92)
n.s.
<0.05
n.s.
1.1 n.s
F) CDC-25.1 comparison gsk-3 and control RNAi
30-40n 23/11
°12/3
17/14
16/10
0.51 (0.76-0.34) 
0 .34(1 .12-0 .10) 
0.90 (0.93 - 0.86) 
1.72 (2.25 - 1.33)
<0.01*
n.s.
n.s.
<0.001
0.9 n.s.
G) CDC-25.1 (S46F) comparison gsk-3 and control RNAi
30-40n 13/8
12/9
15/17
16/8
1.00 (1.51 -0.67) 
1.32 (1.83 - 0.95) 
1.17(1.19- 1.13) 
1.07(1.42-0.80)
n.s.
n.s.
n.s
n.s.
1.1 n.s.
Table 8.1 Detailed quantification of CDC-25.1 and CDC-25.1 (S46F) protein levels after 
immunostaining.
For T ab le  le g e n d  s e e  n ex t p ag e .
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A v e ra g e  in tensity  of f lu o re sc e n c e  a fte r  C D C -25.1 im m unosta in ing  of e m b ry o s  derived  from  th e  
w ild-type s tra in  JR 1 8 3 8  c o m p a re d  to  IA530 cdc-25.1 (ij48) w a s  quan tified  from  individual 
e x p e r im e n ts , p -value: S tu d e n t’s  f-te st for tw o-tailed  d istribution , co m b in ed  p -value: S tu d e n t’s  f-test 
for o n e -ta ile d  d istribu tion  of co m b in ed  d a ta s e ts ,  n .s.: p -va lue  > 0 .05 . A) C D C -2 5 .1 (S 4 6 F ) protein  
lev e ls  a r e  in c re a se d  c o m p a re d  to  C D C -25.1  b e tw e e n  th e  10- to 60-cell s ta g e  of e m b ry o g e n e s is . 
M utan t fold in c re a s e  (AmeanwT/Mutant (95%  u p p e r  a n d  low er co n fid e n c e  limits), n u m b e r  of em b ry o s  
(C D C -2 5 .1 /C D C 2 5 .1 S 4 6 F ), * = 0 .95  tail w a s  utilised for ca lcu la tion  of th e  co m b in ed  o n e-ta iled  p- 
value . Tw o a n d  th re e  in d e p e n d e n t e x p e r im e n ts  for 3 0 -40n  an d  10-20n , 50 -60n , 100-200n , 
resp ec tiv e ly . B-E) C D C -25.1  bu t not C D C -2 5 .1 (S 4 6 F ) is in c re a se d  a f te r  lin-23 a n d  cul-1 RNAi. Fold 
in c re a se : A m ea n ctri/gene-sPecific RNAi (95%  u p p e r  a n d  low er c o n fid e n ce  limits), n u m b e r  of em b ry o s  
(co n tro l/g e n e -sp e c if ic  RNAi), tw o an d  th re e  in d e p e n d e n t e x p e r im e n ts  for lin-23 an d  cul-1 RNAi, 
resp ec tiv e ly . F, G ) C D C -25.1  a n d  C D C -2 5 .1 (S 4 6 F ) a b u n d a n c e  is no t a ffec ted  by gsk-3  RNAi. 
A n a ly sed  a s  (B-E), 0 = d a ta s e t  w a s  no t inc luded  in co m b in ed  p -value , * = 0 .9 9  tail w a s  u tilised for 
ca lcu la tio n  of th e  co m b in ed  p-value. T h re e  an d  four in d e p e n d e n t e x p e r im e n ts  for F a n d  G, 
resp ec tiv e ly . F o r a  d e ta iled  d escrip tio n  of th e  s ta tis tic s  app lied , p le a s e  s e e  C h a p te r  2, (2 .2 .9 .1).
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